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Abstract 
In order to guide critical care therapies that are personalized to a patient’s unique disease 
state, a diagnostic or theranostic medical device must quickly provide a detailed biomolecular 
understanding of disease onset and progression. This detailed molecular understanding of 
cellular processes and pathways requires the ability to measure multiple analytes in parallel. 
Though many traditional sensing technologies for biomarker analysis and fundamental biological 
studies (i.e. enzyme-linked immunosorbent assays, real-time polymerase chain reaction, etc.) 
rely on single-parameter measurements, it has become increasingly clear that the inherent 
complexity of many human illnesses and pathways necessitates quantitative and multiparameter 
analysis of biological samples. Currently used analytical methods are deficient in that they often 
provide either highly quantitative data for a single biomarker or qualitative data for many targets, 
but methods that simultaneously provide highly quantitative analysis of many targets have yet to 
be adequately developed. Fields such as medical diagnostics and cellular biology would benefit 
greatly from a technology that enables rapid, quantitative and reproducible assays for many 
targets within a single sample. 
In an effort to fill this unmet need, this doctoral dissertation describes the development of 
a clinically translational biosensing technology based on silicon photonics and developed in the 
chemistry research laboratory of Ryan C. Bailey. Silicon photonic microring resonators, a class 
of high-Q optical sensors, represent a promising platform for rapid, multiparameter in vitro 
measurements.  The original device design utilizes 32-ring arrays for real-time biomolecular 
sensing without fluorescent labels, and these optical biosensors display great potential for more 
highly multiplexed (100s-1000s) measurements based on the impressive scalability of silicon 
device fabrication (a 128-ring array chip design is currently under development).  Though this 
technology can be used to detect a variety of molecules, this dissertation establishes the utility of 
microring resonator chips for multiparameter analysis of several challenging protein targets in 
cell cultures, human blood sera, and other clinical samples such as cerebrospinal fluid.  
Various sandwich immunoassay formats for diverse protein analytes are described herein, 
but the bulk of this dissertation focuses on applying the technology to cytokine analysis. 
Cytokines are small signaling proteins that are present in serum and cell secretomes at 
concentrations in the pg/mL or ng/mL range. Cytokines are very challenging to quantitate due to 
their low abundance and small size, but play important roles in a variety of immune response and 
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inflammatory pathways; cytokine quantitation is thus important in fundamental biological studies 
and diagnostics, and complex and overlapping cytokine roles make multiplexed measurements 
especially vital.  In a typical experiment, microfluidics are used to spatially control chip 
functionalization by directing capture antibodies against a variety of protein targets to groups of 
microring sensors. In each case, binding of analytes to the rings causes a change in the local 
refractive index that is transduced into a real-time, quantitative optical signal. This photonic 
sensing modality is based on the interaction of the propagating evanescent field (that extends 
outside of the microring) with molecules near the ring surface. Since each microring sensor in 
the array is monitored independently, this technology allows multiple proteins to be quantified in 
parallel from a single sample. 
This dissertation describes the fabrication, characterization, development, and application 
of silicon photonic microring resonator technology to multiplexed protein measurements in a 
variety of biological systems. Chapter 1 introduces the field of high-Q optical sensors and places 
microring resonator technology within the broader context of related whispering gallery mode 
devices. The final stages of cleanroom device fabrication, in which 8‖ silicon wafers that contain 
hundreds of ring resonator arrays are transformed into individual functional chips, are described 
in Chapter 2. Chapter 3 characterizes the physical and optical properties of the microring 
resonator arrays, especially focusing on the evanescent field profile and mass sensitivity metrics. 
Chapter 4 demonstrates the ability to apply ring resonator technology to cytokine detection and T 
cell secretion analysis. Chapter 5 builds on the initial cytokine work to demonstrate the 
simultaneous detection of multiple cytokines with higher throughput to enable studies of T cell 
differentiation. In preparation for reaching the goal of cytokine analysis in clinical samples, 
Chapter 6 describes magnetic bead-based signal enhancement of sandwich immunoassays for 
serum analysis. Additional examples of the utility of nanoparticles and sub-micron beads for 
signal amplification are described in Chapter 7, also demonstrating the ability to monitor single 
bead binding events. Chapter 8 describes an alternative cytokine signal enhancement strategy 
based on enzymatic amplification for human cerebrospinal fluid (CSF) analysis. Chapter 9 adds 
work with other CSF protein targets that are relevant to the continuing development of a 
multiparameter Alzheimer’s Disease diagnostic chip. Future directions for multiplexed protein 
analysis as it pertains to important immunological studies and in vitro diagnostic applications are 
defined in Chapter 10. 
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1.1 Introduction 
 Optical sensors represent a vitally important class of analytical tools that have been used 
to provide chemical information ranging from analyte concentration and binding kinetics to 
microscopic imaging and molecular structure. Optical sensors utilize a variety of signal 
transduction pathways based on photonic attributes that include absorbance, transmission, 
fluorescence intensity, refractive index, polarization, and reflectivity. Within the broad 
classification of optical sensors, refractive index (RI) sensors, which include devices such as 
surface plasmon resonance instruments, interferometers, diffraction gratings, optical fibers, 
photonic crystals, and resonant microcavities, have emerged as promising technologies over the 
past two decades.  These optical sensors based on the change in RI associated with analyte 
binding involve an impressive array of instrumentation that allows for label-free
1
 molecular 
sensing without the added complexity of fluorescent or enzymatic tags. By removing the 
requirement for labels, RI-based sensing allows for real-time and direct detection of molecular 
interactions at a dielectric interface. Though many manifestations of RI-based sensors have been 
proposed and demonstrated, high-quality factor (high-Q) optical sensors based on multi-pass 
photonic microstructures have recently emerged as an extremely promising, and perhaps the 
most sensitive, class of label-free sensors. Major advantages of many high-Q sensors include 
multiple-pass interactions between the propagating electromagnetic radiation and the respective 
analyte binding event, as well as the intrinsic chip-integration and wafer-scale fabrication that 
accompany many semiconductor-based sensing modalities. 
 High-Q optical sensors involve microstructures that confine light due to differences in RI 
between a micropatterned material and its surrounding. This confinement supports multi-pass 
light interactions based on either multiple reflections or many circumnavigations. In both cases, 
this results in an increased effective optical path length that improves the sensitivity of the 
device. The Q factor of a given device is a measure of the resonant photon lifetime within a 
microstructure (higher Q factor = longer lifetime), and therefore Q is directly correlated to the 
number of times a photon is recirculated and allowed to interact with the analyte.
2
 Light is 
confined by either total internal reflection at a core/cladding interface (microcavities) or by the 
spatially periodic modulation of materials with different RI properties (photonic crystals), and 
resultant high-Q sensors interact with their local environments via an evanescent optical field 
that extends from the sensor surface and decays exponentially with distance.
3, 4
 A more detailed 
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treatment of microcavity technology involving whispering gallery mode (WGM) sensing will be 
presented in the following section. High-Q optical sensors, whether based on guided-mode optics 
or photonic crystal (PC) structures, support resonances at very specific wavelengths, and these 
resonances are responsive to changes in the effective RI at the device surface. For most 
microcavity sensors, the wavelengths of light transmitted between an adjacent waveguide or 
optical fiber and the cavity is attenuated at narrow resonant wavelengths that are a function of the 
RI at the microcavity surface; for most PC sensors, light is back-reflected only at precise 
resonance wavelengths.  As the Q factor of a device increases, the photon lifetime increases, and 
the resonance wavelength peak becomes narrower. For both microcavity and PC sensors, the 
relative shift in resonance wavelengths is directly proportional to the effective RI sampled by the 
confined optical mode, which samples the dielectric interface via the evanescent wave extending 
from the sensor surface. Since most analytes, such as organic (bio)molecules in water or gases in 
air, have a greater dielectric permittivity (and thus higher RI) than the surrounding medium, their 
binding or association with the sensor surface leads to an increase in effective RI sampled by the 
optical mode.
4
 Though factors such as biological and spectroscopic noise often set the practical 
limit of detection for any sensor system, the narrow resonance wavelengths associated with high-
Q cavities provide an opportunity to resolve tiny spectral shifts that accompany a very small 
number of analyte binding interactions. The impressive sensitivity of microcavity and PC 
devices to minute changes in the effective RI at the sensor surface is the basis for most of the 
recent applications of high-Q optical sensors. 
The development of high-Q photonic devices has been tremendously enabled by recent 
advances in micro- and nanofabrication methods, and the application of these devices for 
chemical and biomolecular analysis has only come to fruition within the past decade. This 
review focuses on the most exciting research in this area over the period of 2009 – 2011, 
although enabling findings and developments that precede this range are also covered. Recent 
reviews have summarized advances that may include some treatment of high-Q sensors, but 
these reviews have been broadly focused on advances in label-free sensors in general,
5-8
 on 
applications of silicon photonics that include sensing among many others,
9
 or on a general 
treatment of optical devices for sensing that includes the devices of interest.
10-13
 Other excellent 
reviews are more narrowly focused and cover different aspects of high-Q technology, focusing 
specifically on ring resonator technology,
14, 15
 microsphere resonators,
16
 photonic crystals,
4, 17
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microfluidic integration with optical sensors,
18, 19
 and high-Q mechanical sensors.
20
 This review 
considers recent advances in high-Q and ultra-high-Q optical sensors for addressing fundamental 
challenges in measurement science, giving special attention to those techniques that demonstrate 
useful chemical or biomolecular measurement capabilities within relevant real-world matrices. 
Although not rigorously fitting within some strict definitions of high-Q devices, photonic crystal 
sensors are covered as they represent an exciting complementary technology that, in many ways, 
is more advanced at present than many high-Q microcavity sensor configurations. As this review 
is intended to target the broad community of practicing analytical chemists, particular focus is 
given to signal transduction mechanisms, surface chemistry, assay methodologies, and 
interesting new measurement applications, leaving detailed explanations of device optics and 
engineering to other, more topical reviews
21, 22
 and the collection of articles from the optics 
community cited herein. 
Specifically, this review will briefly discuss the theoretical basis of high-Q optical 
sensing, including the multitude of sensor geometries within the category of multi-pass optical 
sensors. Recent advances in high-Q sensor surface chemistry, capture agent immobilization, 
assay design, and amplification techniques are covered, as well as interesting demonstrations of 
these technologies in impact areas such as quantitative detection, affinity profiling, multiplexed 
sensing, nanoparticle analysis, light manipulation, lasers, thermal sensing, and integrated 
detection techniques. Finally, we provide our own critical analysis of the field in general, 
offering thoughts on areas in which improvements are most needed to inform the future outlook 
and reach the goals of high-Q optical sensing. 
 
 
1.2 Whispering gallery mode sensing 
 As most of the high-Q optical sensors discussed in this review involve the propagation of 
whispering gallery modes (WGMs) in microcavities, a brief description of the theory behind this 
interesting sensing modality is provided first. The whispering gallery phenomenon was initially 
described by Lord Rayleigh based on observations in St. Paul’s Cathedral in London, where he 
observed that a whisper at one side of the cathedral’s dome could be heard on the opposite side 
of the large room, an effect that is manifested by constructive interference of acoustic waves 
traveling along the circumference of the dome.
23
  WGM optical sensors involve the guidance of 
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photons in a manner that is similar to this acoustic effect. A brief treatment of WGM sensing 
fundamentals as it applies to an analytical chemistry audience is provided, but we also refer 
readers to an excellent overview of WGM sensing theory by Vollmer and Arnold.
2
 
 Microcavity resonators support optical WGMs that circumnavigate the outer edge of a 
microcavity, confined by total internal reflection at the boundary between the higher-index 
dielectric cavity and lower-index surrounding medium. The light waves of the WGM 
constructively interfere as circulating photons return to the point of optical insertion in phase 
with photons of the same wavelength propagating down an adjacent linear input (fiber optic taper 
or chip-integrated waveguide). Light is inserted into the microcavity through coupling from a 
tapered optical fiber (Figure 1.1A) or adjacent waveguide (Figure 1.1B), and the light source is 
typically a tunable laser that is capable of scanning a window of possible resonant wavelengths 
with high spectral resolution. Only wavelengths of light that meet the constructive interference-
based resonance condition are coupled into the microcavity, while all non-resonant wavelengths 
are transmitted down the adjacent waveguide or optical fiber. The resonance condition for a 
circular microcavity with radius R supporting a circulating WGM is:  
(1)  𝑚𝜆𝑟 = 2𝜋𝑅𝑛𝑒𝑓𝑓  
and demonstrates that an integer (𝑚) number of multiples of the wavelength (𝜆) must equal the 
microcavity circumference (2𝜋𝑅) multiplied by the effective RI (𝑛𝑒𝑓𝑓 ) sampled by the optical 
mode. In this form, it is clear that changes to either the radius of the microcavity or the effective 
RI of the optical mode will change the wavelength that fulfills the resonance condition (𝜆𝑟 ). This 
can be more clearly stated in relative terms of the appropriate variables as: 
(2) 
∆𝜆𝑟
𝜆𝑟
=
∆𝑅
𝑅
+
∆𝑛𝑒𝑓𝑓
𝑛𝑒𝑓𝑓
 
that highlights that any small relative change in 𝑅 or 𝑛𝑒𝑓𝑓  must be balanced by an equally small 
relative shift of the resonance wavelength. From this relationship, it is clear that the relative shift 
in resonance wavelength, as opposed to the value of the resonance wavelength itself, is the 
critical parameter for sensing.  
The sensitivity to RI changes is based on the interaction of analytes with the evanescent 
tail of the WGM that extends from the sensor surface into the surrounding medium. As the 
WGM circumnavigates the microcavity via total internal reflection, an evanescent field extends 
from the surface of the device according to the electromagnetic wave equation boundary 
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conditions that necessitate a non-zero electric field at the dielectric interface.
3, 24
 The evanescent 
field strength (𝐼) decays exponentially (with decay constant 𝛾) from its initial value (𝐼0) with 
increasing distance (𝑧) from the sensor surface according to: 
(3) 𝐼 𝑧 = 𝐼0𝑒
−2𝛾𝑧  
The strength of the interaction with the analyte near the high-Q sensor, which is proportional to 
the intensity of the evanescent field extending from the sensor/solution boundary,
25
 decreases 
with distance from the sensor surface and thus has only limited sensitivity to bulk solution 
contributions.  
Since all wavelengths except those that meet the resonance condition in Equation 1 are 
not coupled into the microcavity and continue to the end of the optical fiber or waveguide, a 
straightforward optical sensing scheme involves monitoring the transmission spectrum past the 
resonator, although alternative schemes involving add-drop configurations have been 
implemented. In the transmission-based detection scheme, resonance wavelengths are observed 
as dips (negative attenuations) in the transmitted spectrum that are monitored by a photodetector 
as the laser is tuned through an appropriate spectral window (Figure 1.1). In order to leverage the 
potential for high sensitivity detection with high-Q microcavities, extremely small relative shifts 
in the resonance wavelength (Equation 2) must be measured. 
 The ability to measure small shifts in the resonance wavelength is enhanced by spectrally 
narrow resonances. High-Q microcavities are therefore fabricated with precision in order to 
realize exceedingly narrow linewidths. The 𝑄 factor is proportional to the number of times a 
photon circulates the microcavity
2
 and thus determines the effective pathlength over which light-
analyte interactions occur.
7
 The effective path length (𝐿𝑒𝑓𝑓 , often on the order of cm) can be 
described by: 
(4) 𝐿𝑒𝑓𝑓 =  
𝑄𝜆
2𝜋𝑛𝑒𝑓𝑓
 
and varies directly with the 𝑄 factor (typically 104-108 for high-Q microcavities).15 The 𝑄 factor 
is mathematically described as the ratio of the resonance wavelength (𝜆𝑟 ) to the spectral 
linewidth (𝛿𝜆; full width at half-maximum) of the attenuation peak: 
(5) 𝑄 =
𝜆𝑟
𝛿𝜆
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Therefore, a higher 𝑄 factor signifies a narrower transmission attenuation at a given wavelength. 
Additionally, higher 𝑄 factors are associated with a higher photon lifetime (𝜏) at a given 
resonance frequency (𝜔): 
(6) 𝜏 =
𝑄
𝜔
 
The ability to achieve high 𝑄 factors in photonic devices is ultimately limited by the capacity to 
fabricate microcavities that simultaneously maximize the photon lifetime (𝜏) and minimize both 
intrinsic and extrinsic power losses due to scattering, radiative losses, bending losses, coupling 
losses, or poor optical confinement.
26-28
 By minimizing surface defects to reduce scattering, 
carefully perfected dielectric toroidal microcavities have demonstrated 𝑄 factors in excess of 108 
in aqueous environments
29, 30
 and photon lifetimes in the nanosecond regime.
2
 It is also worth 
noting that taking advantage of a high 𝑄 factor also requires the ability to routinely measure the 
small ∆𝜆𝑟  that can be as low as 0.01 pm. Indeed, the ability to control thermal fluctuations, 
spectroscopic noise, and biological background to levels associated with sub-pm ∆𝜆𝑟  is a large 
challenge for all high-Q sensors. 
 Though the 𝑄 factor sets the fundamental limit for spectroscopic resolution, 
spectroscopic noise is often not the dominant source of error for optical sensors applied in useful 
contexts. Optical engineers and physicists have successfully devoted significant effort toward 
creating ultra-high-Q microcavities, but interesting real-world applications that require 
quantitation in truly complex matrices such as human serum, cell culture, or environmental 
samples remain challenging.  Though the multiple interactions with an analyte that are afforded 
by a multi-pass high-Q optical sensor are vital to achieving impressive surface binding 
sensitivity, the Q factor sets the limits of sensitivity only when other sources of error are not 
dominant. 
 The use of high-Q WGM microcavities for sensing applications is a relatively new field, 
albeit with somewhat older origins. Though the idea for resonators based on total internal 
reflection within integrated optics dates from the 1960s,
31
 it was not until the 1990s (when 
micro/nanofabrication techniques came of age) that the use of high-Q ring resonators for 
telecommunications applications such as optical signal filtering and switching was realized.
32-34
 
Building on a prediction by Serpengüzel et al. that adsorption of a species to a microcavity 
would cause a change in the resonance characteristics,
35
 the idea of using WGM-supporting 
microdisks for direct label-free detection of biomolecules was put forth by Boyd and Heebner in 
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2001.
36
 This proposed microcavity device suggested the incorporation of other technologies such 
as critical coupling
37
 and high-level optical integration
38
 to achieve a highly sensitive and 
potentially multiplexable biosensor. Some of these ideas were realized by subsequent reports of 
the first demonstrations of WGM biosensing based on microsphere,
39
 microring,
40
 optofluidic,
41
 
and microtoroid
42
 geometries. Though the first demonstrations of biosensing were based on 
simple adsorption of a model protein to the microcavity and observing the associated shift in 
resonance wavelength, more sophisticated experiments have followed over the past several 
years. These exciting recent developments in the field form the basis of this review. 
 In order to demonstrate the utility of WGM microcavities for applications such as 
biological, environmental, chemical, and biomedical sensing, many key technical advances have 
recently been made. These technical advances include developments such as temperature 
compensation,
43, 44
 methods for sensor multiplexing,
45-47
 and evanescent field profiling and 
electric field distribution optimization
3, 24, 48
 that are imperative to creating an analytically useful 
device. Beyond improvements to existing microcavity geometries, innovative device geometries 
such as adiabatic microring resonators with lossless contacts,
49
 concentric nanocavities with sub-
/super-radiant modes,
50
 and cascaded ring resonators that take advantage of the Vernier effect
51
 
have recently been proposed. In addition to discussing improvements in device fabrication and 
materials for various microcavity and photonic crystal geometries, new developments in surface 
chemistry and assay methodologies that are equally, if not more, critical to the realization of 
highly specific and multiplexed chemical and biomolecular sensing are covered. Finally, the 
many interesting recent applications of high-Q optical sensors are covered, highlighting the 
technical and methodological advances that make these technologies applicable to performing 
biomolecular assays, monitoring reaction kinetics, sizing and transporting nanoparticles, and 
manipulating light, among others. 
 
   
1.3 High-Q optical sensors: geometries, fabrication, and instrumentation 
 There are a variety of microcavity geometries that are capable of supporting WGMs, 
including spheres, toroids, disks, rings, cylinders/capillaries, and slot waveguides. These can be 
fabricated using a variety of materials, including glass, quartz, silicon, silicon-on-insulator (SOI), 
silicon nitride, polymers, and various hybrid materials. Among photonic crystal sensors, 1-
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dimensional, 2-dimensional, and 3-dimensional confinement is possible with a variety of 
materials that allow high index contrast with periodic modulation. The most common geometries 
are covered while focusing on recent developments in fabrication techniques, newer designs, and 
accompanying read-out instrumentation. 
 Microsphere resonators. Vollmer et al. demonstrated the fabrication of glass (silica) 
microspheres (~300 µm in diameter) by melting the tip of a stripped single mode fiber into a 
spheroid-on-a-stem structure with a butane/nitrous oxide torch.
39
 WGM resonances were excited 
by carefully placing the microsphere within optical coupling distance of a HF-etched single-
mode optical fiber connected to a tunable distributed feedback laser diode with emission 
centered at 1340 nm. Using an InGaAs photodiode to detect light intensity transmitted past the 
resonator through the coupling optical fiber, Lorentzian-shaped resonance peak minima were 
detected with a parabolic fit and tracked as a function of time. With a measured Q factor of ~2 × 
10
6
, additional microsphere experiments were conducted on quartz microspheres of sizes 
between 88 and 232 µm.
25
 Similar experiments involving a microsphere-on-a-stem adjacent to an 
etched optical fiber have also been used in more recent, real-time experiments aimed at 
biomolecule detection and protein conformation analysis that will be discussed in subsequent 
sections.
52-54
 One important consideration in these experiments is that the position of the 
microsphere relative to the optical fiber must be rigorously maintained, as any movement of the 
microsphere could compromise detection of the resonance.
55
 More recent work has centered on 
fabricating smaller microspheres with larger relative shifts that enable discrete particle binding 
assays. 100-µm silica microspheres (Figure 1.2A) are also fabricated from tapered optical fiber 
tips, but this time by melting with a 10-W CO2 laser.
56
 After suspending this spheroid-on-a-stem 
structure in a sample cell constructed from o-rings and glass coverslips, and tuning the 763-nm 
distributed feedback laser wavelength across one or more resonances, transmission spectra were 
collected with 10-20 ms time resolution (Figure 1.1A).
56, 57
 Temperature and humidity were 
controlled by enclosing the sample cell. While this experimental configuration is reliant upon 
careful device fabrication and precise alignment of the optical fiber and the adjacent 
microsphere, excellent quality factors and single-particle detection experiments, which will be 
highlighted in subsequent sections, are possible with microspheres. 
 Other microsphere materials and experimental configurations have also been 
demonstrated. For example, rather than suspending the microsphere-on-a-stem within a static 
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droplet, a flow-based experiment has been realized by mechanical immobilization of a ~100-µm 
poly(methyl methacrylate) (PMMA) microsphere within photolithographically-defined Invar 
channels.
58
 In this setup, a prism is used in place of an etched optical fiber to couple light and 
excite multiple modes in the PMMA microsphere. These experiments are complicated by the 
need to maintain the position of the microsphere with a microneedle and by the required 
collection of a complex multi-modal transmission spectrum by a CCD camera. Instead of 
fashioning microspheres wholly out of PMMA, it has also been proposed that glass microspheres 
could be coated with a sub-micron layer of PMMA to improve the thermal stability of the 
sensors.
59
 An added advantage of this strategy is that PMMA is a low optical loss material, thus 
not compromising the Q factor. PMMA has a thermo-optic coefficient that is opposite in sign to 
that of silica (and silicon), meaning that appropriate coating thicknesses might allow for an 
elimination (or at least reduction) of temperature-induced resonance drifts, which often impose 
fundamental limits of sensitivity in WGM measurements. A high-surface area nanoporous zeolite 
coating on a silica microsphere has also been proposed for its potential to adsorb analytes such as 
gas molecules with improved sensitivity.
60
 Other examples of polymeric microspheres include 
the use of ~5-µm polystyrene spheres for WGM sensing based on intrinsic polystyrene 
fluorescence,
61
 emission from fluorophore-doped polystyrene,
62
 or on emission from embedded 
CdSe/ZnS quantum dots.
61, 63
 These studies utilize an elaboration of Mie theory
64
 to explain the 
scattering interaction between plane waves and microspheres that allows WGM excitation 
without evanescent coupling from an optical fiber or prism. Though these methods open the 
possibility of remote sensing, they require a complex algorithm to analyze the multiple 
microsphere modes, and their associated Q factors (~2000) are relatively small.
61
 It should be 
noted, however, that ―low-Q‖ microspheres benefit from larger resonant wavelength shifts and 
decreased spectral mode density, which may actually be advantageous in some circumstances.
62
 
 Microtoroid resonators. Ultra-high-Q toroidal microcavities were first fabricated by 
Armani et al. on oxide-coated Si wafers through a combination of photolithography, wet and dry 
etching, and laser reflowing.
29, 65
 Specifically, photolithography is performed on a Si wafer 
containing 2 µm of thermally grown oxide to define 160-µm photoresist pads that act as a mask 
during the subsequent buffered HF etch.  Photoresist removal leaves behind SiO2 disks, and an 
isotropic XeF2 dry etch undercuts the oxide disks to create Si pillar structures under the disks. 
The final CO2 laser reflow step selectively heats the periphery of the SiO2 disk, causing the 
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formation of a surface tension-smoothed and optically isolated toroidal structure as the disk 
shrinks.  This reflow step effectively removes lithographic flaws and allows tremendously high 
Q factors (>10
8
) to be achieved.
29
 Microtoroid sensing experiments require precise alignment of 
a tapered optical fiber for excitation of WGMs using a tunable laser in the optical 
telecommunication band (~1500 nm). Only through incredibly careful alignment of the 
separation distance and tilt angle of the fiber taper with respect to the toroid could low-loss 
critical coupling be achieved. Though the original microtoroids had a final diameter of 120 µm, 
subsequent work has demonstrated a range of diameters of 30-150 µm (Figure 1.2B).
42, 66
 
 Toroidal microcavities can also be fabricated from other materials. PDMS can be cast 
around the aforementioned silica microtoroid structures and subsequently filled with thermal- or 
UV-curing polymer in order to create replicates.
66
 Though the PDMS molds can theoretically be 
used to replicate polymeric toroids many times over, structural imperfections limit the Q factor 
to 10
5
. By combining traditional silica microtoroids with a thin (~100 nm) layer of a polymer 
applied by spin coating, hybrid silica-polymer microtoroids have also been demonstrated.
67
 Both 
polystyrene and PMMA were tested in the hybrid devices, utilizing a thermal reflow for 
enhanced polymer smoothness that produced material-limited Q factors of ~10
7
. Aside from 
polymer-silica hybrid devices, metal-coated microtoroids have also been proposed for the 
purpose of concentrating the WGM in the exterior of the device where the external mode is 
assisted by a propagating surface plasmon.
68
 Simulations have shown that silica microtoroids 
with a 100-nm Ag coating concentrate ~90% of the optical mode in the surrounding medium (i.e. 
outside the hybrid device), but Q factors for these lossy, metal-coated devices were limited to 
~10
3
.
68
 Though not the only important consideration for microcavity devices, a sufficiently high 
Q factor is critical for measuring the very small shifts in resonance wavelength required for 
sensitive analysis. Despite efforts to achieve the maximum theoretical and material-limited Q 
factors of >10
9
, microtoroids fabricated on thermally oxidized Si wafers suffer from diffusion of 
dopants (such as boron) from the Si layer that change the RI and negatively impact Q.
28
 
Regardless of whether toroids can achieve even higher Q factors beyond 10
8
, the impressive Q 
factors of both microspheres and microtoroids come at the cost of (1) fabrication processes that 
are (as of now) difficult to standardize for reproducible, high-throughput, and scalable sensor 
devices and (2) a requirement for complicated alignment with an optical fiber for WGM 
excitation. 
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Microdisk resonators. The first example of microdisks for sensing by Krioukov et al. 
involved lithographically defined and vertically coupled 30-µm silicon nitride disks.
69
 These 
early microdisk sensors were complicated by multiple radial modes that required interpretation 
of a complex transmission spectrum. As described above, silica disks can now be produced as an 
intermediate step in the fabrication of microtoroids.
29
 60-µm silica microdisks on pillars 
demonstrated Q factors of ~10
7
 if wedge-shaped edges were fabricated by an HF etch.
70
  Recent 
improvements in fabrication methods have further increased the range of cavity geometries that 
can be achieved, including silicon nitride (SiNx) microdisks on a pedestal that have been 
fabricated with a 40-nm slot to increase modal overlap with the sensing environment.
71
 To 
fabricate these slot disks, thin layers of SiNx (255 nm), SiO2 (40 nm), and then SiNx again (255 
nm) were deposited by reactive ion beam sputtering on a Si wafer and annealed. After coating 
with a Si etch mask, 15-µm disks were created by photolithography and dry etching, and then 
undercut with a hot KOH etch to define a 3-µm support pedestal below the disk. Finally, the slot 
was produced by selective etching of the SiO2 layer. By coupling infrared light from a tunable 
laser into the disk through a bent, tapered optical fiber, a scattering-limited Q factor of ~10
4
 was 
demonstrated with 21.6% of the mode confined within the slot.
71
 Aqueous measurements 
demonstrated a resonance wavelength peak shift resolution of 78-pm.
72
  
Microdisks can also be fabricated from high-index chalcogenide glass materials, such as 
As2S3 and Ge17Sb12S71, which can be thermally evaporated onto silicon. Microdisks fabricated 
from these materials were optically accessed by 800-nm wide bus waveguides in a pulley coupler 
design in which the waveguide wraps around the planar microdisk.
73
 The horizontal pulley-
coupled chalcogenide disks relax coupling tolerances, and the entire device was fabricated in a 
single lithographic step. These unsupported chalcogenide structures can be interfaced with 
PDMS microfluidics and permit easily fabricated 800-nm gaps between bus waveguide and 
microdisk, while maintaining an aqueous Q factor of ~2 × 10
4
. Planar devices such as the 
unsupported microdisk design allow more consistent coupling with the adjacent bus waveguide, 
removing the requirement for careful alignment with an optical fiber that is required for pillar-
supported toroids/disks and microspheres.  
Other variations of microdisks that have been recently realized include polymeric and 
metal-capped microdisks. PMMA microdisks are fabricated by spin-coating 1 µm PMMA on a 
Si wafer, patterning into ~50 µM disks by standard UV or electron beam lithography, and 
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isotropically etching with XeF2 to form a pillar-supported microdisk.
74
 A PMMA thermal reflow 
reduces surface roughness and creates a conical disk geometry that supports Q factors of ~10
6
. 
Alternatively, metal-capped microdisks allow for the creation of surface-plasmon-polariton 
(SPP) WGM cavities (Figure 1.2C).
27, 75
 Using wedge-shaped silica microdisks described 
above,
70
 Ag is deposited on the disk by sputtering, and SPP WGM’s are excited by an optical 
fiber that passes just under the elevated disk to avoid the Ag coating.
27
 Simulation results of SPP 
modes for a variety of metal thicknesses and microdisk sizes demonstrate maximum Q factors of 
~4 × 10
3
; Q factors for these devices are limited by the lossy metal layer.
75
 A final interesting 
cavity geometry that combines the lossless pillar contact of a microdisk with the single-mode 
coupling properties of microrings, termed adiabatic microring resonators, has also recently been 
proposed.
49
  
 Microring resonators. By adding an interior boundary instead of a continuous span of 
material as in sphere/toroid/disk geometries, annular-shaped microrings permit single-mode 
excitation at the cost of lower Q factors. Unlike pillar-supported microcavities that require 
complicated etching and laser reflow processes, microrings and bus waveguides can be more 
easily fabricated in planar arrays by direct extension of commercial semiconductor processing 
techniques. Microring sensors have been fabricated from a variety of materials including silicon 
oxide,
40, 76
 silicon nitride,
77, 78
 silicon-on-insulator (SOI),
43, 79-81
 polymers,
82-84
 and plasmonic 
hybrid materials.
85
 Vertically-coupled 120-µm silicon oxide microrings fabricated by chemical 
vapor deposition (CVD) of Hydex were first demonstrated for sensing by Yalcin et al.
40
 Vertical 
coupling of the input and output waveguides to the microring, as opposed to lateral coupling, 
prevents exposure of the waveguide to surface treatments and offers easy waveguide-ring 
spacing control (without lithography/etching) to optimize the coupling gap. These rings 
demonstrated Q factors of ~10
4
, and accompanying transmission scanning instrumentation 
permitted a 20-pm wavelength resolution.
40
 Similarly, a vertically-coupled array of five 100-µm 
silica rings with U-shaped input and output waveguides, demonstrated the inherent scalability 
potential and broad biosensing applicability of microrings.
76
 Additionally, this work utilized an 
optical spectrum analyzer, broadband light source, and optical switch to permit sequential 
channeling of light to each of the five rings with a 15 s/ring scan rate. In addition to silica, 140-
µm Si3N4 microrings were fabricated by a combination of low-pressure CVD, electron beam 
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lithography, and inductively-coupled plasma etching.
77
 Interrogation using a tunable laser light 
source (1260-1370 nm) revealed a Q factor of 1800 and 50 pm wavelength resolution. 
 Due to their fabrication using straight-forward commercial processes, SOI microring 
resonators have attracted considerable attention for highly scalable and cost-effective sensing 
applications. Through a combination of deep-UV lithography
86
 and etching, 200 nm × 500 nm Si 
waveguides and microrings (along with diffractive grating couplers for free space optical 
scanning) can be fabricated in the top layer of SOI wafers. A perfluoropolymer cladding layers 
was used to protect the waveguides and restrict solution access to annular openings over each 
microring (Figure 1.2D). 6x6-mm chips, each containing an array of 32 microring resonators 
(30-µm), are individually addressed by a laterally-coupled single-mode waveguide.
87
 Critical 
coupling of light from an external cavity tunable diode laser (centered at 1550 nm) is achieved 
by ensuring a waveguide-ring gap of ~200 nm, and these microrings demonstrate a ~6-nm free 
spectral range (FSR; the spectral spacing between resonance peaks)  and Q factors of 4 × 10
4
.
43
  
High-speed optical scanning instrumentation constructed by Iqbal et al. provides the ability to 
sequentially scan a 12-nm spectral window on all 32 rings in the array with unprecedented scan 
speeds of ~250 ms/ring.
87
 By using a 25 GHz Fabry-Perot etalon as a simultaneous wavelength 
reference to measure relative wavelength shifts (without regard to the absolute wavelength), 
wavelength shifts (~0.2 pm) far below the wavelength resolution of the laser (~20 pm) can be 
resolved, which greatly improves the device’s limit of detection.43 The surface binding 
sensitivity (1.5 pg/mm
2
) and evanescent field profile (1/𝑒 decay length= 63 nm; see Equation 3) 
for these ring resonators have been empirically determined, agreeing well with theoretical 
results.
3
 Other examples of Si waveguides demonstrate innovative waveguide fabrication and 
sensor miniaturization. Amorphous Si, deposited by a relatively low-cost damascene process 
involving CVD of amorphous Si into etched SiO2 trenches, provides an alternative method for 
creating Si waveguides.
88
 These low-loss amorphous Si structures were shown to have Q factors 
up to 10
5
. Other advances in SOI microring fabrication by De Vos et al. include the ability to 
limit the microring cavity footprint to <10 µm
2
 using small racetrack microrings (Q factor ~ 2 × 
10
4
) with input and output waveguides accessed by grating couplers.
80
 The high index contrast of 
SOI microrings (as compared to silicon nitride on silica) allows for smaller ring footprints 
without excessive bending losses that reduce the Q factor. Beyond demonstrating the high 
scalability and small footprint afforded by ring geometries, the work by De Vos et al. also further 
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demonstrates the utility of diffractive grating couplers that permit high alignment tolerances.  
The ability to insert light into the microcavity without the need for careful alignment of a tapered 
optical fiber is a clear advantage of planar microrings over other geometries. 
 Microring sensors fabricated from polymeric and plasmonic materials have also been 
demonstrated. Polymer microrings fabricated from materials such as polystyrene, polycarbonate, 
PMMA, and SU-8 in both single- and double-coupled variations were achieved using a 
nanoimprint lithography technique developed by Chao et al.
82, 89, 90
 For these polymeric 
structures, a silicon mold was first created by electron beam lithography and reactive ion etching 
(RIE).
89
 Polymeric microstructures were stamped on a polymer-coated Si substrate, residual 
polymer was removed by O2 RIE, and an HF etch was used to form pedestals under the polymer 
rings and bus waveguides. A thermal reflow technique, analogous to the silica laser annealing 
method of Armani et al.,
29
 was used to improve the Q factor to 2 × 10
4
 in the IR.
82
 800-µm 
polymeric microrings have also been demonstrated in a vertically-coupled geometry with an 
embedded polymeric waveguide, yielding a Q factor of 10
4
.
84
 Beyond polymers, hybrid 
plasmonic devices have also been proposed.
85
 Building off of work on hybrid plasmonic 
waveguides that impressively confine surface plasmon polaritons,
91
 hybrid plasmonic ring 
resonators combined a Si bus waveguide with a 2-µm Si ring surrounding a metal (Au) disk core. 
A hybrid mode results from coupling of the silicon photonic and surface plasmonic modes in the 
metal-Si gap, creating strong RI sensitivity and improved optical confinement within a very 
small footprint.
85
   
Beyond the traditional ring resonator design of a circular waveguide within coupling 
distance of a linear or bent waveguide, innovative microring designs have been proposed. These 
designs include racetrack geometries that contain a straight segment within the ring to improve 
coupling efficiencies,
80, 88, 92
 cascaded geometries that allow multiple sensors to be swept with a 
single wavelength scan,
93
 concentric microrings for higher sensing surface area,
94
 folded spiral 
geometries for enhancing the Q factor within a small footprint,
79, 95
 and notched ring geometries 
that improve mode splitting for single-particle detection.
96
 Each of these geometries still 
leverages the relative ease of coupling light into planar device configurations. 
 Optofluidic, microcapillary, and microtube resonators. Though microrings have 
demonstrated the ability to be interfaced within microfluidic channels by adhering PDMS
45, 93, 97, 
98
 or gasket-defined channels
3, 87
 on to the device-containing substrate, optofluidic geometries 
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directly incorporate the fluidic function into the sensor itself. Glass optofluidic resonators 
(known as liquid-core optical ring resonators or LCORR) were first reported by White et al. as a 
novel technology for combining photonics with well-established capillary fluidic handling.
99, 100
 
WGMs are excited in a circular cross section of a fused silica capillary by using a 
perpendicularly aligned tapered optical fiber (Figure 1.2E). RI changes within the capillary core 
are probed by the evanescent field that interacts with molecules near the inner wall. To produce 
the necessary thin-walled capillary, a ~1-mm glass capillary was drawn while heated in a flame 
to a diameter of ~100 µm, and then wall thickness was reduced to ~3 µm by HF etching.
99
 
Alternatively, a mechanically controlled method utilizes two translational stages and two CO2 
lasers focused on the capillary in order to direct the temperature and speed at which the capillary 
is drawn for optimal aspect ratio.
100
 Q factors of ~10
5
 have been demonstrated for the LCORR 
device,
24, 99
 with device quality limited by surface roughness created during the wall-thinning 
etch. Typically, experiments are conducted by connecting the capillary to external tubing, and 
the flow rate is controlled with a peristaltic pump. The sensitivities of the LCORR to both bulk 
RI changes
41
 and surface binding
24
 have been rigorously quantified, and the unique optical mode 
properties of LCORR and other microtube/capillary devices has also been well-characterized.
48, 
101
 Additionally, detailed theoretical analyses of thermal and RI sensitivity as it relates to wall 
thickness for the optical modes characteristic of the microcapillary geometry have been 
performed.
102
 Interestingly, multiple LCORR devices have been arrayed in parallel for such use 
as on-column capillary electrophoresis detectors.
103
 
Variations of the original LCORR device have also been reported. As an alternative to 
drawing a heated capillary, microtube resonators can be fabricated by a roll-up self-assembly 
process.
104
 In this method, a strained 20-nm Si layer was deposited on a sacrificial Ge layer by 
molecular beam epitaxy, and a silicon oxide layer was thermally evaporated onto the Si layer. 
Removal of the sacrificial Ge layer with a hydrogen peroxide etch caused downward bending of 
the strained Si layer, resulting in a rolled-up Si/SiOx microtube (~2 µm diameter) geometry that 
was annealed into an optically active device. Another fabrication method focuses on the ability 
to create capillaries with sub-µm walls.
101, 105
 After first drawing commercial capillaries in a 
flame to a diameter of ~100 µm, further narrowing and wall thinning was performed with a fiber 
taper rig while pumping an inert gas to pressurize the capillary.  Though Zamora et al. report 
walls as narrow as 0.6 µm with improved RI sensitivity, Q factors were observed to degrade at 
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sub-µm wall thickness.
101
 A very analytically promising variation of the optofluidic resonator 
involves the fabrication of a micro gas chromatography (GC) detector in a capillary-based 
optical ring resonator (CBORR) format.
106-108
 Similar to the LCORR device, the CBORR device 
uses a long capillary stretched from a preform under heat to a length of ~10 cm with a wall 
thickness of 4 µm obtained by a HF etch step. To function as a GC detector, the capillary was 
coated with a 200-nm polar stationary phase (Carbowax) and joined to a silica guard column that 
interfaces with a commercial GC injection system.
106
 Real-time, on-column gas detection was 
achieved by placing a tapered optical fiber at a point 6 cm from the CBORR inlet. Gas pulses 
interact with the stationary phase adjacent to the optical fiber, and multiple tapered fibers at 
different points on the CBORR allowed for multi-point on-column gas detection to assess 
separation purity at both the start and end of the column.
108
 
 Other microcavity resonator geometries. In addition to the multitude of classes and 
subclasses of high-Q sensors already mentioned, other interesting resonator geometries have 
been reported in the last few years. These include the hurricane geometry,
109
 microbubble 
resonators,
110
 and a variety of slot waveguide designs.
78, 98, 111
 The hurricane geometry (Figure 
1.2F) pioneered by Koch et al. uses direct core coupling, which simplifies the device fabrication 
process by completely eliminating the need for evanescent coupling for WGM excitation.
109
 The 
hurricane device consists of a 20-µm disk structure directly attached to 1-µm-wide input and 
output bus waveguides, and the device is fabricated in silicon nitride on silica using lithography 
and RIE. Connection to a broadband power source is performed through polished single mode 
optical fibers, and lower-cost reflection-mode sensing is also possible.
112
 Another interesting 
microcavity geometry pioneered by Sumetsky et al. involves blowing silica microbubbles from a 
heated capillary.
110
 By rotating a capillary in a CO2 laser beam, ~370-µm microbubbles with a 
wall thickness of ~2 µm are formed by radiative heating. The size and wall thickness can be 
optimized by altering capillary thickness and laser power, achieving a Q factor of ~10
6
. The 
microbubble defines a path for solution flow through the device (as in a microcapillary 
resonator), preventing disruption of alignment between bubble and optical fiber. 
 Slot waveguide sensors (Figure 1.2G) have also garnered substantial interest due to their 
ability to create a nanoscale area of high WGM localization, yielding an increased field overlap 
with the sample volume than conventional rectangular waveguides.
113
  By careful fabrication of 
two high-index waveguides separated by a sub-wavelength (~200 nm) low-index (i.e. air) slot, 
18 
 
the dual-core device selectively supports only the lowest order TE and TM modes.
14
 A large 
portion of the TE mode is confined to the slot where it overlaps with the sensing region or 
sample. Slot devices have been fabricated in a variety of geometries and materials, including 
Si3N4–SiO2 slot waveguide ring resonators,
77
 SOI double-coupled slot racetrack microrings,
111
 
multiplexed etched silicon nitride slot microrings on a Si substrate,
14, 44, 98
 and horizontally 
slotted silicon nitride microdisks.
71, 72
 The multiplexed silicon nitride slot microring device 
demonstrated by Carlborg et al. provides the best example of integrated slot waveguides to 
date.
98
 By using standard silicon fabrication on a thermally oxidized Si substrate with 300 nm 
silicon nitride deposited by CVD, silicon nitride optical components were patterned by electron 
beam lithography and dry etching. A silica cladding layer was then added by CVD, and optical 
access points opened by HF etching. The device also used a grating coupler for optical insertion 
into the device, and a multimode interference splitter provided access to an array of 8 rings. 
Double-slot microring devices have also been studied, and optimization of fabrication 
considerations suggests that double-slot rings actually have higher fabrication tolerances than 
single-slot rings.
114
 
 Photonic crystals and surface plasmon cavities. Though not generally considered high-
Q sensors in the strictest sense of the definition, photonic crystal structures can similarly support 
multi-pass label-free sensing and optical confinement that is analogous to their higher-Q WGM 
counterparts. Photonic crystal sensors generally have Q factors between 10
1
-10
3
,
46, 115, 116
 
although notable examples of high-Q photonic crystal geometries have been demonstrated 
recently with Q factors of 10
4
-10
7
.
117-119
 Due to these recent improvements in Q factor and also 
the highly complementary advances in surface chemistry and assay methodology that are 
relevant to microcavity sensors, photonic crystal sensors and photonic-plasmonic hybrid devices 
are briefly introduced here. 
 Photonic crystals are composed of two materials with different refractive indices that are 
periodically modulated in one, two, or three dimensions.
4, 120
 A variety of geometries, including 
1-D,
6, 46, 115, 121
 2-D,
122-125
 and 3-D
119, 126
 structures have been demonstrated in material systems 
such as TiO2/SiO2,
127, 128
 SOI,
118, 129
 GaAs,
130
 and hybrid plasmonic/photonic components.
131
 
Though many manifestations of photonic crystal architectures have been demonstrated, only the 
1-D geometries are discussed as they have found the most widespread use as optical sensors.  
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Fabrication and signal transduction for 1-D SOI photonic crystals are very similar to 
some of the microcavity devices already discussed, but do not involve WGM propagation. By a 
combination of lithography and etching techniques, 1-D Si photonic crystal structures containing 
a central defect cavity and 16 ~200-nm resonant holes are patterned adjacent to an input 
waveguide (Figure 1.2H).
46
 The central cavity creates a defect in the photonic bandgap that 
determines a specific optical resonance, and a large portion of the resonant optical mode resides 
in the photonic crystal holes (1/𝑒 distance = 80 nm from hole wall).46 Changes in the RI at the 
surface adjacent to the holes lead to a shift in the resonant wavelength, similar to the 
aforementioned high-Q geometries. Other important photonic crystal fabrication techniques 
utilize a polymer substrate fabricated by replica molding under a 1-D periodic grating structure 
composed of TiO2/SiO2 (Figure 1.2I).
127, 128
 Broadband illumination excites an optical mode that 
is guided in the high-index TiO2 layer and extends into the sensing media above the device 
surface. The resonance condition is observed as a dip in the transmission spectrum for both TE- 
and TM-polarized light.
128
 The periodic structure can also be thought of as a reflective optical 
filter where only specific combinations of incident wavelength and incident angle of the exciting 
light source are reflected.
132
 Though fabrication techniques, dimensionality, and geometries vary 
widely, the myriad of photonic crystal and microcavity devices are connected by their ability to 
support highly efficient light-matter interactions at precise resonant wavelengths. 
 
 
1.4 Surface chemistry, device functionalization, and capture agents 
 After careful fabrication of an optical sensor that supports high-quality modes, surface 
chemical functionalization must be utilized to confer specificity for a particular analyte. Though 
many devices with high Q factors have been demonstrated, only a handful of devices have been 
applied to real-world detection challenges. Regardless of the narrowness of the resonance, high-
Q devices will only meet their full sensing potential with highly optimized surface chemistry and 
functionalization techniques that support subsequent quantitative analyses. 
Selection of capture agents. It is important to highlight at the outset that, for many 
bioanalytical applications, the ultimate sensitivity and specificity of the device is fundamentally 
limited by the properties of the biomolecular capture agents, irrespective of the device 
sensitivity. For this reason, it is desirable to obtain capture agents with high affinity, selectivity, 
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and stability. The most commonly used capture agents for biomolecular analysis include 
antibodies, antibody fragments, complementary DNA (cDNA), and aptamers. While antibody 
production relies on immune challenge and hybridoma formation, nucleic acid capture agents 
can be obtained from solid-phase DNA synthesis or multiple rounds of selective enrichment 
(SELEX) to identify or evolve the most effective capture agent. Beyond the capture agent itself, 
careful attention must be paid to the manner by which surface attachment is achieved, as 
consideration of such factors as molecular orientation, specific attachment site, and capture agent 
stability over time may greatly influence the sensor performance. If a sensor array is to be 
multiplexed, a quality that is often very desirable when multiparameter analysis provides 
increased information from a single sample, the potential for capture agent cross reactivity is an 
additional concern. Spatial control over functionalization must also be maintained. The following 
discussion of chemical methodologies for imparting unique surface chemistry describes 
important recent advances in device functionalization for a variety of targets. 
Physisorption and streptavidin-based attachment. The most straightforward method 
for capture agent functionalization involves simple physisorption of a biomolecule that 
recognizes a particular analyte onto the sensor surface. This non-covalent method for capture 
agent immobilization provides a simple route to proof-of-concept biosensing results, but 
physisorption has limitations for complex assays that require reproducible surface blocking and 
efficient surface regeneration. Several of the pioneering WGM biosensing demonstrations with 
microspheres and microtoroids were based on simple adsorption of biotin,
30, 42
 Protein G,
30, 42
 or 
biotinylated bovine serum albumin.
39
 In these formats, the initial biomolecular physisorption 
provided a handle (biotin, Protein G) to recognize binding partners such as streptavidin or IgG 
molecules. Tetravalent streptavidin can also be adsorbed or bound to biotinylated surfaces for 
subsequent immobilization of biotinylated capture probes
133
 or biotinylated Protein A.
115
 Though 
important for demonstrating the sensing capabilities of high-Q sensors, more advanced assays 
have implemented robust, specific, and reproducible surface chemical treatments. 
Covalent capture agent functionalization chemistry. Covalent attachment of capture 
agents is widely thought to provide the best stability and durability in the face of changes in ionic 
strength, pH, temperature, and flow rate that accompany many assays. Due to the abundance of 
silicon and silica materials in the field of high-Q sensors, the vast majority of covalent 
functionalization techniques centers on the use of silane chemistry. Initial work with silane 
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chemistry involved the deposition of (3-Aminopropyl)triethoxysilane (APTES) or (3-
Aminopropyl)trimethoxysilane (APTMS) to provide amine functionality.
40, 43, 46, 72, 80, 87, 100, 134, 135
 
3-(Glycidyloxypropyl)trimethoxysilane (GOPTS) has also been used to a lesser extent to form an 
amine or sulfhydryl-reactive epoxide surface.
76, 111, 127, 128
 Silane deposition can be effectively 
carried out in solvents such as ethanol, dimethylformamide, isopropanol, toluene, or acetone 
using flow-based, vapor phase, or spotting methods. Amine-functionalized sensors can then be 
functionalized with amine-reactive N-hydroxysuccinimide (NHS)-biotin
3, 43, 72, 80, 134, 136
 or 
succinimidyl-6-hydrazino-nicotinamide (S-HyNic).
87, 135
 Indeed, by incorporating amine 
functionality, a variety of bioconjugation strategies for capture agent attachment are possible. As 
an added benefit, high-Q sensors permit real-time monitoring of silane deposition to verify 
reproducible surface coverage. Since silanization is often a disordered process, it is likely that 
multiple layers of silane are deposited onto the sensor surface
40
 unless reactions are performed 
with extreme care, although multilayer silane deposition does not necessarily preclude successful 
device operation. Nonetheless, techniques such as vapor-phase silane deposition
47, 127, 128
 and 
sonic agitation
137
 have been used in attempts to achieve a more ordered surface with reproducible 
binding capacity, and special care has been taken to ensure maintenance of the Q factor 
(Equation 5) during silanization and subsequent steps.
136
 
Once silanization provides a foundation for bioconjugation reactivity, surfaces can be 
covalently modified with capture agents such as antibodies, cDNA, or aptamers with 
crosslinking chemistry based on glutaraldehyde,
98, 138, 139
 hydrazone bond-forming HyNic/4-
formyl benzamide (4FB) cross-linking,
43, 87, 135, 140
 or 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC)/NHS.
6, 100, 115
 In each case, amines on the device 
surface are coupled with amine or carboxyl groups on the capture agent. Antibodies contain 
amine-terminated amino acids (such as lysine residues and the N-terminal amino acid) as well as 
carboxy groups (such as aspartate and glutamate residues, as well as the C-terminal amino acid), 
and cDNA probes can be directly synthesized with a 5’-amine termination. Glutaraldehyde acts 
as a homobifunctional linker to join capture agent amine groups to aminated silane or silicon 
nitride surfaces, although reactions between glutaraldehyde oligomers can also achieve capture 
agent attachment.
141
 However, the resulting Schiff base formation by the reaction of aldehydes 
and amines is reversible and thus should be further reduced with a reagent such as sodium 
cyanoborohydride to the secondary amine for increased attachment stability. Similar 
22 
 
homobifunctional amine cross-linking has also been demonstrated with dimethyl adipimidate 
(DMA),
142
 dimethyl pimelimidate (DMP),
143
 and disuccinimidyl carbonate (DSC).
97
 In the case 
of HyNic/4FB cross linking, amine groups on the surface and capture agent are functionalized 
with hydrazine and aldehyde moieties, respectively, which then react to form a stable hydrazone 
bond to link the capture agent to the surface. Notably, this linkage, which involves an alpha-
effect nitrogen in the hydrazine (also in aminoxy groups), directly forms an irreversible bond 
between the capture agent and sensor surface that does require further reduction. The hydrazone 
bond-forming reaction proceeds more rapidly at lower pHs, although aniline has been shown to 
catalyze this hydrazone bond formation effectively even at neutral pH.
140
 Additionally, a 
commercially available HyNic-silane reagent can be used to deposit a hydrazine moiety on the 
sensor surface in one silanization step.
144, 145
 In the case of EDC/NHS chemistry, antibody 
carboxyl groups are converted to amine reactive NHS esters. Sulfo-NHS can be used to improve 
solubility in aqueous solutions,
100
 and NHS ester formation stabilizes the O-acylisourea 
intermediate that is susceptible to hydrolysis. Succinic anhydride can also be used to convert 
amine-terminated silanes to carboxyl groups for subsequent EDC/NHS coupling to protein 
amines.
115
 These conjugation reactions, among other possibilities, provide a range of 
functionalization approaches that are highly amenable to high-Q sensors. 
Other methods for capture agent functionalization of sensor surfaces. Recently, 
several useful and innovative conjugation strategies have been applied to high-Q sensors, and 
these involve the use of dendrimers,
6
 dextran hydrogels,
133
 Si-binding proteins,
146
 plasma-based 
polymer functionalization,
147
 and Ni-NTA chemistry.
148
 Dendrimers are known to improve DNA 
immobilization efficiency while maintaining high stability,
149
 and Goddard et al. used carboxy-
terminated generation 4.5 dendrimers linked to APTMS via EDC/NHS chemistry on a 1-D 
photonic crystal surface as tethers for DNA probes.
6
 They show that negatively charged 
dendrimers can electrostatically repel non-specific DNA binding, prevent deleterious surface 
effects that restrict analyte binding, and lessen steric hindrance. Another method to improve 
capture agent immobilization efficiency makes use of a biotinylated dextran hydrogel, and 
Vollmer et al. utilized this approach to immobilize streptavidin-conjugated DNA capture probes 
at a density of 4.6 × 10
13
 probes/cm
2
.
133
 In order to attach proteins directly to silicon photonic 
sensors, another innovative approach takes advantage of a silica-binding protein called Si-tag 
that facilitates direct attachment of recombinantly expressed protein capture agents to silica 
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surfaces, thereby eliminating the requirement for chemical modification (such as silanization).
150
 
Furthermore, the Si-tag (a fusion protein of silica-binding bacterial ribosomal protein L2 with a 
capture agent or ProteinA) should provide control over capture agent orientation and thus has the 
potential to prevent the loss of binding activity this is unavoidable when using non-oriented 
immobilization methods.
146
 Outside of silicon-based photonic structures, polymer-based high-Q 
devices can be functionalized by oxygen plasma treatment. O2 plasma treatment of PMMA, SU-
8, polycarbonate, and polystyrene was demonstrated as an effective method to introduce 
carbonyl, carboxyl, or hydroxyl functionality to polymer devices.
147
 Finally, device 
functionalization using Ni
2+
-nitrolotriacetic acid (Ni-NTA) surface chemistry for immobilization 
of histidine-tagged proteins provides a useful handle for studying recombinant proteins. Heeres 
et al. synthesized a biotin-tris-NTA molecule to functionalize a streptavidin-coated photonic 
crystal device, and Ni
2+
-charged surfaces were used to study protein-protein interactions.
148
 Each 
of these alternative functionalization strategies successfully demonstrates the merits of 
optimizing surface chemistry for defined sensing applications in aqueous environments. 
High-Q sensor functionalization for gas sensing applications. Beyond aqueous-phase 
sensing, innovative surface chemistry has also been developed for gas sensing applications. The 
discussion of optofluidic sensors included a potentially very powerful application of this 
technology for gas chromatography based on introducing a stationary phase polymer coating to 
the surface of a microcapillary resonator.
106-108
 Related optofluidic sensors have been coated with 
poly(ethylene glycol) (PEG)-1000 and used for vapor detection of the explosive DNT.
151
 A 
microcapillary was soaked in a methanolic solution of PEG-1000 for 1 h, followed by solvent 
evaporation under vacuum. Various PEG-1000 concentrations were tested to achieve an optimal 
and uniform PEG-1000 thickness of 60 nm.
151
 In addition to the gas chromatography surface 
chemistry, other methods also permit detection of important explosives in vapor, such as a 
silicon nitride microring that was functionalized with a triphenylene-ketal receptor/cladding layer 
for reversible and selective TNT vapor detection.
152
 In this instance, the 150-nm receptor layer 
was applied by an electrospray method utilizing tetrahydrofuran as solvent and a metal cannula 
with an applied voltage of 5 kV.
153
  
Beyond the detection of vapor-phase explosives, high-Q gas sensors have also been 
functionalized with coating materials such as ZnO nanoparticles,
154
 a Pt-doped tungsten oxide 
catalyst,
155
 and a zeolite.
60
 These examples utilize inorganic adlayers on the photonic device in 
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order to increase the surface area probed by the sensor, which permits elucidation of measurable 
wavelength shifts even at low analyte concentrations. A uniform and porous 200-nm layer of 
ZnO nanoparticles, with deposition controlled by photoresist-localized drop casting, provided a 
high-surface area coating for ethanol vapor sensing on a SOI microring platform.
154
 ZnO was 
also chosen for ethanol sensing due to its high affinity for volatile compounds, low cost, and 
transparency in the near infrared, which is critical for the maintenance of high microring Q 
factors (> 10
4
). Catalytic materials have also been employed as coatings for gas sensing. A Pt-
doped WO3 catalyst was deposited by dip coating fully silica-coated SOI microring into a sol-gel 
solution, yielding a few-µm-thick catalytic layer.
155
 The Pt-doped WO3 material provided a 
platform for catalytic H2 combustion that leads to an 80-pm/K resonance wavelength shift by the 
thermo-optic effect. Additionally, the crystalline aluminosilicate zeolite has, due to its 
(sub)nanometer-scale pore size, also been proposed as a sensitivity-enhancing coating for 
microsphere resonators. A zeolite layer could enhance the sensitivity by increasing sensor 
surface area and effectively trapping adsorbed vapor-phase chemical analytes.
60
 Despite these 
few important advances, the use of high-Q sensors in vapor detection challenges remains largely 
underdeveloped and thus looms as a potentially fruitful application area. Aqueous-phase sensors 
have dominated the high-Q sensor landscape due to the heavy focus on biological and 
biomedical applications, and more advances in surface chemistry for vapor sensing will likely be 
required to enable important homeland security and environmental monitoring applications. 
Directed immobilization of capture agents by microfluidic and high-precision 
spotting methods. All of the methods described thus far have focused on bulk, uniform 
functionalization of a high-Q sensor substrate without spatial control. Bulk functionalization is 
suitable for many applications, but directed capture agent immobilization methods are needed in 
order to fully leverage the promising multiplexing capabilities allowed by highly scalable high-Q 
sensor geometries. Planar and near-planar devices with small footprints are most amenable to 
microfluidic and microspotting approaches for spatially directed surface derivitization. 
Microfluidics based on PDMS and fluidic cartridge/gasket designs have been 
demonstrated, especially for multiplexed SOI microring
 
and 1-D photonic crystal devices.
45, 46, 87, 
93, 98, 156
 For multi-element micron-scale sensor arrays, microfluidics are well-suited to delivering 
specific capture agents to individual sensors or groups of sensors. After a bulk silanization or 
other chemical functionalization step, sensors can be selectively functionalized with various 
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capture agents. For example, Washburn et al. used 6-channel PDMS fluidics to functionalize 6 
groups each containing 4 microrings with unique capture antibodies (Figure 1.3A).
45
 Similarly, a 
5-channel PDMS device was used by Mandal et al. for localized immobilization of capture 
antibodies and a control protein on an array of 1-D photonic crystals.
46
 PDMS fluidics, though 
widely used, suffer from the need to align each custom device and then achieve leak-free 
adhesion to the sensor device surface. Conversely, packaged fluidic cartridges can allow routine, 
reproducible, and reusable device/fluidic alignment. A multi-channel fluidic design based on a 
0.007‖-thick Mylar gasket sandwiched between a sensor chip and a fluidic cartridge with input 
and output ports has allowed for deposition of up to 4 capture agents, including such classes as 
antibodies, aptamers, or cDNA, on independently addressable groups of rings.
156, 157
 
Other spatially directed capture agent immobilization techniques take advantage of hand-
spotting,
47, 76, 135, 137
 piezoelectric (inkjet),
158
 or lithographic
159
 printing techniques. Hand-spotting 
techniques can have mm-scale resolution with a simple plastic micropipette tip
137
 or 100-µm 
resolution with the use of a microcapillary mounted on a translational stage and guided by a 
stereoscope.
159
 Alternatively, non-contact inkjet printing dispenses pL-sized droplets from a 
glass capillary with fine positional control for individual functionalization of multi-sensor arrays 
on silicon photonic devices (Figure 1.3B).
47, 95, 97, 134, 158, 160
 A potential complication of spotting, 
particularly as it applies to protein-based capture agent deposition, is the denaturation and 
instability of the capture agent when the spots dry. Thus, many successful applications of 
spotting-based functionalization have used nucleic acid probes,
135, 137
 stable model proteins (i.e. 
bovine serum albumin),
47, 158
 or taken special care to control humidity to prevent proteins from 
drying out.
76
 To take advantage of the high stability of DNA probes in the creation of antibody 
arrays, Washburn et al. employed a DNA-encoding scheme to localize antibodies to specific 
locations on the basis of nucleic acid hybridization and self-assembly.
161
 After cantilever-based 
lithographic spotting of short 4FB-modified single-stranded DNA (ssDNA) sequences on a bulk 
HyNic-silane surface containing 32 microrings, the ssDNA array can be used as a stable platform 
to self-assemble antibodies encoded with orthogonal ssDNA complements (Figure 1.3C).
159
 In 
this way, antibodies were continuously exposed to an aqueous microfluidic environment, rather 
than dehydrated during spotting, and directed to specific microrings based on the 
complementarity of their cognate ssDNA.  
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Non-fouling surface modifications. A majority of contemporary, real-world sensing 
applications necessitate analysis within complex matrices such as serum, cell culture, or 
environmental samples. This complication is particularly profound for many RI-based detection 
strategies described herein as the universal detection characteristics of label-free sensors make 
the analytical challenge akin to finding a ―needle in a haystack,‖ but where there is no contrast in 
terms of response between the needle and hay. Sensor specificity is largely achieved by selection 
of target-specific capture agents, but there is also interest in deploying anti-surface fouling 
chemical coatings that help discriminate specific signals from a complex background. 
Poly(ethylene glycol) (PEG)
162
 and zwitterionic polymer brushes
163
 are two surface coatings 
known to inhibit non-specific adsorption, especially for biological samples. De Vos et al. 
demonstrated the use of ~2-nm-thick carboxy- and amine-terminated PEG layers on silanized 
SOI microrings to resist non-specific binding of BSA.
97, 164
 Additionally, the zwitterionic 
polymer brush poly(sulfobetaine methacrylate) (pSBMA) was grown directly on SOI microrings 
by Limpoco and Bailey using atom transfer radical polymerization (ATRP). The non-fouling 
pSBMA surfaces were generated with controllable thickness and reduced non-specific binding in 
undiluted fetal bovine serum to 260 pg/mm
2 
(compared to 1400 pg/mm
2
 for PEGylated 
surfaces).
165
 Though PEG and pSBMA greatly reduce non-specific binding, the high sensitivity 
of microcavity sensors to surface binding (LOD~1 pg/mm
2
)
3, 24
 means that for even the highest 
performance non-fouling surfaces, readily detectable amounts of non-specific protein binding 
will always be observed during analysis of highly complex samples (e.g. serum). For this reason, 
effective surface blocking processes and proper controls are essential components of assay 
development. 
Real-time monitoring of surface chemistry. It should be noted that label-free sensors, 
which often permit real-time sensing, can provide vital information for studying surface 
reactions such as silanization,
43, 81, 135
 capture agent loading,
45, 138, 140, 156, 159, 166
 and polymer 
growth processes.
3, 46, 165
 Apart from the obvious utility for label-free sensing, the ability to 
observe surface chemistry in real time has been utilized for optimizing covalent antibody ligation 
catalysis,
140
 ensuring reproducible capture agent density,
159
 and comparing polymerization 
kinetics for various conditions.
165
 Beyond screening reaction conditions and monitoring surface 
chemistry, real-time binding analysis also provides an effective means for sensor characterization 
by mapping the evanescent field decay.
3, 46
 By alternating positively and negatively charged 
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polymer electrolyte layers of known and consistent thickness, the decrease in signal intensity 
with increasing distance from the surface (Equation 3) is due solely to the evanescent field decay 
properties of the optical sensor (Figure 1.4A). Using this strategy, the 1/𝑒 distances of the 
evanescent field, which is a vital metric for optimization of capture agent presentation, were 
determined for both SOI microring resonators (63 nm)
3
 and 1-D photonic crystals (80 nm).
46
 
Notably, the high RI contrast between the silicon-based optical cavities and the surrounding 
environment gives an exceptionally rapid decay of the evanescent field that signifies enhanced 
surface (as opposed to bulk solution) sensitivity. Based on the determined evanescent field decay 
constant, microrings have also been used to probe more complex protein multilayer growth 
patterns (Figure 1.4B).
3
 
Surface regeneration. A variety of methods for chemical and biological 
functionalization of sensor devices have been described, but once functionalized, for some 
applications it is desirable to reuse the same functionalized surfaces in consecutive assays. 
Furthermore, once a device is fabricated, it may be desirable to use the device to study a different 
target in a similar assay, or for an altogether different application. Thus, maximizing the utility of 
a high-Q sensor requires the ability to both 1) restore the capture agents for inter-assay 
regeneration, with conditions mild enough to not destroy the capture agent and also 2) totally 
regenerate the sensor by removing all chemical and biological functionalization. 
For inter-assay regeneration that restores the capture agents without destroying them, 
various techniques have been developed for both protein and DNA capture agents. For 
regeneration of protein capture agents such as antibodies, a short rinse (1-2 min) using a pH 2 
glycine buffer can be used to disrupt some protein-protein interactions.
45, 87, 124, 145
 To regenerate 
DNA capture probe surfaces by breaking DNA-DNA interactions, the chaotropic reagent 8M 
urea can be introduced to disrupt hydrogen bonding between complementary bases of the target-
capture probe duplex.
144
 For regenerating RNA or miRNA sensors that utilize DNA capture 
probes, an enzyme called RNase H was used to selectively cleave only DNA-RNA 
heteroduplexes, with full regeneration in ~30 min.
135
 Aptamer capture agents specific for protein 
targets can be regenerated with proteinase K that digests the bound protein.
156
 Phage capture 
agents can be regenerated with either an ionic solution (KSCN/MgCl2/urea/guanidine-HCl) or a 
chelating solution (EDTA).
138
 Studies have also been carried out using kinetic titrations for 
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antibody-antigen binding, in which a series of small, non-saturating concentrations are flowed 
without inter-assay regeneration.
76, 139, 159
 
For total device regeneration, harsher conditions are used to remove all chemical and/or 
biochemical species from the sensor surface. These include the use of hot piranha (3:1 
H2SO4:30% H2O2) solutions,
87, 140, 145
  O2 plasma treatment (120 W, 200 mTorr)
65
 to remove all 
organic molecules, or dilute (1-2%) HF chemical etching,
138, 142, 143
 which strips away a thin layer 
of the oxide surface to which chemicals and/or biomolecules were attached. In our lab, SOI 
microring resonator chips can be regenerated 10+ times before sensor performance degrades 
significantly. HF etching of optofluidic microcapillaries allowed 4-5 full regenerations before the 
capillary wall was compromised,
138
 and oxygen plasma-treated  microtoroids maintain high Q 
factors through at least a few regeneration cycles.
65
 Though many future application areas for 
high-Q devices will likely require single-use/disposable sensors that leverage the potential cost-
effective fabrication of many device architectures, the ability to regenerate sensor devices 
remains valuable in both assay development and surface chemistry optimization. 
 
  
1.5 Recent developments in assay design 
 Once effective surface chemistry has been developed for detection of a particular analyte, 
assays must be designed and optimized for requisite sensitivity, specificity, and quantitative 
utility. Though it is critically important to have high-quality sensors and robust optical scanning 
instrumentation, useful applications of optical sensors require that tremendous attention is given 
to surface chemistry and assay design considerations; these considerations have only recently 
begun to be addressed in the high-Q sensing community. Non-trivial systems and assay 
integration remain significant obstacles to widespread applications of many of the device 
architectures described in this review. In order to reach its full potential, high-Q optical sensor 
technology must be further developed by focusing on assay design considerations and related 
issues such as matrix effects, temperature and sample background controls, strategies for 
multiplexed and high-throughput analysis, fluidics integration, and signal amplification for 
difficult targets. The important recent developments in assay design will be discussed here, and 
the interesting applications enabled by these assays will be discussed in the next section. 
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 Measurement techniques for high-Q sensing: intensity vs. resonant wavelength shift. 
The basis for signal transduction has been described in detail in the section about WGM sensing 
and different device configurations will be discussed in the Recent Applications section. In a 
typical assay, the interaction of an analyte with a functionalized sensor surface results in a 
binding-induced change in the RI sampled by the optical mode and a corresponding shift in the 
resonance wavelength (Equation 1). Despite their high Q factors, resonance spectra of 
microcavities still have finite line widths, and an early example of biosensing with SOI 
microrings  used the real-time change in transmission intensity at a defined wavelength to 
monitor binding.
40
 This early example of measuring binding responses required the ability to 
track the intensity at only a single wavelength; however, the vast majority of high-Q sensor work 
utilizes more complete spectral information.
39, 43, 87, 103
 A Lorentzian fit to the transmission 
spectrum and subsequent mathematical determination of the peak resonance wavelength allows 
for a more accurate resonance wavelength determination that is not as susceptible to laser 
intensity fluctuations. Even stable tunable lasers have wavelength uncertainties that are often >20 
pm due to variations in laser sweep velocity, but multiple resonances of a fine FSR etalon can be 
monitored to improve wavelength determination accuracy.
43
 In most applications, the relative 
wavelength shift (as opposed to the absolute resonance wavelength itself) is the metric used for 
quantitative analysis (Equation 2), and high-Q optical sensor data plots commonly display the 
relative shift vs. time. 
 Temperature control. The ultra-sensitivity of high-Q sensors to thermally-induced 
changes in RI (commonly 10
-5
-10
-4
 RIU/K) means that any successful assay must account for 
temperature fluctuations. Differences in thermo-optic coefficients as well as thermal expansion 
of the device itself are known to lead to a strong dependence of resonance wavelength on 
temperature, which often limits the sensitivity of high-Q sensors. Indeed, ring resonators have 
been used as miniature temperature sensors, as described in the subsequent applications section. 
Reliable temperature control for sophisticated assays must involve more attention than simply 
allowing samples to equilibrate at room temperature. Even under well-controlled ambient 
conditions, temperature variations lead to signal aberrations upon sample introduction.
39
 Some 
have addressed the thermal control issue through the use of active temperature control in the 
form of a Peltier heat pump device and thermistor.
77, 98
 Though active temperature control may 
be built directly into the instrument, as in surface plasmon resonance (SPR) instruments where 
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temperature is controlled to within ±0.01-0.1 K, these systems add complexity, cost, and size to 
the instrument,
160
 and are also insufficient to fully compensate for small, but very detectable 
temperature fluctuations.  Athermal planar waveguide-based SiN and SOI devices was designed 
such that core and cladding have thermo-optic coefficients with opposing signs, and the 
structures are designed to balance the fraction of light propagating in each.
167, 168
 However, a 
more straightforward temperature control method uses on-chip temperature references in thermal 
contact with functionalized sensors. Gylfason et al. demonstrated the use of on-chip temperature 
compensation through the use of a separate fluidic channel dedicated to blank buffer samples that 
act as temperature references.
14, 44
 This temperature compensation method, while reducing the 
temperature sensitivity of their slot waveguide ring sensors from 16 pm/K to 0.3 pm/K, is limited 
by the ability to maintain equal temperature and bulk RI control between sample and reference 
solution. This separate channel technique is similar to the reference arm layout for temperature 
control that has been used for Mach-Zehnder interferometry.
134
  
Ideally, however, temperature controls should simultaneously be exposed to the exact 
solution conditions as the analyte sensor elements. By providing in situ thermal controls that are 
adjacent to active sensor elements but coated in cladding and unfunctionalized, thermal control 
elements experience the same ambient or fluidic conditions and are directly adjacent to 
functionalized sensors, with only a rapidly equilibrating thermal gradient lag as the thin cladding 
layer transmits temperature from the overhead solution. The most effective on-chip thermal 
referencing has involved coating one or more Si ring resonator sensors (within the same fluidic 
channel as sensor rings) with SU-8,
160
 SiO2,
98, 160
 or a perfluoropolymer
43, 87
 cladding layer. The 
cladding layer ensures that reference rings respond only to temperature variations, and not to 
other matrix effect. Implicit in the use of chip-integrated, in situ temperature controls is the need 
to fabricate multiple identical resonant structures. It is thus no surprise that the best temperature 
controls have been integrated into planar ring resonator devices that allow for the most 
straightforward, on-chip sensor multiplexing. 
Advances in multiplexed high-Q sensors. The ability to incorporate multiple sensors 
onto a single device not only allows for in situ thermal controls, but multiplexed sensors that 
simultaneously assay many target analytes are highly desirable for a variety of applications. 
Though it is possible to use two microspheres together in a single sensor
133, 169
 or to fabricate 
arrays of microtoroids,
66
 non-planar high-Q devices are intrinsically more difficult to 
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simultaneously interrogate in a scalable manner due to complications associated with demanding 
optical fiber alignment tolerances and the more complex multimodal resonance spectra. 
Microring resonators have to date been by far the most amenable to sensor multiplexing, with 
published examples of planar arrays containing 5,
76, 170
 8,
98
 12,
97
 and 32 rings
43, 87, 145
 that can be 
monitored simultaneously using separate access waveguides for each ring. Another clever design 
for using arrays of planar microrings for multiplexed sensing, called wavelength division 
multiplexing (WDM), utilized multiple microrings of different size but attached to a single 
waveguide.
47
 However, as with using different sized microspheres and a single transmission 
spectrum with multiple sets of resonance dips, the multiplexing capabilities of WDM devices are 
potentially limited by the FSR overlap of multiple sensors. For this reason, as well as their 
relative ease of design and fabrication, configurations with one sensor per waveguide are most 
common. These small-footprint planar ring resonator devices utilize scalable semiconductor 
fabrication techniques on SOI substrates, and these devices have the added benefit of relatively 
easy fluidics integration. 
Fluidic strategies for integrated assays. The integration of optical components, high-Q 
sensors, and microfluidics into a low-cost and automated device represents an important goal for 
enabling diverse applications such as medical diagnostics, environmental monitoring, and 
homeland security.
18, 19
 Robust fluidics have the potential to reduce sample consumption,
18, 137
 
automate assays,
3, 159
 and increase directed mass transport to address the prohibitive timescales 
required to detect sub-pM analyte concentrations under passive diffusion conditions.
171, 172
 
Indeed, recent studies by Choi et al. carried out with photonic crystal substrates to compare the 
same assay in microplate, microspot, and microfluidic formats demonstrated the superiority of 
microfluidics for faster assays with lower detection limits.
173
 Optofluidic resonators such as 
LCORR effectively incorporate a microcapillary into a resonant cavity, demonstrating the most 
straightforward photonic/fluidic integration.
99, 100
 Additionally, rather than unidirectional mass 
transport from a microfluidic channel down to a resonator sensor, optofluidic resonators take 
advantage of radial diffusion of the analyte in solution to the capillary wall. Other important 
fluidic advances involve the use of PDMS
14, 45, 46, 93, 97, 98, 109
 or gasket-defined fluidic channels
3, 
43, 87, 156
 to deliver solutions directly to a specific sensor or a group of sensors for differential 
sensor functionalization or more complex assay techniques (Figure 1.3A). In all fluidic 
strategies, it is important to ensure an effective seal between the fluidic structure and high-Q 
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sensor substrate below. Fluidic channels not only allow spatial control over surface chemistry 
and faster reaction kinetics, but also offer the potential to greatly improve assay reproducibility
3, 
159
 and to recirculate an analyte solution to improve capture efficiency in sample-limited 
applications.
135, 137
 Digital fluidic techniques, which use an array of electrodes to manipulate 
discrete droplets,
174
 also have the potential to interface with optical sensors.
175
 It should be noted 
that not all geometries are equally compatible with fluidic integration; it is known that fiber-
coupled geometries such as spheres and toroids suffer from hydrodynamic fluctuations that cause 
unstable fiber taper-to-device coupling.
176
 However, planar devices, where the interrogation 
waveguides are rigidly part of the physical device architecture, are more amenable to fluidic 
integration. Virtually all applications of high-Q sensors for relevant assays have incorporated a 
microfluidic component for controlling surface chemistry and/or delivering samples. 
Strategies for making relevant measurements in complex matrices. Useful 
applications of high-Q sensors, such as bioanalysis, require the ability to conduct assays in 
complex matrices within a relevant analyte concentration regime. These important assays not 
only often require impressive sensitivity, but the complex sample matrix necessitates the use of 
carefully designed controls and strategies for improving specificity. High-Q sensors have only 
recently begun to be combined with carefully constructed quantitative assay strategies for useful 
targets. The difficulties in transitioning from proof-of-principle sensing in buffer to the 
realization of detection from within real-world samples, such as human serum or cell culture 
media, cannot be overstated. Real-world samples often require the ability to differentiate specific 
responses from a very large background response from non-specific binding. The use of well-
blocked sensors reduces non-specific adsorption of biomolecules such as proteins, and sensors 
are routinely blocked following capture agent functionalization with reagents such as BSA,
45, 46, 
76, 87, 138, 140, 145
 a mixture of blocking proteins such as BSA and casein,
3, 137, 157
 PEG,
139
 10% 
FBS,
139
 protein A,
166
 and/or Tween-20.
46
 By coating the entire device surface in a controlled 
blocking step, non-specific adsorption during the assay is avoided. Buffer additives such as 
Tween and BSA are also often used to continuously re-block the surface during the assay itself, 
as non-covalent blocking agents are often displaced from the surface over time. After blocking, 
quantitative assays can be performed (1) on the basis of the pseudo-equilibrium net shift of the 
binding response after a defined time or (2) the initial slope of the response during the first few 
minutes of analyte binding. Traditional analytical chemistry techniques such as calibration plots 
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or standard addition analyses are then used to quantitate unknown sample concentrations. If an 
array of high-Q sensors is available, one or more elements can also be used as a reference for 
non-specific binding.
45, 145
 These control sensors that are not functionalized to be specific for any 
targets but are exposed to the same sample can simultaneously serve as controls for temperature 
fluctuations, bulk RI changes, and non-specific binding that is common in complex samples such 
as serum. 
Sensing in serum or serum-containing cell media, for example, often decreases the limit 
of detection of the assay by roughly an order of magnitude due to difficulties in fully eliminating 
or correcting for non-specific adsorption.  For example, in a direct, label-free assay involving the 
quantitation of the cancer biomarker carcinoembryonic antigen (CEA) based on the initial slope 
of the binding interaction, the limit of detection worsened from 2 ng/mL in buffer to 25 ng/mL in 
undiluted serum due to the high serum background that varied in time.
87
 Initial slope-based 
assays take advantage of real-time binding monitoring capabilities of high-Q sensors by fitting 
the first few minutes of binding data to a linear regression. Though assays based on the initial 
slope of the binding interaction demonstrate excellent time-to-result,
45, 87, 157
 the sensitivity in 
complex samples can be limited by the non-specific background slope. In addition to initial-slope 
analysis, quantitation in biological samples can also be performed based on the net shift of the 
binding response after a defined sample incubation time.
87, 139
 After subtracting the control ring 
response, the net shift represents only the specific analyte binding contribution to the overall 
signal. Additionally, though a departure from strictly label-free sensing, sandwich assays can be 
used to enhance assay specificity in complex samples by adding a secondary recognition element 
(Figure 1.5). After analyte binding during an initial primary binding step requiring incubation 
with a complex sample, a rinse to remove non-specific sample elements is followed by a 
secondary antibody introduced in buffer. Sandwich assays have been demonstrated to be highly 
quantitative for the detection of proteins (Figure 1.5A),
145
 viruses,
166
 and nucleic acids (Figure 
1.5B),
137
 and perhaps even more importantly, the use of a second target-specific binding event 
confers an extra level of selectivity to the assay that is vital for sensing in complex samples. 
In some realizations of high-Q sensors, the ability to monitor each step of the assay in 
real time is a tremendous advantage over detection protocols based on endpoint analysis. Assays 
can be designed to take advantage of the large quantity of real-time binding data for more 
quantitative fitting of time-dependent data, directly observable quality control during the assay, 
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and rapid kinetic analyses. The ability to observe resonance responses evolve in time during an 
assay provides an opportunity to catch and diagnose erroneous behaviors that often go unnoticed 
in endpoint assays. In addition to the initial slope methods already described, real-time binding 
data can be used to study desorption rates for single-nucleotide polymorphism detection,
144
 to 
profile capture agent affinities,
156, 159
 and to compare polymerization kinetics.
165
 These types of 
real-time assays have only begun to be realized, and future pursuits will undoubtedly take 
advantage of these capabilities for applications in areas such as biophysical interaction screening 
and discovering inhibitors of specific interactions, amongst many others. Despite the multitude 
of uses of high-Q devices established to date, there remain a number of intriguing new 
applications of high-Q technologies, particularly in the area of scalable and multiplexable 
biomolecular analysis, that still require improvements in sensitivity, dynamic range, and 
detection limits, even if it is necessary to sacrifice the ―label-free‖ moniker. 
Signal enhancement techniques. The response arising from target binding to high-Q 
sensors can be increased through a variety of methods aimed at improving the signal-to-noise 
ratio. High-Q optical sensor signal enhancement can involve massive tags to increase the RI 
change associated with analyte binding, as well as a variety of techniques associated with 
photonic/plasmonic interactions and enhanced fluorescence. Beyond the use of secondary 
antibodies to increase specificity and augment the primary binding signal,
137, 145, 166
 high-RI 
microbeads or nanoparticles act as large mass tags that can amplify the signal and expand the 
dynamic range of assays. Luchansky et al. recently demonstrated the use of ~100-nm 
streptavidin-conjugated beads to augment the signal arising from a two-step sandwich assay 
(Figure 1.5C).
177
 By combining primary, biotinylated secondary, and bead-based assay steps, the 
dynamic range for protein biomarker detection was shown to expand the dynamic range to at 
least 6 orders of magnitude. Witzens and Hochberg also recently proposed the use of target-
induced nanoparticle aggregation for ring resonator signal enhancement.
178
 Based on derived 
time constants for optical trapping of small gold nanoparticle clusters, they estimate ~10 fM 
detection limits and stress the ability to take advantage of the well-established chemistry of gold 
surfaces. Another example of gold nanoparticle-based high-Q analyte detection involves the use 
of microspheres to quantitate protein adsorption to gold nanoparticles captured on an aluminum 
oxide membrane.
53
 Though promising results have been recently demonstrated, the use of 
nanoparticles and other high-RI labels for signal enhancement has only begun to be explored in 
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the context of high-Q sensors. It is likely that future signal amplification strategies will 
incorporate ideas from well-established enhancement strategies for SPR and fluorescent 
techniques. These potential strategies include rolling circle amplification,
179, 180
 enzymatic 
amplification,
181
 gold nanospheres
182, 183
 and nanorods,
184
 and the immuno-hybridization chain 
reaction.
185
 
Other recent advances in signal enhancement have centered on enhanced fluorescence 
and quantum dot-coupled high-Q sensors. Enhanced fluorescence takes advantage of the long 
photon lifetimes (Equation 6) and highly localized optical intensity of WGM sensors to increase 
the probability of fluorophore excitation.
186
 Photonic crystal enhanced fluorescence generates 
improved signal-to-noise for microarray-based immunoassays,
128, 132
 and photonic crystal 
substrates can be rationally designed such that their TM and TE-polarized resonant wavelengths 
overlap with the fluorophore excitation and emission wavelengths, respectively. This augments 
the fluorescent signal-to-noise ~6x through both enhanced excitation with the localized high-
intensity field as well as enhanced extraction of the emitted fluorescence. A similar principle 
leads to ~100x enhancement of quantum dot fluorescence emission on a 2-D photonic crystal 
slab engineered with leaky eigenmodes that also overlap with quantum dot excitation and 
emission wavelengths.
125
 High-Q microspheres have also been used to excite embedded quantum 
dots.
61
 Beyond enhanced fluorescence and quantum dot coupling, high-Q sensors could also be 
engineered to take advantage of non-traditional optical signals such as band-edge fringe effects 
in photonic crystals.
187
 Further advances in signal enhancement have the potential to open doors 
to more demanding assays, further increasing the broad utility of high-Q optical sensors for a 
variety of interesting applications within chemistry, biology, and physics. 
 
 
1.6 Recent applications of high-Q optical sensors 
 The first several years of high-Q optical sensing applications generally focused on 
rudimentary proof-of-concept biosensing demonstrations that involved biotin/streptavidin 
binding or the detection of BSA physisorption to the sensor surface in buffer.
25, 39-41, 79, 82
 These 
pioneering studies were incredibly important for demonstrating the potential of high-Q optical 
sensing, and excitingly, the last few years have witnessed the rapid expansion of high-Q optical 
demonstrations for increasingly relevant, real-world detection challenges. Recent applications 
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have involved such important endeavors as clinically relevant measurements for in vitro 
diagnostics, fundamental biological studies, drug screens, exquisite light manipulation, and 
detailed kinetic analyses. After an extensive review of novel assays for a host of molecular 
classes, we describe recent applications of high-Q optical sensors for such tasks as affinity 
profiling, high-throughput multiplexing applications, nanoparticle transport and sizing, light 
manipulation and lasers, and novel uses of high-Q sensors for imaging and thermal sensing. 
 Biomolecular and cell-based assays. The majority of high-Q sensing applications have 
involved the creation of biomolecular assays for proteins and nucleic acids. Recent work in the 
realm of nucleic acid analysis has focused on DNA
133, 142, 144
 and microRNA (miRNA)
135, 137
 
detection, as well as methylation analysis,
188
 single-nucleotide polymorphism (SNP) 
discrimination,
133, 142, 144
 and nucleic acid-protein interaction screens.
189
 Vollmer et al. first 
showed the utility of high-Q microspheres for label-free DNA detection, using two microspheres 
of different sizes modified with two different 27-mer single-stranded (ssDNA) capture probes.
133
 
They were able to specifically detect 1 µM complementary ssDNA and discriminate between 
single nucleotide polymorphisms (SNPs). Using the LCORR system, Suter et al. demonstrate 
quantitative 25-mer DNA quantitation from 0.5-500 nM using the equilibrium binding shift after 
15-20 min,
142
 and utilized the same platform to analyze oligonucleotide methylation using both 
methyl-binding protein and anti-5-methylcytidine antibodies as capture agents.
188
 Recent studies 
by Qavi et al. using microring resonator arrays demonstrate the ability to quantify 15-mer DNA 
across 3 orders of magnitude (nM-µM) in a 10-min assay based on the initial slope of the DNA 
binding curve, demonstrating a detection limit of 195 fmol of target DNA.
144
 Moreover, the 
authors then used differential desorption rates and high stringency buffers to distinguish perfect 
complements from (SNPs) having variable GC contents.
144
 Microring resonator arrays allow for 
various SNPs to be arrayed and screened to compare variable desorption rates that are indicative 
of binding affinity. Beyond the analysis of DNA, small (19-24 nucleotide), non-coding miRNAs 
that regulate gene expression at transcriptional and post-transcriptional levels are also important 
targets. Qavi and Bailey demonstrated the ability to simultaneously detect 4 miRNAs with DNA 
capture probes in 10 min with a detection limit of 150 fmol, applying the microring resonator 
chip to miRNA expression profiling of a glioblastoma model cell line.
135
 Subsequent work with 
miRNAs has focused on signal amplification using an antibody specific for the DNA:RNA 
heteroduplex (Figure 1.5B), improving detection limits by 2-3 orders of magnitude to 10 pM 
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(350 amol) in a 40-min assay.
137
 Outside of WGM resonator sensors, photonic crystals have also 
demonstrated interesting nucleic acid sensing applications. For example, Chan et al. 
demonstrated the utility of replica-molded photonic crystal microwell plates for high-throughput 
screening of small-molecule inhibitors of protein-DNA interactions,
189
 and photonic crystals 
were also used to characterize the DNA printing quality and uniformity of widely used cDNA 
microarrays.
127
 
 Protein analysis is another popular application of high-Q optical sensors that has received 
extensive attention due to the large number of protein assays used at present in the clinic. High-Q 
protein biosensing has largely focused on disease biomarker analysis
45, 87, 128, 139, 143, 169, 177
 and 
cytokine profiling.
46, 132, 145, 157
 An early, stimulating report of high-Q protein analysis by Armani 
et al. described the use of a silica microtoroid for label-free detection of the cytokine interleukin-
2 (IL-2) in undiluted serum with single-molecule sensitivity.
42
 This unprecedented sensitivity 
was attributed to the thermo-optic effect, which was claimed to result in a quadratic dependence 
of sensitivity on the Q factor (10
8
) as bound IL-2 causes an increase in the local temperature of 
the microtoroid. However, recent theoretical studies by Arnold et al. contest these results by 
asserting that the thermo-optic enhancement mechanism is dwarfed in magnitude by the well-
understood reactive mechanism associated with binding-induced RI changes.
190
 Arnold went on 
to show that the thermo-optic effect can account for no more than 0.1% of the wavelength shift 
magnitude associated with single-molecule binding events.  Despite the controversial nature of 
this single-protein detection paper,
42
 it has generated significant interest, activity, and 
conversation within the high-Q biosensing community. Many researchers in the field are 
anxiously awaiting follow-up reports that would help to robustly establish fundamental limits of 
high-Q sensors, particularly for applications in complex matrices where single molecule binding 
events would almost certainly be difficult to observe independent of competition with non-
specific binding. 
In other protein detection work, Washburn et al. demonstrated the ability to detect the 
cancer biomarker carcinoembryonic antigen (CEA) at clinically relevant concentrations using an 
array of SOI microring resonators.
87
 This CEA assay, based on initial slope-based quantitation 
performed in just 5 min, yielded a limit of detection of 2 ng/mL in buffer, comparable to a 
commercial ELISA, and CEA was also detected in undiluted fetal bovine serum, albeit with a 
less impressive detection limit (25 ng/mL). Zhu et al. used the LCORR system to detect the 
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cancer biomarker CA15-3 in diluted serum samples from stage IV breast cancer patients, with a 
detection limit of ~20 units/mL (~1 unit/mL in buffer) for a 30-min equilibrium shift assay.
139
 
Healthy samples were differentiated from cancer patient samples, and CA15-3 levels agreed well 
with pathology test results. Gohring et al. also used the LCORR system to demonstrate detection 
of the breast cancer biomarker HER2 between 13 and 100 ng/mL in serum based on a similar 30-
min equilibrium shift assay.
143
 Multiplexed protein biomarker detection has also been 
demonstrated, with Washburn et al. showing the simultaneous quantitation of 5 cancer 
biomarkers (CEA, alphafetoprotein [AFP], prostate specific antigen [PSA], tumor necrosis 
factor-α [TNFα], and interleukin-8 [IL-8]) from the same solution using 5-min initial slope 
analysis on microring resonators.
45
 Though this initial multiplexed biomarker assay was 
performed in buffer, it demonstrates the ability to design useful assays for multiple proteins with 
limited cross-reactivity and no loss of sensitivity or precision in the extension beyond single-
parameter assays. Current protein biomarker efforts have centered on improving sensitivity and 
dynamic range in the analysis of clinical samples, and a recent report showed the ability to detect 
the cardiac biomarker C-reactive protein (CRP) in diluted human serum and plasma samples 
across six orders of magnitude of dynamic range with a limit of detection of 30 pg/mL.
177
 
Beyond protein biomarker assays, cytokines represent an even more challenging target 
due to their small size (5-40 kDa)
191
 and low relevant concentrations (pg/mL-ng/mL).
192
 
Luchansky and Bailey demonstrated the ability to detect the cytokine IL-2 down to 100 pg/mL (6 
pM) in buffer with a 45-min sandwich immunoassay performed on microring resonators (Figure 
1.5A), and this assay was applied to IL-2 temporal secretion analysis of Jurkat T cells.
145
 More 
recently, the same authors developed a method for extremely rapid, multiplexed cytokine (IL-2, 
IL-4, IL-5, TNFα) analysis based on 5-min initial slope quantitation of one-step sandwich assays 
on a ring resonator chip.
157
 This multiplexed cytokine platform can be applied to immunological 
studies with improved temporal resolution, showing the ability to discriminate differentiated 
primary T cell lineages based on their cytokine secretion profiles. Also focusing on cytokines, 
Mandal et al. used 1-D photonic crystal sensors for the multiplexed detection of IL-4, IL-6, and 
IL-8 at concentrations >1 µg/mL with two-step sandwich assays .
46
 Other work with replica-
molded photonic crystal sensors has focused on using enhanced fluorescence for improved 
performance and augmented signal-to-noise in fluorescent protein microarrays for both cancer 
biomarkers
128
 and cytokines.
132
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 Interesting high-Q sensor applications have also emerged in the area of cell and particle 
analysis, including bacteria,
54, 76
 T cell,
193
 and virus detection,
56, 57, 166, 176, 194
 as well as studies 
that analyze cell growth
170
 and cellular processes such as apoptosis and activation.
17
 
Microorganisms were first detected with microspheres by Ren et al., who observed random 
adsorption of rod-shaped E. coli bacteria cells and the accompanying decrease in Q factor caused 
by increased scattering losses.
54
 Ramachandran et al. later demonstrated the use of high-RI glass 
microring resonators for specific capture of E. coli cells only on rings coated with anti-
lipopolysaccharide, with a detection limit of 10
5
 colony-forming units (CFU)/mL.
76
 Human 
CD4
+
 and CD8
+
 T cells at concentrations as low as 2 × 10
5
 cells/mL were also detected with 
optofluidic ring resonators, albeit with limited dynamic range.
193
 Virus detection has also been 
achieved with microsphere,
56, 57
 microtoroid,
176
 microring,
194
 and optofluidic resonators.
166
 Zhu 
et al. detected the bacteriophage M13 at concentrations down to 10
3
 plaque-forming units 
(PFU)/mL using optofluidic resonators,
166
 and Vollmer et al. demonstrated single-virus detection 
of ~100-nm Influenza A particles with spherical microcavity resonators.
56
 In the latter report, 
microsphere sensitivity to viral particle binding was also observed to increase with decreasing 
microsphere size (and accompanying increase in radius of curvature) that leads to greater 
wavelength shift per bound particle. Lu et al. also recently reported single-virus detection of 
Influenza A particles by adsorption to microtoroids.
176
 They utilize a thermal-stabilized reference 
interferometer to minimize noise associated with laser frequency jitter and scan-voltage control, 
achieving an incredible 0.1 fm wavelength shift resolution. McClellan and Bailey recently 
utilized microring resonator arrays for an agricultural application of virus detection, 
demonstrating the quantitative analysis of bean pod mottle virus particles from minimally-
processed leaf extracts.
194
 
 Beyond quantitation of cell and particle binding to WGM sensors, high-Q sensors can 
also be used for monitoring cellular processes. Wang et al. demonstrated the ability to use 
microring resonators to observe cell growth, cellular adhesion processes, and cellular response to 
toxins.
170
 By attaching MS1 endothelial cells to the microrings, changes in cell volume and 
motility led to RI perturbations that allowed for on-chip cell proliferation monitoring after 
seeding. They also demonstrated the ability to detect cellular toxins at relevant levels based on 
the root mean square (RMS) of resonance wavelength fluctuations that varies with cell viability. 
In recent work, Wilson et al. used fibronectin-coated microspheres to culture neurons and 
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skeletal myoblasts and to study the effects of surface adsorption on cellular function.
195
 Beyond 
the analysis of whole-cell attachment, a biomimetic coating composed of a lipid bilayer has been 
self-assembled on microspheres by Freeman et al.
196
 This could provide a useful model of the 
cell membrane for monitoring processes such as membrane transport. Photonic crystals, most 
notably incorporated into a microplate format, have also been used for a wide array of cell-based 
assays based on either aggregate cell behavior or single-cell measurements. Recent progress in 
this area, including applications to studies of cell attachment, cytotoxicity, apoptosis, GPCR 
activation, ion channel activation, and chemotaxis, have been nicely reviewed.
17
 Though 
ensemble measurements of aggregate cell behavior have been widely reported, label-free 
photonic crystal imaging
197
 has been developed to study cell attachment distribution within 
individual cells with a pixel resolution of <1 µm
2
.
198
 By coating photonic crystal sensors with 
proteins that model the extracellular matrix (ECM), Lidstone et al. use photonic crystal enhanced 
microscopy (PCEM) to study cell adhesion during growth, apoptosis, and differentiation 
processes (Figure 1.6).
198
 Without the need for fluorescent labels, PCEM permits increased cell 
viability for long-term studies of the same cells. This new imaging technique could provide 
important insights into cell-ECM interactions that are vital in processes such as wound healing 
and cancer metastasis. 
Chemical assays: Vapor-phase sensing, reaction monitoring, and molecular 
orientation. Beyond aqueous biomolecular assays that have received a large amount of attention 
from the high-Q sensor community, applications in chemical analysis have also been reported – 
applications such as detecting gases
106-108, 130, 154, 155, 199, 200
 and vapor-phase explosives,
151, 152
 
studying thin films
201
 and polymer growth,
3, 46, 165
 and discriminating chirality,
202
 
photoisomerization,
203
 and molecular orientation.
204
 High-Q devices have demonstrated vapor-
phase sensing applications such as acetylene sensing with slotted microring resonators,
199
 
microsphere analysis of He/Ar mixtures based on changes in gas thermal conductivity,
200
  
ethanol vapor sensing with ZnO nanoparticle-coated racetrack microring resonators,
154
 and 
hydrogen sensing based on combustion at a Pt/WO3 catalyst-coated microring.
155
 Gas detection 
methodology was described in the surface chemistry section, and the most important applications 
have centered on gas chromatography (GC) detectors and explosives detection for security 
applications. Optofluidic ring resonators have emerged as an extremely promising platform for 
GC detection that combines WGM optical interrogation with a stationary-phase coating for 
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vapor-phase separation.
106-108
 In another use of an optofluidic resonator, Sun et al. demonstrated 
the specific detection of DNT at room temperature from a nitrotoluene background with a 200 pg 
limit of detection.
151
 Similarly, Orghici et al. used microring resonators to demonstrate specific 
vapor-phase detection of TNT at concentrations down to 1 ppb, though the dynamic range of the 
analysis was limited to a factor of 10.
152
 Though tools such as GC-MS remain more sensitive, 
high-Q sensors have yet to be fully realized for these gas sensing applications and thus represent 
a promising platform for portable detection systems. 
Other chemical assays have centered on real-time reaction monitoring, especially in the 
realm of polymer chemistry. Real-time analysis of surface chemistry functionalization, capture 
agent immobilization, and assay monitoring has been described in previous sections, but the 
ability to monitor surface-based changes in real-time is also useful for polymeric processes. 
High-Q sensors have demonstrated the ability to monitor polymer electrolyte multilayering,
3, 46
 
observe temperature-induced changes in optical properties (i.e. RI) of polymer thin films,
201
 and 
compare atom transfer radical polymerization growth processes under different catalytic reaction 
conditions.
165
 Due to the high temporal resolution, potential for parallel screening of reaction 
conditions, and label-free operation, high-Q optical sensors are extremely promising for reaction 
monitoring, and the potential of these technologies has only begun to be realized in this arena. 
In addition to polymer applications, properties such as chirality and molecular orientation 
can also be probed with WGM sensors. Vollmer et al. showed that a ring resonator can be used 
to observe the circular birefringence of a chiral liquid based on the relative wavelength position 
of optical modes associated with left and right circularly polarized light.
202
  Specifically, the 
variation in splitting of left and right circularly polarized modes was shown to be a function of 
the enantiomeric excess of the optically active liquids. Beyond studying chirality, molecular 
orientation on a surface can also be studied with WGM sensors.  Topolancik et al. demonstrated 
the ability to observe photoinduced isomerization transformations of a bacteriorhodopsin (bR) 
layer adsorbed to a poly(dimethyldiallyl)ammoniumchloride–coated microsphere.203 They utilize 
time-resolved switching data to probe the polarization transformations that accompany the 
cis/trans isomerization of the retinal chromophore within bR. Specifically, polarization 
transformations were observed by measuring the shift ratio of the TM- and TE-polarized WGMs. 
A similar TM/TE WGM shift ratio technique can also be used to probe the orientation of BSA on 
a silanized microsphere.
204
 Though these studies demonstrate truly innovative uses of WGM 
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sensors, additional follow-up studies will be required to extend these findings to the study of 
molecular orientation within additional protein systems. 
Multiplexed measurements: Screening, kinetic analysis, and affinity profiling. 
Beyond the demonstration of interesting applications for chemical and biomolecular sensing, 
multiplexed assay techniques must be developed in parallel to leverage the scalability of high-Q 
geometries such as microring resonators and photonic crystal sensors. Arrays of microring 
resonators have become a valuable tool for efficient parallel screening of capture agent affinities, 
allowing direct comparison of association and dissociation rates.
156, 159
 Once a high-Q sensing 
platform has been established, the first (and often rate-limiting) step in developing a new assay is 
the search for effective capture agents, such as an antibodies or aptamers. SOI microring 
resonators have shown the ability to screen several capture antibodies in parallel based on DNA-
encoded antibody technology (Figure 1.7A),
159
 and the ring resonator array platform has also 
been used to directly assess the relative utility of antibodies and aptamers for a common target.
156
 
By providing real-time kinetic analysis of target binding to potential capture agents, the optimal 
antibody or aptamer can be chosen based on direct comparison of important physical properties 
such as association and dissociation rate constants, robustness, reproducibility after regeneration, 
specificity, and suitability to amplification steps such as sandwich assays. Importantly, 
information about capture agents gained on scalable high-Q platforms is useful not only in assays 
performed on the same platform, but also for a host of fluorescent, enzymatic, plasmonic or 
electrochemical assays carried out with a variety of alternative transduction modalities 
techniques. After careful selection of a capture agent, microring resonators also permit 
multiplexed assays of proteins 
45, 97, 98, 157
 and nucleic acids,
135, 137
 as described in previous 
sections. Some of these assays also make use of fast, kinetic-based quantitation based on initial-
slope analysis,
45, 87, 157, 177
 which further showcases the importance of real-time binding 
capabilities of many high-Q devices. For example, multiplexed, initial-slope based quantitation 
has found an interesting application in monitoring cellular secretion of cytokines (Figure 
1.7B).
157
 Finally, another sensing methodology that could eventually be amenable to high-level 
multiplexing involves optical spectroscopy in 200-µm silicon nitride ring resonator cavities.
205
 
Within a ~100-fL reaction volume enclosed by the ring resonator, changes in optical absorbance 
lead to resonant wavelength shifts that are not dependent on thermal fluctuations. This concept 
could be extended to perform fast ELISA-type absorbance assays in very small volumes with 
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inherently multiplexable microring resonators. Continued development of ring resonator 
technology will continue to take advantage of the inherent scalability of planar silicon-based 
devices, and arrays of hundreds of sensors on a chip are in sight. 
Multiplexed assays have also been developed based on 1-D photonic crystals
46
 and 
photonic crystal microplate devices.
121, 148, 173, 189
 Beyond the 1-D photonic crystal fluidic devices 
already discussed,
6, 46
 the ability to interface photonic sensors with plastic 96- or 384-well plates 
(Figure 1.7C) represents an important development for label-free, high-throughput screening 
applications. Photonic crystal sheet biosensors have been used to screen small-molecule 
modulators of protein-protein interactions (Figure 1.7D),
148
 to discover inhibitors of protein-
DNA interactions,
189
 and to analyze biomolecular binding kinetics.
121
  Applications such as these 
require excellent sensor uniformity on low-cost substrates that are compatible with automated 
fluid handling robotics. A recent extension of replica-molded photonic crystal substrates is the 
creation of distributed feedback laser biosensors (DFBLB).
206
 The DFBLB system achieves Q 
factors of 10
4
-10
5
 through stimulated emission from a rhodamine dye-doped SU-8 layer over a 
periodic polymer grating, allowing any area of the substrate to act as a sensor without rigorous 
alignment requirements. These sensors can be fabricated by standard roll-to-roll manufacturing. 
As developments in fabrication techniques continue and new applications emerge, photonic 
crystals will remain important for multiplexed studies involving screening, detection, and 
imaging. 
 Nanoparticle analysis and optical manipulation. The impact of high-Q optical sensors 
on nanotechnology has expanded in recent years, with novel examples of nanoparticle 
detection,
56, 109, 176, 207-209
 sizing,
56, 210, 211
 sorting,
96, 210
 and optical manipulation.
212-215
 Vollmer et 
al. first showed single particle detection of 500-nm polystyrene spheres using 90-µM WGM 
microsphere resonators.
56
 Discrete wavelength shifts accompanying single-particle binding 
events were clearly resolved. Recent experiments by Lu et al. demonstrated the ability to detect 
single-particle binding of much smaller 25-nm polystyrene particles, observed as a 0.4±0.2 fm 
resonance wavelength shift on a thermally-stabilized microtoroid resonator.
176
 Single-particle 
binding is accompanied by both a longer WGM pathlength (and corresponding shift to longer 
resonance wavelength) as well as an increase in backscattering, which work together to create a 
measurable binding signal. Vollmer and Arnold describe an important optical trapping 
mechanism, dubbed the WGM carousel, that is responsible for attraction and subsequent orbiting 
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of particles at the region of highest evanescent intensity in microsphere devices.
216
 Though 
nanoparticles in solution are governed by Brownian motion, nanoparticles are drawn toward the 
resonator surface by attractive opto-mechanical gradient forces similar to those employed by 
optical tweezers.
57
 Due to this opto-mechanical force, the nanoparticle binding timescale in very 
dilute solutions (aM or less concentrations) is sped up well beyond that predicted by the 
theoretical diffusive or convective binding models.
171
 The WGM carousel force is a function of 
the device Q factor (Equation 5) and laser power, drawing the nanoparticles toward the highest 
intensity of the decaying WGM evanescent field at the microsphere equator surface. Once 
particles are held in orbit near the surface by a combination of optical forces and interfacial 
interactions, the probability of particle binding approaches unity.
57, 216
 These optical trapping 
forces are helpful for detection of particles at low concentrations, and they may find utility in a 
number of high-Q detection strategies. 
 In theoretical work describing modified microbubble or microbottle optofluidic ring 
resonator geometries, Li et al. showed that the three-dimensionally confined fluidic path should 
improve the sensitivity for nanoparticle detection beyond that of traditional microspheres by an 
order of magnitude.
207
 By optimizing capillary wall thickness and bubble curvature, modified 
optofluidic resonators should permit detection of sub-40- nm nanoparticles. In addition to sphere, 
toroid, and optofluidic geometries, single-nanoparticle detection has also been proposed based on 
using the gap area in a system of two microdisk resonators, and finite difference time domain 
models suggest that the sensitivity should increase with both decreasing gap size between the 
disks as well as increasing microdisk thickness.
208
 Other examples of nanoparticle detection by 
Koch et al. involve the previously described hurricane geometry for 100-nm gold nanoparticle 
detection
109
 as well as reflection-mode sensing based on nanoparticle-induced backscattering in 
an add/drop filter microring device.
112
 The reflection-mode sensor is based on reflection from a 
bound nanoparticle that causes light to circulate the cavity in the opposite direction, leading to an 
intensity build-up of backward propagating modes that can be detected with a broadband 
detector. Though most nanoparticle detection platforms are based on a red shift to longer 
resonance wavelengths, consistent with an increase in the local RI, it is also possible to detect 
nanoparticle binding through a negative or blue shift in the resonance wavelength.
209
 Because of 
the unusual optical properties of gold nanoparticles, a blue shift in the resonance wavelength 
during binding to a microring in air was observed and explained to be the result of the smaller 
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real component and large imaginary component of the RI for gold relative to air in the near IR 
spectral region. This ―negative‖ signal differentiates gold nanoparticle binding from dielectric 
particle (biomolecules, polymers, etc.) binding, which could lead to interesting methods to 
circumvent signal-to-noise limitations in high-background matrices. It should also be noted that 
metallic nanoparticles degrade the WGM resonance through scattering losses, leading to a 
broadening of the resonance wavelength peak and thus reduced spectral resolution. 
 Beyond nanoparticle detection, WGM sensors also enable nanoparticle sizing and sorting. 
In addition to the proportionality of the discrete wavelength shift to the particle size/mass,
56
 
particles can also be sized or ―weighed‖ through mode splitting. Zhu et al. show that the 
deposition of single nanoparticles as small as 60 nm to a high-Q microtoroid leads to splitting of 
the WGM into two spectrally shifted resonance modes (i.e. a doublet).
210
 Nanoparticle deposition 
causes scattering that breaks the perfect azimuthal symmetry in the microtoroid, lifting the 
degeneracy in the WGM modes that propagate in opposite (clockwise and counterclockwise) 
directions in the toroid (Figure 1.8). This phenomenon allows for the sizing of both KCl and 
polystyrene nanoparticles (60-350 nm) based on the accompanying normalized magnitude of the 
WGM splitting.
210
 A benefit of mode splitting analysis is that mode splitting is independent of 
nanoparticle position on the resonator, an advantage over shift analysis that depends on where on 
the high-Q structure the particle resides. In addition to splitting-based sorting of nanoparticles on 
the basis of size, nanoparticles can also be sorted based on their composition. Notched ring 
resonators, which contain a ~100-nm notch fabricated by e-beam lithography, feature an area 
within the core of the waveguide with a strong (non-evanescent) electromagnetic field that 
greatly enhances the optical interaction with a nanoparticle within the notch.
96
 Nanoparticle 
binding, simulated by a 20-nm nanoparticle AFM tip placed in the notch, caused large (nm-scale) 
resonant wavelength shifts.  Easily discernible shift and splitting behaviors for both silicon and 
gold particles have been proposed, although not yet realized, as a way to sort nanoparticles of 
differing compositions. A final innovative method for nanoparticle sizing involves the 
interrogation of nanoparticle Brownian motion as it relates to WGM resonance wavelength 
fluctuations.
211
 Virus-sized nanoparticles near a microsphere cause ―noise‖ in the resonant 
wavelength based on stochastic processes associated with Brownian motion, which was well-
characterized by an autocorrelation function. The normalized autocorrelation of resonance 
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wavelength fluctuations provides a good estimate of nanoparticle size, especially for 
nanoparticles less than 100 nm in diameter. 
 Beyond detection and characterization applications, WGM resonators can also be used to 
manipulate the motion of particles. For example, Yang and Erickson recently created an optical 
switch by using a 200-µm SU-8 polymer ring resonator to trap and manipulate particles.
212
 By 
switching between on- and off-resonance wavelengths inserted into the bus waveguide, the 
motion and position of 3-µm polystyrene particles was controlled; particles trapped on the bus 
waveguide could be routed to the microring by on-resonance wavelengths that caused a build-up 
of the optical-trapping WGM carousel forces (Figure 1.9A). Similar work by Cai and Poon 
demonstrated optical transport and manipulation of slightly smaller 1-µm polystyrene particles 
on a silicon nitride microring platform.
213
 They used the optical trapping effects to create a 
particle add-drop filter device (with both a throughput/input and a drop/output waveguide) that 
functions as a type of ―particle circuit.‖ Lin et al. used smaller 5- and 10-µm silicon microring 
resonators (Figure 1.9B) and 200 frame/s videos to measure the particle velocity (~10
-4
 m/s) and 
revolution frequency (~3Hz) of similar fluorescent ~1-µm polystyrene particles.
214
 Particle 
trapping in the ring required only 0.67 mW of optical power, and particle revolutions were stable 
for several minutes. Finite-difference time-domain (FDTD) studies show that the 
electromagnetic field intensity on top of the small microrings follows a Gaussian distribution 
(Figure 1.9C). Interestingly, the particles were observed to slow at the far end of the microring 
distal to the bus waveguide, likely due to bending-loss induced attenuation of the field 
enhancement. Impressively, Mandal et al. demonstrated the ability to statically trap smaller 48- 
and 62-nm polystyrene particles with 1-D silicon photonic crystals.
215
 The photonic crystal 
device allows optical trapping capabilities beyond those of traditional optical tweezers, and this 
device could permit applications in particle trapping, storing, and sorting independent of 
microfluidic flow. Various optically trapping photonic crystal geometries have been 
characterized, and comparison of trapping stiffness and stability for different geometries allows 
for optimization of field enhancement and confinement.
217
 In addition to the potential benefits of 
the high-Q optical trapping approach for single-molecule manipulation, nanomanipulation of this 
type also holds promise for bottom-up nanomaterials synthesis by directed assembly. 
 Microcavity and photonic crystal lasers. Outside of passive microcavity sensing, 
another interesting application of high-Q devices is the development of microcavity and photonic 
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crystal lasers. Although not the focus of this review, there are several historical examples of 
improved laser designs significantly impacting analytical detection methodologies, and thus the 
subject is covered here in brief. Compact, single-mode, low-threshold (4 mA) lasing was 
demonstrated with 50-µm hybrid devices composed of InAlGaAs/InP microrings on a SOI 
microdisk (Figure 1.10A). These devices were proposed for use as on-chip optical 
interconnects.
218
 Further reductions in device size and increases in facet reflectivity will likely 
lead to further reductions of lasing thresholds (Figure 1.10B). Though lasing from a microcavity 
device is non-directional due to the cavity’s radial symmetry, highly unidirectional lasing is 
possible from a high-Q WGM based on incorporation of a wavelength-scale notch at the 
boundary of an elliptical quantum cavity laser.
219
 Single-mode lasers can also be formed based 
on coupled microcavities. A single-mode coupled cavity laser, formed from 2 adjacent ~100-µm 
silica microrings of slightly different sizes, has been demonstrated by Li et al. as a biosensor for 
monitoring biomolecule-induced coupling changes that alter laser light intensity.
220
 Based on the 
Vernier effect where light from a resonant cavity is lost to the adjacent nonresonant cavity,
221
 RI 
change-induced mode hopping allows for sensing based on the cavity laser intensity measured by 
a spectrometer (rather than monitoring the resonance wavelength shift). A similar single-mode 
coupled optofluidic device, which also uses the Vernier effect to suppress unwanted side modes, 
has been created in replica-molded PDMS, thus potentially allowing for simple mass 
production.
222
 Another interesting optofluidic cavity device, developed by Sun et al., is a dye 
laser in which an optical fiber is fused to the inner wall of the microcapillary (Q = 10
5
-10
6
), 
which permits fluidic control of the rhodamine 6G dye-based gain media.
223
 Optofluidic dye 
lasers can also be excited by DNA scaffold-controlled FRET interactions.
224
 Photonic crystal 
lasing has also been demonstrated with a GaAs photonic crystal waveguide
225
 and a 2-D 
GaInAsP slab with a 30-nm nanoslot lattice discontinuity.
226
 The GaAs photonic crystal 
waveguide laser features spatial localization of various lasing modes along the waveguide, while 
the nanoslot discontinuity leads to high laser localization within the slot for possible sensing 
applications. Though microlasers tend to have smaller photon numbers and broader mode 
linewidth than traditional (larger) lasers,
21
 microlasers benefit from small mode volume and low 
lasing thresholds. Recent progress in the development of silicon lasers
227
 and rare earth ion-
doped microsphere lasers
16
 have been recently reviewed. 
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 Thermal sensing. Temperature-induced resonance wavelength fluctuations were 
discussed earlier as a limitation of high-Q devices, requiring careful temperature control or on-
chip referencing to prevent thermal noise-limited sensing. However, the high temperature 
sensitivity of high-Q devices can also be advantageously harnessed for accurate, small-footprint 
thermal sensing. As described earlier, WGM microcavities were used for analysis of thermal-
induced changes to polymer thin films in hybrid silicon-polymer devices.
201
 Kim et al. 
demonstrated and quantified the strong impact of temperature changes on the resonance 
wavelength in silicon microrings owing to the thermo-optic effect, observing a thermal 
sensitivity of 82 pm/ºC.
228
 The 8-µm ring resonator thermal sensor displayed an impressive 6-µs 
response speed, and the small ring dimensions led to an improved FSR that was associated with a 
broad dynamic range of ~300 ºC. By incorporating a 2.25-µm PDMS thin film on a silica 
microtoroid, superior temperature sensitivity of 151 pm/ºC and resolution of 10
-4
 ºC was 
reported.
229
 For thicker PDMS films, the negative thermo-optic coefficient of PDMS dominates 
the positive coefficient of Si, leading to a blue shift in resonance wavelength with increasing 
temperature. Based on their high thermal sensitivity and low response times, arrays of WGM 
resonators may one day function as high-spatial density thermal detectors for high-performance 
thermal imaging.
230
 Watts et al. showed that silicon nitride microring resonator thermal detectors 
(Figure 1.10C) are sensitive to thermally induced changes caused by an incident CO2 laser beam, 
demonstrating excellent response time and temporal resolution (Figure 1.10D). For room-
temperature thermal imaging, the advantages of high-Q structures over cryogenically cooled 
devices are expected to include lower thermal noise, smaller pixel size, lower response time, and 
high inherent scalability.
230
 Many-element (10
2
-10
3
) arrays of photonic sensors are currently 
being developed for multiplexed sensing applications, but thermal imaging applications should 
further drive scalability of integrated devices due to their requirement for an array of >10
6
 
sensors. 
Other applications: Ultrasonic detectors, spectral imaging, and integration with 
other techniques. Microcavity devices have also found utility in other detection and imaging 
applications. Beyond the ability to act as a detector of RI changes, molecular binding, and 
temperature, microring resonators can function as ultrasonic detectors. Ninety µm polymer 
microrings fabricated from thermally reflowed resist molds, as described earlier, have smooth 
sidewalls and demonstrate high Q factors of 10
5
, allowing for 36.3 mV/kPa acoustic sensitivity.
90
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For ultrasonic imaging applications, this high acoustic sensitivity on a small footprint is very 
desirable. Low noise at high frequencies is another important attribute of ultrasonic detectors, 
and these polymeric microrings demonstrated a pressure noise floor of 88 Pa in a 1-75 MHz 
bandwidth range, which is substantially better than piezoelectric transducers of similar size and 
bandwidth. Further work by Ling et al. has demonstrated similar noise levels and Q factors on a 
smaller footprint (60-µm polystyrene microrings) by shifting the working wavelength from the 
near-IR to 780 nm to reduce water and polymer absorption.
83
  
High-Q devices can also be used as polarization-sensitive IR detectors. Rosenberg et al. 
showed that a metal-coated dots-in-a-well (DWELL) photonic crystal cavity can be designed to 
achieve significant free-space coupling of normal-incident light.
231
 Additionally, Boriskina et al. 
show that the large confinement of high-Q cavities could be combined with the superior light 
concentrating properties of nanoantennas to create optoplasmonic superlenses for low-loss 
energy transfer within optical circuits.
232
 The proposed superlens is composed of a polystyrene 
microsphere sandwiched between two gold nanodimer antennas, creating a device that is well 
suited for frequency-sensitive enhancement and switching of light at the nanoscale. Regardless 
of the application, high-Q optical detectors benefit from multi-pass interactions, large optical 
confinement, scalability, and high sensor spatial density. 
Beyond detector applications, additional uses of high-Q technology may be enabled 
through integration of microring resonators with other photonic devices including 
interferometers and Bragg reflectors. High-Q Mach-Zehnder interferometer (MZI)-coupled 
silicon microrings have been demonstrated with Q factors as high as 10
5
-10
6
.
233
 By adjusting the 
relative lengths of the arms of the MZI coupler to carefully select the interference order, it is 
possible to depress all except for one resonant wavelength. This leads to an unusually large FSR 
(up to 180 nm), which allows for sensing over a broad RI range of up to 0.5 RIU. Numerical 
simulations have also shown that a MZI-coupled microring has up to 30% greater sensitivity than 
a traditional microring of the same size and material while using 25% less circulating power.
234
 
These types of MZI-coupled improvements are not drastic and may not justify the extra design 
complexity for sensing applications, but the potential for a very large FSR could be useful for 
applications involving extreme RI shifts, such as those requiring sensing in both liquid and gas 
environments. In addition to sandwiching a microring between the arms of a MZI as described 
above,
233
 it is also possible to create a dual-microring-resonator interference sensor that features 
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two ~1-µm microrings of slightly different sizes, with one on both arms of a MZI.
235
 In this 
design, the output transmission spectrum depends on the interference overlap of the two 
microring spectra, demonstrating improved sensitivity but a small FSR. Outside of MZI-coupled 
microrings, distributed Bragg reflectors on microring resonators (DBR-MRR) have been used to 
create a single-wavelength microring mirror. After laying out design parameters and suggesting 
applications in the area of compact tunable lasers,
236
 DBR-MRR designs were realized by 
removing 50 nm
2
 sections from the inward side of the half of a 30-µm Si3N4/SiO2 microring 
distal to the bus waveguide.
237
 By only covering half of the microring with the DBR, reflectivity 
nulls coincide with all resonant wavelengths save one,
238
 leaving only one reflected resonance 
wavelength, which is the basis for a single-wavelength mirror that features 92% peak-power 
reflectivity.
237
 The integrated device could be used as an in-line mirror for low-threshold, narrow 
linewidth single mode laser diodes. Though many applications of integrated optical devices have 
been demonstrated, only a few were chosen as representative of interesting recent examples of 
microring resonator-integrated devices. High-Q devices in optical communications applications, 
such as filtering, modulating, switching, routing, and delaying, has been recently reviewed.
9
 
While it is clear that the use of high-Q optical devices for biosensing and other analytical 
applications has become a vibrant research community in itself, it is important to be cognizant of 
the massive amount of effort that has been invested in applying high-Q devices to fundamental 
optics and telecommunications applications. 
 
 
1.7 Perspectives 
 Summary of recent advances and areas of needed improvement. A multitude of 
advances in high-Q sensing have been realized in the last few years. Though most of the high-Q 
geometries in use today have been around in some form for at least the better part of a decade, 
exciting recent improvements include new geometric architectures, novel fabrication techniques 
and material systems, innovative methods for improving device quality and scalability, and 
increased control and robustness of optical interrogation. Beyond fabrication considerations, 
surface chemistry and functionalization strategies have both evolved to include reproducible, 
covalent sensor modification, effective non-fouling modifications and blocking strategies, and 
surface regeneration methods. Once functionalized with appropriate capture agents, high-Q 
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sensors have been used in a variety of increasingly well-developed assays, as described at length 
earlier. Key assay developments of the past few years include advances such as on-chip thermal 
referencing, the creation of robust microcavity interrogation hardware, improved signal 
quantitation and calibration methods, integration of microfluidic sample handling, and the 
realization of multiplexed sensing. The development of increasingly complex assays in relevant 
sample matrices has also been aided by a variety of new strategies aimed at improving specificity 
and boosting signal-to-noise for trace analysis. All of these advances in fabrication, surface 
chemistry, and assay methodology have enabled the wealth of new applications of high-Q 
sensing that have emerged in the past few years. Important recent applications range from 
multiplexed protein assays to vapor-phase explosives analysis, from single nanoparticle analysis 
to WGM carousel optical manipulation, and from miniature high-Q lasers to sensitive ultrasonic 
and thermal detectors. 
 Despite the successes, improvements are still needed on several fronts in order for the 
ultimate potential of these technologies to be realized. Though excellent quality factors have 
been reported for a variety of geometries, the noise floor in relevant assays is often based on non-
specific binding, not spectroscopic resolution. Put another way, the community is rapidly 
approaching, if it has not already reached, the situation where the optics are no longer the 
limiting factor. To combat and circumvent non-specific binding and surface fouling, improved 
surface chemistry and added levels of assay specificity must be realized. Though PEG layers and 
effective surface blocking have been helpful, sensing in very complex media such as human 
serum remains a challenge to all surface-based biosensing techniques, regardless of transduction 
modality. Beyond surface fouling considerations, the ultimate sensitivity of many assays is also 
limited by the ability to find suitable capture agents. Antibodies are notoriously difficult and 
time-consuming to produce and optimize beyond nM (or at best pM) binding affinities (KD). As 
assays develop that permit high-level multiplexing, the requirements for high-affinity capture 
agents with little or no cross-reactivity increase dramatically, and highly selective sandwich 
assays additionally require a pair of high-affinity antibodies for each target. Though progress has 
been made in creating alternative capture agents,
239-241
 their affinity, robustness, and/or 
specificity will increasingly limit high-Q assays as more demanding analytical challenges are 
attempted. If the field is to progress at a rapid rate commensurate with the promise of the high-Q 
technologies themselves, researchers must increasingly take on real-world analytical challenges. 
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Reports featuring detection of model proteins in buffer need to be left behind in favor of 
demonstrations of sensing in relevant and useful matrices such as environmental samples, cell 
culture media, and clinical samples. Though progress is beginning to be made in this area, the 
future of the field rests in realizing truly novel applications of high-Q sensing technologies aimed 
at elucidating fundamental biological processes, creating clinically viable platforms for 
development of personalized diagnostics, monitoring and/or comparing reaction conditions for 
catalytic processes, characterizing and sorting nanomaterials, and imaging cellular, thermal, and 
acoustic processes. To achieve some of these highly useful applications, additional specifics 
about some of the most important goals and challenges are presented below. 
 Future goals and challenges for high-Q sensors. Some of the main goals of high-Q 
sensing include integrated sensor systems, high-level multiplexing, fundamental biological 
studies, and high-throughput clinical diagnostics. The challenges associated with each of these 
goals, in our opinion, are defined below:  
1. Integrated sensor systems. In order to achieve widespread use outside the academic lab, 
many aspects of large-scale systems integration must be considered, including the 
development of robust instrumentation that features facile optical coupling to the 
photonic microstructures, integration with automated fluidic handling, and customizable 
data processing capabilities. For many of the most promising applications, high-Q optical 
devices will need to reach their potential for cost-effective mass production by leveraging 
semiconductor processing methods, rapid prototyping, or roll-to-roll fabrication 
approaches. Since developing assays is a challenge in and of itself, the optics, device 
fabrication, and engineering work for the accompanying instrumentation can be 
addressed separately but in consultation with end users who have specific applications 
and particular specifications in mind. The challenges associated with creating a truly 
useful, well-packaged, and versatile high-Q sensor analytical platform are significant but 
attainable. Progress in this area requires broad expertise in optical engineering, device 
design, and assay/method development, which means that effective, multidisciplinary 
collaboration will be vital. 
2. High-level multiplexing. Multiplexed assays are desirable for many applications that 
require high information content and fast sample throughput. Scalable geometries such as 
planar microrings and photonic crystal sheets appear at present to offer the highest 
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potential for creating the multiplexed sensing platform necessary for many interesting 
applications such as clinical diagnostics, drug screening, and environmental monitoring. 
The ability to perform multiple simultaneous assays on the same sample demands the 
fabrication of many sensors on a small footprint. This requirement seems, at present, to 
be a limiting factor for many of the demonstrated non-planar geometries, such as 
microspheres and microtoroids that require particularly onerous optical fiber alignment. 
However, this is an active area of research and innovative solutions may overcome this 
limitation. Another engineering consideration is the capability to reproducibly determine 
the resonance wavelength for each element in a multiplexed sensor array with  a 
sufficient repetition rate to achieve acceptable temporal resolution for a given analytical 
challenge. Additionally, multiplexed assay methodologies, regardless of transduction 
modality, face considerable challenges associated with capture agent availability, 
specificity, and cross-reactivity, as outlined earlier. Many multiplexed detection strategies 
also observe reduced sensitivity compared to corresponding single-parameter assays 
because the multiplexing is complicated by the inability to individually optimize the 
assay for each target within a panel. Furthermore, analyte concentrations vary widely 
both from one sample to the next and also vary among different analytes in the same 
sample. This means that assays and sensors with broad dynamic ranges will be needed to 
prevent multiple time-consuming dilutions. Photonic crystal sensors have been quite 
successful in several of these regards and should serve as a model for the development of 
alternative high-Q sensing platforms.  
3. Fundamental biological studies. In order to harness advances in systems integration and 
high-level multiplexing, researchers should seek out systems in which insights into 
fundamental questions are considerably easier to answer with the scalability and real-time 
analysis capabilities of high-Q sensors. Although single-molecule studies have been 
suggested, results of this kind may not be feasible in complex environments. Nonetheless, 
high-Q sensors have demonstrated requisite sensitivity for many applications of 
contemporary importance. Some of these applications, among many others, include 
screening modulators of protein-protein interactions, analyzing binding kinetics, and 
monitoring cellular secretion processes. The movement away from proof-of-concept 
experiments will require well-validated assays that can be similarly robust, but more 
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informative, than currently available competitive technologies. The extension of high-Q 
sensors to fundamental biological studies will be facilitated by collaborations between 
scientists from varied disciplines so that expertise in biological systems can be combined 
with the wealth of sensor development and quantitative analysis expertise that is already 
present in the high-Q sensing community.  
4. High-throughput clinical diagnostics and environmental monitoring. Some of the most 
important areas that require effective collaborations are those for which patient or 
environmental samples will need to be analyzed. By forging interdisciplinary 
collaborations, the quantitative analysis and method design capabilities of analytical 
chemists can be combined with deep knowledge and expertise of a particular subject as 
well as access to interesting samples. In these areas, large numbers of samples need to be 
run via standard assay protocols in order to establish a conclusion, again requiring robust 
instrumental platforms. Additionally, it seems that many of the most interesting 
applications generally require high sensitivity in a challenging sample matrix. For this 
reason, researchers must continue to investigate new strategies for increasing the signal-
to-noise ratio for complex analyses—a feat that will likely involve signal amplification, 
surface chemical optimization, and perhaps sample pre-treatment methods. Effective 
capture agents, either natural or artificial, will also need to be developed, and 
multidisciplinary collaborations involving synthetic chemists, biochemists, and 
immunologists will likely be essential. Solutions to most of the profound problems for 
which high-Q devices are well-suited will ultimately involve highly collaborative 
interactions between multiple, seemingly disparate scientific areas. 
 
Though many of the challenges outlined above are significant, the field of high-Q optical 
sensors is young, vibrant, and continuously expanding. Keeping in mind that great strides in 
assay design and surface chemistry have been made in just the last few years, it is clear that the 
field has not reached maturity. The next few years should witness continued progress in 
enhancement of assay sensitivity and specificity, integration into user-friendly lab-on-a-chip 
formats, and application to previously intractable problems. Stimulating collaborations should 
develop naturally as the impressive capabilities of these sensors become more widely known. 
These collaborations should help to shift the field’s focus from that of optimizing Q factors and 
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detecting model proteins to that of creating robust assays for defined targets in systems where 
traditional tools are insufficient. Although a great deal of interdisciplinary progress must be 
made to realize the lofty goal of ultrasensitive, multiplexed, and real-time chemical and 
biomolecular detection, the future for high-Q optical sensors will likely include exciting 
advancements with previously intractable analytical challenges. 
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1.8 Figures 
 
 
 
Figure 1.1 Whispering gallery mode (WGM) sensing. (A) For a non-planar WGM microsphere 
geometry, light is coupled into a spheroid-on-a-stem structure from an adjacent, carefully aligned 
optical fiber. Light from a tunable laser propagates by total internal reflection through the fiber, 
and coupling to the microsphere occurs at resonant wavelengths (Equation 1). A photodetector 
records the resonance wavelength as a dip in the transmission spectrum. Adapted with 
permission from ref 56. © 2008 National Academy of Sciences, U.S.A. (B) Planar WGM 
microrings can be fabricated in silicon-on-insulator, allowing straightforward coupling form a 
linear waveguide to the ring. Interaction of molecules with a microring (in this case proteins 
binding to a capture antibody) causes a change in the local refractive index. When the resonance 
condition is met, light (~1560 nm) is coupled from the linear waveguide into the microring and 
constructively interferes to set up a standing wave. Attenuations in the transmission spectrum 
collected at the output of the linear waveguide coincide with the resonance wavelength. Changes 
in refractive index shift the resonance wavelength, as depicted by the shift from the black to red 
transmission spectrum. Adapted from ref 87. © 2009 American Chemical Society.  
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Figure 1.2 High-Q geometries, as visualized by scanning electron microscopy. (A) Glass 
microsphere formed by heating a tapered optical fiber by Vollmer et al. Reproduced with 
permission from ref 56. © 2008 National Academy of Sciences, U.S.A. (B) Silica microtoroid 
fabricated by lithography, etching, and thermal reflow by Armani et al. Reproduced by 
permission from ref 42. © 2007 American Association for the Advancement of Science. (C) 
Silver-coated surface-plasmon-polariton WGM microdisk fabricated by Min et al. Reproduced 
by permission from ref 27. © 2009 Nature Publishing Group. (D) Silicon microring resonator 
inside lithographically defined annular opening in perfluoropolymer cladding by Luchansky et 
al. Reproduced by permission from ref 3. © 2010 Elsevier. (E) Liquid core optofluidic ring 
resonator fabricated from glass microcapillary by Zhu et al., with adjacent optical fiber taper for 
coupling. Adapted from ref 103. © 2007 American Chemical Society. (F) Hurricane 
microresonator device, showing association with gold nanoparticles by Koch et al. Reproduced 
by permission from ref 109. © 2010 Elsevier. (G) Coupling region of 140-µm slot microring 
resonator by Carlborg et al. Reproduced by permission from ref 98. © 2010 The Royal Society 
of Chemistry. (H) 1-D photonic crystals fabricated in silicon-on-oxide in a multiplexed geometry 
by Mandal et al. Reproduced by permission from ref 46. © 2009 The Royal Society of 
Chemistry.  (I) Grating structure of TiO2/SiO2-coated replica-molded polymer photonic crystal 
by Huang et al. Adapted from ref 128. © 2011 American Chemical Society.  
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Figure 1.3 Surface functionalization methods for microring arrays. (A) Use of 6-channel PDMS 
microfluidics for differential capture antibody functionalization of 6 groups of 4 microrings each. 
Adapted from ref 45. © 2010 American Chemical Society. (B) Non-contact piezoelectric (inkjet) 
method for spotting of air-stable glycans on individual microrings. Fluorescently labeled 
streptavidin alignment calibration is shown here. Reproduced by permission from ref 158. © 
2011 The Royal Society of Chemistry. (C) One-step self-assembly of a DNA-encoded antibody 
library (DEAL) on individual DNA-functionalized microrings. DNA can be spotted robustly on 
microrings and retains functionality when dried, allowing subsequent direction of antibody 
loading. Adapted from ref 159. © 2011 American Chemical Society. 
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Figure 1.4 Sensor characterization by evanescent field profiling. (A) Real-time plot showing the 
cumulative growth of 72 polyelectrolyte bilayers on a silicon microring. Inset shows sequential 
addition of 3 representative bilayers of polyallylamine HCl (PAH) and polystyrene sulfonate 
(PSS). The relative shift for each layer models the exponential decay of the evanescent field with 
increasing distance from the sensor surface, yielding a 1/𝑒 distance of 63 nm. (B) Protein 
multilayer growth plot displaying relative shift per biotin-antibody/streptavidin bilayer. After 
reaching a peak response of 250 pm at bilayer 8 as initial holes (incomplete surface coverage) of 
protein monolayer are annealed, subsequent layers show exponential signal decay as they are 
deposited farther from the ring surface. Error bars represent the standard deviation for n=4 rings. 
Reproduced by permission from ref 3. © 2010 Elsevier.  
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Figure 1.5 Strategies for increased specificity and signal enhancement. (A) A sandwich 
immunoassay for the cytokine interleukin-2 (IL-2) utilizes a secondary antibody for added 
specificity and to amplify the primary signal. The surface can be regenerated with a low-pH 
rinse. Adapted from ref 145. © 2010 American Chemical Society. (B) Similarly, the use of a 
secondary antibody specific for the DNA:RNA heteroduplex (S9.6) amplifies the signal 
associated with miRNA 24-1 binding. Adapted from ref 137. © 2011 American Chemical 
Society.  (C) A tertiary enhancement step can be used to amplify the signal further. In this case, 
streptavidin-conjugated 100-nm beads bind to a biotinylated secondary antibody in a three-step 
assay for the cardiac biomarker C-reactive protein (CRP). A low CRP concentration (blue curve) 
that was difficult to quantitate with a sandwich assay becomes easily observable with bead-based 
signal enhancement. Adapted by permission from ref 177. © 2011 The Royal Society of 
Chemistry. 
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Figure 1.6 Photonic crystal enhanced microscopy (PCEM) for cellular attachment imaging. (A) 
By illuminating a photonic crystal surface from below with a laser that is scanned through a 
range of incident angles, a transmission spectrum is obtained for each 0.61-µm
2
 pixel to find the 
angle of minimum transmission (AMT). On-cell pixels have a reduced angle of minimum 
transmission relative to off-cell pixels. (B) Lidstone et al. use PCEM to image the attachment of 
hepatic carcinoma cells by mapping the AMT on a pixel-by-pixel basis with a CCD camera. (C)  
The morphology of cardiomyocte attachment visualized by a PCEM surface plot corresponds 
with optical microscopy observations (gray-scale inset). Adapted by permission from ref 198. © 
2011 The Royal Society of Chemistry. 
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Figure 1.7 Multiplexing applications of high-Q sensors. (A) DNA-encoded antibody libraries 
allow for rapid, parallel capture agent affinity profiling on a microring resonator array platform. 
In this case, 6 anti-prostate specific antigen (PSA) antibodies are screened in parallel with a 
kinetic titration (PSA concentrations, in ng/mL, noted above arrows) to allow rational selection 
of the best antibodies from multiple vendors. Real-time analysis allows for the calculation of 
association and dissociation rates. Adapted from ref 159. © 2011 American Chemical Society. 
(B) Microring resonator sensor arrays also allow for multiplexed cytokine profiling for T cell 
differentiation analysis. Normalized cytokine secretion levels for three differentiated primary T 
cell subsets (Th0, Th1, and Th2) were determined by one-step sandwich immunoassays. Control 
cultures on the left are compared to PMA/ionomycin-stimulated (Stim) cultures on the right, with 
a comparison of secretion levels by a paired difference t-test (*/** indicate significance at 
95%/99%). Adapted from ref 157. © 2011 American Chemical Society.  (C) These 96-, 384-, 
and 1536-well photonic crystal microplates permit high-throughput screening assays. 
Reproduced by permission from ref 17. © 2011 The Royal Society of Chemistry. (D) As an 
example of multiplexing applications of photonic crystal microplates, a 384-well high-
throughput screen of protein-protein modulators correctly reveals rapamycin as necessary for 
FRB binding to immobilized FKBP12. Among the 320 compounds screened, a large peak 
wavelength value (PWV) only occurs in the presence of rapamycin. Reproduced by permission 
from ref 148. © 2009 American Chemical Society. 
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Figure 1.8 Single nanoparticle detection and sizing. Zhu et al. utilize silicon microtoroids to 
detect and analyze single nanoparticles. (A) The fiber-coupled microtoroid and finite-element-
method simulation of the WGM field profile in a toroidal cross-section are shown. (B) SEM 
allows for visualization of a 300-nm particle deposited on the high-Q resonator. Nanoparticle 
deposition causes scattering that breaks the symmetry in the microtoroid, lifting the degeneracy 
in the WGM modes that propagate in opposite directions in the toroid. (C) The resulting mode 
splitting doublet is the basis for single particle detection and sizing, and a representative 
transmission spectrum shows both symmetric (left) and asymmetric (right) modes. (D) Five 
transmission spectra show the splitting changes that accompany the deposition of successive KCl 
particles (zero to four particles, from top to bottom). Corresponding particle deposition images 
for particle counting are shown at the right. Reproduced by permission from ref 210. © 2010 
Nature Publishing Group. 
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Figure 1.9 Optical trapping and manipulation of particles.  (A) CCD images of a racetrack 
microring and its adjacent bus waveguide (a) show the optical switching process for 3-µm 
polystyrene particles. (b) Initially, a string of particles is trapped on the bus waveguide. (c) The 
trapped particles are diverted to the microring at the resonance wavelength. Optical switching 
can be performed by moving from on-resonance to off-resonance wavelengths. (d) At off-
resonance wavelengths, already-trapped particles remain on the ring, but the next group of 
particles is not diverted to the ring. (e) More particles can be diverted onto the ring upon return 
to the resonance wavelength. Reproduced by permission from ref 212. © 2010 The Royal 
Society of Chemistry. (B) Similar experiments by Lin et al. were used to trap polystyrene 
particles on much smaller (5-10-µm) microrings. Particle velocities and revolution frequencies 
were measured for trapped particles recirculating the microring. (C) The cross-section of a 10-
µm microring and its accompanying WGM intensity below a trapped microsphere is shown. 3D-
finite-difference time-domain (FDTD) simulations of electromagnetic field strength (in A/m) 
were performed at 1 W input power in the waveguide. The FDTD simulations show that the 
intensity on top of the ring follows a Gaussian distribution. Sections B and C reproduced by 
permission from ref 214. © 2010 American Chemical Society.  
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Figure 1.10 Additional applications of high-Q devices: Compact silicon lasers and thermal 
imaging. (A) An electrically pumped microring resonator laser by Liang et al. is shown with an 
adjacent SOI bus waveguide, with the expanded view at right showing the fundamental 
transverse electrical mode localized toward the edge of the device. Stimulated emission is 
bidirectional. The inset at lower left is a cross-sectional SEM showing the metal layers and 
contacts. (B) Reduction of device diameter and improvements in facet reflectivity (R) will 
further reduce lasing thresholds, with 400 µA lasing threshold possible with a 4.5-µm device (red 
dot). The inset shows the top view of a 15-µm device. Sections A and B reproduced by 
permission from ref 227. © 2010 Nature Publishing Group. (C) Another interesting application 
of high-Q sensors is the creation of microphotonic thermal detectors. A representative silicon 
nitride resonator thermal detector device and adjacent waveguide is shown. (D) To demonstrate 
thermal sensitivity, the transmission through the adjacent waveguide is shown to vary with 
thermal fluctuations induced by a chopped CO2 laser signal. Sections C and D reproduced by 
permission from ref 230. © 2007 Nature Publishing Group. 
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Chapter 2 
 
LARGE-SCALE FABRICATION OF  
SILICON PHOTONIC MICRORING RESONATOR 
CHIPS BY PHOTOLITHOGRAPHIC PATTERNING  
AND REACTIVE ION ETCHING 
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2.1 Background and goals of late-stage chip fabrication steps 
 By leveraging standard semiconductor fabrication techniques, arrays of microring 
resonators can be mass-produced on silicon-on-insulator (SOI) wafers.
1, 2
 When fabricating 
photonic elements associated with ring resonator technology, it is possible to take advantage of 
complementary metal-oxide-semiconductor (CMOS) technology that has been extensively 
optimized by the electronics and telecommunications industries. Mass production at silicon 
foundries takes advantage of economies of scale to drive down per-device costs; though 
designing a working photonic device is very labor intensive, a proven design can be effectively 
scaled up to manufacture  many devices in bulk.  
Microring resonator technology development in the Bailey lab has been done in concert 
with Genalyte, Inc. Genalyte designed a robust high-speed optical scanning instrument to 
provide real-time monitoring of resonance shifts for each microring sensor in the array.
3
 
Genalyte’s original microring resonator chip design involves a 6.2 mm2 device with 64 
individual microring sensors arranged in 4 rows, 32 of which are monitored simultaneously. As 
shown in Figure 2.1, the chip contains microrings, U-shaped waveguides, alignment marks for 
lithographic patterning, and barcodes that allow the optical scanning instrument to identify the 
waveguide that corresponds to each microring. However, this 6.2 mm
2
 final chip product begins 
as one element of an array of chips on an 8‖ SOI wafer. Photonic elements are fabricated en 
masse on the 8‖ wafers at the Leti silicon foundry (Grenoble, France) using deep-UV 
photolithography
4, 5
 and etching that enables routine sub-micron resolution and uniformity. An 
8‖ wafer, which contains several hundred individual chips (or ―die‖) is shown in Figure 2.2. 
 In order to produce a final working product, the 8‖ Si wafers from the Leti foundry 
containing hundreds of chips must undergo several processing steps: spin-coating a cladding 
layer, patterning a photoresist mask over the cladding via photolithography, removing portions of 
the cladding by selectively etching through the mask, and dicing into individual devices. A 
representative microring in the SEM in Figure 2.3 depicts the degree of alignment and integrity 
that is desired at the end of the late-stage processing: microrings and other features are centered 
in the cladding openings with minimal etch debris and smooth sidewalls. Each of these late-stage 
processing steps are carried out in the MNTL cleanrooms, yielding thousands of chips for 
diverse biosensing experiments. Throughout this batch process, great care is taken to ensure 
negligible chip-to-chip variability, to maintain device integrity, and produce excellent 
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lithographic alignment. All of these considerations are necessary to make sure that a large 
percentage of the chips on each wafer are fully functional. 
 
 
2.2 Cytop spin-coating process optimization for uniform 1100-nm thickness 
 Cytop™ (Asahi Glass Company) is an amorphous perfluoropolymer (Figure 2.4) that has 
physical and optical properties that are ideally suited to its function as a polymeric cladding layer 
on the microring resonator chips.
6
 The Cytop cladding layer has a variety of functions: 
1) Cytop covers 8 of the 32 active microrings, allowing them to serve as thermal controls 
without being in contact with solutions. These rings only respond to temperature 
fluctuations independent of analyte/non-specific binding or bulk refractive index changes. 
2) Cytop protects the waveguides that access the microrings. The cladding layer is only 
opened up in annular openings directly over the 24 remaining microring sensors. 
3) The optical properties of Cytop are ideally suited for minimizing insertion losses during 
through-space insertion of infrared light via on-chip grating couplers. Genalyte found via 
internal testing that 1100 nm is the optimal Cytop thickness for minimizing optical 
insertion losses. 
4) The ―non-stick‖ hydrophobic nature of the fluorinated polymer helps to restrict binding to 
the annular opening above each of the microring sensors. 
It is vital that the Cytop coverage is uniform and as near to 1100 nm as possible. The coating 
process was optimized by spin-coating the polymer on blank wafers, curing the polymer, and 
measuring the thickness and thickness variability via ellipsometry at various wafer locations. 
All Cytop coating was performed with the CTL-809M variety. The proprietary name 
designation from Asahi Glass Company (Tokyo) indicates: low molecular weight Cytop for extra 
thickness (CTL), high solvent boiling point (180 ºC) designed for spin coating and 9% Cytop 
concentration (809), and direct Si adhesion without ashing (M). Initial Cytop spinning conditions 
were developed outside the cleanroom on 3‖ Si wafers, but the spin conditions for 3‖ wafers did 
not perfectly scale up to 8‖ wafers. This led to a thicker-than-optimal Cytop thickness of 1300 
nm on initial fabrication runs (see Table 2.1). Though the 1300 nm thickness produced sub-
optimal insertion losses during optical coupling, it still resulted in functional chips after 
instrumental adjustments. Genalyte reported that chips from wafers 11 and 12 (with 1300 nm 
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Cytop thickness) can be made to work (i.e. register and maintain stable resonance peaks) by 
adjusting the angle at which light from the external cavity diode laser is coupled into the grating 
couplers. It is possible that problems with chips may be due to either extra Cytop thickness 
and/or grating coupler fabrication (from Si foundry deep-UV lithography); however, the 
observed interference fringe and increased transmission spectral noise was likely due to thicker-
than-desirable Cytop. 
Future work utilized a Cytop spin curve developed using 8‖ silicon wafers to more 
accurately hit the 1100 nm target thickness. Blank 8‖ Si wafers (725 μm thickness, which is 
same as patterned wafers from LETI) were obtained from Wacker Silitronic and brought to 
MNTL. In the past, the following spin protocol yielded ~1300 nm Cytop: 
1) 500 RPM (100 RPM/s ramp), 5 s 
2) 1790 RPM (300 RPM/s ramp), 20 s 
This recipe was empirically tweaked for 8‖ wafer optimization, and the CMOS spinner in MNTL 
Room 207 (see Figure 2.5) was used. This spinner is equipped with a 200-mm (7.874") self-
centering chuck that is well-suited for 8‖ wafers. To optimize the spin protocol, 5 8‖ wafers were 
spun with the following protocols: 
1) 500 RPM (100 RPM/s ramp), 5 s 
2) Wafer 1: 1600 RPM (500/RPM/s ramp), 20 s 
Wafer 2: 1800 RPM (500/RPM/s ramp), 20 s 
Wafer 3: 1900 RPM (500/RPM/s ramp), 20 s 
Wafer 4: 2000 RPM (500/RPM/s ramp), 20 s 
Wafer 5: 2200 RPM (500/RPM/s ramp), 20 s 
In each case, the wafer was centered on the 200 mm chuck and given a test spin prior to pouring 
~30 mL Cytop CTL-809-M (brought to room temperature) onto the center of wafer (1/2 
covered). Immediately after the spin, the hotplate directly built into the spinner instrument was 
used for a 3-min soft bake at 100 ºC. Following the soft bake, the Cytop was cured in a 1-h bake 
at 200 ºC. 
Ellipsometry was performed on the 5 wafers using the Rudolph Fe-III Focus Ellipsometer 
to generate a spin curve. This single-wavelength ellipsometer uses a 640-nm HeNe laser and 
horizontal stage to measure the thickness of layers in a film stack of varying refractive index 
materials. By inputting estimated thickness, refractive indices (n) and extinction coefficient (k) 
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values, the program fits the data with a goal of obtaining a fit error of <1 for a reliable 
measurement. The ellipsometer is unable to measure Cytop thicknesses on patterned wafers due 
to interference caused by waveguides in the beam spot. For each wafer, 8 ellipsometry 
measurements were made at different areas and averaged together to get a mean Cytop thickness 
using the following film stack: 
Cytop [T* (thickness) = 11,000 A (1.1 μm), n* = 1.34, k = 0.00)] 
Si [Substrate (bulk thickness), n = 3.729, k = 0.016] 
*Allow T (thickness) and n (refractive index) to vary while holding k at 0 
 
  As shown in Figure 2.6, increasing spin speed led to thinner Cytop. By fitting a plot of 
Cytop thickness as a function of spin speed with a linear regression, it was determined that 1100 
nm Cytop thickness is associated with a spin speed of 2022 RPM. This spin speed would be used 
in subsequent Cytop spinning on chip-patterned 8‖ wafers. 
 For spin-coating Leti wafers with Cytop, a combination of the spin curve in Figure 2.6 
and empirical analysis should be used to ensure the desired 1100 nm thickness. Though 2022 
RPM worked well in 2010 for getting very close to 1100 nm, the spin curve has to be re-
optimized to take into account the age of the Cytop (stored at 4 ºC). The Cytop solvent can 
evaporate slowly even at cold temperatures and change the viscosity, and precipitates may form 
in the stored bottle over time (which would mar the cladding layer with streaks and specks 
during the spin). Thus, the 2012 fabrication run used the following re-optimized spin recipe on 
Cytop that was vacuum-filtered through a 0.2-µm filter: 
1) 500 RPM (100 RPM/s ramp), 5 s 
2) 2122 RPM (500/RPM/s ramp), 21 s 
This recipe yielded a Cytop thickness of 1114 ± 4 nm. When optimizing the spin recipe, both the 
spin speed and spin time can be tweaked to make sure that the 1100 nm target is attained within 
acceptable error. Additionally, in order to conserve the expensive Cytop, it was found that only 
15 mL poured directly onto the center of the 8‖ wafer is sufficient for full surface coverage. The 
relative coverage of the wafer on pouring relative to volumes used in previous runs is depicted in 
Figure 2.7. 
 Once Cytop is spun and cured on the 8‖ Leti wafers, the wafers are shipped to Grinding 
and Dicing Services, Inc. (GDSI, San Jose, CA) for sectioning into 9 coupons per wafer. The 8‖ 
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wafers were packaged in wafer boxes specifically designed for safe shipment, and all packaging 
was performed in the cleanroom. The sectioning at GDSI results in 9 coupons, 5 of which are 
completely rectangular and 4 of which have 1 curved edge. The sectioning pattern is shown in 
Figure 2.8, yielding smaller coupons for easy handling during lithography and etching at MNTL. 
 
 
2.3 Photolithographic patterning of Cytop 
 Following initial sectioning at GDSI, the wafer sections are received back in individual 
labeled gel packs (adhesive plastic cases that fit 1 coupon each). Of the 9 sections per wafer (see 
Figure 2.8), sections 2, 4, 5, 6, and 8 are regular rectangles (nearly square), while sections 1, 3, 7, 
and 9 have an irregular curved edge on one side. Each section measures 62 mm × 55.8 mm and 
contains 90 chips, arranged in sets of 6 chips (chips also called ―die‖, with slight differences 
between dies 1-6). Thus, there are 5 columns and 3 rows of the 6-chip groups in each coupon. 
Each 6-chip set will represent 1 exposure through the reticle on the wafer stepper, so the reticle 
pattern is repeated for 15 exposures across the chip. Figure 2.9 is a schematic describing the flow 
from wafer to sections to final chips, clearly delineating the dicing workflow and terminology. 
It is vital to make sure that each section is consistently maintained in its labeled gel pack, 
as it is easy to mix them up during processing. To this end, it is best to only work with one 
section at a time and use a checkout sheet to track each processing step for each section. 
Removing the sections from the gel packs is best accomplished by proceeding as follows: 
1) Use flat-edge plastic tweezers to gently separate the edge of the section from the gel. 
2) Very slowly begin to work section off of the gel a little bit at a time by using tweezers 
to push down on stretched gel as the section is gently pulled up. NOTE: Moving too 
fast will result in a torn gel pack. 
3) Once the section is removed, handle it only at the corners with gloved hands. 
4) Place a cleanroom wipe (cut to the size of the gel pack) over the gel for the wafer to 
rest on for easy access during processing. 
Beyond the wafer sections that must be brought into the MNTL cleanrooms, it is also important 
to bring all necessary supplies for the entire fabrication run. An exhaustive list of all necessary 
supplies can be found in Table 2.2.  
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 Spin coating of photoresist on wafer sections. A photoresist coating on the Cytop-
coated wafer sections must be photolithographically patterned as a mask for the subsequent 
Cytop etching step.  Shipley 1813 (Dow Chemical via Microchem) photoresist was used 
exclusively. Shipley 1813, a positive PR, contains a diazo photoactive compound, halogenated 
fluoropolymer esters, and cresol novolak resin in propylene glycol monomethyl ether acetate 
(PGMEA) solvent. As a positive resist, wherever Shipley 1813 is exposed, it becomes soluble to 
the developer solution. Shipley 1813 was aliquotted into 100 mL amber glass bottles for easier 
pouring, and it was important to: 1) degas the bottles overnight after pouring to prevent bubbles 
during pouring onto the wafer sections; 2) to avoid filling bottles above ¾ full for ease of 
pouring; and 3) to wipe the bottle rim between pours to prevent dried PR from flaking off in 
subsequent pours. The PR can be stored in the metal PR cabinet in MNTL Room 211. It is 
important to wear two pairs of gloves (―double glove‖) when working with photoresist, as it is 
messy. When done with a spinning step, the messy top glove can be removed and replaced with a 
fresh one without ever baring skin that causes particulate contamination. 
To prep the spin coater (can use any spin coater in MNTL Room 211), line chamber with 
double layer of foil, punch hole for drain, and center section on 3‖ wafer chuck. Use an 
acetone/isopropanol rinse (2-s squirt with acetone followed immediately by 2-s squirt with 
isopropanol while spinning at high speed) to ensure a pristine wafer surface. The PR was poured 
to completely cover the wafer section (even the corners) to reduce edge bead problems. Thicker 
PR on the edge bead may prevent full development of edge features. The wafer section is then 
spun at 2000 RPM for 30 s (at 600 RPM/s ramp) to yield an approximately 1.8-µm-thick PR 
layer (the ―18‖ in Shipley 1813). After verifying that no streaks are present in the PR coating, the 
section can be picked up carefully at the corners and placed immediately on a 115 ºC hotplate for 
a 60 s soft-bake. At this point, the wafer section is ready to be exposed using the wafer stepper. 
The section can be stored in its labeled gel pack between steps. 
Alignment and exposures with wafer stepper. Exposures of the PR were carried out 
with the GCA DSW-6100 G wafer stepper in MNTL Room 211 (Marty Harris was the super user 
for this tool until 2012, but the tool is currently orphaned since Marty left MNTL and a new 
stepper is being procured). This tool has an independent climate-controlled box (shown in Figure 
2.10), but is very dated (from 1983, running an MS-DOS emulator program in Windows 95). 
Since the wafer sections are rectangular (not circular), it was difficult to get the offsets and 
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alignment of the sections using the available circular chucks. The below protocol is optimized 
for this non-standard use of this wafer stepper.  
Once the stepper is powered up, it can be left on during the fabrication run. However, 
since the stepper is likely powered down (as it is rarely used) when the fabrication run begins, 
the following steps should be taken to bring the instrument online: 
1) Consult Ken Tarman to ensure that proper electrical wiring, wall outlet, and circuit 
breakers are in working order. 
2) Consult John Hughes to replace Hg lamp light source (180 mW/cm2), as it has likely 
been sitting for too long. The light source must be ―brought up‖ with the lamp 
controller box on the bottom of the control console tower, and it takes about 15 min 
to equilibrate at ~180-190 ºC. The N2 flow must be carefully tuned to get the 
temperature to be stably maintained indefinitely. 
3) After the lamp is powered up, turn on the instrument power. There are actually 6 
different on/off switches that must all be on. All click-type switches should be turned 
to on before turning the main power switch on the automatic wafer handler box. 
NOTE: one of the switches is very hard to find since the middle console box must be 
pulled out and the switch accessed behind the front façade. 
4) Once the computer boots up, use the pullout keyboard (no mouse) and Alt + O to 
select the ―Operate Stepper‖ menu and Start Stepper button. This will switch to a 
DOS control menu. 
5) Delete the text after the bracket in the command prompt (should look like [ ?...] and 
hit enter, then enter date and time as prompted. The stepper is now ready to be used. 
6) Perform maintenance on stepper to include: ensuring proper vacuum pressure for 
stage and table, oiling all tracks (3 x- and 3 y-direction rails) in the translational stage 
with a generous coating of top and side surfaces, and ensuring that stage can move to 
full extent of travel range by typing ORIG in the command prompt. 
7) Consult stepper manual in large blue binder for further instructions, as well as the 
following user guides found on the Bailey group shared server folder: 
Luchansky shared/Research Materials/MNTL/GCA Stepper Guide 
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A 5‖ chromium-coated reticle/mask labeled GEN_LETI01A_MNTL is used to make 15 
exposures per regular wafer section (less for irregularly shaped sections) in the pattern depicted 
in Figure 2.9B. The reticle can be placed in the stepper’s optics above the chuck (darker chrome 
side down, which allows the reticle wording to appear legible from above) and carefully aligned 
using the left (series of parallel lines) and right (layers of crosses) alignment marks. Consult the 
manual for instructions on proper reticle alignment. It is also vital to ensure that no particles are 
present on the reticle, as these will lead to unwanted photoresist artifacts in the final 
development. To access the optimized Leti wafer exposure protocol, the following login 
information can be used: 
LOGIN: $MI$DX1 
PASSWORD: GROOBE 
FILE NAME: TEST 
The proper parameters for the multitude of process settings are clearly described in Table 2.3, 
and these parameters should be verified by typing EDIT TEST at the command prompt. Any 
necessary changes to the key offsets after an initial exposure can be carried out by changing 
values in the EDIT TEST command, though little if any changes should be necessary. 
Each wafer section contains 15 sets of 6 die each (5 columns and 3 rows); each exposure 
represents 1 of 15 sets (Figure 2.9B) of 6 die (Figure 2.9C). The removable 3‖ vacuum chuck can 
be removed from the stage to allow wafer section placement. The wafer section was placed on 
the vacuum chuck by carefully pushing up and to the left against the alignment pins (2 on top, 1 
on left side), essentially pushing the section into the upper left corner of the chuck as shown in 
Figure 2.11. The irregular-looking Die 6 (central cluster of rings instead of typical channel 
layout) should be in the lower right of each of the 15 sets of 6 die when looking down at the 
section on the chuck. Then, the chuck vacuum switch can be turned to ―on,‖ and the chuck can 
be placed back on the stage and the stage vacuum switch turned to ―on.‖ NOTE: 
positive/negative directionality indicated below for the software parameters is such that positive 
x is to the right when looking down at the section on the chuck (―user view‖) and positive y is 
down when looking down at the section on the chuck (―user view‖).  Also NOTE: the camera 
view used for alignment is inverted to the user view when loading the wafer section (thus, when 
looking at the alignment screen, up on the screen is positive y (down in user view), and left on 
the screen is positive x (right in user view). 
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As some wafer sections are irregularly shaped (rounded edges), it is also necessary to 
adjust the exposure pattern for sections 1, 3, 7, and 9 to prevent erroneous exposures that shine 
on the chuck itself and reflect back to the light source (causes error due to ―failed‖ exposure). To 
remove appropriate reticles from the exposure pattern, use the dropout option to remove 3 of the 
15 exposures for the irregular sections: type ―D‖ (during ―LAYOUT‖ portion of :EDIT TEST 
above) to display dropout layout. As an example, for wafer section 3 (bottom left corner is 
curved), remove exposures for row 2/column 1, row 3/column 1, and row 3/column 2 by typing: 
R: 2 
C: 1 
R: 3 
C: 1 
R: 3 
C: 2 
NOTE: typing negative numbers next to R and C will restore dropouts to exposures. Irregular 
sections are also difficult to align properly on the vacuum chuck, so it may take a few tries to get 
the position on the chuck straight enough to be within the available range of theta alignment 
adjustment. 
After entering all the correct parameters outlined above, the next step is to finely align the 
wafer section (especially theta alignment) and to perform exposures to ensure that all exposures 
yield well-aligned rings and littrow boxes. After the LOGIN and EDIT TEST functions above, 
type ORIG to tune the laser and reset stage. Then type EXEC TEST to execute the TEST file. 
(NOTE: If ―RETRY‖ appears on the command prompt, type CTRL + Q quickly to abort the 
rogue exposure.) Next, ensure that BRIGHT knob is ―on‖ and alignment crosshairs are visible on 
the screen. The next part takes a bit of practice with the space-age red/green button-keypad: hold 
the RESET button on the keypad for 5 s, then press MANUAL just before pressing the S/C 
button and release the MANUAL button just before releasing S/C. If done correctly, the camera 
should now scan to the correct area of the wafer section for alignment as detailed above. The 
stage should come to rest with the crosshairs between 2 die as shown in Figure 2.12. Move the 
joystick down and right (remember camera is inverted, so actually moving up and left on user 
view) to align crosshairs to the center of the second largest cross in the series. NOTE: Ctrl + O 
allows for the ability to adjust the coarse and fine motion of the joystick (ranging from 1 for 
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smallest step size to 10 for largest step size), depending on whether it is desirable to move over 
large distances. Scan farther to the right with the joystick to confirm that GENCIRCUIT label 
feature is present nearby (this confirms that correct alignment marks have been found). Use the 
following steps in an iterative fashion to achieve proper alignment prior to exposure: 
(1) After centering the crosshairs on the middle cross, use CTRL + D (jog mode, which 
moves by 1-die increments) to move to other die in row 2, and use the most distal (farthest left) 
reticle to perform theta (θ) alignment. NOTE: Theta alignment is counter-intuitive. Use CTRL + 
E to switch out of jog mode once the farthest left reticle is reached. Adjust theta control stick 
appropriately, then  
(2) CTRL + D to jog back 5 clicks to original alignment mark. After typing CTRL + E, 
tweak the x and y positions into the center of the cross. CTRL + O can be used to adjust joystick 
movement step size as needed for coarse, then fine adjustments. It is vital that the crosshairs are 
perfectly centered in the cross, so great care (and lots of practice) must be employed to get this 
just right. 
The alignment process involves repeating steps (1) and (2) until every CTRL + D jog 
from the original centered alignment mark moves the crosshairs to an identical centered position 
on the identical alignment marks on each die in the row. Once the crosshairs remain centered on 
the second-largest cross during scrolling across the entire row in CTRL + D mode, return to 
original alignment mark (where the screen originally initiated) and hit the EXP button (green 
button at top) on the keypad to start the exposure run. Carefully observe the exposures to ensure 
that 15 2-s exposures occur at proper positions on the wafer (should raster from Row1/Column1 
to Row3/Column5 in a serpentine fashion as shown in Figure 2.9B). If an ―Auto-focus failure‖ 
occurs, an adjustment to the lens micrometer is needed. However, a slightly out-of-focus 
exposure will probably still be sufficient, so it is possible to hit enter after each exposure’s auto-
focus failure to manually override through the 15 exposures. Type CTRL + Q when exposures 
are completed. Type LOGOUT and turn off BRIGHT knob when all section exposures are 
completed, and turn off the chuck vacuum and remove the section. The exposed photoresist is 
now ready for development and alignment verification by microscopic inspection. 
Development of exposed photoresist. Photoresist development is carried out in one of 
the acid/base hoods in MNTL Room 235. The wafer section must be safely transported across 
the hall in its appropriately labeled gel pack, taking care when handling to only touch at the 
90 
 
corners and not on the top surface. MF-319, the developer of choice for this process, is stored in 
the base cabinet below the acid/base hood. The MF-319 developer is poured into a glass Petri 
dish within the acid hood. To develop, the wafer section is dunked into the developer for 1 min, 
using plastic tweezers to continuously agitate the wafer by raising the section from below (while 
keeping fully submerged). Since it is better to err on the side of over-development, going slightly 
over 1 min on the development is much better than under-developing. After 1-1.25 min, the 
section should be removed by hand, and the water spray hose in the hood is used to immediately 
stop development by rinsing thoroughly for 1 min. The wafer section is best held at 2 diagonal 
corners with finger and thumb on one hand; finger positions on the corners of the section should 
be rotated halfway through the rinse step to make sure that all developer is washed from the 
corners. Dry the section in the N2 stream in the hood, taking care to ensure all droplets are gone 
and streaking is prevented. The best way to do this is to dry from one side of the wafer section to 
the other, pushing the water boundary off the edge of the section in one continuous sweep. 
Inspection of feature alignment and photoresist integrity. Using the optical 
microscope with camera in Room 235, it is vital to verify that all areas of every wafer section are 
appropriately patterned following development. Especially, it is vital to ensure that all littrow 
windows have centered bar codes (with none covered), all rings are centered in the middle of 
annular openings, all fiducial marks (alignment crosses) are perfectly patterned, and 
―GENCIRCUIT‖ label is centered in a rectangular box (to verify that exposure was not shifted 
by a die). The 22 × 221-µm littrow windows over the barcodes offer the least alignment 
tolerance, so checking their alignment is crucial (and they are easiest to find). It is also important 
to look at disparate areas of the section (4 corners plus center of each section) to verify theta 
alignment across the entire wafer section; small alignment errors lead to ever-increasing 
deviations from ideal from one side of the section to the other. The schematic in Figure 2.13 
depicts perfect alignment, which is the goal of every exposure. However, 1-2 µm errors are 
generally still acceptable for providing functional devices as long as no areas of the wafer reveal 
buried rings or barcodes. If the alignment is sub-optimal, the PR must be stripped with acetone 
and isopropanol on the spinner and the above process repeated (from spin-coating PR to 
inspecting the development). The best way to strip the PR is to center the section on the spin 
coater chuck in Room 211 and start a fast spin, then liberally squirt with acetone followed by 
isopropanol to restore to uncoated Cytop surface prior to reapplying PR. 
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If the alignment must be improved, it is important to take note of the specific nature of 
the misalignment by asking specific questions: 
1. Are all features grossly misaligned or shifted to the wrong die? Is GENCIRCUIT not 
appearing within a rectangular opening? If so, ensure that alignment to the proper set 
of fiducial marks is being carried out (see Figure 2.12). 
2. Is the theta alignment off, as indicated by a change in alignment quality as the chip is 
scanned horizontally or vertically? If so, be more careful when performing alignment 
of the crosshairs before exposures on the stepper. 
3. Are features slightly off-center in roughly the same fashion at all areas of the chip? 
This is the most common scenario, and proper alignment involves adjustment of the 
key offset (see Table 2.3) by micron-scale increments. Key offsets in x and y are in 
units of mm, so adjust the thousandths place after the decimal point. 
A useful example of slight misalignment and the resulting correction is depicted visually in 
Figure 2.14; this figure should be used as a guide for understanding alignment corrections. To 
properly adjust the offsets, it is best to think about the annular opening moving, not the ring 
itself. As far as sign conventions for adjusting the key offsets, they are as follows: +Y direction 
is down and +X direction is to the right on the microscope screen. Once a proper alignment is 
obtained, the Cytop on that section is ready to be etched through the PR mask. It is best to obtain 
proper alignment on all 9 sections of a wafer prior to proceeding to the etching step, as an entire 
wafer can be etched at once. 
 
 
2.4 Reactive ion etching of Cytop through photoresist pattern 
Cytop etch rate analysis. Prior to performing reactive ion etching (RIE) on the patterned 
wafers, the Cytop etch rate had to be determined in order to optimize the etch time. First, 3‖ Si 
test wafers were coated with Cytop at 500 RPM for 5 s (100 RPM/s ramp) and then 1800 RPM 
for 20 s (300 RPM/s ramp). An immediate soft bake at 100 ºC on a hotplate for 3 min was 
carried out prior to curing for 1 h at 200 ºC in oven. For the etch rate analysis, it was important to 
get an accurate starting Cytop thickness. Using the Rudolph FE-III Ellipsometer in MNTL Room 
241, the following parameters were entered as a film stack starting point for the fit (―Luchansky‖ 
recipe): 
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Cytop [T* (thickness) = 10,000 A (1.1 μm), n* = 1.34, k = 0.00)] 
Si [Substrate (bulk thickness), n = 3.729, k = 0.016] 
*Allow T (thickness) and n (refractive index) to vary while holding k at 0 
 
Ellipsometry measurements were performed at 6 areas around the wafer, converging on a pre-
etch thickness of 1006 ± 2 nm and refractive index of 1.326. It is important to adjust starting 
parameters and tweak the position of the measurement to get the fit error <1. 
Next, oxygen/argon RIE was carried out for short, carefully controlled times under the 
optimized conditions described in the next section (9.8 sccm O2, 50 sccm Ar, 16 mTorr, 100 W, 
310 V DC bias). In RIE, a dry etching process, a plasma is generated by applying RF power 
between two electrodes in a chamber. The ionized gas molecules in the plasma chemically react 
selectively with areas of the substrate, often using PR as an etch mask. 3 consecutive etches (of 
20 s, 34 s, and 42 s) were performed, taking care to note the exact time spent under RIE 
conditions. After each etch step, the Cytop thickness was measured at 8-12 positions around the 
wafer to monitor the etch depth variation with time. The Cytop thickness was noted to gradually 
decrease from 1006 ± 2 nm to 877 ± 9 nm to 676 ± 8 nm to 301 ± 7 nm with each RIE step. 
NOTE: At later etch times, it was necessary to let k vary as the surface became rougher and less 
glossy; as the thickness decreased, the refractive index began to substantially deviate from the 
known refractive index of Cytop (n = 1.34).  
As shown in Figure 2.15, by performing a linear regression of the thickness at etch time t 
vs. t, the etch rate (slope) was calculated to be 7.3 nm/s (440 nm/min). Thus, a 4-min RIE time 
for chip fabrication is ideal for ensuring the complete removal of ~1100 nm of Cytop without 
excessive degradation of the PR mask. 
Optimization of RIE protocol. RIE on exposed Cytop below developed PR had to be 
optimized to ensure a clean final product with smooth sidewalls, minimal undercutting of 
features, and complete Cytop removal (as shown in Figure 2.2). Many RIE parameters were 
varied and optimized prior to settling on the parameters discussed in the following section. In 
general, SEM was used on blank wafers with Cytop patterns following RIE to observe how 
specific changes to the RIE protocol resulted in changes in Cytop cladding integrity. Overall, the 
goal was to avoid a rough Cytop top layer (Figure 2.16A shows a sub-optimal roughened Cytop 
surface), furry Cytop side walls when the chip is viewed at an angle (Figure 2.16B defines furry 
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sidewalls), and excessive PR debris (Figure 2.16C depicts a dirty etch that leaves behind a large 
amount of Cytop and PR debris). Profilometry was also used to confirm the flat bulk surface of 
Cytop and absence of PR, as well as the Cytop thickness. Since it is known that O2 etches 
polymers (like Cytop)
7
 with the native oxide layer of the SOI wafer as a natural etch-stop,
8
 
various O2 mixtures were evaluated. The following observations regarding RIE conditions were 
made prior to settling on an optimized protocol: 
1) O2 plasma in RIE should be yellow, but typically appears blue/gray/purple due to 
residual polymers and PR in the chamber. 
2) Exclusive use of O2 in RIE leads to ―furry‖ sidewalls in Cytop. 
3) CF4 in combination with O2 RIE promotes smooth Cytop sidewalls in ring wells and 
improves selectivity of the etch for Cytop over PR, but CF4 will etch the underlying 
native silicon oxide layer. 
4) CF4 has no natural etch stop, which is not ideal, but O2 has a natural etch stop of SiO2 
(thus it will not etch Si through SiO2 layer). 
5) Pure O2 descum (even a short 15-s descum) at the end of an RIE protocol leads to 
surface roughness and debris. 
6) Ar acts as a passivating carrier gas to reduce the roughness of the Cytop and chip 
surface caused by RIE. 
7) Low chamber pressure is vital (the lower the better) to exhaust etching debris and 
maintain a clean surface, especially if several wafer sections are etched together.  
8) Hard baking PR prior to RIE (5-10 min at 120 ºC) does not improve PR robustness, 
but only leads to decreased resolution and feature broadening. 
9) Curved features in profilometry inspection of littrow window areas after RIE are good 
indicators of incomplete PR removal, and straight/level features should be verified. 
10) Piranha can be used as a final descum step to remove small (<10 nm) particles. 
11) It is important to etch off a large portion of PR to ensure complete stripping of PR in 
resist stripper after RIE. 
 
The PlasmaLab Freon/O2 Reactive Ion Etcher System in MNTL Room 232 was used in 
the optimized RIE protocol (training is obtained with Yaguang Lian, the super user, and he 
should be consulted to ensure safe use). Importantly, the addition of Ar as a passivating (carrier) 
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gas to the O2 led to smooth sidewalls and a cleaner etch. Since low pressure was found to be vital 
to removing etch debris, the PlasmaLab RIE system is ideal because the turbo pump can get 
down to pressures approaching 10 mTorr. The Cytop etch rate analysis (Figure 2.15) showed that 
a 4-min etch should be able to remove all 1100 nm of Cytop and some, but not all, of the PR 
mask. The final optimized RIE parameters are listed in Table 2.4. NOTE: Before and after the 
RIE run, the chamber should be thoroughly cleaned by 1) wiping plate, sides, and lid with 
deionized water and coarse green scrub pad, 2) wiping down with isopropanol on a cleanroom 
wipe until wipe comes off clean, 3) plasma cleaning with a 30-60-min cycle of 50% O2 (Gas2) at 
20% RF power (90W at 190V DC bias) and 350 mTorr chamber pressure, and 4) wiping down 
again with isopropanol. Also NOTE: Since CHF3 is also used as an etch gas in the same channel 
as Ar, gas line 3 must be purged before and after use of Ar while the T-valve is closed. Also, it is 
vital to ensure that appropriate gas cylinder (O2 and Ar) valves are opened before the run and 
tightly closed after the run. 
In the initial chip fabrication runs, RIE was performed on one section in the chamber at a 
time with a 5-min oxygen plasma cleaning between each section, but it was eventually noted that 
it is possible to perform RIE on up to 9 sections (entire 8‖ wafer) simultaneously and still get a 
clean etch. Later fabrication runs (Table 2.1) took advantage of the ability to etch an entire wafer 
(9 sections) simultaneously to cut down on time. NOTE: take care to re-assemble the wafer 
sections at known locations (Figure 2.8) so that they do not get mixed up in the RIE chamber. 
Stripping of photoresist after etch. There is roughly 1.8-2 μm of PR on the sections 
after spin coating, and most of that should remain through the RIE step. Though it is possible 
that the PR be left on the chips until after dicing into chips (and removed directly before using 
the chips in ring resonator experiments), initial fabrication runs concluded with bulk stripping of 
PR from sections prior to being sent for dicing into individual chips. Shipley 1813 PR was 
effectively stripped after RIE with Shipley 1165 stripper (Microchem) as follows: 
1) 12-min soak in 1165 stripper in glass Petri dish 
2) 5-min sonication in acetone while section is leaned nearly vertical against a plastic 
pipette box insert placed inside of a 500 mL glass beaker holding acetone 
3) Dunk in isopropanol, the dried in a nitrogen stream 
4) Section placed in appropriate gel pack for storage and shipment to GDSI for dicing 
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Stripped (or not stripped of PR, depending on needs) sections are sent to GDSI for final 
dicing (―sub-dice‖) into individual chips. Jeremy Favia is the contact at GDSI, and he has access 
to the dicing travelers for past Leti fabrication runs. Regardless of whether or not the PR is 
stripped before dicing, it is vital to ensure that no PR residue is left on the back side of the wafer 
sections. This will lead to delaminating of the wafer section from the dicing tape during final 
dicing (Figure 2.17). Delamination can allow the dirty dicing water to contaminate the top chip 
surface and must be avoided; backs sides of wafer sections can be carefully wiped with acetone 
to remove PR residue. GDSI will return the gel packs full of individual chips (Figure 2.18). 
 
 
2.5 Parting thoughts regarding chip fabrication 
 The protocols that are described at length (and possibly, ad nauseum) in this chapter are 
meant to not only serve as a record of dissertation work, but also a guide for future students 
faced with a shortage of microring resonator chips. The next generation of 128-plex Genalyte 
chips will be fully commercially available (with no need for late-stage Cytop processing at 
MNTL described here); however, this information remains far from obsolete due to the reliance 
on the Leti chip design (Figure 2.1) when working with the original (first-generation) 
instruments in the Bailey lab. 
 When working with these protocols, the goal is to obtain a large majority (ideally >90%) 
of high-quality, fully functional microring resonator chips from each 8‖ wafer. Factors such as 
improper Cytop thickness, misalignment, a thick PR edge bead, a dirty etch process, and 
scratching/mishandling during processing all contribute to lower-than-desirable chip yields. 
These protocols, if properly followed, should yield a very high percentage of well-aligned Cytop 
openings within an 1100 nm cladding layer with smooth sidewalls and a pristine microring 
surface. This will allow the user to take full advantage of the inherent scalability of microring 
resonator technology based on CMOS processing. 
 Now that the chip design and the associated fabrication steps have been fully described, 
the next logical step is to understand how silicon photonic microring resonators work in practice. 
The following chapter will characterize the physical and optical properties of the sensing 
platform, including a focus on signal transduction, contributions to signal intensity (with a focus 
on the evanescent field), and a firm definition of the mass sensitivity metrics. 
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2.6 Figures 
 
 
 
Figure 2.1 Original microring resonator chip design. 64 microring sensors are arranged in 4 rows 
of 16 each on a 6.2 × 6.2 mm SOI substrate. The 30-µm-diameter Si rings and associated U-
shaped waveguides are 500 nm wide and 200 nm tall. Each ring is accessed by an independent 
U-shaped waveguide; 32 rings are accessed from the right side of the chip, and 32 from the left. 
Of the 32 rings accessed from the left and monitored simultaneously by Genalyte optical 
scanning instrumentation, 8 serve as thermal controls and are buried beneath the Cytop 
(perfluoropolymer) cladding layer. Barcoded littrow boxes are used to register each ring in the 
array. Boxes containing fiducial marks for lithographic alignment are evident in each of the 4 
corners of the chip. 
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Figure 2.2 8‖ SOI wafer containing ~700 individual chips. Following initial patterning of 
photonic elements at the Leti silicon foundry, this chip is ready to be coated in Cytop before 
completing the final processing steps that are conducted in the MNTL cleanroom. The colorful 
diffraction pattern evident in the picture is created by diffractive grating couplers used to insert 
light into the Si waveguides that access each ring. 
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Figure 2.3 Scanning electron micrograph of a silicon photonic microring resonator. The 30-µm 
Si ring is centered within the annular opening in the cladding layer, which features smooth 
sidewalls and minimal etching debris. The linear waveguide is evident at critical coupling 
distance (100-200 nm) from the ring waveguide. 
 
 
 
 
 
 
 
Figure 2.4 Cytop structure. Both the monomer and polymeric structure of the perfluoropolymer 
are shown. Figure adapted from Cytop technical brochure, Asahi Glass Company. 
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Figure 2.5 CEE 100 CB programmable spinner. This spinner is able to fit 8‖ wafers using a 200 
mm self-centering chuck and contains a built in hot plate (at left) for immediate Cytop soft-bake 
prior to curing. These functionalities are vital as they minimize any variation during transport of 
wafers to an external hot plate or oven. 
 
 
 
 
Figure 2.6 Cytop spin curve on 8‖ 725-µm-thick Si wafers. Cytop thickness, as determined by 
ellipsometry, decreases with increasing spin speed. Error bars represent the standard deviation 
for 8 measurements made at various locations around the wafer. By inverse regression, the target 
1100 nm thickness is achieved at a spin speed of 2022 RPM. 
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Figure 2.7 Cytop coverage of 8‖ wafer upon pouring and before spinning. 15 mL of Cytop, 
which covered only the inner circle of the wafer, was found to be sufficient for full surface 
coverage after the spin. Though 30 mL (~1/2 surface coverage on pour) and 70 mL (complete 
coverage of wafer on pour) also give full coverage after the spin, only 15 mL should be used in 
order to conserve the expensive polymer. 
 
 
 
 
 
Figure 2.8 Sectioning pattern. 8‖ wafers are initially diced into 9 sections each. 5 of the sections 
(2, 4, 5, 6, and 8) are regular rectangles with dimensions of 55.8 mm × 62 mm, while 4 of the 
sections (1, 3, 7, and 9) have 1 curved edge. A full rectangle contains 90 chips in a 9 × 10 array. 
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Figure 2.9 Wafer sectioning schematic. (A) Each 8‖ wafer is initially diced into 9 sections. Each 
section measures 62 mm × 55.8 mm and contains 90 chips, arranged in sets of 6 chips (chips also 
called ―die‖, with slight differences between dies 1-6). The sectional numbering system is also 
delineated. (B) Each of the sections contains 5 columns and 3 rows of the 6-die groups. The 
numbers in each die group represents the order in which sets of 6 chips are exposed on the wafer 
stepper. (C) Each 6-die set represents 1 exposure through the reticle on the wafer stepper, so the 
reticle pattern is repeated for 15 exposures across the chip. Final dicing (the second dicing step) 
results in individual chips. Die numbers (1-6) correspond to minor differences in chip design, 
and the die identity can be found in the upper left corner of each device. 
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Figure 2.10 GCA DSW-6100 G-Line Series wafer stepper at MNTL. The wafer stepper is 
housed in an environmental chamber and consists of a Hg lamp light source, a translational stage 
with vacuum chuck for moving the substrate for aligned exposures, a wafer handling system for 
manual fiducial alignment, and imaging optics and interferometers for precise movements. 
Figure taken from http://mntl.illinois.edu/equipment/Images/FullScale/gca_dsw6100.jpg. 
 
 
 
 
Figure 2.11 Schematic depicting rectangular wafer section alignment on round wafer stepper 
vacuum chuck. To achieve optimal placement on the chuck, the section (red rectangle) is pressed 
firmly up against the alignment pins (small blue circles at edge), and then the chuck vacuum is 
switched on to hold it in place. Though the section still covers the vacuum hole (green circle at 
center), it is no longer centered on the chuck since the chuck is designed for round wafers. 
Parameters had to be optimized to account for 1) a translation of the origin (center of the 
substrate) up and to the left of the chuck center as well as 2) for the top left corner overhang 
outside the normal range of the exposures for a round wafer. Wafer sections with curved edges 
(sections 1, 3, 7, and 9) are more difficult to load on the chuck properly. 
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Figure 2.12 Alignment starting point for effective section alignment prior to exposing 
photoresist on wafer stepper (alignment TV screen view). If the wafer section is properly 
positioned on the vacuum chuck, the automatic wafer handling controls should automatically 
cause the alignment crosshairs to travel to the proper location (black X). NOTE: the microscope 
lens should be visible over the left center portion of the wafer section as it is viewed by the user 
on the stage within the stepper chamber. The alignment screen image should come to rest 
between die as shown above, and by moving down and to the right with the alignment joystick 
over the littrow box barcodes, the fiducial marks in the bottom left corner of the die are found. 
Since the die look almost identical (each has alignment fiducial marks in each corner), it is vital 
to scan to the right to verify that the ―GENCIRCUIT‖ label is present immediately to the right of 
the fiducial marks. This verifies that those fiducial marks are the proper ones to align to, and that 
the alignment is not off-center on the wrong die. Once verified, the alignment process can begin 
on the second-largest alignment mark (cross shape), as indicated by the red X above. From this 
point, theta alignment must be carried out by jogging horizontally (Ctrl + D) to other die and 
adjusting the theta joystick in the same direction as the theta error (NOTE: this is 
counterintuitive!). When the section is properly aligned, jogging horizontally between identical 
alignment marks on adjacent die will show maintenance of the crosshair (red X) as perfectly 
centered within the proper alignment mark cross. 
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Figure 2.13 Fiducial marks depicting perfectly aligned photoresist features after development. 
PR boxes that remain after development should perfectly line up with the fiducial crosses across 
the entire wafer section to verify suitable theta alignment. Since over-development often occurs, 
the boxes may not perfectly touch the crosses, but nevertheless, the crosses should still be 
centered within the sets of 4 boxes. These features are also useful for adjusting any misalignment 
as they provide excellent scale references for choosing a magnitude for altering the key offsets in 
the stepper parameter sequence. The bars in the central cross (used for aligning stepper 
crosshairs) are 5 µm wide. 
 
 
 
Figure 2.14 Example of adjusting key offsets based on careful alignment inspection. (A) When 
the wafer section is inspected with the microscope in MNTL Room 235 (20x lens works best in 
addition to the extra 4x zoom afforded by the built-in video camera and TV), a misalignment is 
evident. The 30-µm ring is off-center in the ~10-µm-wide annular opening, sitting down and to 
the right of the annular opening. The offsets used in the exposure that resulted in the 
misalignment are indicated, as are the proper directional sign conventions. (B) To fix the 
alignment, the PR must be stripped, re-spun, re-exposed, and re-developed with different offsets. 
To properly adjust the offsets, it is best to think about the annular opening moving, not the ring 
itself. It is clear that the annular opening must move down (+Y direction) and to the right (+X 
direction) to be properly centered over the ring. In this case, a 2-µm adjustment of the offsets in 
each direction was sufficient upon the second round of inspection. However, it often takes a few 
rounds of re-alignment to get it just right. 
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Figure 2.15 Determination of Cytop etch rate under low-pressure O2/Ar conditions. Cytop was 
coated on a 3‖ blank Si wafer and cured. Reactive ion etching was performed under the 
following conditions: 9.8 sccm O2 (10%), 50 sccm Ar (18%), 16 mTorr, 100 W, 310 V DC bias. 
Cytop thickness was verified by ellipsometry after stopping the etch at defined times. Error bars 
represent the standard deviation of n = 8-12 ellipsometry measurements taken at various areas of 
the wafer at each time point. By fitting a linear regression to the data, an etch rate of 7 nm/s was 
determined. This etch rate was used to optimize the etch time to fully remove 1100 nm of Cytop 
through a patterned PR mask. 
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A          B 
 
C          D 
 
 
Figure 2.16 Scanning electron microscopy (SEM) analysis of RIE conditions. SEM analysis of 
Au-sputter-coated blanks and microring resonator chips was performed with Ji-Yeon Byeon at 
MRL to observe changes in the bulk Cytop surface and sidewalls in a variety of etch conditions. 
RIE etch gases, pressures, times, and powers were optimized to avoid (A) excessive Cytop 
surface roughness, (B) furry sidewalls and sidewall undercutting, and (C) large amounts of 
PR/Cytop debris in the etched wells. (D) A 4-min low-pressure O2/Ar etch was found to be ideal. 
Scale bars are indicated in each figure section. 
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Figure 2.17 Delaminated chips during final dicing. If PR residue is not removed from the back 
side of wafer sections prior to final dicing, poor adhesion leads to delaminated chips. This can 
allow contamination of the top side of the ring resonator arrays with dirty dicing water, which 
must be avoided. Image courtesy of Rey Sana, Grinding and Dicing Services, Inc. 
 
 
 
 
Figure 2.18 Final dicing results in ~700 chips from each 8‖ Leti wafer. 
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2.7 Tables 
 
Table 2.1 Fabrication runs and logistical timelines 
 
Run 
# 
Dates* 
(Lithography/Etch) 
Wafer sections processed 
(Wafer #-Section #) 
Cytop thickness 
(from ellipsometry on blank) 
1 11/5/09-11/13/09 4 (11-3, 11-7, 12-3, 12-7) 1300 nm 
2 1/4/10-1/6/10 14 (remaining from wafers 11, 12) 1300 nm 
3 7/6/10-7/9/10 31 (27 LETI sections, 4 IMEC) 1135 nm 
4 8/15/12-8/24/12 45 (5 LETI wafers) 1114 nm 
*Includes fabrication time only while excluding time for optimization and preparatory work 
 
 
 
 
Table 2.2 Necessary supplies for transport into cleanroom 
 
 
 
 
 
 
 
 
 
Supply Quantity Notes 
Fabrication instructions 
and parameters 
- Must be on cleanroom paper 
Cytop CTL-809M 
15 mL per 8‖ wafer 
(from Asahi Glass) 
Sold in 100 mL bottles, stored at 4 ºC, allow to 
degas before pouring 
Wafer sections 
9 sections per wafer  
(1 wafer ~ 700 chips) 
Should always be transported in gel packs within 
sealed plastic 
Mask (reticle) 1 
Previously used GEN_LETI01A_MNTL (load Cr 
side down) 
Shipley 1813 
photoresist 
1 qt  
(from Microchem) 
Aliquot into 100 mL amber vials for easy pouring 
(allow to degas), check expiration date 
MF 319  
developer 
1 gal  
(from Microchem) 
Only sold in 4 gal case 
Tweezers 3-4 
Assorted plastic tweezers with various tip shapes 
and metal wafer tweezers 
Glassware 2 
Glass Petri dish for development and beaker for 
stripping photoresist (if desired 
Lab glasses 1 Common-use cleanroom goggles are dirty 
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Table 2.3 Starting point for optimizing parameters on GCA DSW 6100 wafer stepper 
 
Command/Prompt Parameter Notes 
Type ―LOGIN‖ 
PASSWORD 
$MI$DX1 
GROOBE 
Hit ―Enter‖ after typing 
FILE NAME TEST Contains Leti parameters 
Type ―EDIT TEST‖  Allows editing of parameters 
TOLERANCE 3  
SCALE CORRECTIONS NONE  
ORTHOGONALITY blank  
WAFER DIA 101.6 
Chuck size is 76.2 mm, but 
rectangular section overhangs 
STEP SIZE IN X 
COUNT 
12.4 
5 
5 columns at 12.4 mm pitch 
(see Figure 2. ) 
STEP SIZE IN Y 
COUNT 
18.6 
3 
3 rows at 18.6 mm pitch 
(see Figure 2. ) 
TRANSLATE ORIGIN 
IN X 
IN Y 
 
-7.1 
-7.452 
To adjust for rectangular 
section on circular chuck 
(units in mm) 
LAYOUT 
Should return proper array of 
5 rows and 3 cols 
1
st
 row, col: should read 
X: -31.9, Y: -26.052 
STANDARD KEY Y Y = yes 
KEY OFFSET 
IN X 
IN Y 
 
6.7658 
-9.0480 
Often requires minor tweaking 
for each new wafer 
(units in mm) 
<<PASS INFO>> 
PASS/NAME 
EXPOSURE (SEC) 
 
1 
2.0* 
Single exposure (called ―1‖) 
with a 2-s exposure at each of 
15 sets of 6 die 
*Lamp = 180 mW/cm
2
, so total dose is 360 mJ/cm
2
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Table 2.4 Optimized reactive ion etch parameters for PlasmaLab Freon RIE in MNTL 232 
 
RIE Parameter Input Value Actual Notes 
Gas 1 (CF4) 0 0 CF4 cylinder should be closed 
Gas 2 (O2) 10% 10.1% 10%  O2 = 10 sccm O2 
Gas 3 (Ar) 18% 18.2% 
Gas 3 line shared between Ar and 
CHF3, so purge T-junction first 
18% Ar = 50 sccm Ar 
Pressure 1 mTorr 14-16 mTorr 
Want pressure as low as possible 
for clean etch 
RF 
(forward power) 
22% (100 W) 10% (100 W) 
Ensure 100W (adjust RF% to get 
desired wattage) 
Time 4 min 4 min, 15 sec 
Automatic Operation leads to some 
lag time 
DC Bias - 320 V 
Will vary slightly depending on 
how many sections in chamber 
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Chapter 3 
 
CHARACTERIZATION OF THE EVANESCENT FIELD 
PROFILE AND BOUND MASS SENSITIVITY OF A 
LABEL-FREE SILICON PHOTONIC MICRORING 
RESONATOR BIOSENSING PLATFORM 
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3.1 Introduction 
Waveguides, including fiber optics, have become valuable tools for detecting chemical 
and biological species through a range of optical transduction mechanisms, including 
absorbance, fluorescence, and refractive index-induced phase or transmission intensity 
modulation.
1-6
 For all waveguide materials and geometries, light propagates through the 
waveguide on account of total internal reflection that occurs due to the contrast in refractive 
index between the core and cladding materials. At the core/cladding interface, an evanescent 
optical field extends from the surface and decays exponentially with distance.
7
 Regardless of the 
particular transduction mechanism utilized for sensing, the measured signal is elicited through 
light-matter interactions between this evanescent field and proximal target molecules. 
 Most relevant to this report are label-free transduction methods whereby the presence of a 
particular analyte causes a fundamental change in the optical transmission properties of the 
waveguide, thus eliminating requirements for chromophoric or fluorescent labels.
8
 In most 
examples, the waveguide is chemically modified to present a target-specific capture element, and 
localization of the analyte at the core-cladding interface leads to an attenuation in the power of 
the transmitted light. 
Recently there have been reports of chemical and biomolecular sensors based upon 
waveguides fabricated from a range of different materials, many of which leverage advances in 
semiconductor processing for micro- or nano-scale device fabrication.
1
 A particularly promising 
waveguide material is silicon-on-insulator (SOI), a feedstock of the microelectronics industry.
9
 
114 
 
SOI waveguides are patterned into the top layer of silicon, and light is effectively guided due to 
the high refractive index contrast between Si and the cladding layers, which include the buried 
oxide and the top/side cladding layers. In addition to the obvious advantages of SOI in terms of 
scalability and potential for mass production, silicon photonic devices also feature good modal 
overlap between the guided optical mode and an analyte recognition layer.
10
  The high refractive 
index of the waveguide core layer leads to a high sensitivity towards surface-confined binding 
events. Several groups have demonstrated silicon photonic waveguide configurations for 
chemical or biological sensing applications, including Mach-Zehnder interferometers,
10-12
 
resonant gratings,
13
 and microcavity resonators.
14-18
 Using arrays of SOI microring resonators, 
we previously reported  a bulk refractive index sensitivity of 7.6 × 10
-7
 refractive index units 
(RIU)
19
 and have demonstrated the sensitive, label-free detection of multiple proteins and nucleic 
acid sequences in both single and multiparameter analytical applications.
20-23
 
Another label-free optical method that is particularly well-suited to analyzing 
biomolecular binding, thus serving as a basis for comparison, is surface plasmon resonance 
(SPR). SPR measures the interaction of an evanescent field extending from a metallic film, 
usually gold, in contact with the analyte-containing solution. Binding events that change the 
refractive index at the gold-solution interface are measured either as a change in the angle or 
wavelength of light which is maximally coupled into the metal film. SPR has been actively 
investigated as a biosensing technique over the past several decades with a number of reported 
sensor geometries and modes of operation, several of which are available commercially.
24-26
 For 
SPR sensors, the evanescent field penetration depth, which is a function of wavelength and 
dielectric environment, is on the order of hundreds of nanometers
27
 with bulk refractive index 
sensitivities usually varying between 10
-5
 and 10
-7 
 RIU.
25, 28
 For reference,
25
 a bulk index 
sensitivity of 10
-6
 RIU corresponds to a surface coverage resolution of 0.91 pg/mm
2
. 
This chapter presents a simulation of the waveguide optical intensity profile as well as a 
direct, experimental interrogation of the evanescent intensity decay profile of a silicon photonic 
microring resonator. We empirically measured the distance dependence of the sensing platform 
utilizing layer-by-layer electrostatic polymer multilayer deposition.
29, 30
 We also directly 
determined the bound mass sensitivity and limit of detection (LOD) of our system by correlating 
the resonance wavelength shifts with the amount of bound 
125
I-lableled streptavidin, measured 
via radiometric methods. Importantly, this chapter presents key, experimentally determined 
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sensitivity metrics for an emerging silicon photonic biomolecular sensing platform. In addition to 
providing a benchmark for comparison, the dependence of device sensitivity on distance from 
the sensor surface will be important when designing coatings for optimal analyte recognition and 
localization within the evanescent intensity profile of the guided optical mode. 
 
 
3.2 Materials and methods 
Materials. N-hydroxysuccinimidobiotin (NHS-Biotin), streptavidin, Zeba spin filter 
columns, and pre-coated iodination tubes were obtained from Pierce (Rockford, IL). 3-
aminopropyltriethoxysilane (APTES) was purchased from Gelest (Morrisville, PA). 
Succinimidyl 4-formylbenzoate (S-4FB) and 3-N-((6-(N'-Isopropylidene-
hydrazino))nicotinamide)propyltriethoxysilane (HyNic silane), were purchased from SoluLink 
(San Diego, CA). Shipley 1813 photoresist, MF 319 developer, and 1165 photoresist stripper 
were purchased from MicroChem Corp. (Newton, MA). Poly(sodium 4-styrene-sulfonate) (PSS, 
MW~70,000 Da) , polyethyleneimine (PEI, 50% w/w in H2O, MW~750,000 Da), and 
poly(allylamine hydrochloride) (PAH, MW~56,000 Da) were obtained from Sigma Aldrich (St. 
Louis, MO). Biotinylated, monoclonal mouse anti-human IL-2 antibody (catalog# 555040, clone 
B33-2 was purchased from BD Biosciences (San Jose, CA). All other chemicals were used as 
received from Sigma Aldrich (St. Louis, MO). 
All buffers were made with purified water (ELGA PURELAB filtration system; Lane 
End, UK), and the pH was adjusted using 1 M HCl or 1 M NaOH. Tris buffer consisted of 0.5 
mM Tris and 100 mM NaCl adjusted to pH 7.1.  Tris/ EDTA buffer was made by dissolving 1.21 
g Tris base, 0.558 g disodium EDTA, and 0.2 g sodium azide in 1 L water and adjusting to pH 
7.4.  PBS was made by dissolving 9.6 g Dulbecco’s phosphate buffered saline mixture into 1 L 
water and adjusting to pH 7.4. Antibody immobilization buffer consisted of 100 mM PBS with 
150 mM NaCl adjusted to pH 6.0. BSA-PBS buffer consisted of 0.1 mg/mL BSA in PBS. For 
blocking, StartingBlock blocking buffer (Pierce) was used. 
Microring resonator array chips and instrumentation. The design and fabrication of 
microring resonator array chips, the accompanying instrumentation, and the fluidics have been 
described in other papers and in Chapter 2.
19, 22
 Briefly, chips having 32 individually addressable 
microrings were used for the experiments. The entire substrate was coated with a fluoropolymer 
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cladding layer that was removed from annular openings over 24 of the sensors. The remaining 
eight microrings were left occluded by the cladding and were utilized as thermal controls, since 
they were not exposed to the solution. Microring resonance frequencies were measured as 
described previously. Briefly, the beam of a 1560-nm center wavelength tunable, external cavity 
diode laser is focused onto an input grating coupler on the chip surface to couple light into the 
linear waveguide adjacent to a given microring. The laser output is then rapidly swept through a 
12-nm spectral window, and the intensity of light projected from the output grating coupler is 
monitored as a function of laser wavelength. Resonance wavelengths are determined as minima 
in output coupler intensity. This process is repeated for each interrogated microring sensor by 
rastering the laser across all 32 input grating couplers, allowing resonance determination with 
~250-ms time resolution. Thermal control ring responses are used to control for ambient thermal 
drift. 
Layer-by-layer deposition. For the layer-by-layer electrostatic deposition of polymers, 
PEI, PSS, and PAH were dissolved in Tris buffer to 5 mg/mL. After cleaning the microring 
surface with piranha solution (3:1 H2SO4:H2O2) and loading the chip into a previously described 
microfluidic flow cell,
22
 chips are exposed to PEI for 5 min at  30 µL/min. Maintaining constant 
flow conditions with a P625 peristaltic pump from Instech Laboratories (Plymouth Meeting, 
PA), the surface is then rinsed with Tris buffer and exposed to PSS for 10 min followed by a 
buffer rinse. The surface is then exposed to PAH for 4 minutes with a 5 minute buffer rinse. The 
PSS and PAH deposition cycles (with the PSS time reduced to 6 minutes) and buffer rinses were 
repeated until a total of 72 bilayers had been grown.  
To facilitate automated solution switching, we constructed a robot using the LEGO 
(Billund, Denmark) MINDSTORMS NXT 2.0 system that automatically moved the inlet tubing 
between solutions. The robot design is shown in Figure 3.1. To automate fluid delivery, 0.38-mm 
inner diameter Teflon inlet tubing was connected from the ring resonator microfluidic system to 
the sipper arm motor of the robot which rotated up and down ~55 to raise and lower the tubing 
into the six different solutions used for the multilayer experiments. Typically, solutions 1–3 
contained running buffer and the two components of the multilayer experiment while solutions 
4–6 contained buffer rinses so that solution on the tip of the tubing would not contaminate the 
other vials. To switch solutions, first the arm was raised, and then the rotating platform turned 
60, and then the arm was lowered into the next vial. The control console was programmed using 
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LEGO MINDSTORMS NXT 2.0 software and powered with a 9.0 V DC power supply. 
Constant fluid flow was maintained via the peristaltic pump fitted with 0.79-mm inner diameter 
silicone tubing which was connected to the 0.5-mm inner diameter Tygon outlet tubing of the 
microring resonator system. 
Deposition of protein multilayers for evanescent field characterization. To verify 
PAH/PSS bilayer thickness ex situ (i.e. outside the resonator setup), we performed a large-area 
layer-by-layer experiment on four different silicon substrates. In order to confirm both the layer 
thickness and the growth linearity, the layer growth process was halted at a different point for 
each wafer section prior to performing ellipsometry. Because ellipsometry requires a wider area 
than what our microfluidic channels provide, we created the multilayers on the silicon wafer 
pieces using a dipping approach rather than a microfluidic flow-based approach. We utilized the 
same concentrations and exposure times for the microfluidics setup, and we reconfigured the 
LEGO robot to dip the pieces of silicon wafer into the solution vials. At the end of the layer 
growth, each substrate was washed briefly with water and then dried under a gentle stream of 
nitrogen. Ellipsometry was performed using a J.A. Woollam variable angle spectroscopic 
ellipsometer (Lincoln, NE). For each spot, three different angles of incidence were measured 
(65, 75, 85) and the thicknesses were calculated assuming a SiO2 thickness of 2.4 nm, and a 
Cauchy layer model for the dried polyelectrolyte bilayers with an assumed refractive index of 
1.68.
31
  
Prior to performing layer-by-layer deposition of proteins, hydrazine moieties were 
installed on the silicon oxide chip surface by flowing a solution of HyNic-silane (1 mg/mL in 
95% ethanol and 5% dimethyl formamide) over the surface for 30 min at 5 µL/min followed by 
rinsing with ethanol. Separately aldehyde groups were introduced to biotinylated IgG antibodies 
by reaction with a 5-fold molar excess of 0.2 mg/mL S-4FB for 2 h at room temperature. After 
buffer exchanging with a Zeba spin column into 100 mM PBS pH 6.0 to remove excess S-4FB, 
the antibody solution was diluted to 0.1 mg/mL and flowed over the entire sensor array for 
covalent attachment via a hydrazone linkage. Aniline (100 mM) was added to catalyze the 
formation of the hydrazone bond between the antibody aldehyde and the hydrazine-
functionalized surface.
32
 After rinsing the chip in buffer, the surface was blocked in 
StartingBlock overnight at 4 ˚C. 
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 For layer-by-layer protein deposition, biotinylated anti-IL-2 and streptavidin were diluted 
in BSA-PBS to 2 µg/mL. After loading the antibody-functionalized chip into the flow cell, BSA-
PBS buffer was flowed at 23 μL/min . Maintaining the same flow conditions, the surface was 
exposed to streptavidin for 20 min, followed by a 2-min buffer rinse, and then to biotinylated 
antibody for 20 min, followed by a 2-min buffer rinse.  This cycle was repeated for a total of 75 
layers (37 bilayers on top of an antibody-functionalized surface). The LEGO robot was again 
used to facilitate automated solution switching over the ~30-hr multilayering process. 
Determination of bound mass sensitivity using radio-labeled streptavidin. 
Streptavidin was labeled with 
125
I, a -emitter, according to the manufacturer’s instructions using 
pre-coated iodination tubes (Pierce). Labeled streptavidin was purified from free 
125
I using a G-
25 Sephadex-packed glass column. The concentration of radiolabeled streptavidin  (> 90% 
purity) was determined to be 1-2 μg/mL for each of three trials. 
 The Storm 840 PhosphorImager (GE Healthcare) utilized to image the amount of 
125
I-
streptavidin deposited on the substrate did not have adequate spatial resolution to allow 
visualization of individual sensing elements. Therefore, the fluoropolymer cladding layer was 
removed in its entirety from half of each chipusing photolithography and reactive ion etching 
(RIE). 
To remove the fluoropolymer layer, the chip was spin-coated with Shipley 1813 (2000 
RPM, 30 sec) photoresist, followed by a 1-min post-bake at 115 ˚C. Half of the chip was then 
exposed for 1 min to a 30 mW/cm
2
 dose of 350-nm light through a mask covering half of the 
chip. The photoresist was then developed for 5 min in MF-319, and the fluoropolymer was 
removed on the exposed half of the chip by performing oxygen RIE (4 min, 9.8 sccm O2, 50 
sccm Ar, 16 mTorr, 100 W, 310 V DC bias) on a PlasmaLab RIE System. The protective 
photoresist layer was subsequently removed by a 15-min soak in 1165 stripper followed by a 10-
min sonication in acetone, an isopropanol rinse, and drying in a nitrogen stream. 
Before flowing 
125
I-streptavidin over the sensor surface, the chip was piranha cleaned as 
and loaded in the microfluidic flow cell with a gasket that allowed exposure of the entire array to 
a single solution volume. The surface was first modified with an amine-terminated silane by 
flowing a 2% solution of APTES in ethanol over the surface at 30 µL/min for 10 minutes, 
followed by rinsing with ethanol. A 0.4-mM NHS-Biotin solution (in 100mM PBS, pH 7.4 with 
4% DMF) was flowed over the surface at 30 μL/min for 30 min, followed by rinsing with PBS.  
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Finally, the sensor surface was exposed to the 
125
I-streptavidin solution for 10-30 min and 
washed with buffer. After the microring resonance shift determination, the chip was imaged on 
the phosphorimager along with a set of spotted protein standard solutions that were allowed to 
evaporate onto a glass slide. The bound streptavidin surface density was determined by 
comparison to protein standards and correlated with the wavelength shifts from rings on the side 
of the chip from which the cladding layer had been removed. This process was performed in 
triplicate. 
 
 
3.3 Calculations 
 Evanescent field theory: sensing modality and distance dependence. For waveguide 
sensors, the sensing modality is based on the interaction of the propagating evanescent field with 
the molecules of interest at or near the waveguide surface. In our silicon-on-insulator platform, 
light is coupled into linear Si waveguides that access the microring waveguides. As shown in 
Figure 3.2, each 30-μm ring is separated from the linear waveguide by 200 nm to allow for 
efficient light coupling between the waveguides only at wavelengths (λ) that match the resonance 
condition defined by:  
(1)        λ = 
2𝜋𝑟𝑛 eff
𝑚
   
where m is an integer, r is the microring radius, and neff is the effective refractive index of the 
optical mode. Since organic and biological molecules have higher refractive indices (n = 1.4-1.6) 
than water (n = 1.33), their binding to the sensor surface increases the effective refractive index 
sampled by the optical mode.
33
 The monitoring of resonant wavelength shift as a function of 
target binding provides the label-free sensing modality. 
The equations describing the evanescent field propagation are derived from the boundary 
conditions of the electromagnetic wave equations that require a non-zero electric field at the 
reflective dielectric interface. As a result, the evanescent wave decays exponentially from the 
surface and, ignoring light scattering, the rate at which the field intensity decays can be described 
by: 
(2)        𝐼(𝑧)  =  𝐼0e
−2𝛾𝑧  
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where I(z) is the intensity of the evanescent as a function of perpendicular distance z from the 
surface, I0 is the initial intensity, and γ is the exponential decay constant. As described 
previously, the shift in resonance wavelength is proportional to the intensity of the evanescent 
field  extending into the surrounding environment.
34
 
Simulation of evanescent field depth. Simulations of the waveguide optical intensity 
profile were performed using the classic eigenfunction approach as described previously.
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Briefly, Maxwell’s equations are solved satisfying the boundary conditions at the dielectric 
interfaces of the waveguides, resulting in a set of transcendental equations that were solved for 
the wavenumber of the transverse optical mode. The mode is oscillatory in the core of the 
waveguide, but in the evanescent region external to the core, it decays exponentially as shown in 
Figure 3.3. The physical constants used in the calculation were matched to those in the 
experimental system, characterized by a 200-nm thick by 500-nm wide waveguide having ncore = 
3.43, nsubstrate = 1.46, nsurroundings = 1.33, and λ = 1.56 µm. The exponential decay coefficient, γ, in 
Eq. 2 was found to be 9.56 µm
-1
 for the optical field at the surface of the waveguide extending 
into the analyte sensing region. At a distance of z = 1/2𝛾 = 52.3 nm from the waveguide, the 
intensity of the evanescent field, I(z), has decreased to (1/𝑒) × I0 or 36.7% of its initial value.   
 
 
3.4 Results and discussion 
Experimental profiling of the microring resonator evanescent intensity decay using 
layer-by-layer electrostatic polymer deposition. To experimentally profile the evanescent 
decay from the microrings, we utilized layer-by-layer assembly of alternating anionic and 
cationic polymers onto the surface to map the intensity of the sensor response as a function of z. 
Specifically, PSS and PAH were selected due to the extensive literature describing  PSS/PAH 
multilayers with linear growth over a wide range of thicknesses.
36-38
 Following these previous 
reports, we prepared our silicon oxide-passivated surface with a layer of the highly branched 
polymer PEI to ensure sufficient coverage of the initial polyelectrolyte, followed by the addition 
of subsequent layers of PSS and PAH. Figure 3.4A illustrates the growth process, starting with 
the negatively charged silicon oxide surface. After addition of a PEI layer, PSS and then PAH 
are added in sequence. This process is repeated to form 72 PSS/PAH bilayers. Figure 3.4B shows 
the real-time shift in resonance wavelength from a representative microring corresponding to the 
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addition of each electrostatic polymer layer. With each additional layer, the differential sensor 
response decreases as multilayer assembly occurs at a greater distance from the surface. The 
decreasing sensitivity to refractive index changes corresponds to the evanescent intensity decay 
profile extending off of the microring waveguide. Figure 3.4C shows the average net sensor 
response (n = 23 rings) for each successive polymer bilayer as a function of the number of 
PSS/PAH bilayers added.  
By fitting the points in Figure 3.4C to an exponential function, it becomes apparent that 
the response for each subsequent layer decays exponentially. From the exponential fitting 
function, the 1/𝑒 decay length for sensor response is 20.9 bilayers, which can be converted to a 
decay distance of 63 ± 4 nm using a 3.0 ± 0.2 nm thickness for each hydrated bilayer.
37, 38
 The 
literature value for PSS/PAH bilayer thickness was also experimentally confirmed through 
ellipsometry performed at several points during a layer-by-layer deposition process on a large 
area substrate. Based on the ellipsometry data shown in Figure 3.5, the thickness at each point in 
the growth process shows a highly linear correlation to the number of bilayers.  The slope of a 
linear regression fit to these points was found to be 2.44 ± 0.04 nm/bilayer (R
2
 = 0.999). This 
corresponds well with the dry thickness of PAH/PSS bilayers given in previous reports.
36, 38, 39
 
By incorporating a ~30% increase
38, 40
 in size due to swelling in water, the hydrated thickness 
can be calculated to be 3.17 nm. This confirms the 3.0-nm value we use to calculate our layer 
thickness. 
 The experimentally determined decay distance of 63 nm is in reasonable agreement with 
the evanescent intensity simulation, which yielded a value of 52 nm (see section 3.3). Possible 
sources of discrepancy include: uncertainty in hydrated bilayer thickness and film uniformity; the 
difference in surrounding index of buffer solution (experimental) versus water (simulation); 
dynamic changes in the mode profile during the course of multilayer growth; and other 
experimental deviations from idealized conditions. However, both simulation and empirical 
measurement provide sufficient information regarding the evanescent decay to interpret the 
results from the following protein multilayer study. 
Monitoring the more complex growth of protein multilayers. After verifying the 
exponential decay length experimentally using the electrostatic polymer system, we turned to a 
biological layer-by-layer system with more complex growth characteristics. As a test case, we 
constructed multilayers of an antibody (biotinylated mouse anti-human IL-2 IgG) functionalized 
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with ~10 biotin molecules, and streptavidin, which binds with high-affinity (Kd ~ 10
-15
 M) to up 
to four biotin molecules. The multivalent nature of both biomolecules ensures that extended 
assemblies can be grown. As shown in Figure 3.6A, the surface is first functionalized with SFB-
modified biotinylated antibody (Ab) as has been described previously,
20
 followed by addition of 
a streptavidin (SA) layer. Additional biotinylated Ab was attached to the bound SA. This process 
was repeated, resulting in multilayer growth (75 total layers). The resonance wavelength shift 
associated with the growth of each layer was monitored in real time under conditions empirically 
optimized to ensure complete layer formation. As shown in Figure 3.6B, the resonant wavelength 
shift for each layer initially follows a non-linear growth trend, as will be further discussed below, 
before the effect of the decaying evanescent intensity dominates as the distance from the ring 
increases. This leads to a pseudo-inflection point in Figure 3.6B at ~300 min. Following this 
inflection point, the average cumulative shift arising from protein layers 16 through 75 can be fit 
to an exponential function, as shown in Figure 3.6C. This fit is in the same form as the 
exponential function used to model the response to polymer multilayers. The shifts 
corresponding to layers 1-15 were not included since layer growth during this stage not only 
involves propagation through a decaying evanescent field, but also likely variations in the 
physical characteristics of each protein layer (packing density, surface coverage, protein 
orientation, etc.). 
From the protein multilayer exponential fitting equation, we can determine that the 1/𝑒 
decay length is 9.6 layers.  In other words, after 9.6 protein layers, the evanescent intensity has 
decreased to 1/𝑒 (or ~37%) of its initial value at the ring surface.  Using the 1/𝑒 distance of 63 
nm determined experimentally with electrostatic polymer layers, these 9.6 monolayers each 
represent a 6.6-nm thickness on average (or ~13 nm per Ab/SA bilayer). IgG antibodies have a 
molecular weight (MW) of ~150 kDa with approximate molecular dimensions of 15 × 7 × 3.5 
nm, and their four-polypeptide-chain structure is highly flexible.
41, 42
 Streptavidin (MW~53 kDa) 
is roughly one-third the size of an antibody with dimensions of 5.8 × 5.4 × 4.8 nm 
43, 44
, and a 
densely packed streptavidin monolayer has a thickness of 4.5-5 nm from studies using 
ellipsometry and electron microscopy.
45, 46
 By simple addition of thicknesses, an Ab/SA bilayer 
is expected to be between 8 and 21 nm thick. Considering that the Abs are randomly oriented on 
the surface and that this disorder propagates with the addition of SA, the average thickness of 13 
nm per bilayer seems quite reasonable. 
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Comparing the cumulative sensor response of the electrostatic polymer and the protein 
multilayers provides additional insights into the nature of the assemblies.  In Figure 3.4C, the 
signal arising from 72 polymer bilayers effectively levels off at a maximum cumulative 
wavelength shift of ~10,000 pm. These 72 bilayers extend ~210 nm from the ring surface before 
the additional signal arising from subsequent layers becomes increasingly negligible due to the 
evanescent intensity decay. However, in the case of the protein multilayers, as depicted in Figure 
3.6C, the cumulative wavelength shift arising from 37 protein bilayers levels off at ~2,700 pm, 
approximately four times less than the maximum signal from polymer multilayers.  This implies 
that, given the similar refractive indices of the proteins and polymers (n ≈ 1.5), the polymers 
form a higher density assembly that yields a larger total response within the bounds of the same 
evanescent field profile. 
In contrast to the linear trend of the initial electrostatic polymer multilayers, the first 15 
protein layers display a non-linear growth profile in which each layer yields a larger resonance 
wavelength shift than the previous layer. This effect can be observed in Figure 3.7, where the 
differential resonance shift between each layer is plotted as a function of layer number. Prior to 
bilayer 8 (the first 15 protein layers), each successive layer corresponds to an increasing 
differential shift despite the decreasing evanescent field intensity, with a maximum shift of 250 
pm/protein bilayer at bilayer 8.  Following this maximum shift, the observed resonance shift 
behavior is dominated by the decay of the evanescent intensity.  We attribute this interesting 
multilayer assembly behavior to an increasing protein binding density throughout the early phase 
of growth (layers 1-15) where later layers are more complete than those initially deposited. We 
imagine initial antibody surface loading yields an incomplete monolayer, and subsequent 
biomolecular layers effectively anneal the initial holes in the film. After the addition of 15 
protein layers (8 bilayers), we suspect that most holes have been filled as further layer growth 
appears linear. This means that subsequent resonance wavelength shifts for the remaining layers 
are completely dictated by the decay in the evanescent intensity. This model of linear layer 
growth following complete annealing by layer 15 is consistent with the measured shift in 
resonance wavelength for layers 16-75. A simple exponential decay function effectively fits the 
behavior of layers 16-75 (Figure 3.6C), where we assume linear growth of the protein 
multilayers and calculate an average protein layer thickness of 6.6 nm. This analysis reveals that 
our understanding of the evanescent intensity decay at increasing distances from the sensor 
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surface allows for the isolation of contributions from non-linear layer growth and estimation of 
the protein layer thickness. Most importantly, however, we can directly observe the diminishing 
signal measured as capture agents are localized farther away from the sensor surface. 
 Determination of the bound mass sensitivity for the microring resonator biosensing 
platform. Another metric that is valuable for comparing the relative performance of different 
sensing methodologies is the number of target molecules required to elicit a measureable sensor 
response. Clearly, the mode of signal transduction, the sensor configuration and geometry, and 
the size or mass of the target molecule play a critical role in determining how best to define this 
metric. Therefore, we decided to determine the absolute LOD of the microring resonator 
biosensing platform in terms of the minimum mass that can be detected. Since most biological 
molecules have similar refractive indices, we assert that this metric can be converted to the LOD 
in terms of the number of molecules for any bound analyte of known molecular weight. 
 In order to probe the mass sensitivity of the microring resonator platform, the amount of 
material bound at the surface must be carefully measured and correlated with the resonance 
wavelength shift upon binding. Our approach involves (1) measuring the wavelength shift of 
radioactive streptavidin binding to a biotinylated microring surface and then (2) determining the 
mass of bound streptavidin using standard radiometric techniques. Specifically, we used 
125
I-
labeled streptavidin and phosphorimagery to determine the amount of mass bound to the surface. 
The relationship between 
125
I-streptavidin surface density and net resonance wavelength shift 
response was measured for three different sensor chips and used to determine the mass 
sensitivity and LOD for the biosensing platform. 
 The phosphorimager utilized for streptavidin mass quantitation has a spatial resolution of 
50 µm, which is not sufficient to resolve individual microring sensing elements, especially 
considering that the fluoropolymer cladding material is only removed from an 8-µm wide 
annular opening over each microring (see Figure 3.2). Furthermore, we observed a non-zero 
radioactive response from the cladding material, meaning not all signal in a single 
phosphorimager pixel can be attributed to a microring. Therefore, we utilized RIE (as described 
in section 2.3-2.4 and Table 2.4) to remove the cladding layer from one half of the chip before 
the surface was functionalized. Etching only half of the chip allowed half of the rings to remain 
unaltered to ensure that no binding artifacts or inconsistencies resulted from the etching process 
and to preserve unexposed thermal control rings for thermal drift correction.  
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Given that the silicon microrings possess a native layer of silicon oxide, we feel it is a 
reasonable assumption that the binding density of 
125
I-streptavidin on a microring will be 
comparable to that of the freshly-exposed bulk silicon oxide surface. To ensure that replicate 
measurements were independent of chip-to-chip variations, we tested the refractive index 
sensitivity of each chip by measuring the relative wavelength shift elicited by switching the 
surrounding solution from water to 1 M NaCl. All rings on all chips responded to 1 M NaCl with 
a 475 ± 25 pm shift. This variation falls well within the precision tolerance required to assess the 
absolute mass bound to the microring surface. 
Each chip was functionalized with APTES and NHS-biotin, and then exposed to 
125
I-
streptavidin, creating a protein layer as shown in Figure 3.8A. To obtain a range of surface 
densities for calculating mass sensitivity, variable streptavidin loadings were produced by 
monitoring the real-time binding of streptavidin and initiating a buffer rinse after different 
exposure times (from 10 to 30 minutes). Figure 3.8B shows a representative binding curve where 
1.2 µg/mL 
125
I-streptavidin is introduced at t = 12. With varied streptavidin exposure times, we 
were able to obtain net sensor responses of 46 pm (low coverage), 165 pm (medium coverage), 
and 216 pm (high/saturated coverage). Following the buffer rinse and net binding shift 
determination, the chips were imaged, and the amount of bound mass was determined by 
comparison with spotted standards. 
As shown in Figure 3.8C,
 125
I-streptavidin bound to all areas over which flow was 
directed, including the half of the chip where the cladding layer was intact (although to a lesser 
extent). A rectangular region directly over the rings on the etched half of the substrate was 
selected on each chip, and the integrated total image intensity from the selected area was 
converted to a mass of bound streptavidin based on calibration with the 
125
I-streptavidin 
standards (see Figure 3.9). Based on the pixel count of the sampled channel area and the pixel 
size of the phosphorimager, the bound mass was converted to a surface density.  By dividing the 
surface density by the average net shift of the rings from within the sampled channel area, the 
average mass sensitivity of the three chips was determined to be 14.7 ± 6.7 [pg/mm
2]/Δpm (see 
Table 3.1). Thus, a resonance wavelength shift of 1 pm represents 15 ± 7 pg/mm
2
 of bound 
protein, or inversely, each 1 pg/mm
2
 of protein density generates a 0.07 ± 0.03 pm shift in 
resonant wavelength.  
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To determine a LOD for the platform, we determined the noise floor to be 0.1 pm based 
on the minimal resolvable peak shift. To obtain the minimal resolvable peak shift, we utilize a 
calculation based on the ability to differentiate two different sets of data at the 95% confidence 
interval. Because measurements are made in real time, we can measure the average microring 
resonance wavelength shift value for 5 min (initial baseline) before a certain amount of substance 
is added to a ring surface, and then measure the average shift over a 5-min period after the 
addition of the substance to the surface. Given a baseline noise level with a standard deviation of 
0.2 pm,
19
 we can calculate the t-statistic for the two sets of data using the formula
47
 as shown 
below:  
(3)     𝑡𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 =
∆𝑥 
𝑠
 𝑛/2 
where ∆𝑥 is the average difference between the two mean values, s is the pooled standard 
deviation (in this case, we assume that both the standard deviations and sample sizes are exactly 
the same, so the pooled standard deviation equals the standard deviation of the single sample), 
and n is the number of points in the sample. To be significantly different at the 95% confidence 
interval, tcalculated must be greater than 2.02. Solving for ∆𝑥 using n = 40 (number of data points 
for each ring collected in a 5-min span) and s = 0.2 pm, we get ∆𝑥 = 0.09 pm. Thus, assuming a 
minimum resolvable peak difference of 0.1 pm for calculating the absolute mass sensitivity is a 
reasonable assumption. 
Based on a 0.1 pm peak shift resolution, the platform’s LOD was calculated at 1.5 ± 0.7 
pg/mm
2
.Using the surface area of 85 μm2/ring and the surface density LOD described above, we 
determine the absolute mass LOD to be 125 ag of bound protein.  This mass sensitivity signifies 
the ability to detect just 0.8 zmol (~500 molecules) of an antibody bound to the microring in a 
direct and label-free assay. The use of secondary antibodies in sandwich assay formats can 
further augment the sensitivity of the platform to a protein target, especially for lower molecular 
weight protein targets.
20
 
 
 
3.5 Conclusions 
 Through a combination of two multilayer studies on a silicon photonic microring 
resonator biosensing platform, the experimentally determined evanescent intensity decay profile 
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was found to be in reasonable agreement with simulation results. The 1/𝑒 decay distance of 
binding sensitivity was measured to be 63 nm, highlighting the outstanding overlap of the 
waveguide mode with the biomolecular sensing region. Since most biological binding 
interactions with a capture probe (i.e. antibody, nucleic acid strand) and target analyte have 
dimensions on the order of tens of nanometers, this platform is well-suited for  sensing specific 
binding events near the ring without large contributions from the surrounding environment.
48
 
Furthermore, with an empirical measure of the decay length characteristics of the microrings, it 
may be possible to design and optimize capture strategies to maximally utilize this property. For 
example, it is clear that assay designs involving non-fouling surface modifications (i.e. PEG 
chains, polymer brushes, etc.) and secondary/tertiary signal amplification steps should take under 
consideration the strong evanescent decay distance dependence of sensor response. These 
considerations become especially clear in the protein multilayer data where the signal is reduced 
by 63% after only 5 SA/Ab bilayers. Understanding the decay length also enables elucidation of 
non-linear growth processes such as those observed in the protein multilayer system.  
 Beyond characterizing the sensing modality and the extent to which the evanescent 
intensity propagates through the sample, the inherent mass sensitivity was also empirically 
determined. Using radio-labeled protein binding to the sensor surface, it was possible to directly 
relate a given resonance wavelength shift to an empirically determined protein surface density.  
This allowed for determination of the platform’s inherent sensitivity, which is 15 [pg/mm2]/Δpm.  
The high sensitivity of ring resonators to binding events at this early stage of technology 
development, with a ~1.5 pg/mm
2
 LOD, is comparable to that of SPR 
25
 and other label-free 
techniques.
3, 8, 15
 By improving peak resolution and reducing system noise, this sensitivity may 
be improved further. In both the multilayering and surface density studies, the ability to monitor 
each ring’s response in real time was vital to the characterization of performance metrics. 
This chapter presents important empirical determinations of key sensitivity metrics for a 
promising silicon photonic microring resonator chemical and biomolecular sensing platform. 
This information will be useful not only in comparing this platform to others, both optical and 
non-optical, but also provides key insights into the current limitations of sensor response which 
will be used to further optimize the technology for detection in complex, real-world 
environments. An example of using this technology for one such application, namely cytokine 
cell secretion studies, is the subject of Chapter 4. 
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3.6 Figures 
 
 
  
Figure 3.1 Picture of LEGO MINDSTORMS NXT 2.0 robot for automation of multilayer 
formation with labels on each component. Not shown: the LEGO control console loaded with 
customized software for the solution switching process and the 9.0 V power supply. 
 
 
 
 
 
Figure 3.2 Scanning electron micrograph of a 30-µm-diameter Si microring resonator 
waveguide adjacent to a linear waveguide. An ~8-µm annular opening in the fluoropolymer 
cladding layer exposes the surrounding SiOx surface only in the immediate vicinity of the ring 
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Figure 3.3 Cross-sectional plot of the evanescent field intensity for the 0.2 × 0.5-µm optical 
waveguide.  The dashed lines represent the top and bottom extents of the waveguide core.  The 
top surface of the waveguide exposed to the chemical reactions is at x = 0. Refractive indices of 
each region utilized in the simulation of the evanescent profile are depicted. 
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Figure 3.4 (A) Schematic showing the layer-by-layer addition of polyelectrolytes to a negatively 
charged silicon oxide surface. Layer 1 involves addition of positively charged, highly branched 
PEI, and Layer 2 involves addition of negatively charged PSS on top of the PEI. Layer 3 consists 
of positively charged PAH adhering to the PSS layer. Multilayers are added by alternating 
deposition of PSS and PAH layers. (B) Real time data showing the relative shift in resonance 
frequency (Δpm) upon addition of PAH and PSS layers. Inset shows six layer-by-layer 
depositions at higher resolution. (C) Plot showing the relative resonance wavelength shift for 
each successive PAH/PSS bilayer as a function of bilayer number. The exponential fit shown in 
the plot models the decay rate as the polyelectrolyte multilayers grow further from the surface 
and experience the decreasing evanescent field intensity, as evidenced by the reduced response 
for each subsequent layer. Error bars represent the standard deviation for n = 23 rings. 
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Figure 3.5 Thickness of PSS/PAH polyelectrolyte multilayers as a function of bilayer # based on 
ellipsometric measurement of the dry multilayers. 
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Figure 3.6 (A) Schematic showing the layer-by-layer addition of biotinylated antibody (Ab) and 
streptavidin (SA) to the ring resonator surface. Layer 1 shows covalent attachment of 4FB-
modified, biotinylated antibody to the HyNic-silane functionalized silicon surface. We 
hypothesize that initial antibody functionalization yields incomplete surface coverage, which is 
followed by an annealing process that initially results in non-linear layer growth as vacancies are 
filled. Layers 2 and 3 depict subsequent addition of streptavidin and biotinylated antibody, 
respectively. Extended multilayers are formed by alternating deposition of streptavidin and 
biotinylated antibody. Though each antibody is functionalized with ~10 biotins, fewer are shown 
for clarity. (B) Real time data showing the relative shift in resonance frequency (Δ pm) upon 
addition of SA and Ab layers. Inset shows six layer-by-layer depositions at higher resolution. (C) 
Plot showing the cumulative relative shift per antibody or streptavidin layer (each individual 
addition of streptavidin or antibody is counted as a single layer). The exponential fit shown in the 
plot indicates the decay rate starting from layer 16. Error bars represent the standard deviation 
for n = 4 rings. 
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Figure 3.7 Plot displaying the relative differential shift per antibody/streptavidin bilayer. 
Notably, the signal increases initially to a maximum shift of ~250 pm at bilayer 8. Beyond this 
point the signal from subsequent layers decreases in an exponential fashion as they are deposited 
further away from the surface and the evanescent field intensity falls off. Error bars represent the 
standard deviation for n = 4 rings. 
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Figure 3.8 (A) Schematic showing the APTES-modified silicon surface coated with a layer of 
NHS-biotin followed by a layer of 
125
I-labeled streptavidin. (B) Real time data showing binding 
of 
125
I-labeled streptavidin to a biotin-functionalized surface. After rinsing the surface with 
buffer, the average net shift (relative shift after streptavidin minus relative shift before 
streptavidin) is measured for multiple rings. (C) Phosphorimage showing the relative intensity of 
125
I-streptavidin standards compared with that bound on the U-shaped area of the chip to which 
flow was directed by microfluidics. The red rectangle highlights the region of interest directly 
over the rings on the chip where the radioactivity intensity was measured. In this selected area, 
the cladding layer was etched off, exposing silicon oxide over the entire surface. (D) Calibration 
curve relating the mass of spotted protein standards (black dots) from (C) to the phosphorimager 
intensity obtained. The blue square represents the signal arising from the selected area (box in 
C). 
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Figure 3.9 (A) Phosphorimager calibration curve for Chip 1, medium coverage 
125
I-streptavidin. 
(B) Calibration curve for Chip 2, high/saturated coverage 
125
I-streptavidin. (C) Calibration curve 
for Chip 3, low coverage 
125
I-streptavidin (same as Figure 3.8D). The blue squares represent the 
phosphorimager intensity of the selected area on each chip used to calculate the mass of 
streptavidin bound. 
 
 
3.7 Table 
Table 3.1 Radiolabeled Streptavidin Surface Density Data 
 
Chip 
Phosphor 
 Intensity 
125
I-SA Mass 
(ng) 
Area 
(mm
2
) 
125
I-SA 
Density 
(pg/mm
2
) 
Average 
Net Shift 
(Δpm) 
Sensitivity 
([pg/mm
2]/Δpm) 
Shift 
Resolution 
(Δpm) 
LOD 
(pg/mm
2
) 
1 60844 2.25 0.65 3465 165 21.0 0.1 2.1 
2 105948 2.18 0.65 3361 216 15.6 0.1 1.6 
3 1011272 0.37 1.05 356 46 7.7 0.1 0.8 
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4.1 Introduction 
The ability to perform multiple simultaneous protein biomarker measurements in 
complex media with picomolar sensitivity presents a large challenge to disease diagnostics and 
fundamental biological studies. Silicon photonic microring resonators represent a promising 
platform for real-time detection of biomolecules on account of their spectral sensitivity toward 
surface binding events between a target and antibody-modified microrings, as described in 
Chapter 3. For all refractive index-based sensing schemes, the mass of bound analytes, in 
combination with other factors such as antibody affinity and surface density, contributes to the 
observed signal and measurement sensitivity. Therefore, proteins that are simultaneously low in 
abundance and have a lower molecular weight are often challenging to detect. By employing a 
more massive secondary antibody to amplify the signal arising from the initial binding event, it is 
possible to improve both the sensitivity and the specificity of protein assays, allowing for 
quantitative sensing in complex sample matrices. In this chapter, a sandwich assay is used to 
detect the 15.5 kDa human cytokine interleukin-2 (IL-2) at concentrations down to 100 pg/mL 
(6.5 pM) and to quantitate unknown solution concentrations over a dynamic range spanning 2.5 
orders of magnitude. This same sandwich assay is then used to monitor the temporal secretion 
profile of IL-2 from Jurkat T lymphocytes in serum-containing cell culture media in the presence 
of the entire Jurkat secretome. The same temporal secretion analysis is performed in parallel 
using a commercial ELISA, revealing similar IL-2 concentration profiles but superior precision 
for the microring resonator sensing platform. The work described in this chapter demonstrates 
the first application of silicon photonic microring resonators for detecting cellular secretion of 
cytokines and represents an important advance for the detection of protein biomarkers on an 
emerging analytical platform. 
Optical biosensors based on refractive index (RI) changes that accompany analyte 
binding have garnered attention for their potential to conduct biological assays without 
fluorescent or enzymatic labels, which can increase cost and complexity, add heterogeneity, and 
perturb native binding interactions.
1, 2
 Within the category of RI-based optical biosensors, 
microcavity resonators have recently been shown to be promising platforms for label-free 
biomolecular detection. Examples of high-Q microcavity resonators, which were described at 
length in Chapter 1, include microtoroids,
3
 microspheres,
4, 5
 liquid-core capillaries,
6, 7
 and 
microrings.
8, 9
 Molecules that interact with the sensor surface through antigen-specific capture 
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probes (antibodies, cDNA, etc.) increase the local RI near the microring, facilitating the 
observation of binding events in real time. We have previously described the operational 
principles of our microring detection platform.
10-12
 Briefly, light is coupled into on-chip, linear Si 
waveguides that access the microrings. At particular wavelengths, photons circulating the 
microring constructively interfere with those propagating down the adjacent linear waveguide 
resulting in an optical resonance as defined by: 
(1) 𝑚λ = 2πr n𝑒𝑓𝑓  
where m is an integer, r is the microring radius, and neff is the effective RI. This resonance is 
measured as a drop in light intensity transmitted down the linear waveguide past the microring as 
the wavelength is modulated using a tunable laser. Biomolecule detection is achieved by 
monitoring shifts in the resonant wavelength on account of binding-induced changes in the local 
RI at the microring surface. The potential of ring resonators has recently been demonstrated in 
biologically relevant systems, including the detection of proteins,
10, 13, 14
 nucleic acids,
15
 phage 
particles,
16
 and whole cells.
17
 Our group is particularly interested in silicon-on-insulator 
microring optical resonators, which are constructed by widely used semiconductor fabrication 
techniques and thus are amenable to the incorporation of many discrete sensing elements onto a 
single millimeter-scale chip.
11, 12
 Previously, we described the use of a newly designed analytical 
platform for the sensitive quantitation of protein biomarkers
10, 18
 and nucleic acids.
11
  
Cytokines, which are cell-signaling proteins secreted by lymphocytes and epithelial cells, 
represent a class of protein targets that are particularly challenging to detect in complex samples 
with label-free biosensors due to their small size and relatively low abundance. Cytokines 
mediate human immune response and are involved in inflammation and cell proliferation 
processes through a complex network of cytokine secretion and cellular recognition.
19
 
Furthermore, they are prospective biomarkers for many diseases, including prostate,
20
 breast,
21
 
and throat cancers
22
 as well as a variety of autoimmune and inflammatory diseases.
23
 Broad 
interest exists in developing sensitive cytokine analysis platforms, as evidenced by notable recent 
reports describing fluorescent fiber-optic microsphere arrays,
24
 microdevices for T-cell capture 
and fluorescence-based cytokine measurements,
25
 and optofluidic 1-D photonic-crystal-based 
sensors.
26
 
Interleukin-2 (IL-2), also known as T-cell growth factor, is a 15.5 kDa cytokine produced 
by T lymphocytes that is responsible for T-cell proliferation.
27
 IL-2 levels are correlated with the 
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relative degree of T-cell activation or inhibition, which in turn serve as a general gauge of 
immune responsiveness. Therefore, IL-2 levels have been used as an indicator of antiretroviral 
response in HIV patients
28
 and immune system health following chemotherapy,
29
 in addition to 
other diagnostic and prognostic applications. Jurkat cells, a well-characterized human cancer cell 
line derived from a childhood leukemia patient, are often used as a model to study T-cell 
activation or inhibition in vitro.
30, 31
 Jurkat T cells are known to secrete IL-2 upon mitogenic 
stimulation with phorbol esters and either lectins or monoclonal antibodies against the T3 
antigen
32
 and thus serve as a suitable in vitro model system for validation of new cytokine 
detection platforms. Herein, we demonstrate the quantitation of IL-2 secretion from Jurkat cells 
stimulated with the phorbol ester PMA and the lectin PHA. For comparison, an enzyme-linked 
immunosorbent assay (ELISA) is used to measure IL-2 concentrations in parallel, and the silicon 
photonic microring resonator sensing platform demonstrates the ability to quantify Jurkat 
secretion with greater precision and shorter incubation times. While not addressed in this 
chapter, it is important to keep in mind that arrays of microring resonators can also be utilized to 
simultaneously detect the levels of multiple cytokines from within a single sample volume (as 
described in Chapter 5). Therefore, this chapter represents a key first step toward the 
development of a powerful immunological analysis platform. 
In this chapter, we employ a secondary antibody in a sandwich assay format which 
allows for more sensitive detection of IL-2 in complex media. Though this assay no longer 
retains the distinction of being fully ―label-free,‖ a term commonly used to describe biosensor 
techniques such as surface plasmon resonance, quartz crystal microgravimetry, and field effect 
transistors among others,
1
 it still avoids limitations of cost and assay complexity associated with 
fluorescent, enzymatic, or radioactive tags.
33, 34
 As has been previously demonstrated using 
surface plasmon resonance, secondary antibody binding increases both assay sensitivity and 
specificity in the detection of low-abundance proteins in complex samples.
22, 35, 36
 Compared to 
the size of an antibody (~150 kDa), IL-2 is relatively small. Thus, its binding to the sensor 
surface generates a smaller increase in the RI, which leads to a smaller shift in resonance 
wavelength. By using a larger anti-IL-2 molecule in a secondary amplification step, the signal 
from IL-2 binding is effectively enhanced, as shown in Figure 4.1. The use of a secondary 
antibody not only lowers the limit of detection to 0.1 ng/mL, a level relevant for the analysis of 
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cellular secretions, but also increases the specificity of the assay by providing an additional 
analyte recognition element. 
 
 
4.2 Materials and methods 
Materials.3-N-((6-(N'-Isopropylidene-hydrazino))nicotinamide)propyltriethyoxysilane 
(HyNic silane) and succinimidyl 4-formyl benzoate (S-4FB) were purchased from SoluLink (San 
Diego, CA). Monoclonal mouse anti-human IL-2 (capture antibody, catalog# 555051, clone 
5344.111) and monoclonal biotin mouse anti-human IL-2 (detection antibody, catalog# 555040, 
clone B33-2), both in phosphate buffered saline (PBS) containing 0.09% sodium azide, were 
purchased from BD Biosciences (San Jose, CA). These served as the primary and secondary 
antibodies, respectively. Recombinant human IL-2 (catalog# 14-8029) in PBS (pH 7.2, with 150 
mM NaCl and 1.0% BSA) was purchased from eBioscience (San Diego, CA). PBS was 
reconstituted in deionized water from Dulbecco’s phosphate buffered saline packets purchased 
from Sigma-Aldrich (St. Louis, MO). Aniline was obtained from Acros Organics (Geel, 
Belgium). Phorbol 12-myristate 13-acetate (PMA, Product# P 1585) was purchased from Sigma-
Aldrich and dissolved in dimethyl sulfoxide to 0.5 mg/mL. The lectin phytohemagglutinin 
(PHA-P) from Phaseolus vulgaris (Product# L 9132) was also purchased from Sigma-Aldrich 
and dissolved in PBS, pH 7.4 to 0.5 mg/mL. Zeba spin filter columns were obtained from Pierce 
(Rockford, IL). A human IL-2 enzyme linked immunosorbent assay kit (OptEIA ELISA Kit II, 
catalog# 550611) that includes the previously described antibody clones was purchased from BD 
Biosciences. Cell culture media, RPMI 1640 supplemented with 10% fetal bovine serum (FBS) 
and penicillin/streptomycin (100 U/mL each), was obtained from the School of Chemical 
Sciences Cell Media Facility at the University of Illinois at Urbana-Champaign. All other 
chemicals were obtained from Sigma-Aldrich and used as received.  
All buffers and dilutions were made with purified water (ELGA PURELAB filtration 
system; Lane End, UK), and the pH was adjusted with either 1 M HCl or 1 M NaOH. Antibody 
immobilization buffer was 50 mM sodium acetate and 150 mM sodium chloride adjusted to pH 
6.0. Capture antibody regeneration buffer was 10 mM glycine and 160 mM NaCl adjusted to pH 
2.2. BSA-PBS buffer used for IL-2 sensor calibration and detection was made by dissolving solid 
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bovine serum albumin (BSA) in PBS (pH 7.4) to a final concentration of 0.1 mg/mL. For 
blocking, 2% BSA (w/v) in PBS was used.  
Silicon photonic microring resonator array chips and the instrumentation for microring 
resonance wavelength determination were designed in collaboration with and built by Genalyte, 
Inc. (San Diego, CA). These materials and instrumentation have been described previously.
10-12
 
Briefly, silicon microring substrates (6.2 × 6.2 mm) contain 64 microrings (30-µm diameter) that 
are accessed by linear waveguides terminated with input and output diffractive grating couplers, 
allowing independent determination of the resonance wavelength for each microring. Up to 32 
microring sensors are monitored simultaneously, eight of which are used solely to control for 
thermal drift. The instrumentation employs computer-controlled mirrors and a tunable, external 
cavity diode laser (center frequency 1560 nm) to rapidly scan the chip surface and sequentially 
interrogate the array of microring resonators, allowing determination of resonance wavelength 
for each independent sensor with ~250 ms time resolution. 
Functionalization of silicon photonic microring resonator arrays. Prior to 
functionalizing the microring surfaces, sensor chips were cleaned by a 30-s immersion in piranha 
solution (3:1 H2SO4 :30% H2O2)
37
 followed by rinsing with copious amounts of water and drying 
in a stream of nitrogen gas. For all subsequent steps, sensor chips were loaded into a previously 
described custom cell with microfluidic flow channels defined by a Mylar gasket,
10
 and flow was 
controlled via an 11 Plus syringe pump (Harvard Apparatus; Holliston, MA) operated in 
withdraw mode. Flow rates for functionalization and cytokine detection steps were set to 5 
µL/min. The flow rate was set to 30 µL/min for all additional steps.  
The chip was first exposed to a solution of 1 mg/mL HyNic silane in 95% ethanol and 
5% dimethyl formamide (DMF) for 20 min to install a hydrazine moiety on the silicon oxide 
chip surface, followed by rinsing with 100% ethanol (Figure 4.2, Figure 4.3). In a separate 
reaction vial, the capture antibody was functionalized with an aldehyde moiety by reacting anti-
IL-2 (0.5 mg/mL) with a 5-fold molar excess of 0.2 mg/mL S-4FB (dissolved first in DMF to 2 
mg/mL for storage and diluted in PBS to 0.2 mg/mL) for 2 h at room temperature. After buffer-
exchanging to remove excess S-4FB using Zeba spin filter columns and dilution to 0.1 mg/mL, 
the antibody-containing solution was flowed over the chip to allow covalent attachment to the 
hydrazine-presenting chip surface (Figure 4.2, Figure 4.4). Aniline (100 mM) was added to the 
antibody solution prior to flowing over the chip, serving as a catalyst for hydrazone bond 
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formation
38, 39
 that improves biosensor surface functionalization. The previously described Mylar 
gasket
10
 allows for selective antibody functionalization on 15 rings under fluidic control. After 
the coupling reaction, a low-pH glycine-based regeneration buffer rinse removed any non-
covalently bound antibody. A final blocking step was carried out by exposing the sensor surface 
to a 2% solution (w/v) of BSA in PBS overnight. 
Calibration of sensors and detection of IL-2. IL-2 calibration standards were prepared 
by serial dilution of recombinant human IL-2 (≥0.1 mg/mL) in BSA-PBS to the following 
concentrations: 50, 25, 10, 4, 1.6, 0.64, 0.26, 0.10, and 0 ng/mL. Blinded unknown samples were 
prepared independently from similar stocks. All sandwich assays performed on the chip surface 
were monitored in real time and involved a 30-min incubation (5 μL/min) in IL-2 standard or 
unknown solution followed by a 15-min read-out with the secondary detection anti-IL-2 antibody 
(2 μg/mL, 5 μL/min). A low-pH glycine buffer rinse, which disrupts non-covalent protein 
interactions, was used to regenerate the capture anti-IL-2 surface. The chip was blocked with 
BSA-PBS prior to subsequent IL-2 detection experiments. 
Data processing. The response from the detection antibody binding to captured IL-2 at 
the surface as a function of IL-2 concentration was used to calibrate the sensor response for each 
ring (n = 15 independent measurements). Prior to quantitation, the shift response of a control 
ring, which was not functionalized with capture anti-IL-2 antibody but was exposed to the same 
solution as the functionalized rings, was subtracted from each of the functionalized ring signals 
to account for any non-specific binding, as well as temperature or instrumental drift. The 
corrected secondary signal after 15 min of detection antibody incubation was measured as a net 
shift for each IL-2 standard and unknown, with the signal from each ring serving as an 
independent measure of IL-2 concentration. The average corrected secondary shift was plotted 
against concentration to obtain a calibration plot, which was then fit with a quadratic regression 
for quantitation of unknowns by inverse regression. 
Jurkat cell culture, stimulation, and secretion profiling. Jurkat T lymphocytes were 
passaged into fresh media at 10
6
 cell/mL (10 mL culture in each of two T25 vented flasks). One 
flask was immediately stimulated to secrete IL-2 by adding the mitogens PMA (50 ng/mL) and 
PHA (2 μg/mL) using an established procedure,31, 32, 40, 41 while the other flask served as a non-
stimulated control. Both flasks were immediately returned to the cell culture incubator (37 ˚C, 
5% CO2, 70% relative humidity). Aliquots (1 mL) were withdrawn from both the control and 
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stimulated flasks at four time points: 0, 8, 16, and 24 h post-stimulation. The cell culture aliquots 
were centrifuged at 1000 RPM for 5 min to pellet the cells, and then the supernatant was 
removed and centrifuged at 10,000 RPM for 5 min to pellet any remaining cellular debris. Cell 
culture aliquots were divided into two identical tubes and stored for less than 24 h at 4 ˚C for 
subsequent parallel analysis by both ELISA and the microring resonator platform. A sensor chip 
was selectively functionalized with anti-IL-2 capture antibody as described above and calibrated 
to secondary antibody response with the following IL-2 standards prepared by serial dilution in 
cell culture media: 50, 20, 8, 3.2, and 1.3 ng/mL. Immediately after calibration, aliquots taken at 
each time point for both control and stimulated cells were flowed over all rings on the chip (30 
min, 5 μL/min) followed by introduction of the detection anti-IL-2 (2 μg/mL, 15 min, 5 μL/min). 
An IL-2 ELISA, conducted as per the manufacturer’s instructions, was performed on the same 
samples from each time point for validation and comparison to results obtained from the 
microring resonator platform. 
 
 
4.3 Results and discussion 
The goal of this study is to establish the use of secondary antibodies to improve detection 
limits and increase sensor specificity for cytokine detection in complex media using a microring 
resonator platform. After demonstrating the utility of the sandwich assay technique for 
quantitative detection of IL-2 with picomolar sensitivity, the platform is applied to the temporal 
monitoring of IL-2 secretion from stimulated Jurkat T lymphocytes. 
Sandwich assay for sensitive, quantitative cytokine detection. The wavelengths of 
light that meet the microring resonance condition are extremely sensitive to the local RI. 
Therefore, biomolecular binding events that increase the effective RI at the sensor surface are 
observed as an increase in the resonant wavelength of the microcavity. This shift in resonance 
wavelength is analyte concentration dependent and serves as the basis for all sensor calibration 
and unknown sample determination experiments. The silicon microring is passivated with native 
SiOx, which allows for initial functionalization with a hydrazine-terminated silane in preparation 
for covalent antibody immobilization. All surface derivitization steps are monitored in real time 
as a shift in the resonance wavelength of each ring (see Figures 4.3 and 4.4). Microfluidics are 
used to confine antibody functionalization to only 15 of the 24 active sensing rings, allowing the 
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other 9 rings to serve as controls for non-specific binding, bulk RI changes, and thermal drift as 
they are exposed to identical IL-2 standards and unknown samples. 
Once the rings are functionalized with capture anti-IL-2, a 45-min IL-2 sandwich assay is 
performed, as shown in Figure 4.1. Initially, binding of the 15.5 kDa IL-2 to the capture antibody 
results in a small wavelength shift (~15 pm over 30 min for 50 ng/mL IL-2, and hardly 
detectable for lower concentrations and incubation times). After this primary binding event, a 
secondary detection anti-IL-2 antibody that recognizes a different IL-2 epitope is allowed to 
bind. The binding of the detection antibody increases the observed signal (~40 pm over 15 min). 
In the absence of IL-2, secondary antibody introduction elicits no measurable binding response 
(see Figure 4.5). While this microring resonator detection modality is, strictly speaking, a RI-
sensitive technique, the observed change in effective RI at the sensor surface is proportional to 
analyte mass under the reasonable assumption that all proteins have an equivalent RI.
4, 5
 Though 
the secondary anti-IL-2 is roughly ten times as massive as IL-2, only a 3- to 5-fold increase in 
signal is observed as secondary antibody saturation at the surface causes the signal to level off at 
high concentrations. We attribute this observation to the limited steric accessibility of secondary 
antibodies to all bound antigens. More specifically, the random immobilization of the primary 
antibodies via modified lysine residues leads to some orientations that, while capable of binding 
IL-2, do not present the antigen in a manner in which the secondary epitope can be accessed for 
subsequent secondary binding. For both the antigen and the detection antibody binding steps, the 
assay speed is limited by protein diffusion to the microrings. Though the 45-min total assay time 
reported herein is considerably shorter than the approximately 4-hr ELISA assay, we are working 
toward further reducing the time-to-result by utilizing more highly optimized fluid delivery 
systems.  
Following the sandwich assay detection, the sensor surface is regenerated with a low-pH 
glycine buffer rinse that disrupts non-covalent protein-protein and protein-surface interactions. 
By removing all IL-2 and anti-IL-2 detection antibody, the capture anti-IL-2 is restored to its 
original state for subsequent assays. Upon returning to buffer, the resonance wavelength returns 
to baseline, indicating effective regeneration. The capture antibody can be regenerated 20-30 
times without substantial loss in binding activity, allowing for the consecutive analysis of many 
standards and samples on a single chip. 
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In order to demonstrate the quantitative sensing capabilities of the platform, IL-2 
sandwich assays were performed on nine calibration standards and two unknowns in BSA-PBS. 
Figure 4.6 shows the response for one representative sensor ring (out of 15 total) as a function of 
time for 11 consecutive sample exposures, IL-2 detection experiments, and surface 
regenerations. For purposes of quantitation, the shift associated with detection antibody binding 
after 15 min of exposure was measured. Though primary IL-2–capture antibody interactions are 
not easily observed at sub-ng/mL concentrations, the secondary amplification step allows a 0.10 
ng/mL (6.5 pM) solution to be readily discerned from baseline. 
The shift in resonance wavelength for each of 15 rings is measured independently of all 
other rings. This multiplexing capability, here applied to a single parameter assay, greatly 
reduces the time required to obtain statistically relevant measured values. In other words, 
redundant measurements are generated in parallel rather than consecutively, which reduces both 
assay time and sample consumption. These 15 independent measurements have the advantage of 
decreasing the inherent uncertainty of the assay, which adds to its quantitative utility. For sensor 
array calibration, the average secondary antibody binding response for all 15 rings is plotted 
against IL-2 concentration, as shown in Figure 4.7. The calibration plot is fitted with a quadratic 
regression (R
2
 = 0.999) since, as expected, it is observed that the secondary signal begins to 
saturate at higher IL-2 concentrations (beyond 25 ng/mL) due to a limited number of accessible 
antibody binding sites. As the concentration approaches 50 ng/mL, a maximum secondary signal 
(32.5 ± 3.6 pm, 95% CI, n = 15 rings) is reached. Linear regression can also be applied to the 
data between 0.1 and 4 ng/mL IL-2, yielding a slope of 1.56 Δpm per ng/mL (see Figure 4.8) that 
is in strong agreement with the quadratic regression (Figure 4.7). Using the quadratic calibration 
curve, the concentrations of IL-2 in two blinded unknown samples (unknown A and unknown B) 
were determined to be 0.40 ± 0.21 and 7.73 ± 0.80 ng/mL, respectively. Reported uncertainties 
in both cases represent the 95% confidence interval for 15 independent measurements. 
Importantly, these values are in excellent agreement with the as prepared values of 0.37 ng/mL 
and 7.64 ng/mL for unknowns A and B, respectively. The ability to accurately determine IL-2 
concentrations over a broad concentration range (0.10 to 25 ng/mL) demonstrates the utility of 
sandwich assays on a microring resonator platform for protein quantitation.  
 To demonstrate the generality of the approach, we also successfully applied the 
sandwich assay methodology to detect another cytokine, IL-8, with similar sub-ng/mL sensitivity 
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and comparable saturation behavior (see Figure 4.9). Similarly to IL-2, the calibration data is 
best fit with a quadratic function that can be used to determine IL-8 at concentrations between 
0.1 and 20 ng/mL. Beyond cytokines, the sandwich assay detection method described herein is 
expected to be generally applicable to analysis of any biomolecule for which a high-affinity 
antibody pair exists. 
IL-2 detection and quantitation in complex media. Building upon the calibration and 
unknown quantitation successes in buffer, we validated the sandwich assay approach for analysis 
in a more complex medium, specifically the detection of IL-2 in cell culture media. The media of 
interest, supplemented RPMI 1640, contains a wide variety of inorganic salts, amino acids, 
vitamins, antibiotics, and sugars at concentrations in the μg/mL – mg/mL range. Furthermore, the 
addition of fetal bovine serum, which contains a variable amount of total protein (ranging from 
30-50 mg/mL),
42
 adds to the complexity of the analysis. A final potentially complicating factor is 
the multitude of biomolecules (proteins and carbohydrates) secreted by the Jurkat cells into the 
surrounding media that are not necessarily the subject of the assay being performed. Clearly, 
assays performed within complex environments such as culture media require high specificity in 
order to detect a single protein species at sub-ng/mL levels in a variable matrix containing 
electrolytes, sugars, and other proteins in excess of mg/mL concentrations.  
Prior to performing IL-2 detection in the Jurkat secretome, calibration was performed 
using IL-2 standards prepared in cell culture media. As in the previously described calibration, 
standards were prepared by serial dilution and flowed over the chip under conditions identical to 
those for detection in buffer. Sandwich assays were performed and monitored in real time (see 
Figure 4.10), and calibration was performed with five standard solutions over a concentration 
range relevant for subsequent cell culture analysis. The resulting calibration plot generated from 
secondary antibody-based detection was again fit with a quadratic function (R
2
 = 0.999, see 
Figure 4.11). In comparing the calibration in buffer (Figure 4.7) to that in cell culture media 
(Figure 4.11), we find that the response sensitivity decreases by a factor of ~2; however, 
sensitivity in the low ng/mL range is retained, enabling the monitoring of cytokine secretion 
from Jurkat T lymphocytes, a common model of immune response, as described below. 
Jurkat IL-2 secretion analysis and validation. A temporal secretion analysis was 
performed on freshly passaged Jurkat T cells (~10
6
 cells/mL) by sampling the cell culture media 
at defined time points over a 24-h period. The secretion analysis was performed in parallel on 
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both non-stimulated (control) cells and PMA/PHA-stimulated cells. After removing cells and 
cellular debris by centrifugation, the raw cell culture media-based samples were flowed across a 
single calibrated chip to maximize consistency in sensor response and accuracy in IL-2 
concentration determination. A bulk RI change was observed upon the addition of cell media 
aliquots on account of differences in ionic strength between sterile media used in calibration and 
media which had supported Jurkat cell growth (see Figure 4.12). After a 30-min incubation in the 
Jurkat secretion aliquot, the secondary antibody response was measured and used to determine 
the IL-2 concentration according to the previous calibration relation (Figure 4.11). Control rings 
were used to subtract the sensor response that arose from non-specific binding of Jurkat secretion 
proteins. After each sandwich assay was performed, the surface was regenerated and allowed to 
equilibrate for 20-30 min in sterile RPMI 1640 + 10% FBS to ensure effective capture antibody 
blocking prior to introducing subsequent Jurkat secretome samples. 
The Jurkat secretion analysis revealed a pronounced difference in secreted IL-2 levels 
between stimulated and non-stimulated cells, as shown in Figure 4.13. Non-stimulated cells did 
not produce measurable levels of IL-2, but PMA/PHA-stimulated Jurkat cells showed an 
accumulation of IL-2 up to 15 ± 2 ng/mL (95% CI, n = 15) after 24 h. This data is supported by 
literature reports that have demonstrated the absence of IL-2 transcripts and protein without 
stimulation
43, 44
 as well as the synergistic effects of PMA and PHA, which must be added 
concurrently to stimulate IL-2 secretion.
32, 40
 Previous reports describe IL-2 levels of 15-20 
ng/10
6
 cells from stimulated Jurkats under the culture conditions employed herein,
41, 45
 consistent 
with microring resonator assay determinations. 
In addition to using the microring resonator platform, the secretion analysis was 
performed in parallel with an IL-2 ELISA for further validation. The ELISA utilized herein was 
obtained from the same vendor (BD Biosciences) as the individual capture and secondary 
antibodies used in the microring resonator determination and therefore serves as a valuable 
comparison given that identical antibody clones were used in both assays. Figure 4 shows the 
strong agreement, both qualitatively and quantitatively, in the IL-2 values measured using the 
ELISA kit and the microring resonator platform. The ELISA, performed on the same Jurkat 
secretion media aliquots assayed using microrings, gave a similar final IL-2 concentration after 
24 h of 21 ± 5 ng/mL (95% CI, n = 3). Additionally, a steady increase in accumulated IL-2 levels 
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over time is observed for both techniques, further validating the quantitative potential of the 
sandwich assays performed on the microring resonator detection platform.  
Though the two assays show strong agreement in average IL-2 levels at each time point, 
the ring resonator sandwich assay exhibits greater precision, as is evidenced by smaller 
uncertainties associated with the data points in Figure 4. Notably, the redundant, simultaneous 
multiplexing of the IL-2 assay on the microring sensor array (n = 15) reduces uncertainty in the 
determined concentration. Sample and reagent requirements generally limit ELISAs to triplicate 
analyses. Thus, the ability to perform many measurements from a single sample without 
requiring additional reagents or rinsing steps is a clear advantage for the silicon photonic 
microring resonator bioanalysis technique. 
 
 
4.4 Conclusions 
Sandwich assays performed on a silicon photonic microring resonator biosensor platform 
have been demonstrated as a highly quantitative tool for protein detection with sub-ng/mL 
sensitivity. This technique is capable of performing precise analyses in complex media, including 
cell culture secretions that include 10% serum and other additives. Sensitive determination of the 
cytokine IL-2 was demonstrated, with a limit of detection that is useful for performing a highly 
resolved temporal analysis of Jurkat T-cell secretion. This result was validated with ELISA, and 
comparison between the techniques revealed superior precision for the microring detection 
platform. The ability to simultaneously perform precise measurements of low molecular mass 
and low abundance proteins on a scalable bioanalysis platform eventually led to multiplexed 
assays in which the measurements of multiple cytokines are integrated onto a single silicon 
photonic sensor array, and this chapter represents an important first step towards this goal. 
Multiplexed cytokine assays, and their application to more interesting T cell differentiation 
studies, are the subject of Chapter 5. 
 
 
 
 
 
153 
 
4.5 Figures 
 
 
 
Figure 4.1 Representative sandwich assay response and schematic for a single microring optical 
resonator functionalized with capture anti-IL-2 antibody. An anti-IL-2 antibody-modified 
microring resonator is initially incubated in buffer (time before A), and then a 50 ng/mL solution 
of IL-2 is introduced to the ring (A) resulting in a ~15 pm net shift in resonance wavelength after 
30 min of binding. Quantitative signal enhancement is then achieved by introducing an anti-IL-2 
detection antibody (B), which gives a ~40 pm net shift in resonance wavelength after a 15 min 
incubation. The sensor is regenerated with a low-pH buffer rinse (C) prior to returning to buffer 
(D) for subsequent IL-2 analyses.  
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Figure 4.2 Schematic illustration of surface derivitization approach. The native oxide layer on 
the silicon microring (A) is functionalized with 3-N-((6-(N'-Isopropylidene-
hydrazino))nicotinamide) propyltriethyoxysilane (1 mg/mL ―Hydrazine silane‖) for 15 min to 
form a hydrazine-terminated silane layer (B). Note: silane layer shown as monolayer for clarity, 
but it is actually a less-ordered multilayer. This functionalized surface can be reacted with the 
anti-IL-2 capture antibody functionalized with succinimidyl 4-formyl benzoate at 1-2 lysine 
residues per antibody to covalently attach antibodies to the surface via hydrazone-bond 
formation (C). 
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Figure 4.3 Silanization of silicon-on-oxide microring resonators monitored in real time. After 
equilibration in ethanol, the silane (3-N-((6-(N'-Isopropylidene-hydrazino))nicotinamide) 
propyltriethyoxysilane, 1 mg/mL in 95% ethanol : 5 % dimethyl formamide) is added to the 
surface to install a hydrazine moiety for subsequent covalent linkage to 4-formyl benzoate-
functionalized antibodies.  After a 15-min functionalization, the reaction is terminated and the 
solution returned to ethanol, yielding a ~250 pm net shift owing to silane covalently tethered on 
the chip surface. The peak shift is corrected to control for thermal drift by subtracting the 
average of eight thermal reference rings. 
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Figure 4.4 Selective loading of capture anti-IL-2 to microring resonator sensors. Upon addition 
of 0.1-0.2 mg/mL anti-IL-2 4FB, capture antibody is loaded onto only the exposed rings as 
governed by the microfluidic design. 4-formyl benzoate-functionalized antibodies were 
covalently attached to the HyNic silane surface via hydrazone-bond formation. This reaction was 
optimized using 100 mM aniline in slightly acidic acetate buffer (pH 6.0). Covered rings (not 
shown) are observed to not respond to antibody, allowing them to serve as control rings to 
account for non-specific binding and baseline drift in future experiments. 
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Figure 4.5 Secondary antibody negative control. After flowing BSA-PBS (no IL-2 added), (A) 
secondary anti-IL-2 detection antibody (2 μg/mL) is added for 15 min, as with the IL-2 standard 
and unknown sandwich assays. No secondary anti-IL-2 binding is observed, as evidenced by no 
appreciable net shift between points A and B. (B) The surface is regenerated with a low pH 
buffer rinse prior to (C) returning to buffer for subsequent IL-2 analyses. 
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 Figure 4.6 Real-time monitoring of resonance wavelength shifts of an anti-IL-2 antibody-
functionalized microring during exposure to a variety of known (0, 0.10, 0.26, 0.64. 1.60, 4, 10, 
25, and 50 ng/mL) and two unknown solutions (unknowns A and B) in BSA-PBS. Following a 
30-min exposure to each IL-2 concentration, anti-IL-2 detection antibody is flowed over the ring 
(dashed lines), and the secondary net shift after 15 min is used for quantitation. A BSA-PBS 
sample without IL-2 produced no secondary anti-IL-2 binding signal, as shown between time 
points 238 and 253 min. After each secondary detection, the microring surface is regenerated by 
a low-pH glycine rinse, and the sample chamber returned to BSA-PBS to achieve a stable 
baseline before subsequent sample injections. The signal is corrected for drift by subtracting the 
shift from an adjacent control ring that is not functionalized with anti-IL-2 but is introduced to 
identical conditions throughout. 
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Figure 4.7 Concentration-response plot of the average control-ring-corrected net shift as a 
function of IL-2 concentration, as determined from 15 microring resonators. Following 30-min 
incubation in IL-2 standard solutions prepared in BSA-PBS, the net shift arising from detection 
antibody binding is measured after 15 min for each ring. The plot is fit with a quadratic 
regression, and the displayed equation is used to successfully quantitate solutions with unknown 
IL-2 concentrations (relative positions of unknowns depicted on curve with red X). The inset in 
the lower right corner is an expanded view of the low concentration range below 4 ng/mL. Error 
bars represent the 95% confidence interval, n = 15 rings. 
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Figure 4.8 Concentration-response plot of the average control-ring-corrected net shift as a 
function of IL-2 concentration, as determined from 15 microring resonators. Following a 30-min 
incubation in IL-2 standard solutions (0.1 – 4 ng/mL) prepared in BSA-PBS, the net shift arising 
from detection antibody binding is measured after 15 min for each ring. This plot contains 
identical data to that in Figure 4.7, but the reduced concentration range is effectively fit via linear 
regression, highlighting the unsaturated linear response for lower concentrations. Error bars 
represent the 95% confidence interval, n = 15 rings. 
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Figure 4.9 Concentration-response plot of the average control-ring-corrected net shift as a 
function of IL-8 concentration, as determined from 12 microring resonators functionalized with 
capture anti-IL-8 (R&D Systems clone 6217, Cat# MAB208). Following a 30-min incubation in 
IL-8 standard solutions (0.1 – 20 ng/mL) prepared in BSA-PBS, the net shift arising from 
detection antibody (BioLegend anti-human IL-8 clone JK8-2, Cat# 508504) binding  is measured 
after 15 min for each ring. The plot is fit with the quadratic regression displayed above, which 
effectively models the response saturation at concentrations approaching 20 ng/mL IL-8. Error 
bars represent the 95% confidence interval, n = 12 rings. 
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Figure 4.10 Real-time, control-corrected responses for calibration standards in cell culture 
media. Five standards were used to calibrate sensor response in RPMI 1640 + 10% fetal bovine 
serum cell culture media. The shift arising from a 15-min secondary anti-IL-2 detection antibody 
(added at dashed lines) binding event was used for quantitation. The antibody surface was 
regenerated between each run by a low-pH glycine buffer rinse. The eight rings shown represent 
one of two identical microfluidic channels used in this assay. 
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Figure 4.11 Calibration of IL-2 secondary response in complex cell media. Following a 30-min 
incubation in IL-2 standards prepared in RPMI 1640 + 10% FBS, the net shift arising from 
detection antibody binding is measured after 15 min for each ring. The plot is fit with a quadratic 
regression, and the equation is used for quantitation of IL-2 from Jurkat cell secretion. Error bars 
represent the 95% confidence interval, n = 15 rings. 
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Figure 4.12 Microring resonator assays for temporal secretion of IL-2 from Jurkat T 
lymphocytes. The eight red traces, observed in real time, represent anti-IL-2-functionalized rings 
in one of two microfluidic channels, while the black trace represents a non-functionalized control 
ring that was subtracted off to correct for non-specific binding. The blue arrows indicate when 
the Jurkat sample was added following the low-pH glycine rinse and a 20-30 min blocking in 
RPMI 1640 + 10% FBS. The dashed lines indicate the time at which secondary anti-IL-2 was 
added. The labels at the top of the dashed lines represent the time in hours (0, 8, 16, or 24) and 
the identity (Control or PMA/PHA-stimulated [Stim]) of the Jurkat culture aliquot. 
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Figure 4.13 Temporal Jurkat IL-2 secretion profile. Aliquots were taken at 8-h intervals over a 
24-h period to compare IL-2 secretion from non-stimulated (squares) and PMA/PHA-stimulated 
(triangles) Jurkat T cells. Results were obtained in parallel by using the microring resonator 
sandwich assay (A) and an IL-2 ELISA (B). Error bars represent the 95% confidence interval for 
n = 15 (A) and n = 3 (B). 
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Chapter 5 
 
RAPID, MULTIPARAMETER PROFILING OF 
CELLULAR SECRETION USING SILICON PHOTONIC 
MICRORING RESONATOR ARRAYS 
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5.1 Introduction  
Building on the single-plex cytokine analysis presented in Chapter 4, we have developed 
a silicon photonic biosensing chip capable of multiplexed protein measurements in a 
biomolecularly complex cell culture matrix. Using this multiplexed platform combined with fast 
one-step sandwich immunoassays, we are able to perform a variety of T cell cytokine secretion 
studies with greatly improved time-to-result. This chapter demonstrates the application of 32-
element arrays of silicon photonic microring resonators to multiparameter cytokine analysis of 
primary cell secretomes; the cytokines interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 
(IL-5), and tumor necrosis factor alpha (TNFα) were simultaneously quantified with high-
accuracy in serum-containing cell media. Utilizing the cytokine panel, secretion profiles were 
obtained for primary human Th0, Th1, and Th2 subsets differentiated from naïve CD4
+
 T cells, 
and we show the ability to discriminate between lineage commitments at early stages of culture 
differentiation. We also utilize this approach to probe the temporal secretion patterns of each T 
cell type using a real-time binding analysis for direct cytokine quantitation down to ~100 pM 
with just a 5-min analysis. 
Cytokines constitute an important class of secreted proteins that are key regulators and 
effectors of the immune response.
1
 These small,
2
 low abundance
3
 cell-signaling proteins are 
secreted by both lymphocytes and epithelial cells, and they are important targets for cell-based 
immunological studies and in vitro diagnostics. Cytokines often have overlapping and 
multifaceted biological functions,
4, 5
 motivating the development of multiplexed detection 
strategies. Given the importance of cytokine analysis for fundamental immunological studies and 
their promise as diagnostic biomarkers,
6, 7
 it is not surprising that the development of advanced 
cytokine detection methods is an active area of research. Recent work in developing novel 
cytokine analysis platforms has involved fiber-optic microsphere arrays,
8
 cytometric bead 
assays,
9
 photonic crystal-enhanced fluorescent protein microarrays,
10
 microegraving,
11
 ELISpot 
assays,
12
 T cell microdevices for fluorescent cytokine detection,
13
 optofluidic 1-D photonic 
crystals,
14
 and microring resonators.
15
 Each of these new approaches features some combination 
of excellent sensitivity, high-level multiplexing, fast time-to-result, real-time binding analysis, 
and/or demonstrated clinical or biological applicability. However, there remains a tremendous 
unmet need for real-time detection methods that allow extremely rapid, quantitative, and highly 
multiplexed cytokine analysis over a relevant dynamic range with minimal sample preparation. 
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In this chapter, we report the simultaneous detection of four cytokines secreted from 
primary T cell populations using only a 5-min assay on an intrinsically scalable silicon photonic 
microring resonator analysis platform. Silicon photonic microring resonators belong to a class of 
high-Q optical microcavities (see Chapter 1) that have recently shown promise for label-free 
bioanalysis.
16-20
 In addition to eliminating the need for fluorescent or enzymatic tags that add 
assay complexity and non-native perturbations to biomolecular interactions,
21, 22
 optical ring 
resonators also feature real-time reaction monitoring capabilities.
23
 The silicon photonic 
microring resonator arrays utilized in this work (Figure 5.1A) are further distinguished by their 
high scalability on a small footprint, low per-device cost, and ease of fabrication by standard 
semiconductor processing methods.
24
 Resonant microcavity sensing is based on the interaction of 
molecules near the ring surface with the propagating evanescent field that decays with distance 
from the surface.
25
 In our platform, infrared light is inserted into linear Si waveguides that access 
each microring and allow efficient coupling to the ring only at wavelengths (λ) that meet the 
resonance condition defined as: 
        (1)                 𝜆 =
2𝜋𝑟𝑛𝑒𝑓𝑓
𝑚
         
where m is an integer, r is the radius of the microring, and neff is the effective refractive index 
(RI) of the optical mode. Target binding to a receptor-modified ring surface increases neff , which 
leads to a corresponding shift in the  resonance wavelength (Δpm). Using this technology, we 
have previously demonstrated the applicability of silicon photonic microring resonator arrays for 
the detection of nucleic acids
26-28
 and proteins.
15, 20, 29
 
Chapter 4 demonstrated the ability to detect the cytokine IL-2 at concentrations as low as 
6 pM using a 45-min two-step sandwich immunoassay.
15
 Though this study demonstrated high 
sensitivity and precision for secreted IL-2 analysis in Jurkat T cell cultures, the (1) incorporation 
of multiplexed cytokine measurements and (2) significant reduction of the assay time-to-result 
remained critically important. Multiplexed measurements are of particular significance in 
cytokine analysis because of their complex interplay and overlapping roles that involve multiple 
signaling pathways.
1, 5
 Higher throughput assays are also clearly needed to more practically 
perform detailed immunological studies that require measuring multiple cytokines in many 
samples in a reasonable time period. To accomplish these goals, we designed a rapid kinetic-
based one-step sandwich immunoassay that combines multiplexed primary cytokine binding with 
secondary antibody amplification in a single step (Figure 5.1B). Other manifestations of one-step 
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sandwich immunoassays have been demonstrated for rapid protein quantitation with surface 
plasmon resonance,
30
 interferometry,
31
 and radioimmunoassays,
32
 albeit in single-parameter 
assay formats. 
In this chapter, we report a methodology to perform fast, multiplexed cytokine 
immunoassays based on 5-min initial slope analysis (Figure 5.1C) using a silicon photonic 
microring resonator array platform. We demonstrate simultaneous quantitation of the cytokines 
IL-2, IL-4, IL-5, and TNFα from unknown solutions in serum-containing cell media with high 
accuracy (10% average error). By monitoring real-time binding of cytokines pre-associated with 
a secondary antibody and subtracting the non-specific binding response on in situ control 
sensors, we overcome the challenges associated with detecting low-molecular weight proteins 
with label-free sensors in a complex sample matrix. We further apply the one-step sandwich 
immunoassay to cytokine secretion profiling of four T cell types: primary human Th0, Th1, and 
Th2 subsets, as well as Jurkat T lymphocytes. The high throughput provided by the one-step 
sandwich assay allows for the redundant, multiplexed analysis of tens of samples within a short 
time frame. Even at short differentiation periods, commitment to particular T cell lineages is 
observed based upon unique cytokine signatures, and multiplexed temporal secretion profiles are 
also obtained. The ability to monitor multiple cytokines simultaneously with real-time binding 
analysis enables primary T cell immunological studies with unprecedented temporal resolution. 
 
 
5.2 Materials and methods 
  Multiplexed capture antibody functionalization and covalent conjugation to 
microrings. Ring resonator optical scanning instrumentation, software and chips were obtained 
from Genalyte, Inc, and have been described previously.
20, 33
 Prior to functionalization, chips 
were cleaned by a 30-s immersion in piranha solution (3:1 H2S04:30% H2O2)
*
 followed by a water 
rinse and drying in a nitrogen stream. After a 30-min sonication in 100% ethanol, chips were 
dried in a nitrogen stream and spotted with 1 mg/mL HyNic silane (3-N-((6-(N’-isopropylidene-
hydrazino))nicotinamide)propylthriethoxysilane, SoluLink) in 95% ethanol/5% dimethyl-
formamide (DMF) for a 20-min incubation at room temperature to install a hydrazine moiety. 
Following silanization, chips were sonicated for 15 min in 100% ethanol to remove physisorbed 
                                                          
* Caution! Piranha solutions are extraordinarily dangerous, reacting explosively with trace quantities of organics. 
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silane. After drying in a nitrogen stream, chips were loaded into a previously described fluidic 
cell
20
 with a custom 4-channel fluidic gasket
34
 (Scarpati Technical Services/RMS Laser) to direct 
antibody solution flow to defined groups of 4-5 rings each (Figure 5.2).  
Capture antibodies [anti-IL-2 clone 5344.111 (555051, BD Biosciences); anti-IL-4 clone 
8D4-8 (14-7049, eBioscience); anti-IL-5 clone TRFK5 (14-7052, eBioscience); anti-TNFα clone 
MAb1 (14-7348, eBioscience)] were first buffer-exchanged into 100 mM phosphate-buffered 
saline (PBS) pH 7.4 with Zeba spin desalting columns (7k molecular weight cutoff, Fisher 
Scientific). In separate reaction vials, lysine residues on the 4 capture antibodies were 
functionalized with aldehyde moieties by reacting 0.5 mg/mL antibody with a 10-fold molar 
excess of succinimidyl-4-formyl benzoate (S-4FB, SoluLink, 0.5 mg/mL in DMF) for 2 h at 
room temperature. After another buffer exchange into 100 mM PBS pH 7.4 to remove excess S-
4FB and DMF, the antibody solutions were diluted to 30 µg/mL in 100 mM PBS pH 6 with 50 
mM aniline. The capture antibody-4FB conjugates were flowed over the chip using the 
previously described fluidics controlled by a multi-channel programmable syringe pump (BS-
9000-8, Braintree Scientific Inc.) operated in withdraw mode at 2 µL/min. Covalent antibody 
attachment by hydrazone bond formation between the hydrazine silane surface and aldehyde-
modified antibodies was catalyzed by aniline
35
 in the running buffer to allow full surface 
coverage after ~30 min. The antibody loading was observed in real time (Figure 5.3) until 200-
400 pm of net antibody shift was observed (~5 ng/mm
2
 surface coverage
25
). Control rings 
covered by the fluidic gasket were monitored to ensure that they were not exposed to any 
antibody solution. After multiplexed antibody functionalization, chips were blocked overnight at 
4 ºC in StartingBlock PBS buffer (37538, Fisher Scientific). Functionalized chips can be stored 
refrigerated for up to a week prior to use. 
Multiplexed one-step sandwich assay protocol. Multiplexed cytokine calibration 
standard cocktails were prepared by dilution in RPMI 1640 + 10% fetal bovine serum (FBS) cell 
media from recombinant human cytokines [IL-2 (14-8029); IL-4 (34-8049); IL-5 (14-8059); 
TNFα (14-8329), all from eBioscience)]. Each cytokine standard cocktail contained variable and 
randomized concentrations of each cytokine (Table 5.1) and 1 µg/mL of each cytokine detection 
antibody [anti-IL-2 clone B33-2 (555040, BD Biosciences); anti-IL-4 clone MP4-25D2 (13-
7048, eBioscience); anti-IL-5 clone JES1-5A10 (16-7059, eBioscience); anti-TNFα clone 
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MAb11 (14-7349, eBioscience)]. In Jurkat analyses, IL-1β (14-8018, eBioscience) was also 
assayed [anti-IL-1β clones CRM56 (14-7018) and CRM57 (13-7016) from eBioscience]. 
Samples were incubated with detection antibodies (≥20-min) prior to performing the 
assay. Blinded unknown samples were prepared independently by a researcher who is not 
connected with these studies. For cell culture studies, premade standards were exposed to the 
same storage conditions (overnight at -20 ºC) as cell culture aliquots for consistency. After 
overnight blocking and prior to running the first assay, the chip was exposed to 10 mM glycine 
pH 2.2 + 150 mM NaCl for 2 min to remove excess blocking proteins by disrupting non-covalent 
protein-protein interactions. For each one-step sandwich immunoassay, RPMI 1640 + 10% FBS 
was used as running buffer. This ensured RI matching between standards, samples, and running 
buffer as well as continuous re-blocking of the surface after each regeneration. All one-step 
sandwich assays were monitored in real time and involved a 6-7-min exposure to standard or 
sample followed by a 1-min low-pH regeneration of the capture antibody surface. The surface 
was re-blocked and equilibrated with cell media for 7 min prior to injecting the next standard or 
sample. Between 15 and 30 one-step multiplexed sandwich assays were performed in series on a 
single chip to collect all calibration and sample data for a given experiment. All experiments 
were carried out at a 30 µL/min flow rate controlled by an 11 Plus syringe pump (Harvard 
Apparatus) in withdraw mode.  
Initial slope data analysis and cytokine quantitation through calibration. The initial 
slope, which is proportional to concentration under mass-transport limiting analysis conditions
20
, 
was measured for each ring upon addition of cytokines pre-incubated with detection antibodies 
(Figure 5.1C). Specifically, 5 min of real-time binding data for each ring was fit with a linear 
regression for each standard and unknown sample. Four individual cytokine calibration curves 
were constructed for each experiment based on the average initial slope for the set of rings 
specific for a particular cytokine. All signals were corrected for non-specific binding by 
subtracting the initial slope for a single control ring (not coated with an anti-cytokine capture 
antibody). The average control ring-corrected initial slope was plotted against concentration and 
well-fit with a linear regression (all R
2≥0.990) to obtain a calibration plot for each cytokine. In 
this way, calibration curves for all 4 cytokines assayed were generated from the same series of 
multiplexed calibration standards. Initial slopes of blinded unknowns were then used to quantify 
each cytokine by inverse regression. 
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Isolation of PBMCs from whole blood. Venous blood (15-20 mL) was collected from 
healthy volunteers into heparin-coated vials. Approval for the use of human volunteers in this 
study was obtained from the University of Illinois at Urbana-Champaign Institutional Review 
Board, and informed consent was documented for each blood donor. Primary blood mononuclear 
cells (PBMCs) were isolated from whole blood by Ficoll-Paque Plus (GE Healthcare) density 
gradient centrifugation according to the manufacturer’s instructions.  In brief, 18 mL whole 
blood was diluted 1:1 with 2% FBS in sterile PBS (Ca/Mg-free), divided into four 9-mL aliquots, 
and carefully layered onto four 15-mL tubes containing Ficoll (4.5 mL) with a serological 
pipette, taking care to minimize mixing. The layered blood on Ficoll was then spun at 400 g for 
30 min (with the rotor brake off) to create a density gradient, from which the middle buffy coat 
layer of PBMCs was extracted by careful pipetting. The PBMCs from all 4 tubes were combined, 
washed with 2% FBS in sterile PBS, and spun at 500 g for 5 min to pellet cells. PBMCs were 
then resuspended in 5 mL 2% FBS in sterile PBS and counted (~20 × 10
6
 PBMCs from 18 mL 
whole blood). Cells were then spun down again and resuspended in 0.4 mL 2% FBS in sterile 
PBS to give ~50 × 10
6
 cells/mL for naïve CD4
+
 T cell enrichment by negative selection.  
Negative selection of naïve CD4
+
 T cells from PBMCs. Negative selection was 
performed using magnetic bead separation with the EasySep naïve CD4
+
 T cell enrichment kit 
(19115, Stem Cell Technologies) according to the manufacturer’s instructions. In brief, a 
cocktail of antibodies against cell surface markers indicative of memory T cells (CD45RO
+
)
36
 
and other cell types are added prior to incubation with magnetic particles that label the unwanted 
cells. By placing the tube inside the EasySep magnet, unwanted cells are held against the side of 
the tube, and the naïve CD4
+
 T cells that remain in solution are decanted into another tube. A 
second round of magnetic separation was performed on the same cells to improve cell recovery. 
Only naïve (CD4
+
CD45RA
+
) T cells (2-3 × 10
6
) remain after magnetic negative selection. The 
negative selection process was verified by flow cytometry analysis (BD Biosciences LSR II) 
before and after magnetic bead separation using APC-conjugated anti-human CD4 (clone RPA-
T4, 17-0049, eBioscience), PE-conjugated anti-human CD45RO (clone UCHL1, 12-0457, 
eBioscience), and FITC-conjugated anti-human CD45RA (clone JS-83, 11-9979, eBioscience). It 
was observed that the CD4
+
/CD45RO
+
 (memory) population disappeared after separation, 
leaving only the CD4
+
/CD45RA
+
 (naïve) population. The naïve CD4
+
 T cells were spun down 
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and resuspended in T cell media: RPMI 1640 (ATCC) supplemented with 10% FBS, 4.5 g L
-1
 
glucose, 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 1.5 g L
-1
 sodium 
bicarbonate, penicillin and streptomycin (100 U mL
-1
 each), prepared by the School of Chemical 
Sciences Cell Media Facility at the University of Illinois at Urbana-Champaign. 
T cell activation and differentiation protocols. Three wells of a 24-well plate were 
coated for primary T cell activation with 10 µg/mL anti-CD3 (clone OKT3, 16-0037, 
eBioscience) and 10 µg/mL anti-CD28 (clone CD28.2, 16-0289, eBioscience) in sterile PBS (1 
mL per well) for 4 h at room temperature (or 8 h at 4 ºC). The 3 wells (1 each for Th0, Th1, and 
Th2 differentiation) were rinsed twice with cell media prior to seeding naïve CD4
+
 T cells at 2 × 
10
6
 cells mL
-1
 (500 µL) per well. All 3 naïve T cell cultures were activated for proliferation and 
differentiation to Th0 by adding 20 ng/mL IL-2 (14-8029, eBioscience). Nothing more was 
added to the Th0 well. To direct Th1 differentiation, 20 ng/mL IL-12 (148129, eBioscience) and 
5 µg/mL anti-IL-4 (clone MP4-25D2, 13-7048, eBioscience) were added to the Th1 well in 
addition to IL-2. For Th2 differentiation, 20 ng/mL IL-4 (34-8049, eBioscience), 5 µg/mL anti-
IFNγ (clone 4S.B3, 14-7319, eBioscience), and 5 µg/mL anti-IL-10 (clone JES3-9D7, 14-7108, 
eBioscience) were added to the Th2 well in addition to IL-2. Cells were activated and 
differentiated in a cell incubator (37 ºC; 5% CO2; 70% relative humidity). 
On day 3, activated cells were expanded under the same conditions but in the absence of 
anti-CD3 and anti-CD28. Cells were split 1:4 with fresh cell media, and differentiation reagents 
were added again to the appropriate wells at the initial concentrations delineated above. On day 
7, the (partially) differentiated cells were removed from the wells, washed twice in cell media to 
remove any secreted or exogenous cytokines, and resuspended in 1-1.5 mL cell media. The Th0, 
Th1, and Th2 cell cultures were counted and divided among 2-4 wells of a fresh 24-well plate for 
either (1) a comparison of stimulated and control (unstimulated) cells at a fixed time point 
following stimulation or (2) a temporal secretion study. To wells designated as stimulated cells, 
10 ng/mL phorbol-12-myristate acetate (PMA, P 1585, Sigma-Aldrich) and 1 µg/mL ionomycin 
(I9657, Sigma-Aldrich), both in dimethylsulfoxide (DMSO), were added prior to placing the 
cells back in the incubator. Cell culture aliquots were harvested at defined time points after 
stimulation.  
Method for sampling cell culture aliquots. After 0, 6, 12, 24, or 48 h of stimulation, 
cell aliquots (400-500 µL) were withdrawn from the wells. The cell culture aliquots were spun at 
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500 g for 5 min to pellet the cells, and ~400 µL cell-free supernatant was obtained for each 
aliquot. A cocktail of protease inhibitors (aprotinin, bestatin, E-64, leupeptin, and pepstatin A; P 
1860, Sigma-Aldrich) in DMSO was added at 1:500 to all cell culture aliquots to prevent 
protease activity on secreted cytokines during storage. All aliquots were stored at -20 ºC for up to 
24 h prior to ring resonator analysis. Prior to analysis, cell aliquots were thawed, spiked with 1 
µg/mL each of anti-IL-2, anti-IL-4, anti-IL-5, and anti-TNFα as described previously, and treated 
a second time with protease inhibitors (1:500, for 1:250 total). Protease inhibitors were necessary 
to prevent degradation of blocking proteins and capture antibodies on the ring resonators that 
caused a downward sloping background. Jurkats were cultured, stimulated with PMA and 
phytohemagglutinin (PHA), and sampled as described previously.
15
 
  Paired difference t-test for comparing cytokine secretion levels. A paired difference t-
test was used to test for statistical significance when comparing cytokine levels between control 
and stimulated cells and also between T cell subsets. Significance was noted if the null hypothesis 
(―the cytokine levels of the two cell types in question are equal‖) could be rejected based on the 
paired t value calculated from: 
         (2)              𝑡 =  
𝑥 −∆
𝑠/√𝑛
 
where 𝑥 is the mean difference between initial slopes (as compared for each ring individually), Δ 
is the hypothesized difference (in this case 0 since testing for any difference), s is the standard 
deviation of the difference, and n is the sample size (number of independent ring sensing 
elements used, in this case 4 or 5 per cytokine). To calculate 𝑥 and s, the difference between 
initial slopes was calculated for each ring. The t value was compared to the Student’s t 
distribution with n-1 degrees of freedom to determine significance at 95% or 99% confidence 
levels. A one-tailed t test was used in all cases based on 1) prior knowledge of Th1 and Th2 
cytokine signatures and 2) the fact that stimulated cells secrete more cytokines.  
 
 
5.3 Results and discussion 
One-step sandwich immunoassays for simultaneous quantitation of 4 cytokines. The 
ring resonator platform, as shown in Figure 5.1A, contains a usable array of 32 30-µm rings 
(including 8 thermal controls) for multiplexed cytokine detection. The ring resonator sensor 
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signal (shift in resonant wavelength) is sensitive to changes in the local RI near the sensor 
surface (see Chapter 3), with the 1/𝑒 decay length of the evanescent field confined to 63 nm25 
due to the high RI contrast between the waveguide and aqueous surroundings. This length scale 
is well-suited to sandwich immunoassays since antibodies have dimensions of 15 × 7 × 3.5 nm,
37
 
while cytokines are roughly a tenth the size of antibodies. For the experiments described herein, 
the rings are first covalently modified with four anti-cytokine capture antibodies that are directed 
by microfluidics to groups of 4-5 rings each (Figure 5.2).  A few rings are not modified with 
capture antibodies and serve as controls for non-specific binding and bulk RI changes in 
subsequent experiments. Antibody immobilization is monitored in real time to ensure an optimal 
density of 3-6 ng mm
-2
 (Figure 5.3). Biomolecular binding of the target cytokine to capture 
antibodies on the ring surface increases neff and results in a shift of the resonance to longer 
wavelengths, which is monitored in real time for each ring as a relative shift (Δpm). The initial 
slope of this response as a function of time (Δpm/min) after sample introduction is analyte 
concentration dependent, as described by Fick’s first law under mass-transport limiting 
conditions.
20, 38
 For the one-step sandwich assay utilized in these studies, the sample was pre-
incubated with all relevant detection antibodies so that cytokines were detected as larger 
cytokine-antibody conjugates (Figure 5.1B). Since antibodies have a molecular weight of ~150 
kDa (compared to ~5-40 kDa for cytokines),
2
 the signal associated with binding of the cytokine-
antibody conjugate is roughly an order of magnitude larger than the cytokine by itself. 
Multiplexed cytokine standards prepared in cell media showed concentration-dependent 
responses in initial slope that were fit to a linear regression from just 5 min of real-time binding 
data (Figure 5.1C). 
Well-blocked chips allow highly selective binding of cytokine-antibody conjugates only 
to the appropriate rings. Each chip was tested for cross-reactivity by serially flowing each of the 
cytokines across all the rings. Figure 5.4 shows that no appreciable cross-reactivity exists 
between rings functionalized to detect specific cytokines, even at a relatively high concentration 
(50 ng/mL). This is especially important since the absence of cross-reactivity is necessary for 
simultaneous calibration and detection of multiple cytokines from the same sample. One-step 
sandwich assay negative control experiments performed in cell media spiked with 1 µg/mL of 
each detection antibody (but without cytokines) indicated no non-specific binding (Figure 5.5). 
After determining that the rings are highly specific for the appropriate cytokine, sensors were 
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calibrated by performing one-step sandwich assays on a series of multiplexed cytokine 
calibration standard cocktails prepared in cell media (Table 5.1A). Each assay involves a 6-7-
min incubation with the standard followed by a low-pH capture antibody regeneration and return 
to cell media running buffer. The low-pH rinse disrupts protein-protein interactions to remove all 
bound cytokines and detection antibodies, restoring the capture antibodies to their original state. 
The capture antibodies can be regenerated up to 30 times without substantial loss in binding 
activity, allowing the consecutive analysis of many standards and samples on a single chip. By 
plotting the control ring-corrected initial slopes as a function of cytokine concentration (Figure 
5.6), a linear calibration plot was obtained simultaneously for each of the 4 cytokines assayed 
(IL-2, IL-4, IL-5, and TNFα). One-step sandwich immunoassays were also shown to have a 
linear dynamic range spanning more than 2 logs, with limits of detection in serum-containing 
cell media ranging from 67-119 pM for each cytokine (Table 5.2). 
In order to demonstrate the highly quantitative multiplexed sensing capabilities of the 
platform, one-step sandwich assays were performed on 3 blinded, multiplexed cytokine 
unknowns prepared in cell media. Based on the calibration curves shown in Figure 5.7A, the 
unknowns were quantitated via inverse regression. Figure 5.7B shows the strong agreement 
between the as-prepared values on the left and the experimentally determined concentrations on 
the right for each of the 3 blinded unknowns. The one-step sandwich successfully quantitated 
each unknown (average error = 10% ; average absolute error = 1 ng/mL), allowing easy 
differentiation between the unknowns based on their cytokine ―fingerprint.‖ This demonstrates 
the simultaneous and highly quantitative analysis of 4 cytokines on a single chip. 
Multiplexed Jurkat cytokine secretion analysis and method validation. In previous 
work, temporal Jurkat T cell IL-2 secretion was quantitated by a two-step sandwich 
immunoassay that required ~45 min.
15
 Due to the longer assay time, it was difficult to achieve 
high temporal resolution; the Jurkat culture was thus sampled every 8 h (t = 0, 8, 16, and 24 h 
post-stimulation). One-step sandwich immunoassays based on a 5-min initial slope analysis 
enable higher throughput sampling. After removing cells by centrifugation, a cocktail containing 
each of the 4 appropriate detection antibodies (anti-IL-2, anti-IL-4, anti-IL-5, anti-IL-1β) was 
added to cell culture media aliquots taken at t = 0, 2, 4, 6, 8, 10, 15, and 24 h from both 
PMA/PHA-stimulated and unstimulated cultures. After calibrating the chip, Jurkat temporal 
secretion aliquots were assayed in series by the one-step sandwich assay. Consistent with our 
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previous study,
15
 the temporal secretion profile displays exclusive IL-2 secretion that increases 
over time, but only from stimulated cells (Figure S5). Additional independent reports confirm 
that PMA/PHA stimulation is effective for stimulating IL-2 secretion
39
 and also that IL-2 
transcripts and protein are absent without stimulation.
40
 Furthermore, the greater temporal 
resolution clarifies the biological nuances of the secretion profile. It was observed that 
appreciable IL-2 secretion was only evident after 4 h of stimulation; no IL-2 was observed at t = 
2 h, signifying a delay between mitogenic stimulation and protein expression/secretion. 
Additionally, the IL-2 concentration leveled off and then decreased slightly after 24 h, 
suggesting IL-2 degradation or uptake by the delayed expression of IL-2 receptor at the cell 
surface.
41, 42
 Improved temporal resolution made possible by faster assay time can have 
important implications for observing details about the cytokine secretion process. This 
multiplexed one-step sandwich assays performed on Jurkat cells was successfully validated by 
conducting 4 commercial ELISAs in parallel (Figure S6). 
Multiplexed analysis of primary T cell subsets based on cytokine secretion 
signatures. After confirming and validating the utility of one-step sandwich assays for T cell 
secretion analysis, a study involving multiple cytokines and multiple cell lines was undertaken. 
Primary naïve CD4
+
 T cells, which can be differentiated into various T helper subsets with 
unique cytokine signatures, provide an interesting application for multiplexed analysis. Naïve 
CD4
+
 T cells, which have not yet encountered an antigen, are produced in the thymus and  
known to differentiate into various effector subsets including Th1, Th2, Th17, and iTregs.
43
 Th1 
and Th2 subsets have been well-studied, and the necessary cytokine signals and genetic 
mechanisms for differentiation have been described.
44, 45
 Th0 cells arise after initial activation of 
naïve T cells but prior to final differentiation to an effector subset. The cytokine differentiation 
cues, relevant pathways, and cytokine secretion signatures for Th0, Th1, and Th2 cell 
differentiation paths are summarized in Figure S7. In brief, activation of naïve T cells with IL-2, 
anti-CD3, and anti-CD28 results in Th0 cells that produce a large array of cytokines. Th0 cells 
differentiate to Th1 upon exposure to IL-12, while Th0 cells differentiate to Th2 upon exposure 
to IL-4.
43, 44
 Th1 cells are known to produce IFNγ, IL-2, and TNFα; Th2 cells produce IL-4, IL-
5, IL-13,
46
 and to a lesser extent, TNFα and IL-2.43 By guiding these differentiation processes in 
vitro starting with primary naïve CD4
+
 T cells isolated from healthy donors, directed 
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differentiation toward Th0, Th1, and Th2 lineages allowed for a comparison of the various T 
helper cytokine secretion profiles.  
Naïve CD4
+
 T cells were isolated via magnetic bead negative, then cultured, activated, 
and differentiated for 7 days in vitro as described previously.
47, 48
 After 7 days, a considerable 
portion of cells remain undifferentiated (especially in the Th2 subset), based on flow cytometry 
experiments performed by Cousins et al.
48
 However, 7 days proved to be sufficient for observing 
significant differences in cytokine secretion among the subsets. At the end of 7 days, cells were 
washed to remove any exogenous cytokines and then stimulated. PMA and ionomycin were used 
as co-stimulators  that act on the T-cell receptor as in vivo stimulation analogues.
45, 48
After 24 h 
of stimulation, cell aggregation and blasting were observed as evidence of stimulation (Figure 
S8). Stimulated and unstimulated cell culture aliquots were obtained for each subset (Th0, Th1, 
Th2). Cells were removed by centrifugation, and one-step sandwich assays on a calibrated ring 
resonator chip (Table S1b; Figure S4) allowed for multiplexed cytokine quantitation. In this case, 
~1% DMSO present in the cell aliquots due to protease inhibitors and PMA/ionomycin addition 
resulted in a ~125-pm bulk RI shift. Slopes for one-step sandwich assays were fit following this 
large bulk shift (Figure S9). All T cell subset cytokine secretion experiments were performed 
three times using different healthy donors, yielding similar results. 
The results of the T cell differentiation studies are summarized in Figure 4. For each T 
cell subset, stimulated cells secrete significantly more cytokines than unstimulated controls. Th0 
and Th1 stimulated cells show much higher (p<0.01) levels of IL-2 and TNFα compared to the 
corresponding controls. Th2 stimulated cells display higher (p<0.05) levels of IL-2, IL-4, IL-5, 
and TNFα compared to the unstimulated Th2 controls. The stimulated secretion levels of the 
signature Th2 cytokines (IL-4 and IL-5), which were significantly higher in Th2 culture than Th1 
culture (Figure 4, p<0.01), agree well with an earlier report by Yano et al. based on the same 7-
day activation/differentiation and 24-h PMA/ionomycin stimulation.
47
 Specifically, one-step 
sandwich immunoassays quantitated Th2 secretion concentrations for IL-4 (3.1 ± 1.6 ng/mL) and 
IL-5 (2.9 ± 2.1 ng/mL) that match well with data collected by Yano et al. using a commercially-
available cytometric bead array kit. 
There were also other notable findings from the cytokine secretion studies performed on 
Th0, Th1, and Th2 subsets. First, high TNFα levels (>10 ng/mL) are consistently observed for 
each subset.  Undifferentiated Th0 cells are capable of producing a wide array of cytokines 
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including TNFα, and Th1 and Th2 cells have been known to secrete TNFα to a lesser extent.43 In 
each case, however, PMA/ionomycin-stimulated levels of TNFα were significantly higher than 
unstimulated controls, suggesting a T-cell receptor mediated activation of TNFα secretion. A 
second notable finding is that high IL-2 secretion levels were observed for Th2 cells. Since IL-2 
is not a signature Th2 cytokine, these high levels are likely attributable to the large proportion of 
undifferentiated (Th0) IL-2-producing cells that remain after 7 days. Cousins et al.found that 
~50% of cells in Th2-differentiating conditions remained as IL-2-secreting cells even after 28 
days of differentiation.
48
 Furthermore, lower levels of IL-2 for Th1 cells could suggest that Th1 
cells differentiate faster from the IL-2-producing Th0 cells; this is also supported by intracellular 
staining of monensin-treated T cells and subsequent FACS analysis performed by Cousins et 
al.under similar in vitro differentiation conditions.
48
 A third notable discovery is that significant 
protease activity was observed in all cell samples, requiring the addition of protease inhibitors. 
Protease inhibitors were added after cell aliquot collection because they are known to affect 
lymphocyte stimulation and alter cytokine secretion.
49, 50
 Without the addition of protease 
inhibitors prior to performing assays, no net binding was observed for any cell subsets (Figure 
S10). Beyond possible proteolytic degradation of secreted cytokines, proteases act to digest 
blocking proteins and capture antibodies on the ring surface, resulting in a progressive, negative 
net shift in resonance wavelength that masks cytokine binding. 
Temporal cytokine secretion profiling of multiple T cell types. In addition to showing 
the utility of ring resonators for comparing T cell cytokine expression levels among subsets, 
multiplexed temporal cytokine secretion studies were also conducted. We monitored 
accumulation of secreted cytokines by sampling differentiated T cell cultures at various time 
points after stimulation. Micrographs of cells at various time points show increasing cellular 
aggregation (Figure S8), consistent with mitogenic stimulation.
41, 51
 Temporal secretion profiles 
were generated for each T cell population by again conducting one-step sandwich 
immunoassays. The IL-2 secretion profiles for Th0, Th1, Th2, and Jurkat T cells are shown in 
Figure 5. In each case, IL-2 levels increase sharply for ~12 h prior to leveling off or decreasing. 
It is hypothesized that after 12 h of stimulation, further IL-2 secretion is balanced by IL-2 
proteolytic degradation and uptake by IL-2 receptors, which are expressed transiently following 
stimulation and only after encountering IL-2.
41, 42
 It is also of note that the absolute concentration 
(Figure 5 concentrations normalized to 10
6
 cells/mL) of IL-2 in Th0, Th1, and Th2 cultures 
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consistently reaches a maximum of 50-60 ng/mL prior to leveling off. This effect seems to be 
more pronounced for Th0 cells as their accompanying IL-2 levels decrease more abruptly from 
the peak concentration at t = 6 h. 
IL-4, IL-5, and TNFα temporal cytokine secretion profiles of Th0, Th1, and Th2 are 
shown in Figure S11. As expected, TNFα levels are observed to be higher for Th0 and Th1 cells, 
reaching a peak of >50 ng/mL after 48 h. IL-4 levels are highest for Th2 cells, but the difference 
becomes less pronounced after 48 h, possibly owing to the significant protease activity. Th2 IL-5 
levels peak at roughly 7 ng/mL after 12 h, similar to levels reported previously.
48
 
 
 
5.4 Conclusions 
Rapid one-step sandwich immunoassays performed on silicon photonic microring 
resonator arrays were demonstrated to be specific, highly quantitative, and applicable to detailed 
multiplexed cytokine analysis of T cell secretion. The ring resonator assays successfully 
distinguished Th0, Th1, and Th2 subsets based on their secretion profiles. Throughout the assay 
development process, the importance of observable real-time binding was displayed; after 
unsuccessful assays without protease inhibitors, the negative-sloping response only observable 
by real-time binding analysis (Figure S10) provides evidence of protease activity. Furthermore, 
as shown previously,
52
 the ring resonator platform offers an excellent tool for screening 
antibodies in order to optimize sandwich pairs for the best combination of durability, cross-
reactivity, and kinetics. In sum, real-time multiplexed reaction monitoring with microring 
resonators is a powerful platform for immunoassay development and execution. 
 By repeating the Jurkat IL-2 analysis performed previously,
15
 running multiple ELISAs 
in parallel, and then comparing to similar literature studies using cytometric bead assays,
47, 48
 the 
one-step sandwich assay described herein is well-validated. It is notable that the previously used 
two-step IL-2 sandwich assay, which permitted ~1 assay h
-1
, can be replaced with a one-step 
sandwich assay that yields 4-5 assays h
-1
 (including surface regeneration). The improved assay 
speed is enabled by the use of initial slope analysis instead of pseudo-thermodynamic net shift 
analysis required for two-step sandwich assays. Batch chip processing will further streamline 
these assays by removing the requirement for individual chip calibration.
53
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By combining one-step sandwich immunoassays with initial slope-based quantitation, 
multiplexed cytokine assays for complex immunological studies are possible without long 
incubation times. Pre-incubation of samples with secondary antibodies essentially transforms 
small, difficult-to-detect cytokines into larger protein conjugates whose binding generates an 
easily observable signal within 5 min. With the one-step cytokine immunoassay, cytokine 
detection limits mirror those for large protein biomarkers (carcinoembryonic antigen, alpha-
fetoprotein, etc.) detected without secondary amplification.
20, 29
 Though ELISAs can feature 
superior sensitivity with much longer incubation times, they are limited in quantitative 
multiplexing capabilities and cumbersome to perform in parallel. The assay developed herein 
provides: (1) sufficient sensitivity (~100 pM) to simultaneously detect cytokines at relevant 
levels, (2) rapid time-to-result (5 min), (3) ample dynamic range (2
+
 logs) to avoid serial 
dilutions, and (4) the ability to quantitate all 4 cytokines from a single sample aliquot. For the 
first time with silicon photonic sensors, multiplexed protein measurements have been performed 
in relevant biological samples to impart fundamental immunological insights. With higher-level 
multiplexing readily achievable, microring resonators represent an attractive technology for 
combining highly quantitative biosensing with fingerprinting capabilities typical of protein 
microarrays. 
 The demonstration of one-step assays also opens the possibility of performing real-time 
cell secretion measurements on single cells. Previous assays performed on cells in microwells 
can quantify cytokine levels at a defined endpoint by fluorescence staining,
13, 54, 55
 but these 
methods provide no information on temporal secretion profiles. By adding detection antibodies 
to the growth media, along with large, high-RI beads to amplify the signal further,
53, 56
 cytokine 
binding to microring(s) within the microwell could be detected within seconds of secretion with 
the benefit of short diffusion distances and high local concentrations. Though real-time detection 
techniques such as microring resonators have mostly been used for kinetic analyses to date, cell 
secretion assays provide another outlet for leveraging real-time monitoring and multiparameter 
measurement capabilities. The small footprint and high scalability of microring resonators offers 
a promising platform for extending these cell secretion studies to much higher levels of 
multiplexing for biosensing and in vitro diagnostics. 
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5.5 Figures 
 
 
Figure 5.1 Microring resonator arrays enable fast and multiplexed one-step sandwich 
immunoassays. (A) Scanning electron micrographs of increasing zoom depict a silicon photonic 
microring resonator chip with an array of 64 rings, 32 of which are monitored simultaneously. 
Sixteen rings are configured for use as thermal controls (indicated by white x’s) and are buried 
under a polymer cladding layer. Rings are arranged linearly to allow straightforward interfacing 
with microfluidic channels.  Each 30-µm ring resonator is accessed by a separate linear 
waveguide. (B) Arrays of microrings can be functionalized with capture antibodies specific for 
various cytokine targets. Following incubation of samples with a cocktail of secondary 
antibodies, the one-step sandwich immunoassay is monitored in real time for each ring. 
Cytokines bind specifically to their capture antibody in complex with the cognate detection 
antibody, thus enhancing the signal. (C) Multiple cytokines at varying concentrations are 
simultaneously quantified based on the initial slope (Δpm/min) of the sensor response upon 
sample introduction. One representative ring specific for each cytokine is shown for clarity, 
including a TNFα negative control. 
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Figure 5.2 Ring resonator chip micrograph with microfluidic schematic. (A) Photograph of 4-
channel microfluidic cartridge and housing for ring resonator chip. The chip (outlined by black 
square) is seated on an aluminum chip holder and covered with a white Teflon flow cartridge 
with 4 independent microfluidic channels, 4 inlet ports, and 4 outlet ports. Each inlet tube is 
placed in a separate antibody solution for chip functionalization, and the outlet tubes are 
connected to syringes operated in withdraw mode that generate solution flow via negative 
pressure. (B) A 0.007‖-thick 4-channel laser-cut Mylar gasket that is placed between the chip 
and the flow cartridge directs solution to one of 4 groups of rings.  (C) Each channel covers 4-6 
sensor rings and 2 temperature control rings, with minor variations in alignment between 
different gaskets. This allows creation of a 4-plex chip (6 mm
2
) for simultaneous detection of IL-
2, IL-4, IL-5, and TNFα with 4-6 redundant measurements each. Rings that are covered by the 
gasket during antibody functionalization (as noted by the black arrows) are not modified with 
antibody and serve as controls in subsequent experiments. Access to waveguide grating couplers 
for optical insertion is permitted by the rectangular opening in the gasket over the top of the chip. 
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Figure 5.3 Real-time plot of 4-plex capture antibody loading. Using the microfluidics described 
in Figure S1, covalent modification of the rings with 4 capture antibodies (Abs) can be observed 
in real time. As indicated, 30 µg/mL of each of 4 Abs modified with an aldehyde moiety (4-
formyl benzamide) can react with hydrazine functionalities introduced to the surface of the rings 
through silanization. Aniline catalyzes the hydrazone bond formation that provides covalent 
antibody loading.
35, 57 
It was found that 200-400 pm of antibody coverage (3-6 ng mm
-2
)
25
 gives 
optimal performance.  * indicates 100 mM PBS pH 6 + 50 mM aniline running buffer, which 
was flowed before and after antibody loading to provide a net shift. 
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Figure 5.4 Cross-reactivity diagram for multiplexed one-step sandwich immunoassay.  Each of 
the 4 cytokines (IL-2, IL-4, IL-5, and TNFα) is introduced in series. All cross-reactivity data is 
collected from a single sensor chip, with a low-pH regeneration between each cytokine assay.  
Rows contain responses from a group of 4 rings functionalized with the same cytokine capture 
antibody, and each column represents a different targeted cytokine. A 50 ng/mL solution of a 
single cytokine prepared in serum-containing cell media in introduced at t = 0 min in each case, 
as indicated by the dashed lines. Only on-diagonal shifts in resonant wavelength are observed, 
confirming that there each detection event is orthogonal to other off-target cytokines. 
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Figure 5.5 Negative control experiment for one-step sandwich assay. There is no signal 
associated with flowing cell media (RPMI 1640 + 10% FBS) containing the 4 detection 
antibodies without any cytokines. After flowing cell media (a) to establish a baseline, the 
introduction of cell media with 1 µg/mL of each of 4 detection antibodies (b) results in no 
appreciable response. A 10 mM glycine pH 2.2 rinse (c) is used to regenerate the surface prior to 
switching back to cell media (d) for a return to the original baseline.
15, 20
 Control rings in green 
are not functionalized with any capture antibodies (Figure S1) but are blocked along with the 
other rings. 
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Figure 5.6 Calibration curves for quantitative multiplexed analysis. The average control-ring 
corrected initial slope is plotted as a function of cytokine concentration for each of 4 cytokines. 
All multiplexed standards were prepared in cell culture media containing 10% serum, and all 
calibration data was obtained on a single chip that was also used for determination of unknowns. 
Each calibration curve is fit well with a linear regression (all R
2
>0.990), and the displayed 
equations are used to quantitate solutions with unknown cytokine concentrations via inverse 
regression. (A) The calibration curves for blinded unknown determination (Table S1a) used 10 
standards between 0 and 50 ng/mL while (B) the calibration curves for cell culture studies (Table 
S1b) used 7 standards between 0 and 100 ng/mL. Minor variations in calibration curve slopes 
between (A) and (B) and also between different cytokines are due to different amounts of capture 
antibody loaded during initial chip functionalization and variable antibody kinetics, respectively. 
Error bars represent the standard deviation of the initial slope for n=4-6 rings. 
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Figure 5.7 Simultaneous quantitation of 4 cytokines from 3 blinded unknowns prepared in 
serum-containing cell media. (A) The average control ring-corrected initial slope is plotted as a 
function of cytokine concentration for each cytokine. All multiplexed standards were prepared in 
cell culture media containing 10% serum, and all calibration data was obtained on a single chip 
that was also used for determination of unknowns. The calibration curves used 10 standards 
between 0 and 50 ng/mL. Each calibration curve is fit well with a linear regression (all 
R
2≥0.992), and the displayed equations are used to quantitate solutions with unknown cytokine 
concentrations via inverse regression. (B) Cytokine cocktails of unknown concentration were 
prepared in RPMI 1640 + 10% FBS. After incubating with all 4 corresponding detection 
antibodies, the unknowns were quantitated by measuring the initial slope of the binding 
interaction in a one-step sandwich immunoassay. For each blinded unknown, the as-prepared 
values (left) show strong agreement with the values determined by the ring resonator array 
(right). Error bars represent the total propagated standard error that includes: (1) the standard 
deviation of n=4-5 rings used to analyze each cytokine and (2) the regression error of the 
calibration curve. 
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Figure 5.8 4-plex cytokine temporal secretion profile for Jurkat T cells. Control (□) and 
stimulated (Δ) aliquots taken from Jurkat T cell cultures (106 cells mL-1) at several time points 
over 1.5 days were analyzed by one-step sandwich immunoassays. One-step sandwich 
immunoassays allow better time resolution (2 h) than two-step assays. As expected, Jurkat T 
cells secrete only IL-2 and only when stimulated with PMA and PHA.
39, 58
 Error bars represent 
the total propagated standard error that includes: (1) the variation in n = 3-6 rings used to analyze 
cytokine levels and (2) the linear regression error resulting from fitting the calibration curve. 
These results were validated by ELISA (Figure S6). 
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Figure 5.9 ELISA validation of temporal secretion study. Aliquots taken from Jurkat T cell 
cultures (10
6
 cells  mL
-1
) at several time points following PMA/PHA stimulation were analyzed 
by (1) one-step sandwich immunoassays using optical ring resonators (□, ORR in legend) and (2) 
a set of four commercial ELISAs (Δ). The four ELISAs [IL-2 (BD OptEIA 550611, BD 
Biosciences), IL-4 (88-7046, eBioscience), IL-5 (88-7056, eBioscience), and IL-1β (88-7910, 
eBioscience)] were run in parallel according to the manufacturer’s instructions to validate the 
results of the one-step sandwich assays. These ELISA kits utilized the same antibody clones as 
those used for ring resonator assays. ELISA results show strong agreement with ORR results for 
all cytokines tested; only IL-2 secretion was observed at appreciable levels. Error bars for ORR 
data represent the total propagated standard error that includes: (1) the variation in n = 3-6 rings 
used to analyze cytokine levels and (2) the linear regression error resulting from fitting the 
calibration curve. ELISA error bars represent the standard deviation for triplicate absorbance 
measurements. 
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Figure 5.10 T cell differentiation schematic and cytokine secretion signatures. This schematic 
summarizes the differentiation cues (curved blue arrows), relevant pathways (italicized under 
dashed black arrows), and cytokine secretion signatures for Th0, Th1, and Th2 cell 
differentiation paths.
43, 44, 46, 59
 Naïve CD4
+
 T cells isolated from donor blood can be activated to 
the Th0 subset with IL-2.  Th0 cells can secrete both Th1 and Th2 cytokines, while Th1 and Th2 
cells have unique signatures. Over a period of weeks or even months in culture, a large portion of 
T cells are known to remain undifferentiated or as Th0.
48
 The cytokine signatures displayed 
include the hallmark cytokines but are not exhaustive of all cytokines secreted by each subset. 
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Figure 5.11 Primary T cell microscope images: Time-course study. (A) T cell subsets (both 
control and PMA/ionomycin-stimulated) were cultured for 24 h at the following cell densities: 
Th0 = 4.3 × 10
6
 cells mL
-1
, Th1 = 1.9 × 10
6
 cells mL
-1
, Th2 = 1.0 × 10
6
 cells mL
-1
. As expected, 
stimulated cells consistently display much greater cell aggregation. (B) Aggregation was also 
demonstrated to increase over time for stimulated Th0 cells at 2.8 × 10
6
 cells mL
-1
.  Significant 
aggregation was evident after only 6 h, and by 48 h almost all cells existed in aggregates. All 
images were acquired at 200x total magnification. 
  
A 
B B 
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Figure 5.12 Real-time multiplexed cytokine binding for Th0/Th1/Th2 culture aliquots. Aliquots 
were taken from both control and PMA/ionomycin-stimulated T cell subsets (7-day activation 
and differentiation followed by 24-h stimulation).
47, 48
 Cell-free aliquots spiked with 4 cytokine 
detection antibodies were flowed across a single chip in a series of one-step sandwich assays for 
(A) Th0 control, (B) Th0 stimulated, (C) Th1 control, (D) Th1 stimulated, (E) Th2 control, and 
(F) Th2 stimulated aliquots. Sterile cell media was used as a running buffer prior to addition of 
each aliquot at t = 2-3 min (signified by the black arrow in each plot). An immediate bulk 
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refractive index (RI) shift of ~125 pm was observed on all rings for all aliquots due to ~1% 
dimethyl sulfoxide (DMSO) present in the aliquots (owing to PMA, ionomycin, and protease 
inhibitors each added as DMSO solutions, with pure DMSO substituted for PMA and ionomycin 
in control aliquots for consistency). Following the bulk RI shift, multiplexed cytokine binding 
was quantified by measuring the initial slope of the real-time data plot for each ring. The black 
dashed lines in each plot signify the range of data used to calculate initial slopes. The insets in 
each plot show control ring-corrected data on which linear regressions were performed prior to 
calibration with cytokine standards. In each case, control cells show little to no cytokine binding 
compared to stimulated cells. The cytokine levels quantified for these T cell aliquots, normalized 
to the number of cells per unit volume, are displayed in Figure 4. 
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Figure 5.13 Cytokine secretion profiling for differentiated primary T cell subsets. Cytokine 
secretion levels for three 24-h differentiated T cell subset cultures were determined by one-step 
sandwich immunoassay and normalized to the number of cells per unit volume in each culture. 
For each T cell subset, control cultures on the left are compared to PMA/ionomycin-stimulated 
(Stim) cultures on the right. Results of one-tailed paired difference t-tests comparing cytokine 
secretion levels both (1) within a T cell subset (between control and stimulated cells, as indicated 
above the stimulated bars) and (2) between T cell subsets (Th1 vs. Th2, as indicated above 
brackets joining pairs of bars) are shown. * indicates significance at the 95% confidence level, 
and ** indicates significance at the 99% confidence level. Error bars represent the total 
propagated standard error that includes: (1) the standard deviation of n=4-6 rings used to analyze 
each cytokine and (2) the regression error of the calibration curve. 
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Figure 5.14 Effect of proteases on real-time binding curves. It was observed that cell culture 
secretion aliquots demonstrate significant protease activity, as shown above by the negative 
slope on all rings when no protease inhibitors are added. Aliquots were taken from 
PMA/ionomycin-stimulated T cell subsets (7-day activation and differentiation followed by 24-h 
stimulation). Cell-free aliquots spiked with 4 cytokine detection antibodies were run over the 
chip in a one-step sandwich assay. Only the Th2 stimulated aliquot is shown as a representative 
example, but all aliquots from all T cell subsets tested showed a similar downward sloping 
response due to proteases. Sterile cell media was used as a running buffer prior to addition of 
each aliquot at t = 2.5 min (signified by the black arrow). An immediate bulk RI shift of ~90 pm 
was observed on all rings due to ~0.7% dimethyl sulfoxide (DMSO) present in the aliquots 
(owing to PMA and ionomycin added as DMSO solutions). Following the bulk RI shift, 
multiplexed cytokine binding could not be quantified by measuring the initial slope because of 
the high protease background. The black dashed line signifies the range of data used to calculate 
initial slopes, with the inset displaying the control ring-corrected plots. Since the addition of 
protease inhibitors remedied the negative sloping background (Figure S9f), the negative slope 
depicted is likely due to protease activity on the blocking proteins and capture antibodies bound 
to the microrings. 
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Figure 5.15 Temporal IL-2 secretion profiles for primary and Jurkat T cells. Aliquots taken from 
T cell cultures at several time points following stimulation were analyzed by one-step sandwich 
immunoassays. IL-2 temporal secretion levels for stimulated Th0, Th1, Th2 and Jurkat T cell 
lines are shown. All concentrations are normalized to the number of cells per unit volume in each 
culture (per 10
6
 cells mL
-1
). Error bars represent the total propagated standard error that includes: 
(1) the standard deviation of n=3-5 rings used to quantitate IL-2 and (2) the regression error of 
the calibration curve. 
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Figure 5.16 Cytokine temporal secretion profiles for Th0, Th1, and Th2 subsets. Aliquots taken 
from T cell cultures at several time points following stimulation were analyzed by one-step 
sandwich immunoassays. IL-4 (A), IL-5 (B), and TNFα (C) temporal secretion levels for 
stimulated Th0, Th1, and Th2 subsets are shown (temporal profiles of IL-2 are shown in Figure 5 
of the main text). All concentrations are normalized to the number of cells per unit volume in 
each culture (per 10
6
 cells mL
-1
). Error bars represent the total propagated standard error that 
includes: (1) the variation in n=3-5 rings used to analyze each cytokine and (2) the linear 
regression error resulting from fitting the calibration curve. 
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5.6 Tables 
 
Table 5.1 Calibration standard cocktails. Multiplexed cytokine calibration standards utilized for 
one-step sandwich assays for (A) unknown determination shown in Figure 3 and (B) T cell 
culture secretion analyses shown in Figure 4 and Figure 5. Each standard is prepared in the same 
cell media as that used for T cell culture and spiked with 1 µg/mL of each detection antibody (4 
µL of cocktail containing 125 µg/mL of each detection antibody). All cell culture standards in 
(B) were prepared and stored in the same manner as cell culture aliquots: stored overnight at -20 
ºC when applicable and spiked with detection antibody at the same time as cell samples. Each set 
of standards contains a negative control (0 ng/mL) standard for each cytokine. 
 
A Volume added (µL) 
Standard RPMI + 10% FBS… Detection Ab cocktail IL-2 IL-4 IL-5 TNFα 
1 431 4 50 5 10 0 
2 439 4 35 2 20 0.5 
3 439 4 20 1 35 1 
4 464 4 15 0.5 15 2 
5 431 4 10 0 50 5 
6 466 4 5 15 0 10 
7 444 4 2 35 0.5 15 
8 450 4 1 20 5 20 
9 410 4 0.5 50 1 35 
10 434 4 0 10 2 50 
 
 B Volume added (µL) 
Standard RPMI + 10% FBS… Detection Ab cocktail IL-2 IL-4 IL-5 TNFα 
1 441 4 40 5 10 0 
2 452 4 20 2.5 20 1.25 
3 442 4 10 1.25 40 2.5 
4 485 4 5 0 1.25 5 
5 461 4 2.5 20 2.5 10 
6 465 4 1.25 10 0 20 
7 411 4 0 40 5 40 
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Table 5.2 Limits of detection: One-step sandwich. The limit of detection (LOD) used herein is 
based on the traditional analytical chemistry definition: the concentration that corresponds to the 
negative control signal (initial slope for 0 concentration of particular cytokine in presence of 
other cytokines, detection antibodies, and cell media) plus 3 standard deviations. LODs were 
calculated for each cytokine in terms of both mass per unit volume (ng/mL) and molarity (pM). 
The LODs showed remarkable similarity, especially in terms of molarity, with all detection 
limits around 100 pM. These LOD values, though slightly inferior to LODs obtained in cell 
media for two-step sandwich assays (generally 0.5 - 1.0 ng/mL),
15
 are still sufficient to conduct 
cell secretion assays performed herein and greatly reduce the time required to perform assays.  
* indicates that IL-5 (monomeric molecular weight = 14 kDa) exists as a glycosylated 
homodimer, which alters the molar LOD. The molar LOD used here is assuming IL-5 
glycosylated homodimer (~45 kDa total molecular weight).
2
  
** indicates that TNFα (monomeric molecular weight = 17 kDa) exists as a homotrimer. The 
molar LOD used here is assuming TNFα homotrimer (52 kDa total molecular weight).2 
 
   Limit of detection 
Cytokine 
Molecular weight 
(kDa) 
Mass per volume 
(ng/mL) 
Molar 
(pM) 
IL-2  15 1.9 119 
IL-4 15 1.0 67 
IL-5 14* 3.6 80* 
TNFα 17** 4.6 88** 
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Chapter 6 
 
SENSITIVE ON-CHIP DETECTION OF A PROTEIN 
BIOMARKER IN HUMAN SERUM AND PLASMA OVER 
AN EXTENDED DYNAMIC RANGE USING  
SILICON PHOTONIC MICRORING RESONATORS AND 
SUB-MICRON BEADS 
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6.1 Introduction 
 After describing applications of ring resonator technology to cell secretion analysis in 
Chapters 4 and 5, this chapter marks the beginning of work with in vitro protein diagnostics. In 
this chapter, we demonstrate a three-step assay on a silicon photonic microring resonator-based 
detection platform that enables the quantitation of the cardiac biomarker C-reactive protein 
(CRP) over a dynamic range spanning six orders of magnitude. Using antibody-modified 
microrings, we sequentially monitor primary CRP binding, secondary recognition of bound CRP 
by a biotinylated antibody, and tertiary signal amplification using streptavidin-functionalized 
beads. This detection methodology is applied to CRP quantitation in human serum and plasma 
samples. Furthermore, the bead-based signal amplification technique can also be applied to 
cytokine analysis, and the improved detection limits and broad dynamic range afforded by the 
three-step assay mark a significant step toward the goal of in vitro cytokine-based diagnostics.  
In vitro diagnostics based on protein biomarkers has been an active area of research for 
the past couple of decades. However, most biosensor development efforts focus almost 
exclusively on improving detection sensitivity for a particular target analyte. While this is clearly 
a vital metric, assay dynamic range is also an important attribute that critically influences clinical 
utility. The dynamic range challenge is even more pronounced for multiplexed analyses, where 
both intra- and inter-analyte concentrations can vary widely. For example, the cardiovascular risk 
biomarker C-reactive protein (CRP) can increase by a factor of 10,000 in serum during an acute 
phase response.
1
 Moreover, protein concentrations in human plasma are known to vary over 11 
orders of magnitude.
2
 Whereas single-analyte assays can incorporate repeated dilutions, 
multiplexed analyses of antigens that natively vary in magnitude represent a significant 
analytical challenge. 
 Recently, chip-integrated, silicon photonic microcavities have been developed for a 
number of biosensing applications (see Chapter 1).
3, 4
 Importantly, the scalability and 
multiplexing capability inherent to these semiconductor-based devices make them attractive for 
many high volume applications, including in vitro clinical diagnostics. Because they are 
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responsive to binding-induced changes to the refractive index (RI) environment near the 
resonator surface, these sensors are intrinsically label-free. As illustrated in Chapter 5, microring 
resonators have been used for protein analysis and detection of analytes in both single
5
 and 
multiplexed
6, 7
 formats using an initial slope-based quantitation technique. This approach 
features a superior linear dynamic range of two or three orders of magnitude, while maintaining a 
limit of detection (LOD) comparable to that of a commercial enzyme-linked immunosorbent 
assay (ELISA). Other work in our group has shown that the incorporation of a secondary 
antibody recognition event can further lower the limit of detection while also increasing assay 
specificity in complex sample matrices.
8, 9
 However, because of surface-saturation effects, 
quantitation at higher concentrations is restricted, resulting in a more limited dynamic range 
similar to that of other sandwich immunoassays.
10
 
 In this chapter, we report the analytical utility of a three-step assay format in which 
primary, secondary, and bead-enhanced tertiary binding events are observed in series in order to 
sensitively quantitate the presence of an antigen over a broad (~10
6
) dynamic range. As shown in 
Figure 6.1, the primary and secondary measurements are conducted as described previously (see 
Chapter 4).
5, 8
 The subsequent tertiary detection event involves the binding of streptavidin (SA)-
coated, sub-micron (~100 nm diameter) beads to biotinylated secondary antibodies. Similar to 
previous reports using nanoparticles,
11-15
 carbon nanotubes,
16
 and enzymatic amplification
17
 to 
enhance the signal of RI-based sensing devices, our tertiary binding assay lowers the LOD by 
enhancing the optical signal arising from a single bound antigen.  
However, more useful here is the integration of a consecutively run assay that includes 
the real-time observation of all three discrete binding regimes. This methodology broadens the 
dynamic range to over six orders of magnitude.  As a representative analyte that is known to vary 
over a wide dynamic range in clinical samples,
1
 CRP is quantitated via a three-step assay 
protocol in buffer, human serum, and human plasma. At the end of the chapter, the analysis is 
also extended to the enhanced detection of cytokine and DNA targets. 
 
 
6.2 Materials and methods 
Materials. 3-N-((6-(N’-Isopropylidene-hydrazino))nicotinamide)propyltriethoxysilane 
(HyNic silane), succinimidyl 6-hydrazinonicotinate acetone hydrazone (S-HyNic), and 
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succinimidyl 4-formyl benzoate (S-4FB) were purchased from Solulink (San Diego, CA).  
Capture and secondary antibodies to CRP (clones M701289 and clones M701288, respectively) 
were purchased from Fitzgerald Industries (Concord, MA).  Capture (MAB206, clone 6708) and 
biotinylated secondary (BAF206) antibodies for interleukin-6 were purchased from R&D 
Systems, Inc (Minneapolis, MN). Recombinant human interleukin-6 and a human CRP ELISA 
kit (88-7502-28) were purchased from eBioscience (San Diego, CA). NHS-PEG4-Biotin was 
purchased from Thermo Scientific and dissolved in DMF to make a 20 mM stock solution.  
Streptavidin-coated polystyrene/iron oxide beads with a mean diameter of 114 nm were 
purchased from Ademtech (Pessac, France).  Human CRP (95% pure from human blood) was 
purchased from Meridian Life Science.  CRP-depleted processed serum and CRP High Plasma 
(with a reported CRP content of 69.1 µg/mL based on a Roche Modular immunoassay) were 
purchased from SunnyLab (Sittingbourne, UK).  Pooled normal human serum and single-donor 
human serum samples #1 and #2 (catalog number IPLA-SER-S, lot numbers K9207 BF 19 and 
55-25114 WM 19, respectively) were purchased from Innovative Research (Novi, MI).  Fresh 
single-donor human plasma was collected from a healthy donor under a plan approved by the 
University of Illinois Institutional Review Board. Zeba spin filter columns and StartingBlock 
(PBS) were purchased from Pierce (Rockford, IL).  Vivaspin molecular weight cutoff filters 
(5000 and 50000 kDa) were purchased from GE Healthcare (Waukesha, WI). 
The capture anti-CRP antibody was immobilized onto the microring sensors using a 
DNA-encoding approach.
18, 19
 30-mer DNA strands for the DNA-encoded CRP capture antibody 
immobilization were synthesized with a C6 spacer and 5′ amination by Integrated DNA 
Technologies (Coralville, IA).  The surface 30-mer sequence was: 
 
 5'-AAAAAAAAAAGCCTCATTGAATCATGCCTA-3',  
 
and the complement sequence conjugated to anti-CRP capture antibodies was: 
 
 5'-AAAAAAAAAATAGGCATGATTCAATGAGGC-3'.  
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 The 3′- biotinylated 30-mer for the simulated human papillomavirus (HPV) DNA target, 
simulated HPV DNA 46-mer target, and HPV surface capture strand were also synthesized by 
Integrated DNA Technologies.  The sequences, respectively, were: 
 
5'-CTCTGGATAATAGAGAATGTAAAAAAAAAA-3' 
5'-TACATTCTCTATTATCCACACCTGCATTTGCTGCATAAGCACTAGC-3' 
5'-AAAAAAAAAGCTAGTGCTTATGCAGCAAAT-3'. 
 
PBS buffer was prepared from Dulbecco’s phosphate buffered saline from Sigma Aldrich 
(St. Louis, MO).  PBST buffer consisted of PBS buffer and 0.05% Tween-20.  The pH of buffers 
was adjusted using 1M HCl or 1M NaOH.  All other chemicals were obtained from Sigma-
Aldrich and used as purchased. 
Antibody and DNA modification. An aldehyde moiety is added to the surface capture 
DNA strand and its complement by incubation with a 20-fold molar excess of 5 mg/mL S-4FB 
for 2-3 h at room temperature in 33% DMF in PBS pH 7.4.  Excess S-4FB is removed by buffer 
exchange using a 5-kDa molecular weight cutoff filter.  Capture antibody-HyNic conjugates are 
prepared by incubating the antibody with a 10-fold excess of 1 mg/mL S-HyNic at room 
temperature for 2 h.  Excess S-HyNic is removed by buffer exchange using Zeba spin filter 
columns.  For biotinylation, 0.5 mg/mL secondary anti-CRP M701288 in PBS pH 7.4 is 
incubated with a 10-fold molar excess of 20 mM NHS-PEG4-biotin for 3 h at room temperature.  
Excess NHS-PEG4-biotin is removed by buffer exchange using Zeba spin filter columns.  
Capture antibody- DNA conjugates are prepared by incubating the capture antibody-HyNic 
conjugate and the 4FB-modified surface DNA strand at a 1:20 protein:DNA ratio overnight at 
4°C.  The mixture is purified using a Superdex 200 10/300 GL column on an AKTA FPLC, both 
from GE Healthcare, and fractions containing the antibody-DNA conjugate are concentrated and 
exchanged into PBS buffer using a 50-kDa molecular weight cutoff filter. 
Bead exchange and surface modification. Of critical importance, beads are exchanged 
into PBST buffer immediately before use to remove free streptavidin via the following 
procedure. NOTE: Without doing so, excess free streptavidin rapidly diffuses to the surface and 
outcompetes the beads for biotin binding sites. To exchange the beads, 30 μL of 5 mg/mL 
streptavidin-coated beads are diluted to 150 μg/mL with PBST buffer and centrifuged at 10,000 g 
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for 4 min.  The bead pellet is held at the bottom of the tube using a magnet while the supernatant 
is removed, leaving about 30 μL of solution.  The beads are then resuspended in 1 mL of PBST 
buffer by pipetting the solution up and down ~50 times with the tube bottom remaining in 
contact with the magnet.  This procedure is repeated for a total of 4 exchanges.  Directly before 
use in the assay, the final bead solution is adjusted to a concentration of 50 µg/mL using the 
absorbance value at 286 nm as determined by calibration based on direct dilution of non-
exchanged beads.  For DNA detection, beads are conjugated to a secondary complementary 
DNA strand.  Streptavidin-coated beads are incubated with a large excess of biotinylated DNA 
for at least 2 h.  The excess DNA is removed by buffer exchange according to the previously 
described method. 
Chip functionalization. Chips are batch-functionalized ex-situ (outside the ring 
resonator instrument) by a spotting method.  After a 20-min sonication in ethanol, chips are 
immersed for 20 s in hot Piranha solution (3:1 H2SO4: 30% H2O2) [Caution: Pirahna solution 
must be handled with care as it can react violently with organic compounds.], rinsed with water, 
and dried under a stream of nitrogen.  Each chip is then spotted with a 30-µL drop of 1 mg/mL 
HyNic silane in 95% ethanol and 5% DMF and incubated at room temperature in an enclosed 
chamber for 30 min.  The chip is then rinsed with ethanol and dried.  A 0.5-μL drop of 4FB-
modified capture DNA strand is then manually pulled across the surface with a 2.5-L pipette 
tip. The 24-sensor chips were functionalized with DNA leaving four sensors on each chip 
unfunctionalized to serve as controls.  The chip is then blocked by submersion in StartingBlock 
at 4ºC for at least 8 h. 
CRP detection assay. The fluidic cell and microfluidic system have been described 
previously.
5
  In these experiments, a Mylar gasket is used to direct flow to two microfluidic 
channels, each addressing 12 of the 24 active rings, allowing two experiments to be carried out 
on one chip.  A consistent amount of capture antibody is loaded by flowing 10 µg/mL DNA-
encoded anti-CRP M701289 at 2 µL/min until the antibody signal reaches ~140 pm. 
To begin the procedure for the analysis of samples, PBST buffer is then flowed over the 
surface to establish a baseline.  A 30 µL/min-flow rate is maintained for all assay segments. The 
sample or standard is introduced and allowed to flow over the surface for 20 min, followed by a 
buffer rinse.  In serum and plasma samples, this rinse is longer (~20 min) than the typical 3 min 
rinse to allow for desorption of non-specifically bound proteins.  The biotinylated secondary 
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antibody is then flowed over the surface for 15 min followed by another short buffer rinse (3-5 
min).  Finally, streptavidin-coated beads (exchanged immediately before use as described above) 
are flowed over the surface for 16 min followed by a final buffer rinse.  For DNA detection, 
there is not a third binding step as the secondary detection strand is directly conjugated to the 
bead. 
Instrumental setup. The microring resonator instrumentation and chips were acquired 
from Genalyte (San Diego, CA), and have been described in detail in previous publications.
5, 20
 
Briefly, each chip is fabricated with 32 active microring sensors covered with a 
perfluoropolymer cladding layer. Eight rings on each chip remain occluded by the polymer layer 
and serve as thermal controls. Twenty-four active sensors rings have an annular opening etched 
over the ring to enable exposure to the solution in the microfluidic channel (see Chapter 2). Each 
ring resonance is monitored via frequency attenuation in an adjacent linear waveguide. Input and 
output diffractive grating couplers are located at each end of the waveguide to enable 
independent determination of the optical cavity spectrum for each microring using a tunable, 
external cavity diode laser (center frequency: 1560 nm).  
Data analysis. Calibration curves for primary binding are generated by determining the 
initial slope as a function of analyte concentration, as described in Chapter 5 and elsewhere.
5
 
Secondary and tertiary binding calibration curves are generated by plotting the total net relative 
shift of the secondary and bead binding, respectively.  Standard additions were prepared based 
on an initial estimate of the unspiked concentration in a diluted sample based on comparison to 
calibration plots generated in buffer.  Small increments of a concentrated CRP solution are added 
to aliquots of diluted sample and then analyzed with the same three-step assay.  Standard 
addition plots were generated based on primary, secondary, or tertiary response as a function of 
the concentration of spiked CRP added, and CRP concentrations are determined based on 
extrapolation of the linear regression fit to the x-intercept. Regression lines for calibration in 
buffer and standard additions were calculated using linear fitting in Origin Pro 8.5 software. 
 
 
6.3 Results and discussion 
Demonstration of three-step assay. As shown in the red trace in Figure 6.1, the addition 
of 10
-1
 µg/mL CRP (t = 5 min) resulted in a visible primary binding response. Subsequent 
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addition of biotinylated anti-CRP (t = 28 min) gave a ~3-fold larger response. Finally, addition 
of 100-nm SA-functionalized beads (t = 46 min) provided an even larger signal enhancement. At 
this relatively high concentration, secondary and tertiary amplification gave large signals, but 
they were not required for CRP detection. However, at lower concentrations such as 10
-3
 µg/mL 
CRP (blue trace in Figure 6.1), amplification was necessary. At or below this concentration, no 
primary binding was detected, and the secondary binding showed ~1 pm resonance wavelength 
shift. Notably, addition of the beads gave nearly a 100-fold signal enhancement at this low 
concentration. Negative control experiments, in which biotinylated antibody and SA-beads were 
flowed over an anti-CRP-functionalized chip without initial CRP incubation, yielded no 
appreciable signal, as shown in Figure 6.2. 
Intra- and inter-chip assay reproducibility and CRP calibration curve. After 
determining the nature of the three-step signal enhancement process, CRP standards were 
measured across a five-order-of-magnitude concentration range using the sequential primary-
secondary-tertiary assay protocol. In order to justify the use of multiple chips to create a 
calibration curve, we first had to verify that chip-to-chip responses for a given sample were 
reproducible. Figure 6.3 shows the response plots from identical analyses on 4 chips (8 fluidic 
channels), with one ring shown for each channel. Figure 6.3A demonstrates the excellent 
reproducibility of the measurements at a higher concentration (10
-1
 µg/mL), and Figure 6.3B 
demonstrates reproducibility for a lower concentration (10
-3
 µg /mL).  
Statistical results of these comparisons are tabulated in Table 6.1. Average shifts/initial 
slopes and standard deviations for 10
-1
 µg/mL and 10
-3
 µg /mL CRP are given in Table 6.1A and 
Table 6.1B, respectively.  The ring-to-ring standard deviation is calculated from the standard 
deviation for all rings (n = 80) on all four chips tested, while the channel-to-channel standard 
deviation is calculated from the standard deviation of the average values for each of eight 
channels (two microfluidic channels/chip). In each case, the ring-to-ring variability exceeds the 
channel-to-channel variability, suggesting that the use of multiple chips for calibrations and 
quantitative analyses is satisfactory. It is also worth noting that the 0.9 ± 1.5 pm secondary shift 
for 10
-3
 µg /mL CRP represents a concentration on the lower boundary of what can be seen with 
a simple CRP sandwich assay. Although difficult to observe with secondary binding, tertiary 
binding creates an easily measurable response (73 ± 15 pm). Thus, in addition to enabling 
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detection at previously impossible levels, beads also are important for amplifying small 
secondary signals. 
After verifying chip-to-chip reproducibility, we then detected CRP across a wide range of 
concentrations to create the calibration curve shown in Figure 6.4. In this figure, the response 
curves from the primary, secondary, and tertiary binding assays overlap, allowing continuous 
CRP calibration over a broad dynamic range (10
-4
 µg/mL to 10 µg/mL). The initial slope of 
primary binding (black squares) is important because, at high concentrations, the surface is 
nearly saturated. Thus, it is impossible to distinguish between high concentrations except by the 
rate at which they approach saturation.
5
 Using initial slopes, it is possible to quantify 
concentrations from 10
-2
 to >10 µg/mL in buffer. The dynamic range is extended (10
-3
 to >10
-1
 
µg/mL) by measuring the relative shift in resonance wavelength following addition of secondary 
antibody (red circles) and further expanded down to <10
-4
 µg/mL though the use of SA-bead 
enhancement (blue triangles). Using the bead-based enhancement, the overall assay LOD is ~3 × 
10
-5
 µg/mL (~200 fM). 
 The dynamic range of each step of the three-part analysis method has a region of overlap 
with one of the other steps (Figure 6.4), providing the opportunity for confirmation of the 
measurement. For example, 10
-3
 µg/mL CRP is quantifiable by secondary detection, but tertiary 
amplification significantly increases the measurement precision. This echoes the results in Table 
6.1B that demonstrate greatly improved relative errors by bead amplification of small secondary 
signals. 
 Detection of CRP in human serum and plasma samples. Following assay calibration, 
the same three-step detection protocol was applied to the quantitation of CRP in human plasma 
and serum samples. Because the expected range of concentrations of CRP in human blood is 
from 10
-1
 µg/mL to 10
3
 µg/mL, each sample was subjected to an identical 1:1000 dilution into 
buffer, bringing concentrations into the range that could most accurately be quantified. This 
uniform dilution, as opposed to repeated dilutions, also helped reduce non-specific adsorption of 
blood proteins and lowered the required sample volumes to less than ten microliters, making the 
assay amenable to fingerprick sampling. 
  For the purposes of quantitation we utilized a standard addition method, as it is amenable 
to the complex and variable clinical sample matrices.
21
 In this method, the diluted serum or 
plasma was first analyzed via the three-step assay, and the response was compared to the 
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calibration curve (Figure 6.4) to roughly estimate the CRP concentration range. Three 
appropriate samples with increasing standard additions were then successively analyzed, and the 
precise CRP concentration was determined via extrapolation. The wide variation in native CRP 
levels required user input into the standard addition procedure, as opposed to simply adding 
uniform amounts of standard. However, the overall methodology is amenable to automation; for 
example, an analytical system pre-programmed with the calibration information could utilize 
integrated microfluidics to create the appropriate standard additions on demand. 
 Figure 6.5 shows the standard addition plots generated for each sample, while Figure 6.6 
shows the results of these serum/plasma analyses. The colors in the graph indicate the method 
used to quantify the CRP concentration. The black bar indicates that a commercially obtained 
pooled plasma sample with elevated CRP was quantified using the primary binding response and 
found to have a CRP concentration of 57.5 ± 3.3 µg/mL.  This value obtained on the microring 
resonator platform agreed reasonably well with the supplier’s provided value of 69.1 µg/mL. 
This result was in closer agreement than the results of an ELISA run in parallel, which gave a 
CRP concentration of 105 ± 11 µg/mL (see Table 6.2). The red bars indicate secondary binding-
based detection, which was used to quantitate the CRP values in the pooled-donor normal serum, 
single-donor serum #2, and single-donor plasma. The blue bars indicate quantitation using the 
tertiary bead binding, which was necessary to detect CRP within single-donor serum #1 as well 
as a commercially-available CRP-depleted serum sample (in which CRP had been removed by 
the vendor). Each of the samples analyzed, with the exception of the CRP-elevated pooled 
plasma, had CRP levels less than 1 µg/mL, placing those donors in the low-risk range for 
cardiovascular disease.
1
 Interestingly, for the CRP-depleted sample, analysis of a 1:100 dilution 
revealed CRP levels at 3×10
-5
 µg/mL. While this concentration is far below what would typically 
be found in human serum, it is noteworthy that this is similar to the lowest levels of CRP present 
in saliva.
22
 This means that the three-step assay format on the silicon photonic-based platform is 
amenable to quantifying CRP in all clinically-relevant sample matrices. 
In addition to microring resonator analysis, a commercial enzyme-linked immunosorbent 
assay (ELISA) was performed for comparison with the results for the six human serum and 
plasma samples depicted graphically in Figure 6.6. Results of this comparison are given in Table 
6.2. In this table, errors for the ring resonator array data represent the error in the x-intercept 
determination used in the standard addition assays (as described above and depicted in Figure 
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6.5). ELISA errors are the standard deviation of triplicate assays run according to the 
manufacturer’s protocol. All ELISA values were measured from samples that were diluted to be 
within the range of the assay, with a 1:1000 dilution proving optimal for all but the CRP-elevated 
plasma which required a 1:40,000 dilution. ELISA failed to detect CRP in the CRP-depleted 
serum at any dilution tested (1:100, 1:1000, 1:4000). While ring resonator analysis was in strong 
agreement with ELISA for most of the samples tested, some varied by as much as a factor of 2-3. 
This variation is typical of what is observed when comparing a variety of immunoassays, 
especially considering different dilution factors. Prior analyses of CRP samples by Khuseyinova 
et al. and Clarke et al. that each compared separate immunoassay methodologies showed a 
similar degree of agreement between methods, with most values in strong agreement and some 
varying by as much as a factor of 3-4.
23, 24
 These variations also tend to be more pronounced at 
higher concentrations, such as the pooled CRP-elevated plasma sample, where additional 
dilution or use of calibration curve extremes are necessary but introduce greater error due to 
pipetting, regression, or signal saturation. 
 In the course of our studies, we observed that several of the serum and plasma samples 
gave abnormally large signals for primary binding to microrings functionalized with the capture 
anti-CRP antibody, but a much smaller secondary binding response. These interactions, which 
we attribute to cross-reactivity between the primary antibody and some unknown component, 
highlight the fact that sample-to-sample heterogeneity can greatly complicate analysis in clinical 
samples.  In the case of the pooled plasma with elevated CRP, the primary binding signal was 
much larger than any of the off-target responses, and thus it did not interfere with primary 
response-based quantitation. However, for the single-donor plasma and serum samples, as well 
as the pooled normal serum, the primary off-target signal indicated abnormally high CRP 
content. Fortunately, the proportionally smaller secondary binding response increased the 
specificity of the assay, giving more reliable levels of CRP. Although some of the complications 
associated with clinical samples might be reduced by employing alternative antibodies or 
improved surface treatments, cross-reactivity and non-specific interactions are particularly 
difficult to completely avoid for multiplexed assays from within complex sample matrices. This 
underscores the utility of this three-step measurement format that allows analytes to be measured 
at multiple levels, increasing both the specificity of the assay and reducing false positive 
responses. 
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 Detection of DNA and IL-6 with bead amplification. As a final demonstration of our 
signal amplification strategy, we not only measure CRP concentrations, but we also demonstrate 
that we can detect DNA strands as well as the cytokine interleukin-6 (IL-6) using the bead 
amplification protocol. Figure 6.7A shows the detection of a 46-mer DNA strand relevant to the 
detection of the human papillomavirus (HPV). This ssDNA target was measured at four 
concentrations: 10 nM, 2 nM, 0.4 nM, and 0.16 nM. Each concentration is undetectable via 
primary binding. However, upon addition of beads conjugated to a 30-mer DNA probe that is 
complementary to a portion of the HPV target, a concentration-dependent response is generated 
in each case.  
 The cytokine IL-6 was detected in a similar manner as CRP using the sandwich assay 
detection format with a biotinylated secondary antibody. Samples at concentrations of 10 ng/mL 
and 0.1 ng/mL were measured using the bead-binding amplification. At the 0.1 ng/mL level, 
primary and secondary signals were undetectable; this concentration was only detected by the 
tertiary use of beads binding to the biotinylated secondary antibody. These results for IL-6 are 
similar to results for other cytokines (IL-2, IL-4, IL-5, IL-8, and TNFa) described in Chapters 4 
and 5. Assuming high-affinity antibody pairs, sandwich assays (the secondary step) can be 
expected to enable detection in the ng/mL range. However, the addition of streptavidin-coated 
beads to a biotinylated secondary antibody in the three-step assay improves the limit of detection 
by 1-2 orders of magnitude. Overall, these two additional examples demonstrate the broad 
applicability of the signal amplification technique to a variety of analytes. Indeed, bead-based 
amplification on the microring resonator biosensing platform has since been used in studies 
involving mRNA
25
 and the bioterrorism protein ricin.
26
 
 
 
6.4 Conclusions 
This chapter demonstrates a three-step immunoassay on a scalable silicon photonic 
biosensing platform that enables a protein antigen to be detected over six orders of magnitude of 
concentration in complex, clinically-relevant sample matrices. While primary binding allows 
detection at higher concentrations, subsequent secondary and tertiary binding events significantly 
lower the LOD. The secondary and tertiary binding also increases the specificity of the assay by 
requiring additional target-specific recognition, allowing discrimination against non-specific 
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interferants. Using this approach in a standard addition format, we determined the concentration 
of CRP in both human serum and plasma across a broad dynamic range while avoiding the need 
for multiple serial dilutions. This methodology, which is facilitated by a real-time and modularly 
multiplexable sensor technology, is applicable beyond the detection of CRP and can be applied 
to other analytes. The generality of this technique should make it useful in multiplexed analyses 
where analytes may differ in concentration by orders of magnitude. 
While magnetic beads (114 nm) were used in this study, it is possible to envision the use 
of diverse sub-micron beads and nanoparticles as signal enhancement tools. While yet to be fully 
realized on this platform, magnetic beads have the added benefit of possibly functioning as a 
separation handle for sample pre-treatment. In theory, any massive, high-RI tag can be used to 
boost the signal. Possible tertiary amplification elements include quantum dots, gold 
nanoparticles, gold nanorods, and polymer beads. An overview of exploratory work using these 
and other materials as tertiary signal enhancement entities is described in Chapter 7. 
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6.5 Figures 
 
 
 
Figure 6.1 Schematic and real-time data plot showing sequential addition of CRP, biotinylated 
secondary antibody, and SA-functionalized beads. The red trace is 10
-1
 µg/mL CRP. The blue 
trace is 10
-3
 µg/mL CRP. * indicates buffer rinse, and arrows indicate solution injection. 
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Figure 6.2 Negative control experiment for 10
-2
 µg/mL CRP sandwich assay with bead 
amplification. The red plot represents the response to 10
-2
 µg/mL CRP (t = 5 min) followed by 
the introduction of 1.6 µg/mL biotin-anti-CRP M701288 (t = 28 min) and subsequent signal 
amplification with 50 µg/mL streptavidin-conjugated beads (t = 46 min). The blue plot 
represents a ring that is first exposed to buffer without any CRP followed by the same secondary 
antibody and bead solutions. No primary, secondary, or bead signal is observed on rings not 
exposed to CRP, which demonstrates no appreciable non-specific binding of secondary 
antibodies or beads. * indicates buffer rinse, and the arrows indicate the introduction of the 
identified solutions at the times noted. 
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Figure 6.3 Demonstration of chip-to-chip reproducibility for (A) 10
-1
 µg/mL and (B) 10
-3
 µg/mL 
CRP sandwich assays with subsequent bead-based amplification. Both plots display eight 
representative rings, with one ring selected from each of two channels on a total of four chips for 
each CRP concentration. * indicates buffer rinse, and the arrows indicate the introduction of the 
identified solutions at the times noted. All assays were conducted in freshly degassed 10 mM 
PBS pH 7.4 + 0.05% Tween-20 with 1.6 µg/mL biotin-anti-CRP M701288 and 50 µg/mL 
streptavidin-conjugated beads. Statistics for the 10
-1
 µg/mL and 10
-3
 µg /mL reproducibility 
studies are summarized in Tables 6.1A and 6.1B respectively. 
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Figure 6.4 A log-log calibration plot showing the response of the microring resonators to 
varying concentrations of CRP using the three-step assay. Black squares indicate the initial slope 
of the primary binding (right axis), red circles indicate secondary antibody shift, and blue 
triangles indicate bead shift (left axis). Error bars represent 95% confidence interval for n = 17-
47 rings for each concentration. Arrows at the top represent overlap of dynamic ranges for each 
assay portion. 
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Figure 6.5 Standard addition plots used to determine CRP concentrations in 6 human serum and 
plasma samples quantified in Figure 6.6. Since CRP levels vary over a wide dynamic range, 
quantitation was performed based on bead shift (A, B), secondary shift (C, D, E), or primary 
initial slope (F). Each plot displays the shift or slope data for an unspiked sample dilution plus 
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three standard additions of CRP determined by the magnitude of the unspiked sample response. 
The sample identity, fitting equation, quality of fit, x-intercept, and observed CRP concentration 
are presented in the inset for each standard addition experiment shown above. 
 
 
 
 
 
 
Figure 6.6 Detection of CRP in human serum and plasma samples. All samples are diluted 
1:1000 in buffer except for the CRP-depleted serum, which was diluted 1:100. Error bars 
represent the error in the x-intercept determination used in the standard addition analysis. 
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Figure 6.7 Bead-based signal amplification universally augments ring resonator signals in assays 
designed for the detection of (A) a 46-mer human papillomavirus (HPV) ssDNA target and (B) 
the cytokine interleukin-6 (IL-6). In (A), four concentrations of HPV DNA prepared by serial 
dilution [10 nM (blue), 2 nM (orange), 0.4 nM (red), 0.16 nM (black)] are each undetectable 
based on primary binding (t = 6-36 min) to rings functionalized with a 30-mer probe 
complementary to the HPV target. Upon the addition of beads conjugated with a separate 30-mer 
DNA probe complementary to the remaining portion of the HPV 46-mer at t = 37 min, all four 
concentrations can be detected in a concentration-dependent manner. HPV DNA assays were 
conducted in freshly degassed 10 mM PBS pH 7.4 + 0.05% Tween-20 with 20 µg/mL HPV 
probe-conjugated beads. In (B), 10 ng/mL (blue) and 0.1 ng/mL (black) IL-6 are detected using 
bead-based amplification of a sandwich immunoassay. The secondary shift for 10 ng/mL IL-6 is 
amplified ~12x through the use of beads. However, the lower concentration of 0.1 ng/mL IL-6 (5 
pM) is only detectable through the use of bead-based amplification to amplify the secondary 
signal. IL-6 assays were conducted in 10 mM PBS pH 7.4 + 0.1 mg/mL BSA with 1 µg/mL 
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biotin anti-IL-6 BAF206 and 50 µg/mL streptavidin-conjugated beads. * indicates buffer rinse, 
and arrows indicate the introduction of the identified solutions at the times noted. 
 
 
 
6.6 Tables 
 
Table 6.1 Average shifts/initial slopes and standard deviations for CRP analysis at (A) 10
-1
 
µg/mL and (B) 10
-3
 µg /mL. The ring-to-ring standard deviation is calculated from the standard 
deviation for all rings (n = 80) on all four chips tested, while the channel-to-channel standard 
deviation is calculated from the standard deviation of the average values for each of eight 
channels (two microfluidic channels/chip).    
 
 
A 
Initial Primary Slope Secondary Shift Bead Shift 
 Δpm/min Δpm Δpm 
Average 3.7  117  369 
St. Dev. (ring-to-ring) 0.7  14  47  
St. Dev. (channel-to-channel) 0.3  8  33  
    
B Initial Primary Slope Secondary Shift Bead Shift 
 Δpm/min Δpm Δpm 
Average - 0.9  73  
St. Dev. (ring-to-ring) - 1.5  15  
St. Dev. (channel-to-channel) - 1.0  8  
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Table 6.2 Comparison of ring resonator and enzyme-linked immunosorbent assay (ELISA) 
results for six human serum and plasma samples depicted graphically in Figure 6.6. 
 
 CRP Concentration (µg/mL) 
 Ring Resonator Array CRP ELISA 
CRP-Depleted Serum 0.0031 ± 0.0015
2
 - 
Single-Donor Serum #1 0.12 ± 0.05 0.19 ± 0.08
3
 
Single-Donor Serum #2 0.70 ± 0.57 0.39 ± 0.08 
Single-Donor Plasma 0.67 ± 0.14 2.05 ± 0.22 
Pooled Normal Serum 0.89 ± 0.18 1.45 ± 0.10 
Pooled CRP-Elevated Plasma 58 ± 3 105 ± 11 
 
1
 All ELISA values were measured from samples that were diluted to be within the range of the 
assay, with a 1:1000 dilution proving optimal for all but the CRP-elevated plasma which 
required a 1:40000 dilution. ELISA failed to detect CRP in the CRP-depleted serum at any 
dilution tested (1:100, 1:1000, 1:4000). While ring resonator analysis was in strong agreement 
with ELISA for most of the samples tested, some varied by as much as a factor of 2-3. This 
variation is typical of what is observed when comparing a variety of immunoassays, especially 
considering different dilution factors. Prior analyses of CRP samples by Khuseyinova et al. and 
Clarke et al. that each compared separate immunoassay methodologies showed a similar degree 
of agreement between methods, with most values in strong agreement and some varying by as 
much as a factor of 3-4.
23, 24
 These variations also tend to be more pronounced at higher 
concentrations, such as the pooled CRP-elevated plasma sample, where additional dilution or use 
of calibration curve extremes are necessary but introduce greater error due to pipetting, 
regression, or signal saturation. 
2 
Errors for the ring resonator array data represent the error in the x-intercept determination used 
in the standard addition assays (as described above). 
3 
ELISA errors are the standard deviation of triplicate assays run according to the manufacturer’s 
protocol.  
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Chapter 7 
 
NANOPARTICLES AND SUB-MICRON BEADS FOR 
SIGNAL AMPLIFICATION AND MONITORING OF 
DISCRETE BINDING EVENTS 
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7.1 Introduction 
 Though Chapter 6 identified 114-nm streptavidin-coated magnetic beads as an effective 
tool for signal amplification, many other materials were also evaluated prior to deciding on the 
magnetic bead amplification scheme for the CRP application. Though no materials can match 
magnetic particles for their utility as pre-concentration and separation handles,
1
 other massive 
labels also have a potential to greatly enhance the signal arising from analyte binding. 
Theoretically, materials with a high refractive index (RI) should provide the greatest signal 
boost. To this end, quantum dots, gold nanoparticles, and polymeric beads were all evaluated as 
potential signal enhancement tools. A variety of amplification techniques should be available in a 
toolbox to choose the most ideal for a specific application. 
 The three-step assay used for CRP analysis in Chapter 6 has met with the most success to 
date,
2
 although attempts have been made to integrate secondary antibody binding and particle-
based amplification into a single step. Much like how the one-step sandwich assay
3
 described in 
Chapter 5 greatly reduced time-to-result over the similar two-step sandwich assay
4
 through pre-
incubation of samples with secondary antibodies, it is also attractive to think about reducing the 
extra time required to flow the tertiary signal enhancement element. However, though it is simple 
to think about pre-coating particles with secondary antibodies in theory,
5, 6
 this process has 
proven difficult in practice. 
 The combination of particle amplification and secondary antibody recognition into a 
single step has met with multiple challenges. First, it is very difficult to ensure that all secondary 
antibodies exist as a complex with the signal-amplifying particle. If any free (unconjugated) 
antibody remains, it will out-compete the antibody-particle complex for binding due to its 
smaller mass and faster diffusion time. This is similar to how free streptavidin would outcompete 
streptavidin-coated beads during the third assay step in Chapter 6, necessitating a bead rinse step 
directly before use.
2
 Due to this complication and the more difficult task of separating non-
magnetic particle-antibody complexes from free antibodies, much data for these combined 
attempts simply resembles normal two-step sandwich assay responses. A second challenge is that 
particle-antibody attachment chemistry is difficult to optimize. Even with straightforward 
EDC/NHS or HyNic/4FB crosslinking, molar ratios, incubation times, particle size, and coating 
density must be carefully optimized to achieve effective amplification. Third, commercial 
sources of particles often display polydispersity and poorly characterized polymeric coatings. For 
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instance, streptavidin-coated particles rarely specify if covalent chemistry is used for the coating 
process. All of these challenges can be overcome by careful design optimization and thorough 
testing of many reaction conditions. However, the three-step approach (primary target binding, 
secondary antibody binding, and then tertiary amplification) has met with the most success to 
date and will be the focus of this chapter. Additional discussion will focus on monitoring single 
bead binding events (digital readout or counting experiment) and the effect of beads on 
microring resonance peaks. 
 
 
7.2 Analysis of various materials for tertiary signal enhancement 
 Outside of magnetic particles, quantum dots, polymeric beads, and gold nanoparticles 
have been tested for their utility as tertiary signal enhancement materials. Quantum dots (QDs), 
which are small semiconductor nanocrystals with size-tunable fluorescence, combine a high-RI 
core (CdSe, CdTe, ZnS, etc.) with relatively fast diffusion times owing to a small diameter (1-12 
nm).
7, 8
 Though attempts were made to directly and covalently conjugate secondary cytokine 
antibodies directly to polymer-coated QDs, efforts to purify unconjugated secondary antibody 
from the antibody-QD conjugate by fast protein liquid chromatography (FPLC) were 
unsuccessful. However, cytokine sandwich assays were able to be effectively amplified in a 
three-step process. 
CdSe QDs with a 525 nm emission maximum were obtained from Invitrogen (Qdot 525 
streptavidin conjugate). These particles contain a ZnS shell and polymeric layer used to support a 
streptavidin coating for a total particle diameter of 15-20 nm. As shown in Figure 7.1, the 
addition of streptavidin-functionalized QDs following an IL-2 sandwich assay (with a 
biotinylated secondary antibody) provided specific signal enhancement. At 20 ng/mL IL-2, the 
~40-nm secondary antibody signal was amplified to a ~250-nm QD signal for a ~6x signal 
enhancement. No QD signal was observed on anti-IL-4 control rings. Though this three-step QD 
assay was successful, the results were difficult to reproduce. The lack of robustness likely stems 
from streptavidin dissociation from the QD or QD aggregation in the presence of small amounts 
of residual biotin anti-IL-2 in the inlet tubing. The utility of this amplification scheme at lower 
concentrations (that necessitate amplification) is yet to be fully explored. 
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Outside of QDs, sub-micron polystyrene particles also were used to as tertiary 
amplification elements in cytokine sandwich assays. As shown in Figure 7.2, 320-nm 
streptavidin-coated polystyrene beads (Spherotech) provide a specific signal boost in an IL-1β 
assay. At 20 ng/mL IL-1β, the polystyrene beads provide a ~60-pm bead tertiary signal on top of 
a ~30-pm secondary antibody shift. No bead signal was observed on the anti-IL-5 control rings. 
Interestingly, 200 fM beads was insufficient for signal amplification, but 2 pM beads provided a 
near-saturation response over 45 min. It is possible that increasing the bead concentration 
relieves issues with particle aggregation or overcomes bead losses to sticking in the inlet tubing. 
Additionally, although the polystyrene particles are more than ten times larger than the QDs even 
after streptavidin conjugation, the QDs afford a much larger signal due to their much higher RI 
contribution. 
Similar efforts with gold nanoparticles were not successful. Attempts were made to attach 
antibodies directly to carboxy-terminated-polymer-coated 100-nm spherical gold nanoparticles 
(SGNPs) obtained from Nanopartz. EDC/NHS coupling of anti-IL-4 to the carboxy polymer on 
the SGNP surface was unsuccessful, as evidenced by a lack of SPR wavelength shift in the 
UV/Vis spectrum following conjugation. When used in an IL-4 sandwich assay, no signal was 
observed when the anti-IL-4-SGNP conjugate (4 pM) was flowed following 5 ng/mL IL-4 
primary binding (data not shown). 
Though tertiary signal enhancement has been successful on the ring resonator platform,
2, 9
 
there remains a large amount of room for improvement. In order to fully realize the potential of 
magnetic bead technology, the magnetic beads must also be used for sample pre-concentration 
and and purification. One-step sandwich assays must then be developed for analytes already 
bound to the magnetic particles. Beyond problems with surface regeneration (―one chip, one 
experiment‖) and increased diffusion times, significant challenges remain in antibody 
conjugation chemistry and the need for improved fluid delivery systems for particle transport. 
 
 
7.3 Monitoring single-particle binding events 
 High-Q optical sensors have been demonstrated as effective tools for monitoring single-
particle binding events, with applications in nanoparticle sizing by mode splitting
10
 and single-
particle virus detection.
11
 Single-particle binding on ultrahigh-Q devices was reviewed in 
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Chapter 1, but ring resonators have yet to be developed as effective tools for monitoring 
stochastic processes based on visualizing discrete binding events. We have demonstrated the 
ability to observe discrete binding events for large particles (>100 nm) including protein-
conjugated polystyrene beads (Figure 7.3) and SGNPs. By using large particles, it may be 
possible to perform quantitation based on counting individual binding events. The use of 
stochastic binding responses could offer a new way to conduct assays, in which binding and 
unbinding events can be directly counted and monitored in real time. In this format, the digital 
response allows for a way to circumvent the spectroscopic noise or non-specific binding 
background that normally limits minimal resolvable shifts (see Chapter 3). This type of digital 
counting assay, which has been used to improve ELISA sensitivity,
12
 may require lower affinity 
(i.e. temporal binding) interactions so that subsequent binding events are not blocked by a 
saturated ring surface. Discrete binding/unbinding event monitoring may be applied to assays 
where binding events are accumulated over a period of time in an analyte concentration-
dependent manner. 
 To date, early work on this front has made progress in assessing conditions under which 
discrete binding events are observable; scanning electron microscopy (SEM) has also confirmed 
the presence of individual bound particles. Additionally, the variance associated with particle 
binding at different areas on a ring has been explored. In the process, evidence has been obtained 
for a direct correlation between the number of binding events and time prior to reaching a 
saturation region (a digital bead version of the traditional Langmuir binding model). 
 In general, discrete binding events are most readily observed at particle concentrations in 
the 100 fM – 10 pM regime (µg/mL range, depending on particle size). At higher concentrations, 
binding events happened too quickly to be effectively monitored as discrete shifts given the ~8-s 
time resolution of the ring resonator instrumentation.
13
 In order to obtain a large number of 
discrete binding shifts, 530-nm ProteinG-coated polystyrene particles (Spherotech) were flowed 
over a mouse IgG-functionalized chip surface. Figure 7.4A shows that dozens of binding events 
are observed for each ring over a 2-h time period. These binding events were manually identified 
and converted to a binding step size by subtracting final minus initial relative wavelength shift 
for each event. On closer inspection (Figure 7.4B), most single binding event shifts are in the 2-5 
pm range. Larger shifts (6-10 pm) are also evident, likely due to multiple beads binding to the 
same ring within the 8-s data collection time resolution window. It is interesting to note that 
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transient spikes are also evident at many areas in the bead binding plot. These spikes in the data 
are likely due to weak bead associations with the surface, such as a transient on/off interaction. 
The use of a weaker capture agent would likely increase the prevalence of these types of 
transient interactions and binding/unbinding events. 
 For each of the 24 rings on the chip, discrete shifts associated with bead binding events 
were measured and compiled. Initially, the first 20 binding events from five rings were compiled 
in a histogram (Figure 7.5A) to get an idea of the binding shift distribution. Interestingly, the n = 
74 single-bead binding events (excluded 26 shifts greater than 6 pm that are likely due to 
multiple beads) show a bimodal distribution with a minimum at the average value (4.1 ± 1.1 pm). 
This bimodal distribution may be explained on the basis of two main modes of interaction 
between the bead and the ring surface: from directly above the 500-nm-wide waveguide and 
from the side of the 200-nm-tall waveguide. It is reasonable to hypothesize that the lower shift 
distribution (2-4 pm) is made up of bead associations with the waveguide sides that allow less 
evanescent field overlap with the bead volume; the higher shift distribution (4-6 pm) could thus 
be made up of the 530-nm beads that sit directly on top of the 500-nm waveguide for maximum 
evanescent field perturbation. This speculation was not borne out by a larger sample, however. 
When the first 20 binding events were compiled from all 24 rings on the chip (n = 480), the 
bimodal distribution all but disappeared (Figure 7.5B). Though the average shift (4.3 pm) 
remained very similar in the larger sample size, no minimum at around 4 pm was observed. More 
data must be collected to understand this size distribution with more certainty. Specifically, 
slight differences in ring sensitivity, flow profile due to position in the microfluidic channel, and 
Cytop thickness around the annular opening may contribute to a general smoothing out of the 
data that masks the bimodal distribution. One way around this would be to collect many bead 
binding events for a single ring without monitoring any other rings. This would greatly improve 
time resolution and also reduce error associated with ring-to-ring variability. 
 By monitoring many bead binding events, the rate of bead binding can also be carefully 
measured. In a traditional protein immunoassay, binding of the analyte to the capture antibody 
follows the 1:1 Langmuir binding model:
14
 surface coverage increases over time, with saturation 
(leveling off of the signal) occurring at high concentrations and long incubation times 
(equilibrium conditions reached). This type of saturation response is also evident for bead 
binding, as shown in Figure 7.4. However, initial binding (initial slope of the binding curve, i.e. 
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first derivative of fitted binding curve at t = 0 min) is linear and directly proportional to 
concentration. This linear dependence of bead binding events on time is depicted in Figure 7.6. 
This figure shows that, for the first n = 20 bead-ProteinG to mouse IgG-ring binding events, 
there is a linear relationships between the number of binding events (n) and the time to the n
th
 
binding event. This provides preliminary evidence, albeit in a simple protein-protein interaction 
system, that counting binding events can be used for quantitation on the microring platform. 
 Beyond this digital version of the Langmuir binding model, interesting calculations can 
be performed to further understand the interaction between the bead and the evanescent field 
extending from the ring resonator surface. The calculations associated with single 530-nm 
ProteinG-coated polystyrene beads are tabulated in Table 7.1. Based on knowledge of the bead 
shift for a single bead binding event (4.3 pm), the mass sensitivity of the microring sensors from 
Chapter 3 (14.7 [pg/mm
2]/Δpm), and the ring surface area (0.0000884 mm2), the apparent bead 
mass can be calculated as 5.6 fg. Since the actual mass of a ProteinG-coated 530-nm polystyrene 
bead is calculated as 83 fg, the ring is picking up only 6.7% of the total bead mass. This makes 
sense given the large size of the bead relative to the evanescent field depth (1/𝑒 distance = 63 
nm).
15
 Since 6.7% of the bead volume is equal to 5.3 × 10
-15 
cm
3
, the bead portion that is 
detected by the ring can be represented as a spherical cap with volume: 
(1)     𝑉𝑐𝑎𝑝  =  
1
3
𝜋ℎ2 (3𝑟 − ℎ) 
where h is the height of the spherical cap and r is the spherical radius. With Vcap and r known, 
solving for h yields a height of 84 nm as the effective bead height that is detected. The 84 nm 
height can be understood in this way: the signal observed during a single 530-nm bead binding 
event (4.3 pm) is equivalent to binding of a spherical cap with a height of 84 nm. However, since 
the evanescent field extends beyond 84 nm (as shown in Table 7.1, field intensity has decayed to 
~20% of its original value at 84 nm from the ring surface), some portion of the bead beyond 84 
nm is detected while some portion of the bead within 84 nm is not detected. Taken together, 
these calculations demonstrate quantitatively that large particles, while providing an easily 
measurable shift for a single binding event, are largely undetectable since the bulk of their mass 
is located far beyond the ―sweet spot‖ of the evanescent field. 
 Besides monitoring polystyrene bead binding, similar experiments were also performed 
with gold nanoparticles with various surface modifications. 90-nm citrate-stabilized SGNPs were 
obtained from Stefano Boulos in the Murphy group. These SGNPs were flowed over bare 
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(unfunctionalized) microrings at a concentration of 890 fM at 10 µL/min, yielding many 
stepwise shifts attributable to single SGNP binding events (Figure 7.7). When the chip was 
removed from the fluidics and imaged by scanning electron microscopy (SEM), SGNPs were 
observed to be stuck to the ring surface (Figure 7.8A). Careful analysis of the SEM taken after 
SGNP binding revealed ~75 particles on a single ring resonator which showed a net shift of 90 
pm during binding, which represents 1.2 pm/SGNP bound. At higher magnification (Figure 
7.8B), both individual SGNPs and SGNP aggregates are observed to be in contact with the ring. 
It is also interesting to note that SGNPs are bound preferentially to the rings and within the 
annular opening in the Cytop cladding, but very few are found on the bulk Cytop surface.  
Similar experiments were also performed with 100-nm carboxy-functionalized SGNPs 
(Nanopartz) interacting with cationic polymer-coated rings. In this experiment, the negatively-
charged100-nm SGNPs were observed to bind to poly(ethylenimine) (PEI) rings, but not to bare 
rings (Figure 7.9). Flowing the 12 pM SGNPs at 5 µL/min resulted in specific binding to rings 
that are coated with cationic PEI, but the response began to slope downward beginning at about t 
= 20 min. This may be attributed to improper peak tracking due to resonance peak broadening as 
the SGNPs erode the ring quality factor through scattering losses, a subject that will be further 
explored in the following section. When the chip was removed from the fluidics and imaged by 
SEM, SGNPs were observed to be stuck to the ring surface (Figure 7.10A) at much higher 
density than in Figure 7.8A. Careful analysis of the associated SEM taken after SGNP binding 
revealed an estimated ~1000 particles on the entire ring resonator, which represents 2.1 
pm/SGNP bound. At higher magnification (Figure 7.10B), many SGNP aggregates are observed 
on the top and side surfaces of the waveguides.  It is interesting to note that SGNPs are bound to 
all areas of the PEI-coated chip, but especially on the Cytop cladding surface. This is in contrast 
to the results for the 90-nm citrate-stabilized SGNPs that barely stuck at all to the bulk Cytop; 
the PEI coating and higher SGNP concentration in Figure 7.10 dramatically alter the SGNP 
interactions as compared to Figure 7.8. 
 
 
7.4 Effects of particle binding on resonance peaks 
 Though it is now clear that single bead binding events can be effectively observed as 
discrete hops, much of the particle binding data is enigmatic. For instance, Figure 7.9 shows an 
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example of a SGNP binding response that initially shows many binding events (increasing RI at 
the surface initially gives a positive shift in the resonance wavelength). However, at t = 20 min, 
the signal levels off at begins to go down, despite the fact that the same 12 pM SGNP solution is 
still being flowed throughout. Though this may be interpreted as particle dissociation (indeed, 
some of the rings show stepwise downward shifts), the suddenness of the downward slope on all 
rings at once and the fact that the SGNP solution is unchanged from t = 11-77 min seem to 
indicate that another process is going on. This effect can at least partially be explained by the 
impact of particles on the microrings’ quality (Q) factors. 
 Though the ring resonator instrumentation normally only provides relative shift data as a 
function of time for each ring in the array (and all of the resonance peak fittings for each time 
point are performed ―behind the scenes‖), it is possible to view information about the real-time 
resonance peaks with the LabVIEW interface. In order to view the resonance peaks, the 
following procedure was followed on a chip loaded on the first generation instrument: 
(1) In the direction c:\Genalyte\Code\brads_stuff\production, run 2 LabVIEW files: 
a. Genalyte__Top 
b. Genalyte_Scan_Module_Real_Time 
(2) Use ctrl + e to open the LabVIEW code program within the 
―Genalyte_Scan_Module_Real_Time‖ window and select ―T‖ in the ―Dump Data 2 
File‖ T/F selector box 
(3) Run the ―Genalyte__Top‖ program by clicking the white arrow, registering the chip, 
and selecting an appropriate destination folder. NOTE: this unprocessed data dump 
will accumulate GB quantities of data in minutes, so it can only be performed for 
short time intervals before filling the hard drive. 
(4) The real-time resonance peaks are now evident in the 
―Genalyte_Scan_Module_Real_Time‖ window. NOTE: the units on the spectra are 
meaningless/incorrect. 
(5) Screen shots of the resonance peaks can be collected (alt + PrtScn) at various stages 
of a bead assay to track the resonance peak shape. NOTE: the resonance peaks will 
consistently scan through four sets of eight rings each, and for purposes of 
comparison, it is vital to collect screen shots at the same point in the cycle of four 
spectra. 
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In this way, resonance peak screen shots were taken at various points in various bead binding 
processes. Figure 7.11 shows the resonance peaks for eight microrings (one of which is a thermal 
reference ring) before (A) and after (B) capture antibody functionalization and before (C) and 
after (D) binding of 530-nm ProteinG-coated polystyrene beads. Figure 7.12 shows similar 
resonance peaks, but this time for binding of the 100-nm carboxy-polymer-coated SGNPs to 
PEI-coated microrings; the data is presented as a time lapse from (A) t = 0 (before SGNP binding 
to PEI surface) through four increasing time points during SGNP binding (B, C, D, E). When 
comparing Figures 7.11 and 7.12, the biggest difference is that the severe resonance peak 
broadening associated with SGNP binding is not observed to the same extent during polystyrene 
bead binding. This is the basis for the differing binding curves in Figures 7.7 and 7.9. Whereas 
polystyrene particles show a continuous binding curve that approaches saturation, the SGNP 
binding curve initially goes up, but then starts to go down as more gold scattering centers attach 
to the microrings and erode their Q factors (broaden the resonance peaks beyond recognition). 
The polymeric particles only lead to minor peak broadening that never causes an inability to 
track resonance peaks. This work demonstrates that the choice of material for bead experiments 
is important due to the impact of particle binding on the ability to maintain a WGM wave 
propagating through many circumnavigations of the ring. High-RI metallic gold nanoparticles 
are much more effective scattering centers than polymeric beads, causing the microrings to 
become more lossy to the supported WGM photons as more and more particles interact with the 
evanescent field.  
  
 
7.5 Conclusions 
 This chapter demonstrates that microring resonator applications are substantially 
expanded by incorporation of nanoparticles and sub-micron beads in a variety of assay formats. 
QDs, nanoparticles, and sub-micron polymeric beads provide an expansive tool box for 
optimizing signal amplification through choice of materials and assay optimization. Furthermore, 
the high sensitivity to surface binding afforded by high-Q microring resonators allows for the 
ability to monitor individual binding events. Sub-micron beads are large enough to permit 
digital-type stepwise binding curves that open the door to quantitation based on counting 
experiments and stochastic binding/unbinding processes. By evaluating many particle types, it is 
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clear that the choice of material for a particular assay format is vital. Though much optimization 
remains to be carried out in terms of antibody conjugation chemistry, assay design, and fluidic 
integration, bead-based assays offer a valuable tool for enhancing protein detection. However, 
bead-based assays are just one method for signal amplification, and a different enzymatic 
amplification strategy will be the subject of Chapter 8. 
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7.6 Figures 
 
 
 
Figure 7.1 Streptavidin-coated CdSe quantum dots as tertiary amplification material. After 
successive two-step sandwich assays for IL-4 and IL-2 are shown to be highly specific at 20 
ng/mL cytokine concentration, the addition of quantum dots (QD) to the IL-2 sandwich is shown 
to effectively enhance the signal. The reagents labeled in the plot are introduced as indicated by 
the black arrows. When 2 nM CdSe 525 nm quantum dots coated in streptavidin (15-20 nm total 
particle size) are added at t = 169 min, the QDs specifically bind to the biotinylated secondary 
anti-IL-2 to give a ~6x signal enhancement. The QDs show no interaction with the off-target 
anti-IL-4 rings. A low pH-rinse was used to regenerate the antibody surface between each of the 
three sandwich assays shown. 
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Figure 7.2 Streptavidin-coated polystyrene beads as tertiary amplification material. After initial 
two-step sandwich assays for IL-5 and IL-1β are shown to be highly specific at 20 ng/mL 
cytokine concentration, the addition of polystyrene beads to the IL-1β sandwich is shown to 
effectively enhance the signal. The reagents labeled in the plot are introduced as indicated by the 
black arrows. When 200 fM streptavidin (SA)-coated polystyrene beads (320 nm total particle 
size) are added at t = 108 min, the beads give no signal enhancement. However, when 2 pM SA-
coated polystyrene beads are added at t = 135 min, the beads specifically bind to the biotinylated 
secondary anti-IL-1β to provide a ~2x signal boost. The beads show no interaction with the off-
target anti-IL-5 rings. A low pH-rinse was used to regenerate the antibody surface between each 
of the two sandwich assays shown. 
 
244 
 
 
 
Figure 7.3 Initial observation of individual polystyrene bead binding events. This plot, which 
shows four representative rings coated in anti-IL-8 MAB 208, clearly displays discrete shifts as 
530-nm ProteinG-coated polystyrene beads (200 fM) bind to the ring surface. Variations in the 
magnitudes of the step sizes may be explained by bead size polydispersity, variation in binding 
location on the microring, and differences in the strength/valency of association between 
ProteinG on the beads and anti-IL-8 IgG on the ring surface. 
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Figure 7.4 Long-term monitoring of single 530-nm ProteinG-coated polystyrene beads binding 
to mouse IgG. (A) By flowing 600 fM ProteinG-coated polystyrene beads at 30 µL/min for 2 h, 
dozens of binding events were observed for each ring in the microring array. The first 20 binding 
events for each ring were analyzed to get a histogram of bead shift magnitudes (Figure 7.5). (B) 
Zoom of t = 55-95 min shows discrete nature of shifts and examples of weak (transient) bead 
association and strong bead association. Spikes in the bead association plots may indicate beads 
transiently binding and unbinding: for example, see t = 62 min (orange trace), t = 67 and 92 min 
(purple trace), t = 77 and 82 min (charcoal trace), etc. 
246 
 
 
 
Figure 7.5 Histogram of shift magnitudes for 530-nm ProteinG-coated polystyrene beads 
binding to mouse IgG-coated microrings. (A) The first 20 beads shifts for 5 rings (rings 19, 37, 
24, 28, and 34) gave n = 100 shift values, of which n = 74 that were <6pm were taken as single-
bead events (excluded putative multiple bead events with shifts >6 pm). These 74 events give an 
average shift of 4.1 ± 1.1 pm/bead in a possible bimodal distribution in which the average bead 
shift range is barely represented.  (B) When the analysis is expanded to the first 20 shifts for all 
24 sensor rings in the array, n = 480 binding events were obtained. In this case, an average shift 
of 4.3 ± 2.0 pm/bead is obtained (includes likely multi-bead binding events). Note that the 
bimodal distribution is no longer clearly observed. 
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Figure 7.6 Consistent bead binding rate is observed based on data from Figure 7.5. A linear 
relationship is found between n (number of bead binding events on a given ring) and the time to 
the n
th
 binding event. This plot shows that the number of bead binding events is directly 
proportional to time. Error bars represent the standard deviation for n = 24 rings on a single chip. 
This data is of potential significance to future work that uses particle counting for quantitation 
purposes. 
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Figure 7.7 90-nm spherical gold nanoparticles (SGNPs) bind to bare Si microrings. 890 fM 
SGNPs were flowed at 10 µL/min, producing many discrete binding interactions. 
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Figure 7.8 Scanning electron micrographs depict 90-nm spherical gold nanoparticles (SGNPs) 
binding to bare rings. After flowing 890 fM 90-nm citrate-stabilized SGNPs over a chip for 1 h 
at 10 µL/min, a net shift of 90 pm was observed for the ring shown in (A). Analysis of the 
associated SEM taken after SGNP binding revealed ~75 particles on the ring resonator, which 
represents 1.2 pm/SGNP bound. (B) By zooming in an additional 10x, individual SGNPs and 
SGNP aggregates are observed to be in contact with the ring. Note that most SGNPs are bound to 
the rings and within the annular opening in the Cytop cladding. Scale bars are shown within each 
image. 
 
 
 
 
 
A B 
250 
 
 
 
Figure 7.9 Negatively-charged100-nm spherical gold nanoparticles (SGNPs) bind preferentially 
to poly(ethylenimine) (PEI) over bare rings. 12 pM 100-nm carboxy-terminated polymer-coated 
SGNPs bind electrostatically only to rings that are coated with cationic PEI. The downward 
sloping plot after t = 20 min may be attributed to improper peak tracking due to resonance peak 
broadening as the SGNPs erode the ring quality factor through scattering losses. 
 
 
 
 
 
 
 
 
 
 
251 
 
 
 
Figure 7.10 Scanning electron micrographs depict 100-nm spherical gold nanoparticles (SGNPs) 
binding to cationic polymer-coated rings. After flowing 100-nm carboxy-terminated-polymer-
coated SGNPs over a poly(ethylenimine) (PEI)-coated chip for 1 h at 10 µL/min, a net shift of 
2100 pm was observed for the ring shown in (A). Analysis of the associated SEM taken after 
SGNP binding revealed an estimated ~1000 particles on the entire ring resonator, which 
represents 2.1 pm/SGNP bound. (B) By zooming in an additional 5x, individual SGNPs and 
SGNP aggregates are observed to be in contact with the ring. To estimate the number of particles 
on the entire ring, the SGNPs counted on the zoomed in region of (B) was scaled to the total ring 
circumference. Note that SGNPs are bound to all areas of the PEI-coated chip, but especially on 
the Cytop cladding surface. Scale bars are shown within each image. 
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Figure 7.11 Screen captures of instantaneous real-time resonance peaks for eight rings during 
various functionalization and assay phases. The basis for ring resonator signal transduction is 
monitoring shifts in the resonance peaks (transmission minima). During ring functionalization 
with IgG, these real-time resonance peaks are observed to shift to longer wavelengths when 
comparing (A) before loading IgG-4FB to HyNic-silane functionalized rings to (B) after loading 
~120 pm IgG-4FB. The antibody increases the effective RI at the ring surface, shifting the 
resonances to longer wavelengths (NOTE: the yellow peak on the far right is a reference ring, so 
it does not respond to antibody loading). Similarly, the resonance peaks are observed to shift to 
longer wavelengths again when comparing (C) a blocked ring surface without beads and (D) the 
surface after binding of ~200 pm worth of 600 fM ProteinG-coated polystyrene beads. Though 
the peaks shift due to bead binding, only minor resonance peak broadening (due to quality factor 
losses) is observed. 
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Figure 7.12 Screen captures of instantaneous real-time resonance peaks for eight rings at various 
time points during binding of 100-nm carboxy-terminated polymer-coated SGNPs to a 
poly(ethylenimine) (PEI)-coated chip. After coating the chips in cationic PEI, the resonance 
peaks are recorded at (A) t = 0 before beads are added at t = 10 min, (B) t = 12 min, (C) t = 25 
min, (D) t = 38 min, and (E) t = 54 min.  As more SGNPs bind to the rings, the peaks 
dramatically broaden as ring quality factor is eroded through scattering losses. (NOTE: the 
yellow double peak on the far right is a reference ring with a split resonance, and as expected, it 
does not respond to particle binding). By later time points, the peaks are so broad that it is 
difficult to identify a peak wavelength (minimum in the transmission spectrum), leading to 
improper peak tracking. This may account for the erroneous downward drifting response in 
Figure 7.9. 
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7.7 Table 
 
Table 7.1 Single polystyrene bead binding calculations 
 
Parameter Known/Calculated Value Notes 
Ring Diameter 30 µm See Figures 2.1 and 3.2 
Ring Surface Area (SA) 88.4 µm
2
, 0.0000884 mm
2
 ~200 nm × 500 nm waveguide 
Mass Sensitivity 14.7 pg/mm
2
 per Δpm See Chapter 3 
Average Shift, Single Bead 4.3 pm See Figure 7.5B 
Apparent Density per Bead 63 pg/mm
2
 Avg. Shift * Mass Sensitivity 
Apparent Bead Mass Bound 5.6 fg Apparent Density * Ring SA 
Bead Diameter 530 nm Spherotech product info 
Bead Volume 7.8 × 10
-14
 cm
3
 4 3 𝜋𝑟
3 
Bead Surface Area 8.8 × 10
-7
 cm
2
 4𝜋𝑟2 
Polystyrene Density 1.05 g/cm
3
 Spherotech product info 
Bead Mass 81.8 fg Bead Volume * Density 
Bead + ProteinG Coating Mass 83.0 fg From ProteinG coating density 
Portion of Bead Detected 5.6/83.0 = 0.067 Apparent Bead Mass/Bead Mass 
Portion of Bead Volume Detected 5.3 × 10
-15 
cm
3
 0.067 * Bead Volume 
   
Height of Bead/Protein G Detected 84 nm 
Solve for height (h) of spherical 
cap with volume 5.3 × 10
-15 
cm
3
: 
Vcap = 1/3 π h
2
 (3r-h) 
   
1/𝑒 Distance, Evanescent Field 63 nm See Chapter 3 
   
Field Intensity at 84 nm 20% of original value 
𝐼
𝐼0
 =  𝑒−2(9.56 µ𝑚
−1)(0.084 µ𝑚) 
  (Equation 3.2) 
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Chapter 8 
 
ENZYMATIC ENHANCEMENT OF SANDWICH 
IMMUNOASSAYS FOR SUB-PICOMOLAR 
CYTOKINE DETECTION 
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8.1 Introduction 
 Beyond the bead-based amplification strategies discussed in Chapters 6 and 7, enzymatic 
precipitate deposition on the microrings represents another method for effectively amplifying the 
signal associated with analyte binding. Enzymatic reactions are commonly used in 
immunoassays, involving enzymes such as horseradish peroxidase (HRP),
1, 2
 alkaline 
phosphatase,
3
 or B-galactosidase
4
 to catalyze a chemical reaction that produces an optical 
(usually colorimetric or fluorescent) readout. These enzyme-linked immunosorbent assays 
(ELISAs), which have been in use for over 30 years,
5
 are the gold standard for protein detection. 
Many ELISAs have been used to validate protein assays developed herein (Chapters 4, 5, and 6), 
with a multitude of commercial products consistently demonstrating limits of detection in the 
pg/mL range.
6, 7
  
Though the ELISA offers excellent sensitivity and highly useful microwell plate 
compatibility, the assay has many drawbacks. Traditional ELISAs are labor-intensive, with 
multiple washing steps and seemingly endless pipetting, and this process is time-consuming (2-4 
h). Additionally, traditional ELISAs are not a multiplexed technique: for each analyte, a different 
microplate must be used. Though progress has been made toward creating ―mix-and-match‖ 
microwell strips that can be assembled into array of microwells specific for different protein 
targets, each analyte requires cumbersome and space-consuming independent calibration wells. 
Even in the multiplexed ELISA format, a single sample must be divided into multiple ELISA 
microwells and tested separately for each analyte. Thus, ELISAs are fundamentally limited in 
multiplexing capabilities by the sample volume (~100 uL per well), the number of wells that a 
researcher is willing to employ for a single study, and the logistics of conducting multiple 
independent ELISAs and separate calibrations in parallel. These limitations can be overcome, 
while still maintaining pg/mL sensitivity, by combining microring resonators with enzymatic 
amplification. 
While the use of enzymatic amplification on microring resonators introduces complexity 
and forfeits the ability to call the assay ―label-free‖ in any sense of the word, it can substantially 
improve the limit of detection. Instead of using an enzymatic process to introduce a colorimetric 
or fluorescent signal, the assay can be optimized to produce an insoluble precipitate that 
substantially alters the effective RI at the ring surface. Li et al. showed that HRP can be used to 
catalyze precipitate formation for signal amplification on a surface plasmon resonance imaging 
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(SPRI) experiment.
8
 Though this initial demonstration on a RI-based sensing platform was used 
for an aptameric assay, it can be adapted to immunoassays on the microring resonator platform. 
With an enzyme-amplified sandwich assay, cytokine concentrations that were previously unable 
to be detected can be observed with ease. 
In this chapter, progress toward the optimization of an HRP-catalyzed amplification 
scheme is presented. This enzymatic process is applied to interleukin-2 (IL-2) and interleukin-6 
(IL-6) detection. Though two-step cytokine sandwich assays typically have limits of detection on 
the order of 10 pM
9
 (and the bead-based assay in Chapter 6 was able to detect 200 fM protein),
10
 
the HRP amplification assay achieves detection of IL-2 down to 67 fM (1 pg/mL). Importantly, 
the enzymatic process displays a lower and more reproducible background than the bead-based 
assay, also removing the need for time-consuming bead exchange directly before running the 
assay.
10
 The ability to quantitate cytokines in the 1 – 100 pg/mL range is vital for a range of 
challenging protein biosensing applications, including serum and cerebrospinal fluid (CSF) 
diagnostics. Additionally, previously lowest-achievable cytokine detection limits (100 pg/mL – 1 
ng/mL), which were barely observable (<1 pm shift) with traditional microring resonator 
sandwich assays, now produce large nm-scale wavelength shifts with enzymatic amplification. 
This chapter will discuss optimizing these assays, calibrating the responses, and applying the 
enzymatic amplification scheme to IL-6 detection in human CSF.  
 
 
8.2 Optimization of enzymatic HRP process for rapid precipitate formation 
 Since highly optimized sandwich assays and antibody pair selections have been 
demonstrated in previous work with IL-2
9, 11
 and IL-6,
10
 these targets represent an excellent 
starting point for designing an enzymatic amplification process. Due to extensive previous work 
with these targets, the advances described in this chapter have a well-defined benchmark for 
assay sensitivity comparisons and assay complexity and time-to-result tradeoffs. Though 
enzymatic amplification introduces complexity and extra time to the assay, the impressive 
sensitivity gains and highly quantitative signals make the assay extremely valuable for expanding 
the potential applications for ring resonator biosensing. 
 Selection of 4-Cl-1-naphthol as HRP substrate. HRP is a commonly used enzymatic 
label that catalyzes decomposition of two molecules of its natural substrate, hydrogen peroxide, 
259 
 
into water and oxygen.
12
  Since HRP has low selectivity for reductants, many chromogenic 
substrates have been developed and compared for use as HRP substrates with ELISA.
13
 These 
include 4-chloro-1-naphthol (4-CN), o-phenylenediamine, 3-amino-9-ethyl carbazole, 2,2’-
azino-bis(3-ethylbenzthiazolone), 4-aminoantipyrene + a phenol, 3,3’-diaminobenzidine (DAB), 
3,3’,5,5’-tetramethylbenzidine (TMB), 2,2’-azino-bis(3-ethylbenzthiazolone), Hanker-Yates 
reagent (HYR), 3-methyl-2-benzothiazolinone hydrazone hydrochloride (MBTH) + 3-
dimethylaminobenzoic acid, o-dianisidine, and dicarboxidine. Of these possible substrates and 
others, only some produce water-insoluble products following oxidation: 4-CN, HYR, DAB, and 
3-amino-9-ethylcarbazole.
12
 HRP is known to catalyze the oxidation of the substrate 4-CN by 
hydrogen peroxide to form the insoluble blue precipitate, 4-Cl-1-naphthon.
14
 This reaction 
scheme is presented in Figure 8.1. Though traditional ELISA makes use of the blue color change 
following substrate oxidation, the requirements of a RI-based ring resonator assay require 
different optimization. Color intensity and resistance to fading is irrelevant to this work, as the 
signal arises simply from precipitation of the oxidized substrate on specific microrings. This 
work requires optimization of precipitation rate, precipitate deposition specificity, and 
reproducibility of the reaction. NOTE: TMB was also evaluated as an HRP substrate without 
success. Though blue color was formed as evidence of the enzymatic process, the TMB did not 
effectively precipitate on the rings to amplify the signal. TMB seems to have poor solubility 
characteristics under the conditions tested, despite its use in SPRI amplification.
8
 In order to 
optimize precipitate formation, it is vital to consider the rate of oxidized substrate nucleation and 
surface deposition relative to the rate of diffusion away from the ring surface. Regardless of the 
HRP substrate chosen, the solubility constant (Ksp) must be exceeded in order to form a 
precipitate before diffusion can substantially dilute the oxidation product. 
Materials. 4-CN solution (0.48 mM 4-Chloro-1-naphthol in 50 mM Tris-HCl/0.2 M 
NaCl/17% methanol), a product normally used for Western Blot visualization, was obtained from 
Sigma-Aldrich (St. Louis, MO). High-sensitivity streptavidin-HRP (SA-HRP) conjugate and EZ-
Link NHS-PEG4-Biotin were obtained from Pierce (Rockford, IL), and 30% hydrogen peroxide 
was obtained from Macron Chemicals (Center Valley, PA). anti-IL-2 clone 555051 (capture Ab) 
and biotin anti-IL-2 clone 555040 (detection Ab) were obtained from BD Biosciences (San Jose, 
CA). anti-IL-2 43-2 and HRP-conjugated anti-IL-2 14-0 were obtained from Abcam (Cambridge, 
MA), while anti-IL-2 MQ1-17H12, polyclonal anti-IL-2, and recombinant human IL-2 were 
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obtained from eBioscience (San Diego, CA). anti-IL-6 clone MAB206 (capture Ab) and biotin 
anti-IL-6 clone BAF206 (detection Ab) were obtained from R&D Systems (Minneapolis, MN). 
Recombinant human IL-6, anti-IL-6 clone MQ2-13A5, and anti-IL-6 clone MQ2-39C3 were 
obtained from eBioscience (San Diego, CA). Mouse IgG1k isotype control clone P3 and anti-IL-
4 clone 8D4-8 (both from eBioscience) were used as control antibodies to verify assay 
selectivity. 
  Antibody functionalization methods. Ring resonator optical scanning instrumentation, 
software, and chips were obtained from Genalyte, Inc, and have been described previously.
15, 16
 
Prior to functionalization, chips were cleaned by a 30-s immersion in piranha solution (3:1 
H2S04:30% H2O2)
†
 followed by a water rinse and drying in a nitrogen stream. After a 10-min 
sonication in 100% ethanol, chips were dried in a nitrogen stream and spotted with 30 µL of 1 
mg/mL HyNic silane (3-N-((6-(N’-isopropylidene-
hydrazino))nicotinamide)propylthriethoxysilane, SoluLink, San Diego, CA) in 95% ethanol/5% 
dimethylformamide (DMF) for a 20-min incubation at room temperature to install a hydrazine 
moiety. Following silanization, chips were sonicated for 5 min in 100% ethanol to remove 
physisorbed silane. After drying in a nitrogen stream, chips were loaded into a previously 
described fluidic cell
16
 with a custom 4-channel fluidic gasket
17
 (Scarpati Technical 
Services/RMS Laser, San Diego, CA) to direct antibody solution flow to defined groups of 4-6 
rings each (analogous to layout shown in Figure 5.2).  
Capture antibodies were first buffer-exchanged into 100 mM phosphate-buffered saline 
(PBS) pH 7.4 with spin desalting columns (7k molecular weight cutoff, Pierce). In separate 
reaction vials, lysine residues on the 4 capture antibodies were functionalized with aldehyde 
moieties by reacting 0.5 mg/mL antibody with a 10-fold molar excess of succinimidyl-4-formyl 
benzoate (S-4FB, SoluLink, 0.5 mg/mL in DMF) for 2 h at room temperature. After another 
buffer exchange into 100 mM PBS pH 7.4 to remove excess S-4FB and DMF, the antibody 
solutions were diluted to 10 µg/mL in 100 mM PBS pH 6 with 50 mM aniline. The capture 
antibody-4FB conjugates were flowed over the chip using the previously described fluidics 
controlled by a multi-channel programmable syringe pump (BS-9000-8, Braintree Scientific Inc., 
Braintree, MA) operated in withdraw mode at 2 µL/min. Covalent antibody attachment by 
hydrazone bond formation between the hydrazine silane surface and aldehyde-modified 
                                                          
† Caution! Piranha solutions are extraordinarily dangerous, reacting explosively with trace quantities of organics. 
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antibodies was catalyzed by aniline
18
 in the running buffer to allow full surface coverage after 
30-60 min. Four-channel antibody functionalization was performed such that each of the two 
channels of 12 sensor microrings had anti-IL-2 or anti-IL-6-functionalized rings upstream of 
control (anti-IL-4 of mouse IgG isotype control) rings, as described in Figure 8.3. After 
multiplexed antibody functionalization, chips were blocked overnight at 4 ºC in StartingBlock 
PBS buffer (cat. #37538, Pierce). 
 Optimized assay conditions. For enzymatic amplification of cytokine sandwich assays, 
a four-step assay was designed. This assay is depicted schematically in Figure 8.2 After primary 
binding of cytokines to anti-cytokine capture antibodies on the rings, secondary biotin anti-
cytokine antibodies were introduced to form a sandwich pair. Next, complexation of 
streptavidin-HRP (SA-HRP) conjugate to the sandwich pair introduces the enzyme at appropriate 
rings in a concentration-dependent manner. Finally flowing hydrogen peroxide with 4-CN causes 
specific precipitation of 4-Cl-1-naphthon at the ring surface. The optimized assay conditions (75-
min total assay time, including rinse steps) are as follows (NOTE: all steps maintain a 30 µL/min 
flow rate and utilize room-temperature reagents):  
1) 20-min primary cytokine binding by incubation with sample or standard in 10 mM 
PBS pH 7.4 + 0.1 mg/mL BSA + 0.05% Tween-20 (PBS-BSA-T) 
2) 2-min buffer rinse (PBS-BSA-T) 
3) 10-min binding of biotinylated secondary anti-cytokine antibody (2 µg/mL in PBS-
BSA-T) 
4) 2-min buffer rinse (PBS-BSA-T) 
5) 10-min binding of streptavidin-HRP conjugate (2 µg/mL in PBS-BSA-T) 
6) 3-min buffer rinse (PBS-BSA-T) 
7) 25-min introduction of 465 µM 4-CN / 0.01% hydrogen peroxide solution in 17% 
methanol for precipitation of 4-Cl-1-naphthon 
8) Buffer rinse (PBS-BSA-T) 
The ratio of 4-CN to hydgrogen peroxide was carefully selected for optimal signal amplification 
and precipitation rate; other ratios of 4-CN : hydrogen peroxide gave little to no signal, and 
excess hydrogen peroxide was observed to quench the reaction. This solution must be prepared 
directly (within 1-2 min) before use by adding 45 µL of 0.3% hydrogen peroxide (1:100 dilution 
of 30% hydrogen peroxide in distilled water) to 1.5 mL of 480 µM 4-CN solution in methanol 
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(from Sigma-Aldrich) that has been already brought to room temperature. The solution is 
vortexed to mix and then immediately used in Step 7 above. The 17% methanol in the 4-CN 
solution causes a ~300-pm bulk RI shift, immediately followed by specific precipitation on 
appropriate rings in a cytokine-concentration-dependent manner. A fast flow rate (30 uL/min) is 
necessary to make sure that substantial uncatalyzed reaction of 4-CN and hydrogen peroxide 
does not occur within the inlet tubing prior to reaching the chip. 
 
 
8.3 Enzymatic amplification of IL-2 sandwich assay 
 The first step in creating an enzymatic amplification assay for IL-2 involved screening a 
variety of antibody pairs to determine the optimal capture and detection antibody combination. 
As shown in Figure 8.4, capture antibody clone 555051 paired with detection antibody 555040 
shows the greatest affinity and signal response in the 10 ng/mL IL-2 test. This result was not 
wholly unexpected, as excellent results have been obtained with this sandwich pair for IL-2 on 
the ring resonator platform in the past.
9, 11
 This result highlights the importance of comparing 
commercial antibodies side-by-side using an identical assay on an identical biosensing platform. 
 With the highest affinity antibody pair chosen, the next step was optimization of 
enzymatic amplification assay conditions. Initial attempts with 1) TMB as an HRP substrate and 
2) with dilute concentrations of 4-CN substrate solution were unsuccessful. Since 4-CN is 
provided in a 17% methanol solution, initial work sought to prevent the bulk RI shift associated 
with high solvent concentration by substantially diluting this methanol solution. An example of 
an enzymatically amplified IL-2 sandwich assay under dilute 4-CN and hydrogen peroxide 
conditions is shown in Figure 8.5. Though 100 pg/mL IL-2 is clearly detected before the fourth 
assay step (addition of 4-CN and peroxide), the final enzymatic amplification step provides only 
a minor signal boost. Furthermore, it was also found that adding additional hydrogen peroxide 
did not improve the enzymatic deposition of 4-Cl-1-naphthon. As shown in Figure 8.6, 
increasing the peroxide concentration from 0.0003% (100 µM) to 0.003% (1 mM) while 
maintaining dilute (48 µM) 4-CN appeared to quench the enzymatic process. This result 
demonstrates the narrow window of 4-CN:H2O2 ratio that is required for effective enzymatic 
deposition of 4-Cl-1-naphthon. 
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 Further testing of reaction conditions demonstrated that a combination of more 
concentrated 4-CN substrate coupled with a higher flow rate are vital to efficient precipitate 
deposition. The final optimized assay conditions have already been described above in section 
8.2, and the final assay step involves 465 µM 4-CN and 0.01% (3 mM) H2O2 at 30 µL/min. As 
shown in Figure 8.7, nm-scale resonant wavelength shifts are observed under optimized 4-CN 
and H2O2 conditions. 100 pg/mL represents the lowest concentration ever detected with a 
traditional IL-2 ring resonator sandwich assay (<1 pm shift), but this concentration generates a 
nearly 1 nm shift with enzymatic amplification. Following an initial ~300-pm bulk RI shift upon 
addition of substrate (due to 17% methanol in the 4-CN solution), 4-Cl-1-naphthon precipitates 
specifically on anti-IL-2 rings. With these optimized conditions, a large-scale calibration of IL-2 
enzymatic response was performed next. 
 As described in Figure 8.3, the chips are functionalized so as to enable two independent 
sets of anti-IL-2 capture antibody rings upstream of anti-IL-4 control rings. Thus, each chip was 
simultaneously used for two IL-2 concentration standards in independent fluidic channels. Figure 
8.8 shows the result of the multi-chip calibration of enzymatic signal for IL-2 sandwich assays 
(concentration range: 1 pg/mL – 1 ng/mL). This calibration plot shows that IL-2 concentrations 
as low as 1 pg/mL can be detected using enzymatic amplification, although 1 and 2 pg/mL 
signals are difficult to differentiate in this case. However, substantial differentiation of 5 and 10 
pg/mL standards shows that the assay is ideally suited for samples containing cytokine 
concentrations between 5 and 1000 pg/mL. This concentration range enables significant 
broadening of the range of applications for cytokine analysis on the ring resonator platform. 
Importantly, all responses are corrected to downstream anti-IL-4-functionalized rings, which was 
necessary for subtracting off the ~300-pm bulk RI shift at t = 50 min due to 17% methanol in the 
4-CN solution. Visual inspection of the chips following the enzymatically enhanced IL-2 
sandwich assay confirmed that precipitation occurs in a concentration-dependent manner and 
only on anti-IL-2 rings (Figure 8.9). Additionally, negative control experiments (0 ng/mL) 
showed no enzymatic signal, demonstrating a low background (data not shown). Though IL-2 
quantitation with the four-step HRP enzymatic amplification assay requires extra time, the total 
assay time of just over 1 h is still reasonable and superior to the ELISA time-to-result. By 
combining the data shown in Figures 8.7 and 8.8, concentration-dependent enzymatic 
precipitation responses were observed over a range spanning four logs (1 – 10,000 pg/mL). To 
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verify the effectiveness of the assay for an additional target, a similar assay was also designed for 
the cytokine interleukin-6 (IL-6). 
 
 
8.4 Enzymatic amplification of IL-6 sandwich assay 
 The same enzymatic amplification assay was applied to IL-6 detection. Capture anti-IL-6 
clone MAB206 and biotinylated detection anti-IL-6 clone BAF206 (both from R&D Systems) 
were chosen for initial characterization of the assay, although similar results were also obtained 
for clone MQ2-13A5 as capture antibody. An example of IL-6 enzymatic amplification is shown 
in Figure 8.10, displaying the signals for 5 and 50 pg/mL IL-6. The magnitudes of the shifts at 
these two IL-6 concentrations are comparable to the IL-2 responses at similar concentrations 
(Figure 8.8). The IL-2 antibody pair shows slightly better affinity for IL-2 than does the IL-6 
antibody pair for IL-6.  IL-6 detection down to 5 pg/mL is possible, but further optimization of 
the antibody pair may permit detection down to 1 pg/mL as was achieved with IL-2. Since CSF 
diagnostics is envisioned as an eventual application for this assay, anti-IL-4 was replaced with 
mouse IgG isotype control antibodies on the downstream control rings; if endogenous IL-4 is 
present in CSF, it would spoil the use of anti-IL-4 as an effective control. Ongoing work with 
this assay is necessary to reproduce and extend this preliminary work with IL-6. 
 
 
8.5 Conclusions 
In this chapter, an optimized HRP-catalyzed amplification scheme was successful for 
achieving unprecedented cytokine detection limits on the ring resonator biosensing platform. In 
the past, traditional cytokine sandwich assays on ring resonators were quantitative down to 100 
pg/mL – 1 ng/mL, depending on the particular analyte and assay format. This chapter shows that 
HRP-catalyzed amplification of the cytokine sandwich assay provides a full two orders of 
magnitude improvement in the detection limit for IL-2. The 1 pg/mL (65 fM) limit of detection 
represents the lowest concentration of any analyte detected with ring resonators to date. 
Importantly, the enzymatic process displays a lower and more reproducible background than the 
bead-based assay, also removing the need for time-consuming bead exchange directly before 
running the assay.
10
 By providing detection capabilities throughout the pg/mL regime, this assay 
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will allow applications that go beyond cell culture work at high cell densities. The ability to 
quantitate cytokines in the 1 – 100 pg/mL range is vital for many challenging protein biosensing 
applications, including serum and cerebrospinal fluid (CSF) diagnostics.  
Initial work with IL-6, which has displayed assay performance similar to IL-2, opens up 
the opportunity to perform CSF diagnostics with a possible Alzheimer’s Disease (AD) 
biomarker. IL-6 is a part of the acute inflammatory response, produced by macrophages and 
monocytes at areas of inflammation.
19
 IL-6, originally known as interferon-beta2, acts as the 
chief stimulator for production of most acute phase proteins (C-reactive protein, factor B 
complement, C3, etc.).
20
 As a general marker of inflammation, IL-6 is released from contracting 
skeletal muscles into the blood plasma during exercise without altering CSF levels of IL-6, 
signifying a separation of the CSF and plasma pools of IL-6.
21
 Outside of exercise-induced 
increases in plasma IL-6 levels, IL-6 concentration changes in CSF have been associated with 
brain trauma,
22
 stroke,
23
 multiple sclerosis,
24
 post-traumatic stress disorder,
25
 assorted infections 
of the central nervous system,
26
 and AD.
27
 These studies,
22-27
 which use commercial ELISAs to 
compare a variety of disease states to healthy controls, report healthy IL-6 CSF levels in the 1-20 
pg/mL range. In general, IL-6 levels noted in these studies
22-27
 are observed to increase in CSF as 
well as plasma or serum, with elevated IL-6 levels often reaching 100-1000 pg/mL. Though a 
number of studies have looked at AD-induced changes in CSF concentrations of IL-6 and other 
cytokines,
28
 the effect of AD progression on IL-6 levels remains unclear.
27
 Discrepancies and 
inconsistencies exist among a variety of studies aimed at evaluating changes in IL-6 levels 
associated with AD: IL-6 levels have been reported to increase
29-31
 or to not change significantly 
in AD.
28, 32-34
 Since IL-6 has definitively been observed by immunohistochemistry in the brain 
plaques of AD patients
35
 and is present at significantly higher levels in AD brain tissue 
homogenates,
36
 it is possible (or even likely) that the discrepancies in IL-6 expression alterations 
in AD CSF are due to assay inaccuracy and imprecision that cause a lack of statistical 
significance. 
By applying a real-time enzymatically amplified immunoassay to CSF diagnostics, we 
hope to obtain a more quantitative and definitive picture of the link between AD and IL-6 CSF 
levels. By running the optimized HRP sandwich assay for IL-6 on banked CSF samples of 
patients of known pathology from the David M. Holtzman lab at Washington University in St. 
Louis, we will look for correlations and patterns relating AD severity and IL-6 CSF levels. We 
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believe that the ring resonator HRP assay, by virtue of its real-time sensing, requisite sensitivity, 
and superior precision to ELISA (through many redundant measurements) will help to improve 
the fundamental understanding of the role of IL-6 in AD pathogenesis. This work is ongoing at 
the time that this chapter was written and represents a significant short-term application of this 
enzymatically amplified cytokine assay. Eventually, enzymatic amplification must be extended 
for multiplexed cytokine biosensing applications in order to fully take advantage of the ring 
resonator platform. Additional AD assay design progress aimed at detecting more commonly 
used AD CSF biomarkers, namely amyloid-β isoforms and tau, is the subject of Chapter 9. 
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8.6 Figures 
 
 
 
Figure 8.1 Horseradish peroxidase (HRP)-catalyzed oxidation of 4-Cl-1-naphthol (4-CN) by 
hydrogen peroxide. Oxidation of the 4-CN substrate produces 4-Cl-1-naphthon, a water-
insoluble blue precipitate. Hydrogen peroxide oxidizes 4-CN, albeit very slowly, without HRP. 
Thus, the substrate and hydrogen peroxide must be combined immediately before the final step 
of the microring sandwich assay. Streptavidin-HRP conjugates bound to biotinylated secondary 
antibodies catalyze 4-Cl-1-naphthon precipitate formation at microrings that have bound the 
target analyte. 
 
 
 
 
 
 
Figure 8.2 HRP-amplified cytokine immunoassay on a microring resonator platform. In this 
four-step assay, a standard cytokine sandwich assay with a biotinylated secondary antibody is 
followed by addition of streptavidin-HRP conjugate. Subsequent introduction of freshly prepared 
hydrogen peroxide in 4-Cl-1-naphthol substrate solution allows for the catalytic formation of the 
4-Cl-1-naphthon precipitate only at rings with bound HRP. 
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Figure 8.3 Capture antibody loading with four-channel microfluidics. Groups of four to six rings 
in each of four channels are functionalized simultaneously. This functionalization strategy allows 
anti-IL-2 rings to be upstream of anti-IL-4 control rings when fluidics are switched to a two-
channel setup after the blocking step. 
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Figure 8.4 Screening of IL-2 antibody sandwich pairs. 10 ng/mL IL-2 sandwich assays were 
performed with a variety of antibody sandwich pairs involving either clone 555051 (BD) or 
clone 43-2 (Abcam) as capture antibody. In each case, primary 10 ng/mL IL-2 binding is evident 
on 555051, but not on 43-2. Only 555051 is a suitable capture antibody for IL-2, and biotin anti-
IL-2 555040 (BD) represents the most effective detection antibody (MQ1-17H12 from 
eBioscience also demonstrated effectiveness as a detection antibody). A low-pH rinse was used 
to regenerate the capture antibodies between each sandwich assay test. All responses are 
corrected to anti-IL-5 control rings. 
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Figure 8.5 100 pg/mL IL-2 sandwich assay with enzymatic amplification: dilute 4-CN/peroxide 
conditions. Though clearly detectable upon addition of streptavidin-HRP conjugate (SA-HRP), 
the addition of dilute 4-CN and peroxide provides only minor signal boost. Interestingly, despite 
no measurable response to the IL-2 sandwich on the clone 43-2 rings during the first three assay 
steps, the final amplification step gave a small signal. All responses are corrected to anti-IL-5 
control rings. 
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Figure 8.6 Quenching of enzymatic deposition of 4-Cl-1-naphthon precipitate by high hydrogen 
peroxide concentration. Following a variety of 10 ng/mL IL-2 sandwich assay antibody 
combinations (which confirm and extend the data in Figure 8.4), enzymatic amplification is 
carried out with streptavidin-HRP conjugate (SA-HRP) at t = 160 min followed by dilute 4-
CN/hydrogen peroxide at t = 173 min. The initial 48 µM 4-CN/0.0003% hydrogen peroxide 
solution is spiked with 0.3% hydrogen peroxide at t = 186 min to a final concentration of 0.003% 
hydrogen peroxide, which appears to quench the precipitation reaction. This process was carried 
out at a low flow rate (5 µL/min). Importantly, no precipitation was observed on control anti-IL-
4 rings. 
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Figure 8.7 Large signal amplification with enzymatic amplification gives nm-scale shifts down 
to 100 pg/mL IL-2. Representative rings for each of three IL-2 concentrations show a 
concentration-dependent resonant wavelength shift upon addition of 465 µM 4-CN and 0.01% 
H2O2 to bound streptavidin-HRP conjugate (SA-HRP) at t = 50 min. The inset shows a zoom into 
the region of t = 0-48 min prior to enzymatic amplification, demonstrating secondary antibody 
and SA-HRP shifts that are evident at 1 and 10 ng/mL IL-2 concentrations. The relative shift axis 
for the zoomed-in region is shown to the right of the inset. These optimized assay conditions 
were used in subsequent IL-2 calibration experiments. 
 
273 
 
 
 
Figure 8.8 IL-2 calibration with four-step HRP enzymatic amplification assay. The addition of 
IL-2 (t = 3 min), biotin anti-IL-2 555040 (t = 25 min), streptavidin-HRP (t = 37 min), 465 µM 4-
CN / 0.01% H2O2 (t = 50 min), and a final buffer rinse (t = 75 min) are marked by the dashed 
lines. Based on two-channel multi-chip calibration at a variety of IL-2 concentrations, this plot 
demonstrates the ability to quantify IL-2 over a broad dynamic range with a detection limit of 1 
pg/mL using a ~1-h assay. Concentration-dependent responses were observed over a range 
spanning 4 logs (1 – 10,000 pg/mL, see Figure 8.7 for 10,000 pg/mL response). All responses are 
corrected to downstream anti-IL-4-functionalized rings, which are necessary for subtracting off 
the ~300-pm bulk RI shift at t = 50 min due to 17% methanol in the 4-CN solution. 
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Figure 8.9 Visual evidence of 4-Cl-1-naphthon precipitation on chip. Following 100 pg/mL 
(Channel 1, left) and 1 ng/mL (Channel 2, right) HRP-enhanced IL-2 sandwich assays, a 
concentration-dependent residue that takes on the shape of the gasket-defined fluidic channel is 
evident on the ring surface. The precipitate is only observed on the top portion of each channel, 
corresponding to anti-IL-2 rings. No precipitation is observed on the downstream anti-IL-4 
control rings (bottom of each channel). 
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Figure 8.10 Enzymatic amplification of IL-6 sandwich assay. The addition of IL-6 (t = 3 min), 
biotin anti-IL-6 BAF206 (t = 25 min), streptavidin-HRP (t = 37 min), 465 µM 4-CN / 0.01% 
H2O2 (t = 50 min), and a final buffer rinse (t = 75 min) are marked by the dashed lines. The 
capture antibody is anti-IL-6 clone MAB206. All responses are corrected to downstream mouse 
IgG isotype control antibody-functionalized rings, which are necessary for subtracting off the 
~300-pm bulk RI shift at t = 50 min due to 17% methanol in the 4-CN solution. 
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Chapter 9 
 
ASSAY DEVELOPMENTS TOWARD IN VITRO 
DIAGNOSIS OF ALZHEIMER’S DISEASE BASED ON 
CEREBROSPINAL FLUID BIOMARKERS 
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9.1 Introduction 
 Alzheimer’s Disease significance. Alzheimer’s Disease (AD), a progressive 
neurodegenerative disorder that involves irregular protein aggregation, has become a pandemic. 
As the most common (50-80%) form of dementia, AD involves a steady progression of 
increasingly severe memory loss and deterioration of functional capabilities over a period of 4 – 
20 years.
1
 While the causes of AD remain unclear, both genetics and environmental factors 
appear to have an impact, and there also seem to be fundamental differences between early-onset 
(before age 60) and late-onset AD.
2
 Though some forgetfulness is a normal part of aging, AD is 
not a normal part of the aging process. Clinical labels for various stages of the disease 
progression range from normal forgetfulness due to aging to mild cognitive impairment (MCI) to 
early AD to severe AD, and patients are evaluated using the clinical dementia rating (CDR) 5-
point scale (0 = normal, 0.5 = very mild dementia, 1 = mild dementia, 2 = moderate dementia, 3 
= severe dementia).
3, 4
 With no cure and few, largely ineffective treatments (such as donepezil 
and memantine) aimed at minor slowing of disease progression,
2
 AD is currently the sixth-
leading cause of death in United States with 83,308 deaths in 2010.
5
 Approximately 5-6 million 
Americans currently have AD,
6
 including 5% of men and women between 65 and 74 years old 
and nearly half of those aged 85 and older.
7
 As the population ages, the incidence of AD is 
projected to double by 2050.
8
 This will only add to the ballooning costs of AD healthcare (of 
which ~70% is funded by Medicare and Medicaid), which is estimated at $200 billion in 2012 
and is expected to surpass $1 trillion in 2050 (in 2012 dollars).
9
 
 AD diagnostics. Though developing useful therapies for AD remains a hugely important 
pursuit, effective diagnostic methods are equally important and must be developed in parallel. At 
present, the only way to know for certain that a patient had AD is to perform a post-mortem 
brain autopsy.
2
 Though not necessarily specific to AD, common AD observations include 
neuronal death (especially in the hippocampus), oxidative stress, disregulated energy 
metabolism, altered metal homeostasis, diabetes-like pathologies, and altered metalloprotein 
expression.
10
 More than any other commonly observed condition, the AD brain contains two 
hallmarks: 1) intraneuronal neurofibrillary tangles that kill neurons and 2) senile amyloid plaques 
(neuritic protein aggregates).
11
 Outside of the post-mortem autopsy, current ante-mortem 
diagnoses of ―dementia of the Alzheimer’s type‖ are educated guesses made purely on clinical 
grounds (CDR evaluation) with no neuropathological or biomarker evidence. Clearly, an in vitro 
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diagnostic method that provides 1) effective initial diagnosis as well as 2) the ability to monitor 
disease progression or response to therapy represents a clinically important goal. The 
requirements for an effective in vitro diagnostic include 1) well-defined biomarker targets with 
proven clinical utility and high predictive power; 2) multiplexed assays with requisite sensitivity 
and robust precision and reproducibility; 3) the ability to rapidly test many samples; and 4) a low 
cost that enables widespread and routine use in the clinical setting, possibly in a preventative 
format (assuming the parallel development of effective therapies). To this end, we believe that 
microring resonators provide a potential platform for high-throughput, low-cost, multiplexed 
analysis of AD protein biomarkers. 
Our collaborators in the Holtzman Lab at Washington University in St. Louis have 
evaluated several AD biomarkers that are present in human cerebrospinal fluid (CSF). As CSF is 
in direct contact with the brain interstitial space, it represents the most direct sampling medium 
for detection of pathological changes to the central nervous system. Important CSF protein 
biomarkers that have shown the greatest ability for statistically significant differentiation of 
healthy and AD states include isoforms of amyoid-β (Aβ), tau, and phosphorylated versions of 
tau.
11
 These biomarkers are aimed at providing earlier diagnoses of AD as well as guiding 
therapy (as prognostic biomarkers) for the rational selection of good patient candidates once 
effective therapies reach clinical trials. We hypothesize that, by conducting multiplexed 
biomarker assays on many banked CSF samples using the ring resonator platform, we can 
provide improved understanding of AD pathology and progression; furthermore, we hope to 
demonstrate effective differentiation of healthy individuals from those with MCI from those with 
AD. To further improve the predictive power of the multiplexed assays, it will also be possible to 
evaluate new potential biomarkers alongside those that are more established. 
CSF biomarkers of AD. The main CSF biomarkers of AD are variations of tau and Aβ. 
Tau, also known as microtubule-associated protein tau, exists as six isoforms (36.8 – 45.9 kDa) 
with three or four tandem repeats of the tubulin-binding domain on the C-terminus.
12
 The 
isoforms are identified by their N-terminal inserts (N) and the C-terminal tubulin-binding 
domains (R). Thus the full length, 441-amino acid version of tau (tau441) is named 2N4R. As tau 
functions as a microtubule stabilizer in neurons (binds to tubulin on C-terminus and neural 
membrane plasma proteins on its N-terminus), it is present in axonal cytosol and can also be 
secreted to the CSF.
13
 A variety of serine and threonine kinases are known to phosphorylate tau 
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at various positions, transforming the normal tau (2-3 mol P/mol tau) to hyperphosphorylated tau 
(6-12 mol P/mol tau).
14
 Hyperphosphorylated tau becomes more twisted and tangled, which both 
destabilizes neuronal microtubules and also leads to the formation of paired helical filaments. 
The paired helical filaments eventually form neurofibrillary tangles, one of the hallmarks of AD 
that correlates with disease progression.
11
 While not completely understood, it is believed that 
tau finds its way into CSF by virtue of neuronal death that may be caused by neurofibrillary 
tangles, head trauma, or some other cell death mechanism. Tau CSF levels are known to rise in 
AD, with average levels rising from ~100 – 400 pg/mL in healthy individuals13 to 400 – 1200 
pg/mL in AD.
15
 Levels of phosphorylated tau (ptau) also increase in AD, although ptau levels are 
significantly lower than total tau levels (30 – 70 pg/mL for healthy to 50 – 130 pg/mL for AD).15 
It is clear that pathological tau concentration changes are often subtle, with significant overlap 
between healthy and AD ranges as well as differences in basal levels caused by specific genetic 
mutations (such as ApoE ε4). Unfortunately, it remains very difficult to obtain homogenous ptau 
with site-specific (non-random) phosphorylations. Expressed protein ligation, which combines 
solid phase peptide synthesis and recombinant protein expression, represents the most promising 
method for generating ptau, although significant limitations remain.
16
 Due to the current 
limitations associated with obtaining homogenous ptau, the work described herein is concerned 
only with the unphosphorylated tau biomarker. 
Amyloid-β (also known as Aβ, Abeta, or beta-amyloid) is a peptide that represents the 
other main CSF biomarker of AD. Aβ makes up the hallmark amyloid plaques associated with 
the Alzheimer’s brain, and accumulation of Aβ aggregates in the brain is central to AD 
pathogenesis. As a cleavage product of the amyloid precursor protein (APP) that extends from 
the neuronal cell surface, the various isoforms of Aβ are produced by varying the order and 
cleavage location of sequential enzymatic processes carried out by β-secretase and γ-secretase.14 
Disregulation of APP metabolism thus plays a vital role in AD pathogenesis by changing the 
relative abundance or the various Aβ isoforms.17 Various isoforms of Aβ range in size from 15-
43 amino acids (full-length peptide molecular weight is 4.5 kDa). Though Aβ1-40 is the most 
abundant isoform, it has been shown that Aβ1-42 is the most important for AD as it plays a central 
role in initiating aggregation.
11
 Furthermore, the ratio between Aβ1-40 and Aβ1-42 levels is also 
important for diagnostic applications,
18
 as are the levels of shorter Aβ fragments such as Aβ1-38.
19
 
Importantly for early diagnostics of AD, evidence exists that Aβ1-42 levels are fully altered 5-10 
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years before the onset of dementia symptoms.
20
 According to the amyloid cascade hypothesis,
21
 
the formation of Aβ aggregates begins with the initiating role of Aβ1-42 in the formation of 
oligomers that have various structural forms (protofibrils, Aβ-derived diffusible ligands 
(ADDLs), Aβ-annular assemblies, etc.).22 Eventual fibril formation is the prelude to final 
creation of β-pleated sheets and insoluble plaques.14, 23 Aβ aggregation is hypothesized to lead to 
neuronal inflammation, glial activation, synapse dysfunction, and eventually neuronal death, but 
the aggregation may take place 10-20 years before AD symptoms emerge.
11
 Additionally, plaque 
formation acts as an Aβ sink that keeps Aβ from being transported out of the brain into the CSF. 
In the progression to AD, it has been observed that Aβ1-42 levels in CSF actually decrease from 
600 – 1000 pg/mL13 down to 300 – 700 pg/mL.15 This implies that free Aβ1-42 monomers are 
replaced by plaques and other aggregates, effectively decreasing the concentration that is 
detectable in immunoassays such as ELISA.  
Goals of in vitro CSF diagnostics on the ring resonator platform. With knowledge of 
potentially useful CSF biomarkers, an assay must first be designed for each target. This involves 
screening antibodies to find the best sandwich pairs that are also compatible (i.e. no cross 
reactivity) with the other antibodies for other AD biomarkers. After designing highly specific 
assays with requisite sensitivity for each target, a multiplexed AD diagnostic chip can be 
functionalized and used for CSF analysis. Based on simultaneous quantitation of multiple CSF 
biomarkers using calibration standards and inverse regression, CSF levels can be compared 
across many banked patient samples and validated with ELISA; It has been shown that CSF 
samples stored at -80 ºC still give reliable responses even after several years of storage,
24
 
opening up a large store of useful samples from older studies. Once validated, the ring resonator 
chips can be used to look for biomarker patterns that will be used to differentiate patient samples 
and disease states. Though this project remains in progress, substantial progress has been made 
toward the creation of a useable multiplexed CSF biomarker assay. 
 
 
9.2 Antibody screening to obtain high-affinity sandwich pairs 
 Tau antibody pair screening. A variety of tau antibodies were tested and compared in a 
series of sandwich assay combinations. These antibodies were obtained from several commercial 
sources as well as from the Holtzman group at Washington University in St. Louis. The anti-tau 
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antibodies that have been tested to date are listed in Table 9.1. By covalently arraying groups of 
four candidate anti-tau capture antibodies on each chip using 4-channel microfluidics (as 
described previously in Chapter 5), the capture antibodies were screened against candidate 
detection antibodies. NOTE: Due to tau’s biological role in binding negatively charged neuronal 
microtubules,
12
 DNA-encoded antibody libraries cannot be used for tau detection (tau fouls 
extensively on negatively charged DNA molecules
25
). The qualitative results of these antibody 
pair tests are depicted in Figure 9.1. anti-tau BT2 is by far the best capture antibody, forming 
effective sandwich pairs with clones HT7, DC39N1, 46, C-terminal, HJ8.5, HJ8.7, HJ9.3 and 
polyclonal antibodies. Other antibody pairs show little or no affinity; the highest affinity 
combination uses BT2 as the capture antibody and HT7 as the detection antibody. Negative 
control experiments where all antibodies were flowed as detection antibodies (but with no tau 
present) showed no net shifts (data not shown). Based on these screening results, the BT2/HT7 
combination was used in all further tau detection experiments. NOTE: In the final sandwich 
assay in Figure 9.1C, a larger secondary signal is observed by combining three detection 
antibodies (HT7, HJ8.7, and HJ9.3). 
 Aβ antibody pair screening. A variety of Aβ antibodies were also tested and compared 
in a series of sandwich assay combinations. These antibodies were obtained from a variety of 
commercial sources as well as from the Holtzman group at Washington University in St. Louis. 
The anti-Aβ antibodies that have been tested to date are listed in Table 9.2. For the Holtzman 
group antibodies, the known binding epitopes on the Aβ peptide amino acid sequence are 
depicted in Figure 9.2. As in the tau antibody screening, arrays of four candidate capture 
antibodies were loaded on each chip and screened against candidate detection antibodies. Two 
isoforms of Aβ were tested separately: a qualitative affinity comparison of sandwich pair 
combinations for Aβ1-40 is shown in Figure 9.3A while Aβ1-42 screens are depicted in Figure 
9.3B. For both isoforms, HJ5.1 (mid-domain) is the only functional capture antibody. Detection 
antibodies HJ2 (Aβ1-40-specific) and HJ3.4 (specific for Aβ amino acids 1-13) form sandwich 
pairs in Aβ1-40 assays, while HJ7.4 (Aβ1-42-specific) and HJ3.4 form sandwich pairs in Aβ1-42 
assays. Based on the lower signals observed for Aβ1-42 relative to Aβ1-40, aggregation was 
hypothesized to be a major problem for Aβ1-42 standards. Since Aβ1-42 is known to be the central 
player in the amyloid aggregation cascade, aggregation is a likely culprit. Disaggregation 
protocols will be described in the following section. 
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 Antibody screens performed after Aβ1-42 disaggregation revealed improved performance 
and the emergence of previously unsuccessful antibody pairs. Antibody sandwich pair tests for 
disaggregated Aβ1-42 are shown in Figure 9.4. In this case, both clone HJ5.1 (mid-domain) and 
clone 12F4 are functional capture antibodies. Following disaggregation, 100 ng/mL Aβ1-42 
generates secondary shifts (up to 70 pm) that are comparable to those for Aβ1-40 in Figure 9.3A. 
The most robust shift involves the HJ5.1 (mid-domain) / HJ7.4 (Aβ1-42-specific) pair. These 
results demonstrate the necessity of addressing peptide aggregation when working with Aβ 
standards, particular when Aβ1-42 is the isoform of interest. 
 
 
9.3 Aβ disaggregation protocols 
 The large difference in sandwich assay affinity for the Aβ1-42 isoform as compared to the 
Aβ1-40 isoform (Figure 9.3), despite the use of the identical capture antibody clone HJ5.1, pointed 
to an aggregation problem. According to the amyloid cascade hypothesis,21 Aβ1-42 has the initiating role 
of in the formation of oligomers that become various types of fibrils (protofibrils, Aβ-derived diffusible 
ligands (ADDLs), Aβ-annular assemblies, etc.).22 These fibrils eventually are formed into β-pleated sheets 
and insoluble plaques.
14, 23
 The aggregation pathway is summarized in Figure 9.5. When aggregation 
occurs in an amyloid peptide standard solution, it causes the effective concentration of peptide to 
fall drastically as most monomers exist as oligomers and higher-level aggregates. This result 
highlights the need for using great care when preparing amyloid peptide standards. Peptides must 
be prepared under strict conditions that limit aggregation, and aggregation state variation 
between peptide standards prepared in buffer as compared to human CSF samples is a legitimate 
concern. In fact, recombinant Aβ1-42 is known to aggregate faster (and has greater neurotoxicity) 
than synthetic Aβ1-42.
26
 
 A variety of methods for preventing amyloid peptide aggregation have been considered. 
These methods include: 
1. Mild basic conditions: 1% NH4OH, as suggested by Anaspec, a commercial solid 
phase peptide synthesizer of amyloid peptides. 
2. Harsher basic pH conditions (Xia et al.: 10 mM NaOH suspension, 1-h sonication, 
centrifuge @13k RPM to remove precipitates)
27
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3. Addition of hexafluoro isopropanol (HFIP) disrupts aggregates, and volatile HFIP 
is then removed by vacuum centrifuge, as described by Brorsson et al.
28
 
4. Acidic pH: 15-min sonication in undiluted trifluoroacetic acid (TFA) as suggested 
by Zagorski et al.,
29
 or a mixture of TFA and HFIP.
30
 TFA and HFIP can then be 
removed by drying under dry nitrogen.  
5. Dissolution in dimethylsulfoxide (DMSO) to solubilize peptide aggregates31 
(DMSO must be removed by buffer exchange or highly diluted) 
6. Various combinations of organic solvents can also be used: trifluoroethanol, 
aqueous acetonitrile with TFA, HFIP/DMSO, etc. 
While some of these methods were used in early test experiments (including a variety of basic 
conditions as well as the addition of DMSO), it was found that the best way to prevent a loss of 
immunogenicity was to dissolve lyophilized Aβ peptides in 100% formic acid. This method is 
used for Aβ peptide preparation in the Holtzman group according to conversations with Mary 
Beth Finn, and the optimized protocol is described below. Though formic acid may contribute to 
Aβ dimer formation32 and may react with serine side chains to create formate esters,29 the formic 
acid dissolution method is effective at preventing aggregation, especially for Aβ1-42. 
 Lyophilized Aβ peptides (0.5 mg) were obtained from American Peptide Company 
(Sunnyvale, CA). Each Aβ isoform (Aβ1-38, Aβ1-40, Aβ1-42) was resuspended in 100% formic acid 
(LC/MS ampules, Pierce) at 1 mg/mL and mixed gently to dissolve. NOTE: Aβ peptides should 
not be vortexed, as this causes aggregation. The formic acid peptide solutions were then 
aliquotted in small volumes into polypropylene PCR tubes and stored at -80 ºC. A fresh aliquot 
of peptide standard was thawed for each experiment. To dilute the peptides to working 
concentrations, the aliquots were first diluted 1:50 in 50 mM Tris pH 9 to 20 µg/mL. Then the 
peptide were further diluted to 1 µg/mL in 10 mM PBS pH 7.4 + 0.1 mg/mL BSA (PBS-BSA), 
taking care to correct dilutions for the percent peptide content noted in the solid phase petpdie 
synthesis data sheet (lyophilized samples often contain 70-90% peptide content, and this 
correction factor must be used for accurate final concentrations). All further dilutions for 
calibration standards were made in PBS-BSA. 
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9.4 AD biomarker calibration curves: tau441, Aβ1-40, and Aβ1-42 
 Once effective antibody pairs were obtained for each (disaggregated) target, calibration 
standards were prepared to verify quantitative concentration-dependent sandwich assay 
responses. For tau detection, capture antibody BT2 was paired with detection antibody HT7 to 
enable quantitation throughout the ng/mL range. As shown in Figure 9.6, tau sandwich assays 
enable detection down to ~1 ng/mL in buffer, and primary tau binding is evident at the higher 
concentrations. Tau detection and calibration was repeated in pooled human CSF (mixed 
gender). As shown in Figure 9.7A, a variety of tau concentrations spiked into CSF were able to 
be detected. When the spiked CSF is introduced, a ~50-pm shift is observed over 20 min on both 
anti-tau and control rings. Since CSF contains ~500 µg/mL total protein, the tau is just one small 
fraction of the total CSF proteome. Though CSF protein content is ~1% that of blood serum, its 
complexity still causes a non-specific background and necessitates the use of secondary 
antibodies for added specificity. Following the non-specific CSF background and a 5-min rinse, 
the tau is quantified by addition of detection anti-tau HT7. Detection limits for tau in CSF (~5 
ng/mL, Figure 9.7B) are slightly worse than in buffer (Figure 9.6), which is expected. However, 
these detection limits are insufficient for tau detection in the clinical range (100 pg/mL – >1 
ng/mL). At this time, tau analysis requires additional signal amplification and/or antibodies with 
better affinities. The Innotest ELISA kit (Innogenetics) for tau makes use of anti-tau clone 
AT120 as a capture antibody, with both biotin-anti-tau BT2 and biotin-anti-tau HT7 as detection 
antibodies for subsequent HRP-based quantitation. Unfortunately, AT120 is not commercially 
available, and a myriad of other commercial antibodies tested (Table 9.1) did not surpass the 
affinity of the BT2/HT7 pair. 
 Aβ calibration showed more promising results with available antibodies obtained from 
the Holtzman group. Though only one antibody (HJ5.1) is effective as a capture antibody (Table 
9.2), the different isoforms of Aβ can be differentiated with Aβ1-40/ Aβ1-42-specific detection 
antibodies HJ2 (for Aβ1-40) and HJ7.4 (for Aβ1-42). In the case of Aβ1-40, robust concentration-
dependent sandwich assay shifts were observed for peptide concentrations spanning nearly 4 
orders of magnitude (Figure 9.8A). The HJ5.1/HJ2 pair demonstrated the ability to detect Aβ1-40 
at concentrations down to 26 pg/mL (6 pM), showcasing excellent assay speed (~30-min for 
two-step sandwich) and on-rates. As shown in Figure 9.8B, the signal for Aβ1-40 secondary shifts 
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begins to saturate in the ng/mL range, making this assay ideally suited for quantitation in the 
clinical range (high pg/mL – low ng/mL levels).  
 Initial Aβ1-42 calibration was based on NaOH/DMSO-disaggregated amyloid peptide. 
Though the sensitivity is not as impressive as that of Aβ1-40, the HJ5.1/HJ7.4 pair demonstrated 
the ability to detect Aβ1-42 between 0.4 and 25 ng/mL (Figure 9.9). Further work that used formic 
acid-based disaggregation was able to improve Aβ1-42 detection limits to below 100 pg/mL, 
which is very comparable to that of Aβ1-40. This optimization will be discussed in the next 
section, which explains a new immunoassay assay advance that gets around problems associated 
with having only a single capture antibody with which to detect all Aβ isoforms. 
 
 
9.5 Consecutive sandwich assay: Aβ1-38, Aβ1-40, Aβ1-42 detected on a single ring 
 Ideally, antibodies specific for each Aβ isoform would be used as capture antibodies, and 
then a single detection antibody that binds to the middle or N-terminus of the peptide could be 
used as the second half of the sandwich pair. However, for reasons not well-understood, the 
isoform-specific antibodies do not function as capture antibodies (see Figure 9.3). Since HJ5.1 is 
the only suitable capture antibody out of the ten Aβ antibodies tested, an alternative sandwich 
assay format had to be developed. Thus, the consecutive sandwich assay format was created in 
order to detect multiple Aβ isoforms with a single capture antibody clone. 
 In the consecutive sandwich assay format, multiplexing happens in the time domain 
instead of the spatial ring array domain. Each Aβ-specific ring uses anti-Aβ HJ5.1 as the capture 
antibody, and the isoform-specific detection antibodies (HJ2, HJ7.4, 7-14-4) are flowed 
sequentially (multiplexed in time domain) instead of as a cocktail. In this way, each ring is used 
to detect all of the isoforms. To verify that the consecutive sandwich assay format remains 
quantitative, controls experiments were performed to compare the secondary shift magnitude in 
the presence of one isoform to the secondary shifts in the presence of two or more isoforms.  
Aβ1-40/Aβ1-42 consecutive sandwich controls were performed at peptide concentrations of 2 
ng/mL (Figure 9.10A) and 10 ng/mL (Figure 9.10B). In both cases, the shifts for the separate 
single-plex sandwich assays are nearly identical to the shifts obtained in the consecutive 
sandwich format. This result indicates that detecting multiple isoforms on a single ring (which 
has a limited number of antibody binding sites) is not limited by saturation effects at 
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concentrations below at least 10 ng/mL. Thus, at all Aβ peptide concentrations that are clinically 
relevant, the consecutive sandwich assay does not add any bias or cause an intrinsic loss in 
quantitative power. The negative control experiment, which involves performing the consecutive 
sandwich in the absence of Aβ peptides, revealed no appreciable cross-reactivity between the 
antibodies in question (Figure 9.11). Taken together, these results indicate that the consecutive 
antibody signals are not impacted by the concentrations (or presence/absence) of the other 
isoforms. 
 Next, the consecutive sandwich assay was evaluated at a clinically relevant set of Aβ 
peptide concentrations. Figure 9.12 demonstrates the ability to detect 500 pg/mL of each Aβ 
peptide in the consecutive sandwich format. Although the signals are small (1-2 pm), there is 
excellent reproducibility in shift magnitude between shifts obtained in the single-plex runs and 
the shifts obtained in the final three-plex run. In this experiment, it was also observed that the 
shift for the first peptide detected (Aβ1-42) was larger than the second and third peptides tested. 
This seemed to indicate that that order in which the detection antibodies are introduced is a 
significant consideration. To test the effect of detection antibody order, the peptide dissociation 
rates were evaluated for each isoform. 
 Figure 9.13 depicts the peptide dissociation effects for each Aβ isoform. In this 
experiment, 2 ng/mL primary binding of each of the three Aβ isoforms was followed by a 
different sequence of detection antibodies (various ordering of anti-Aβ1-38 7-14-4, anti-Aβ1-40 
HJ2, and anti-Aβ1-42 HJ7.4) at 2, 9, and 16 min after primary binding. In each case, as the 
peptides dissociate from the capture antibodies, the secondary signal decreases with additional 
time since the primary incubation step. This indicates that dissociation from the capture antibody 
is not negligible and must be factored into the assay optimization. Furthermore, the dissociation 
effects are more pronounced for Aβ1-38 than for the other two isoforms. This indicates that 1) it is 
important to minimize the dissociation time and that 2) the order in which detection antibodies 
are flowed is highly significant. Based on the data in Figure 9.13, the optimal detection antibody 
order is 1) anti-Aβ1-38 7-14-4, 2) anti-Aβ1-42 HJ7.4, and 3) anti-Aβ1-40 HJ2. In subsequent test 
assays, it was found that this detection antibody order could be carried out with 3-min detection 
antibody steps separated by 1-min rinse steps. This minimized the consecutive sandwich assay 
steps to t = 1, 5, and 9 min after primary peptide binding. Using these optimized conditions, 
calibration plots were constructed for each of the three Aβ isoforms simultaneously. Figure 9.14 
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shows that the optimized calibration data produces similar calibration plot slopes for the three 
isoforms while maintaining sub-ng/mL sensitivity. It is important to note that, although there are 
disadvantages to the consecutive sandwich format (namely increased dissociation time, 
marginally slower time-to-result, and more pronounced saturation effects at high concentrations), 
there is a significant advantage: by using each ring for three targets, even more independent 
measurements can be made on a single chip, which improves the precision of the assay. 
 
 
9.6 Multiplexed CSF sandwich assays with anti-biotin signal boost 
 With a successful consecutive sandwich assay in place, attention can turn to applying the 
assay to CSF analysis. However, though the Aβ1-40 assay is comfortably situated within the 
clinical range, the Aβ1-42 assay remains only sensitive enough to reach the high end of the clinical 
range (just under 1 ng/mL). To address this problem, a simple yet effective amplification scheme 
was used to boost the secondary signal by increasing the mass of the secondary antibody. To 
accomplish this signal boost, the Aβ1-40 detection antibody HJ7.4 was biotinylated with a 20x 
molar excess of NHS-PEG4-Biotin (Pierce) to yield ~4 biotins per IgG. This biotin-HJ7.4 
detection antibody was then incubated with equal portion (2 ug/mL) of anti-biotin phycoerythrin 
(anti-biotin-PE, eBioscience) prior to performing the secondary antibody binding step. As shown 
in Figure 9.15, the 1 ng/mL secondary shift of 2.0 ± 0.2 pm was increased to 5.2 ± 1.0 pm by 
adding the anti-biotin-PE to the anti-Aβ1-42 HJ7.4-biotin. This 2-3x signal boost based on anti-
biotin-PE was also attained at 5 ng/mL Aβ1-42 (data not shown). This anti-biotin-PE-amplified 
Aβ1-42 sandwich assay was also shown to be highly quantitative. Figure 9.16A shows the 
overlayed responses to Aβ1-42 standards between 0 and 9.6 ng/mL. By taking the net shift after 
just 3 min of primary binding, the amplified secondary shifts can be used to construct a useful 
calibration plot (Figure 9.16B). With the anti-biotin-PE amplification, the Aβ1-42 assay has a 
detection limit of 97 pg/mL (taken from setting the noise floor at the 0 ng/mL response + 3 
standard deviations). 
 Using this more sensitive version of the Aβ1-42 sandwich assay, a consecutive sandwich 
assay for Aβ1-40 and Aβ1-42 was carried out. Figure 9.17 demonstrates that the combination of 
anti-biotin-PE amplification with a two-step consecutive sandwich permits calibration in the 
relevant clinical range (100 pg/mL – 1 ng/mL). Though the shifts are frustratingly small, the 
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results demonstrate that this assay format has the potential to make clinically relevant 
measurement. The next step was to try the assay on human CSF samples to see if any reliable 
quantitation can be achieved. 
 Aβ1-40 is easily quantified in human CSF samples with the ring resonator sandwich assay. 
Secondary shifts are consistently observed when HJ2 is flowed following CSF protein binding. 
For instance, when pooled normal human CSF is spiked with 125 pg/mL Aβ1-40, the spiked shift 
is 9.0 ± 0.6 pm compared to 3.4 ± 0.7 for the unspiked CSF. Based on Aβ1-40 calibration 
performed in parallel, the difference of 5.6 pm corresponds to an endogenous CSF Aβ1-40 
concentration of 150 pg/mL. This value is reasonable relative to the normal Aβ1-40 range. In 
attempts to extend the quantitation to tau and Aβ1-42, the consecutive sandwich assay was applied 
to CSF analysis. Figure 9.18 shows responses to a set of five undiluted, unprocessed human CSF 
samples purchased from Bioreclamation (Westbury, NY). Interestingly, large disparities in 
primary binding behavior were observed across the five samples. The shapes and slopes of the 
curves show significant variability, indicating the heterogeneous nature of CSF samples from 
different individuals. After a 3-min rinse step, the consecutive sandwich assays were performed. 
Since non-specifically-bound CSF proteins are consistently rinsing off of the rings, it is difficult 
to observe very small shifts against the downward sloping background. For this reason, it is 
necessary to correct for non-specific CSF effects by subtracting the response on biological 
control rings. At this time, it remains a challenge to balance the need for longer rinse times with 
steady dissociation of the target from capture antibodies over time. 
 Human CSF was analyzed for tau, Aβ1-40, and Aβ1-42 using a two-channel fluidic setup. 
Following a 2 ng/mL standard that is used to normalize the CSF response, the five CSF samples 
were tested (see Figure 9.19). In one channel, anti-biotin-PE is used to amplify the anti-tau-HT7-
biotin signal. In the other channel, a consecutive sandwich is performed for Aβ1-42 (with anti-
biotin-PE amplification) and then Aβ1-40. Though this two-channel setup uses twice as much 
sample as a similar one-channel experiment, the total volume required is less than 800 µL (well 
within the limit of what is obtained in routine CSF patient sampling). All signals were 
normalized to the highest shift among the six assays (five CSF samples and one 2 ng/mL 
standard benchmark). Figure 9.19A shows that there are clear shift differences across the CSF 
samples for each of the three biomarkers. However, when reproducibility tests were conducted 
(Figure 9.19B), only the Aβ1-40 assays clearly demonstrated robust quantitation results. When 
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identical samples were run on different days on the same chip, only Aβ1-40 levels were 
reproduced. This result was not unexpected, as the shifts resulting from tau and Aβ1-42 were 
difficult to observe at best. 
 At this point, CSF quantitation has been demonstrated for the most abundant Aβ1-40 
isoform. However, quantitation of Aβ1-42 and tau remain elusive. It is likely that improving the 
assay sensitivity by one or two orders of magnitude (to have limits of detection between 1 and 10 
pg/mL) would open up the ability to analyze even the least abundant CSF protein biomarkers. 
This required sensitivity could be reached by obtaining higher affinity antibodies (such as anti-
tau clone AT120 that is used in ELISA kits) or by adding a signal amplification strategy. Though 
both bead-based (Chapter 6 and 7) and enzymatic (Chapter 8) amplification strategies should 
provide the requisite sensitivity boost, quantitation of Aβ isoforms remains hindered by the lack 
of isoform-specific capture antibodies. It is difficult to envision an amplification strategy that 
would work well with the consecutive sandwich assay format. To address these issues, better 
antibodies must be raised against each Aβ isoform and against tau, and traditional sandwich 
assays with some form of tertiary amplification can then be employed in the usual fashion. 
 
 
9.7 Conclusions 
 The body of work described in this chapter explored a large number of considerations and 
confronted many of the challenges associated with in vitro AD diagnostics. It is safe to say that 
there are many good reasons that explain why no effective in vitro Alzheimer’s diagnostics have 
been created to date: the particular complications associated with AD diagnostics include 
extensive analyte aggregation at fast time scales, very low target protein abundance, minor 
(barely statistically significant) variations in biomarker levels from healthy to AD cases, and the 
lack of availability of quality capture agents. Beyond these hurdles, AD remains poorly 
understood on all levels: pathology, disease progression, diagnostics, and treatments. For 
example, a recent study suggests that AD may be an infectious disease (with Aβ functioning as a 
prion),
33
 a surprising finding which shows how little we know about what has become a 
pandemic. 
 Despite the challenges, progress was made toward understanding and dealing with AD 
biomarker aggregation as well as with designing effective CSF immunoassays. Though 
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handicapped by a lack of high-affinity capture antibodies, multiplexed detection of four AD 
biomarkers (tau, Aβ1-38, Aβ1-40, Aβ1-42) was demonstrated at or near their respective clinical 
ranges. The consecutive sandwich assay was also developed as a way to multiplex in the time 
domain when an analysis is limited by the availability of good capture agents. Additionally, the 
anti-biotin-PE amplification strategy demonstrated a very straightforward means to achieve a 2-
3x sensitivity boost without adding additional time; this method can be applied to any sandwich 
assay in need of minor signal boost to reach a relevant concentration. In the future, higher 
affinity antibody pairs should enable this project to reach the goal of performing AD protein 
biomarker quantitation in CSF. Once a working multiplexed assay is attained, there will be no 
shortage of banked CSF samples to run. This large quantity of data can then be compared and 
classified in the search for patterns and clustering based on disease state. Though the framework 
and experimental methods for this project have been laid out, the same experiments must be 
performed with better capture agents and/or signal amplification strategies. In this way, this 
chapter serves to clearly identify the problems with tau and Aβ immunoassays and to specifically 
bring to light the areas that must be improved to achieve the ultimate goal of quantitative, 
multiplexed CSF diagnostics. 
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9.8 Figures 
 
 
 
Figure 9.1 Tau sandwich assay pair tests. A large variety of antibody combinations were tested 
at 10 ng/mL (A and B) and 100 ng/mL tau (C), with a low-pH rinse for regeneration between 
each assay test. The capture antibody clone designations are noted in the legend in each plot, and 
the variety of antibodies screened as detection antibodies are recorded above the plot at 
appropriate time positions. (A) anti-tau BT2 is by far the best capture antibody, forming effective 
sandwich pairs with HT7, DC39N1, 46, C-terminal, and polyclonal antibodies. Other antibody 
pairs show little or no affinity. (B) No effective pairs are observed. (C) Once again, anti-tau BT2 
is the only functional capture antibody, forming sandwich pairs with HT7, HJ8.5, HJ8.7, and 
HJ9.3. In the final sandwich assay, a larger secondary signal is observed by combining three 
detection antibodies (HT7, HJ8.7, and HJ9.3). All signals are corrected to unfunctionalized and 
blocked control rings. 
 
A B 
C 
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Figure 9.2 Aβ amino acid sequence and antibody binding epitopes. The full-length peptide is 
shown, with binding epitopes defined for Aβ1-13/HJ3.4 (amino acids 1-13), Aβmid-
domain/HJ5.1 (amino acids 13-28), Aβ40/HJ2 (amino acids 35-40), and Aβ42/HJ7.4 (amino 
acids 37-42). These four antibodies represent the clones obtained from collaborators at 
Washington University in St. Louis. 
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Figure 9.3 Antibody sandwich pair tests for (A) Aβ1-40 and (B) Aβ1-42 sandwich assays. All 
sandwich assays were conducted at 100 ng/mL Aβ, with a low-pH rinse for regeneration of the 
capture antibody surface between each assay test. (A) For Aβ1-40, HJ5.1 (mid-domain) is the only 
functional capture antibody, forming sandwich pairs with HJ2 (Aβ1-40-specific) and HJ3.4 
(specific for Aβ amino acids 1-13). (B) For Aβ1-42,HJ5.1 (mid-domain) is again the only 
functional capture antibody, forming sandwich pairs with HJ7.4 (Aβ1-42-specific) and HJ3.4 
(specific for Aβ amino acids 1-13). Substantial Aβ1-42 aggregation likely limited the responses 
(see Figure 9.4 for disaggregated Aβ1-42 sandwich pair tests). A negative control experiment 
showed no substantial response. Responses are not corrected to control rings (control responses 
shown in green).  
 
A 
B 
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Figure 9.4 Antibody sandwich pair tests for disaggregated Aβ1-42. All sandwich assays were 
conducted at 100 ng/mL Aβ1-42, with a low-pH rinse for regeneration of the capture antibody 
surface between each assay test. Disaggregation substantially improves the results (compare 
shifts to Figure 9.3). HJ5.1 (mid-domain) is the consistently functional capture antibody, forming 
sandwich pairs with HJ3.4 (specific for Aβ amino acids 1-13), HJ7.4 (Aβ1-42-specific), G2-11 
(Aβ1-42-specific), and G2-13 (Aβ1-42-specific). Additionally, clone 12F4 is also functional as a 
capture antibody, albeit to a lesser extent. 12F4 forms a sandwich pair with HJ5.1 (mid-domain) 
only. All signals are corrected to unfunctionalized and blocked control rings. 
 
 
 
 
Figure 9.5 Formation of Aβ aggregates and fibrils. Aβ monomers spontaneously aggregate to 
form both fibrillar and non-fibrillar aggregates. Non-fibrillar aggregates include small oligomers, 
protofibrils, and ADDLs. Some non-fibrillar aggregates can continue on to form fibrils (solid 
black arrow), while some remain non-fibrillar (dashed arrow with red x). This figure is adapted 
from that of Jan et al.
22
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Figure 9.6 Series of tau calibration standards show concentration-dependent sandwich assay 
signals. The use of the BT2/HT7 anti-tau antibody pair enables quantitative sandwich assays in 
buffer.  Tau441 concentrations (ng/mL) are noted above each appropriate secondary shift. Primary 
tau binding is evident at the higher concentrations. All signals are corrected to anti-tau DC39N1 
control rings, and the surface was regenerated with a low-pH rinse between each standard. 
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Figure 9.7 Tau calibration performed in pooled human CSF. (A) Various concentrations of 
tau441 were spiked into pooled human CSF directly before each run, and sandwich assays were 
performed using the BT2/HT7 antibody pair. In each case, the spiked CSF was added at the 
dashed line, and the HT7 detection antibody was introduced (at times indicated by the black 
arrows) following a 5-min buffer rinse. A differential response between anti-tau BT2 rings and 
control rings is evident. The surface was regenerated with a low-pH rinse between each standard. 
(B) The resulting calibration plot demonstrates highly quantitative tau detection in the low 
ng/mL range in human CSF. All signals are corrected to mouse IgG isotype control antibody 
rings. 
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Figure 9.8 Aβ1-40 calibration standards and associated calibration plot. (A) Aβ1-40 can be 
effectively detected with the HJ5.1/HJ2 sandwich pair. A robust concentration-dependent 
response is observed for increasing concentrations varying across nearly 4 logs (26 pg/mL – 100 
ng/mL). Calibration standard concentrations are labeled at top. All signals are corrected to anti-
IL-2 control rings, and the surface was regenerated with a low-pH rinse between each standard. 
(B) The resulting calibration plot demonstrates the highly quantitative detection of Aβ1-40 in the 
pM – nM regime with a two-step ~30-min sandwich assay. Since the signal begins to saturate in 
the low ng/mL range, a quadratic fit is used to encompass the seven standards in the low 
concentration regime. The inset depicts the linear response below 0.5 ng/mL. 
B 
A 
R2 = 0.997 
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Figure 9.9 Aβ1-42 calibration standards and resulting calibration plot. (A) 100 ng/mL 
disaggregated Aβ1-42 can be detected with a variety of sandwich pairs based on HJ5.1 as capture 
Ab, but detection antibody HJ7.4 provides the highest affinity and the fastest on-rate. Following 
the detection antibody screening, a concentration-dependent response is observed for 
concentrations varying from 25 down to 0.4 ng/mL. Concentrations are noted for calibration 
standards under the bracket. All signals are corrected to unfunctionalized and blocked control 
rings, and the surface was regenerated with a low-pH rinse between each standard. (B) The 
resulting calibration plot demonstrates the highly quantitative detection of Aβ1-42 in the pM – nM 
regime with a two-step ~35-min sandwich assay. 
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Figure 9.10 Consecutive sandwich assay control experiments performed at (A) 2 ng/mL and (B) 
10 ng/mL of Aβ1-40/Aβ1-42. In both cases, a 20-min peptide binding step is followed by HJ7.4 and 
then HJ2 consecutive sandwich assays. (A) Four sandwich assays at 2 ng/mL were performed, 
each separated by a low-pH rinse to regenerate the surface. In the first two assays, Aβ1-42 is 
flowed without Aβ1-40 (and vice-versa) to get a benchmark shift for the single-isoform case. In 
the final two (identical) assays, both Aβ1-40 and Aβ1-42 are flowed together in the 20-min primary 
step, and the secondary shifts in the presence of both isoforms are obtained sequentially. No 
significant difference in shifts was observed when comparing separate, single-plex sandwich 
assays to the consecutive sandwich. (B) The process is repeated at 10 ng/mL peptide 
concentrations. Again, the shifts for the separate single-plex sandwich assays are nearly identical 
to the shifts in the consecutive sandwich format. All signals are corrected to anti-IL-2 controls. 
A 
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Figure 9.11 Consecutive sandwich assay negative control. In the absence of Aβ peptide 
isoforms, the three detection antibodies (anti-Aβ38 7-14-4; anti-Aβ40 HJ2; anti-Aβ42 HJ7.4) 
were flowed in sequence. As expected, there was no response, signifying that the various 
antibodies have no appreciable cross-reactivity. All signals are corrected to anti-tau BT2 control 
rings. 
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Figure 9.12 500 pg/mL consecutive sandwich assays with single-plex controls. The consecutive 
sandwich format was evaluated at clinically relevant Aβ isoform concentrations. In the first three 
assays, each of three isoforms is tested in a single-plex fashion with the consecutive sandwich 
assay. As detection antibodies are flowed in sequence (as defined by the dashed lines), an 
asterisk at the top of a dashed line defines if a shift is expected. In each case, secondary shifts 
occur only when the appropriate isoform-specific detection antibody is introduced. In the final 
run, all three isoforms are flowed together, producing three secondary shifts that are equivalent 
to those obtained in the three single-plex runs. All signals are corrected to unfunctionalized and 
blocked control rings, and the surface was regenerated with a low-pH rinse between each run. 
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Figure 9.13 Peptide dissociation effects are more severe for Aβ1-38 than for other isoforms. By 
running consecutive sandwich assays (after incubating 2 ng/mL of each peptide isoform), the 
relative secondary shift are observed to vary depending on the order in which the detection 
antibodies are introduced. In each case, as the peptides dissociate from the capture antibodies, 
the secondary signal decreases with additional time since the primary incubation step. However, 
the dissociation effects are more pronounced for Aβ1-38 than for other isoforms. This result 
indicates that the order in which detection antibodies are flowed is highly significant, and it is 
also important to minimize the dissociation time in general; the optimal detection antibody order 
is thus anti-Aβ1-38 7-14-4, anti-Aβ1-42 HJ7.4, and finally anti-Aβ1-40 HJ2. 
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Figure 9.14 Optimized three-isoform consecutive sandwich calibration performed at t = 1, 5, and 
9 min after primary peptide binding. Using the optimized detection antibody order (Figure 9.13), 
three-plex calibration of Aβ isoforms produces three calibration curves with very similar slopes. 
3-min detection antibody steps and 1-min rinse steps between consecutive sandwich assays were 
chosen in order to limit dissociation time. All signals are corrected to anti-tau BT2 control rings. 
Error bars represent the standard deviation for n = 12 anti-Aβmid HJ5.1 rings, and all three 
calibration plots have R
2
 > 0.98. 
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Figure 9.15 anti-biotin-PE amplification of Aβ1-42 sandwich assay. A 2-3x amplification of the 
sandwich assay signal is generated by pre-incubating detection anti-Aβ1-42 HJ7.4-biotin with anti-
biotin-PE. Following incubation with 1 ng/mL of Aβ1-42 peptide, secondary amplification occurs 
at the dashed lines in each case. As the anti-biotin-PE can bind to the detection antibody more 
than once (~4 biotins per HJ7.4), the anti-biotin-PE can easily double or triple the mass 
associated with secondary binding. All signals are corrected to anti-tau BT2 control rings, and a 
low-pH rinse was used to regenerate the capture antibody surface between assays. 
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Figure 9.16 anti-biotin-PE-amplified Aβ1-42 sandwich assay calibration. (A) Representative 
secondary shifts at eight concentrations are overlayed for a single ring. Quantitation can be 
performed by using the net shift at t = 3 min. (B) The resulting calibration plot shows a linear 
response between 0 and 9.6 ng/mL. All signals are corrected to anti-tau BT2 control rings. Error 
bars represent the standard deviation for n = 12 anti-Aβmid HJ5.1 rings. The 3σ limit of 
detection is 97 pg/mL.  
 
 
 
 
 
 
 
A 
B 
Shift = 4.3 (Conc) + 0.47 
R2 = 0.98 
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Figure 9.17 Clinical range calibration plot for Aβ1-40/Aβ1-42  consecutive sandwich assays. By 
adding anti-biotin-PE amplification for Aβ1-42 to the consecutive sandwich assay, the consecutive 
sandwich assay is quantitative between 100 pg/mL and 1 ng/mL (the clinical range for the 
important AD biomarker Aβ1-42). All signals are corrected to mouse IgG isotype control rings. 
Error bars represent the standard deviation for n = 12 anti-Aβmid HJ5.1 rings. With the 
consecutive sandwich (HJ7.4, then HJ2), the detection limits are ~100-200 pg/mL for both Aβ1-40 
and Aβ1-42.  
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Figure 9.18 Differential chip response to five human CSF samples. Rings specific for Aβ 
peptides are shown alongside mouse IgG isotype control rings. For each consecutive sandwich 
assay, detection anti-Aβ1-42 HJ7.4-biotin/anti-biotin-PE is flowed (black dashed lines) prior to 
detection anti-Aβ1-40 HJ2 (green dashed lines). Following test responses to 1 ng/mL of Aβ 
peptides, five human CSF samples from Bioreclamation (labeled 688 – 692) were flowed in 
sequence. Each heterogeneous sample shows a differential primary binding curve shape and 
slope prior to the buffer rinse and the consecutive detection antibodies. A low-pH rinse was used 
to regenerate the capture antibody surface between assays. 
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Figure 9.19 Human CSF analysis: Normalized consecutive sandwich responses and 
reproducibility study. (A)  Using a two-channel fluidic setup, three-plex consecutive sandwich 
assays were performed on five human CSF samples to simultaneously test for tau, Aβ1-40, and 
Aβ1-42. Following test responses to 2 ng/mL of each analyte, five human samples from 
Bioreclamation (labeled 688 – 692) were flowed in sequence. All signals were normalized to the 
highest shift among the six assays. All shifts are based on correction to mouse IgG isotype 
control ring response, and error bars represent the standard deviation for n = 5 rings. Anti-biotin-
PE amplification was used for tau and Aβ1-42. (B) The reproducibility study, in which three CSF 
samples were run on the same chip on two different days, shows that only the Aβ1-40 data (green 
bars) is reproducible. In this case, any net shifts that remain following control ring correction for 
tau and Aβ1-42 are not robust enough for reliable quantitation. 
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9.9 Tables 
 
Table 9.1 Tau antibody clones tested for sandwich pair utility 
 
Clone 
(Capture Ab) 
Vendor/Source Notes 
Sandwich Partner 
(Detection Ab) 
HJ8.5 
Holtzman Group 
From Kaoru 
Yamada: 
These clones made 
for mouse studies, so 
have not been tested 
with human CSF 
analysis 
 
HJ8.7 
HJ8.5  
(opposite of expected) 
HJ9.1  
HJ9.3  
HJ9.5  
BT2 Thermo 
Sole functional 
capture Ab 
HT7, HJ8.5, HJ8.7, 
HJ9.3, DC39N1, 
polyclonal 
HT7 Thermo 
No activity as 
capture antibodies at 
any reasonable tau 
concentration 
 
DC39N1 rPeptide  
DC4R rPeptide  
46 Abcam, Covance  
12 Abcam  
Hyb338-01 Abcam  
C-terminal Invitrogen  
Polyclonal Dako  
 
 
Table 9.2 Aβ antibody clones tested for sandwich pair utility 
 
Clone 
(Capture Ab) 
Vendor/Source Notes 
Sandwich Partner 
(Detection Ab) 
HJ5.1 (Aβ mid-domain) 
*referred to as AβN in 
notebook based on 
original terminology 
Holtzman Group 
provided 
hybridomas; grown 
at UIUC IRC 
Best capture Ab 
With Aβ1-40: HJ2, 
HJ3.4 
With Aβ1-42: HJ7.4, 
HJ3.4, G2-11, G2-13 
With Aβ1-38: 7-14-4 
HJ3.4 (Aβ1 residues1-13)   
HJ2 (Aβ40-specific) Aβ1-40 detection Ab  
HJ7.4 (Aβ42-specific) Aβ1-42 detection Ab  
G2-11 (Aβ42-specific) Millipore   
G2-13 (Aβ42-specific) Millipore   
12F4 (Aβ42-specific) Covance 
Functional capture 
Ab 
With Aβ1-42: HJ5.1 
BA3-9 (Aβ42-specific) Covance   
BA1-13 (Aβ38-specific) Covance   
7-14-4 (Aβ38-specific) Covance Aβ1-38 detection Ab  
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Chapter 10 
 
FUTURE DIRECTIONS 
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 In this dissertation, I have described the fabrication, characterization, and development of 
silicon photonic microring resonator sensor technology for multiplexed biosensing applications 
that span a range of cellular systems and disease targets. In addition to developing methods to 
enable bulk fabrication of ring resonator devices, I have also clearly defined the optical 
sensitivity metrics that describe this platform. In applications of the biosensing platform, I have 
shown that multiple cytokines, some of the smallest and least abundant proteins in the human 
body, can be simultaneously quantified in complex matrices. By designing amplification 
techniques that include nanoparticle-based assays and enzymatic methods, microring resonator 
protein detection limits have reached the femtomolar regime for the first time. These sensitivity 
improvements have opened the door to a host of in vitro diagnostic applications that require 
ultrahigh sensitivity in order to make meaningful clinical measurements. 
 Proof-of-principle assays and first-level introductory studies have been demonstrated in 
this dissertation and those of a few others from the group who have gone before me; future work 
will involve going after even more difficult analytical problems and fundamental biological 
studies. Instead of validating that the technology is useful for a variety of target molecule 
classifications (cancer biomarkers, cytokines, DNA, miRNA, RNA, viruses, nanoparticles, etc.), 
the technology must now be used to discover previously unknown biological interactions and to 
describe intricate cellular pathways. From this point on, work with the microring platform must 
be concerned with applying the technology to fundamental biological studies, specific clinical 
diagnostic and theranostic problems, and medium-throughput (secondary) quantitative screening. 
All of these applications require cross-functional collaborations, so existing interactions with 
other research groups must be maintained while fresh collaborations with synthetic chemists, 
biochemists, and immunologists are sought. 
 In particular, many of the projects described in this dissertation represent excellent 
starting points for future, more complex projects. In the realm of cytokine detection, recent 
advances in signal amplification have opened the door to a host of applications in cell biology, 
immunology, and clinical diagnostics. With the femtomolar detection limits generated by 
enzymatic amplification, it should be possible to detect cytokines in human samples as well as in 
cell culture environments that no longer must be stimulated for maximum cytokine density. In 
particular, it is possible that measurements can now be made from small numbers of cells. Future 
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directions for cell-based cytokine research include studies of cells in microwells and other 
microfluidics-based manipulations of cellular processes in small volumes. 
 Other projects, such as the cardiac biomarker serum analysis of CRP, involved making a 
single clinically relevant measurement. Though microring arrays provide great potential for 
multiplexing, multiparameter in vitro diagnostics have not been fully realized. Single-plex assays 
for CRP must be extended to creating a panel of cardiac biomarkers (troponins, cytokines, and 
other blood proteins) on a single chip. Designing immunoassays for an entire panel of 
biomarkers is exceedingly more difficult than designing any one single assay, so large efforts in 
antibody screening and cross-target optimization must be made to create a working panel. As 
was the case for the Alzheimer’s Disease diagnostics project, finding ways to make clinically 
meaningful multiplexed measurements in complex human samples remains a great challenge. 
 The Alzheimer’s Disease diagnostics project has a strong foundation, but needs some key 
advances in order to reach its ultimate goal of multiplexed and highly quantitative human CSF 
analysis. First, better capture agents must be developed or obtained. Once excellent antibody 
pairs exist for each target, amplification strategies such as bead-based tertiary binding or 
enzymatic amplification may be brought to bear on CSF analysis. In the near term, enzymatic 
amplification will be applied to cytokine biomarker analysis in CSF. Since excellent cytokine 
antibodies are already available, demonstrating enzymatic amplification for quantitation of 
cytokines in CSF would ensure that specific and high-affinity sandwich pairs are the only 
missing pieces for effective tau and Aβ diagnostics. 
 Outside of diagnostics, many applications remain for using the microring platform for 
understanding various protein interactions. Existing methods, such as protein microarrays and 
high-throughput screens, are excellent tools for identifying hits associated with a particular 
molecular interaction (inhibitor screens, mutagenesis studies, protein-protein binding kinetics, 
macromolecular complex formation, etc.). However, once a smaller group of possible hits 
(molecules with particular promise) are identified, the ring resonator platform represents an 
excellent tool for secondary screening; the current number of individual rings per chip is well 
suited for medium-throughput arrays with dozens (not hundreds) of unique molecules. 
 Though this dissertation has made exclusive use of the first generation Leti chips with 32 
active rings each, chips with considerably more rings are currently available. The latest chip and 
instrument design features 64 active rings and a straightforward 96-well plate fluidics interface, 
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with a clear path to 128 active rings per chip. This larger potential for multiplexing on a single 
chip will open up higher-level multiparameter biosensing applications, as well as the ability to 
further improve precision with more redundant measurements per target. To fully take advantage 
of the 64- and 128-ring chips, future protein work with the new chip designs must involve 
developing fluidic strategies that allow for effective functionalization of 8 – 16 capture 
antibodies per chip. At this point, multiplexed assay optimization, capture agent availability, and 
complex fluidics integration for chip functionalization are the limiting factors.  
 As a relatively new field, high-Q sensors such as microring resonators have made many 
important advances in just a few years. As the technology continues to mature, optics and Q 
factors are no longer the limiting factor. For ring resonators to become truly transformative and 
attain widespread commercial and clinical use, the technology must clearly demonstrate the 
ability to make highly multiplexed measurements with excellent sensitivity and fast time-to-
result. The ability to observe multiple parallel reactions in real-time must continue to be 
highlighted as a distinguishing advantage of ring resonator arrays. By continuing to build on the 
methods and assay advances described in this dissertation, microring resonators will make 
increasingly more impressive measurements necessary to address previously intractable 
analytical challenges. 
 
